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Abstract 
 
Once thought to be a benign accumulation of hepatic fat, non-alcoholic fatty liver disease 
(NAFLD) is now recognised as a prevalent complication of obesity with serious consequences 
if left untreated. This includes liver inflammation and impaired glucose metabolism, and with 
time may result in cirrhosis and organ failure. While basic diagnostic tools exist, such as 
ultrasound and serum protein markers, these are often unreliable and warrant the use of more 
invasive techniques such as tissue biopsy. Given most patients only become symptomatic once 
the disease is advanced, there is an urgent need to develop a better diagnostic strategy for 
NAFLD. This project aims to address the issue by exploring a novel biomarker candidate: 
extracellular vesicles (EVs). These submicron vesicles can be isolated from the circulation and 
tracked back to their parent cells by nature of their surface markers. EVs are constitutively 
released by all cell types, however, their abundance and molecular cargo are shown to be 
changed in various conditions and disease states, which also affects the functions they mediate 
as “intercellular messengers”. Using rodent models of diet-induced NAFLD, we aim to 
determine whether plasma or liver-derived EVs could be effectively used as a marker for the 
progression of NAFLD, and whether suitable interventions exist to slow or even reverse the 
disease. Finally, using in vitro models of hepatocyte EV uptake, the project will also investigate 
how EVs impart signals within the liver, in a paracrine fashion and from extraheptic tissues. 
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1.1.  Liver Overview 
 
The liver is the largest solid organ of the body and is situated in the upper right quadrant of the 
abdominal cavity. While the microscopic architecture is consistent across the lobes and 
conserved between species, the liver is involved in a variety of metabolic functions that 
contribute to systemic homeostasis and health (see section 1.1.2) (VanPutte et al., 2010, Pocock 
et al., 2013). In this regard, the loss of liver function through acute or chronic disease has a 
range of extrahepatic consequences, from impaired glycaemia to vascular dyshomeostasis. 
However, the liver is also highly regenerative, such that a small fraction of healthy tissue (20-
30%) is able to compensate for the activity of the whole organ (Guglielmi et al., 2012). This 
value increases in liver disease, to around 40% in the case of steatosis, for example. Further 
details of relevant cell populations and their physiological roles are given below. 
 
1.1.1.  Normal liver structure 
 
The human liver is divided into four lobes, including the large anterior left and right lobes, and 
the smaller caudate and quadrate lobes on the posterior (or visceral) surface. These lobes are 
further divided into functional units called lobules, which have a typically hexagonal structure 
delineated by portal triads at the vertices (VanPutte et al., 2010, Kmieć, 2001) (Figure 1.1). 
The triads encompass a portal vein, hepatic artery, and bile duct each, where the two former 
drain into sinusoids and then subsequently into a central vein at the centre of the lobule. The 
bile ducts receive bile from canaliculi that run counter-current to the sinusoidal blood, 
eventually draining into hepatic ducts and the cystic duct of the gallbladder where the bile is 
stored. 
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Figure 1.1. Liver structure. The liver is comprised of functional units called lobules, arranged 
in hexagonal structures where the vertices are defined by a portal triad: the hepatic artery (red) 
and portal vein (blue) drain into the sinusoid then to the central vein, while the bile duct (green) 
opens into a larger hepatic duct that delivers bile to the gallbladder. In the lobules, the liver 
parenchyma is composed mainly of hepatocytes, which perform the metabolic functions of the 
liver. Between the hepatocytes and sinusoids, which are lined by endothelial cells, is the space 
of Disse containing quiescent hepatic stellate cells. Within the sinusoids, the Kupffer cells act 
as the resident macrophages and contribute to the liver’s immunotolerance. The location and 
shape of a mouse liver is shown for comparison (not to scale).  
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1.1.1.1. Hepatocytes 
 
The vast majority of the liver parenchyma within the lobules is comprised of hepatocytes, the 
main functional cells of the liver. The role of hepatocytes is diverse, including the processing 
of nutrients received from the portal circulation, the storage of glucose as inert glycogen as 
well as glycogenolysis, the detoxification of ammonia and alcohols, and the synthesis of blood 
proteins such as albumin, to name a few (Kmieć, 2001). Impaired lipid metabolism and storage 
also results in the accumulation of large fatty vacuoles within these cells, displacing much of 
the organelles and giving the liver a perforated appearance on histology (steatosis). 
 
1.1.1.2. Sinusoidal endothelial cells 
 
The sinusoidal endothelial cells (SECs) line the vessels of the hepatoportal circulation within 
the lobules. These cells are in immediate contact with the blood draining the mesentery, and 
act as a nutrient sieve for the hepatocytes (Kmieć, 2001). The endothelium is discontinuous 
and the SEC membranes are fenestrated with pores that allow the selective passage of 
macromolecules between the sinusoid and parenchyma. This passage is impaired during liver 
injury or by aging (see section 1.2.1.3), where defenestration leads to metabolic decline of the 
organ (O'Reilly et al., 2010). 
 
1.1.1.3. Hepatic stellate cells 
 
The hepatic stellate cells (HSCs) are located in the perisinusoidal space of Disse and under 
normal conditions are metabolically inert, or quiescent (Bataller and Brenner, 2005, Kmieć, 
2001). The primary function of HSCs in the healthy liver is the storage of retinol (vitamin A) 
in lipid droplets, for which they were originally termed “lipocytes”. In chronic liver diseases 
however, a persistent background of inflammation and extrinsic stress will result in HSC 
activation, whereby the cells adopt a myofibroblastic phenotype and begin producing collagen 
(Bataller and Brenner, 2005). Excessive collagen deposition into the extracellular matrix, 
without sufficient turnover or degradation by matrix enzymes, will ultimately result in the 
accumulation of scar tissue, known as fibrosis. 
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1.1.1.4. Resident immune cells 
 
Under normal conditions, resident macrophages known as Kupffer cells patrol the hepatic 
sinusoids, preventing incident contamination from gut microflora and dietary toxins or 
pathogens by antigen presentation to T lymphocytes (Doherty, 2016). They are also responsible 
for the breakdown of degenerate erythrocyte haemoglobin into bilirubin. However, given the 
abundance of foreign substances that the liver is exposed to following gastrointestinal 
digestion, immune cells must also exercise selectivity to allow a small level of tolerance 
towards our dietary nutrients. During liver disease, resident immune cells will proliferate along 
with other infiltrating cells, and a sustained inflammatory response will subsequently mediate 
fibrogenesis in the liver (Bataller and Brenner, 2005).  
 
1.1.1.5. Extracellular matrix 
 
Under normal circumstances, the extracellular matrix (ECM) in the liver is a dynamic micro-
environment that facilitates normal cell function. It is composed of various types of structural 
proteins – collagen, laminin, fibronectin and proteoglycans – as well as matrix enzymes and 
growth factors, that accommodate the bidirectional diffusion of plasma products across the 
space of Disse (reviewed in detail elsewhere (Hernandez-Gea and Friedman, 2011)). Ergo, this 
space is predominantly comprised of the more “soluble” or basement collagen IV, which is 
regulated by matrix metalloproteinase (MMP) activity during normal ECM turnover. In a 
fibrogenic environment, the high-density “insoluble” or fibrillar collagen I and III are 
incorporated into the perisinusoidal region and undergo cross-linking by hydroxyproline. 
Consequently, regulated turnover by MMPs is replaced by ECM accumulation, such that 
diffusion becomes less efficient and liver function is impaired. 
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1.1.2.  Normal and abnormal liver function 
 
The liver is arguably the most metabolically versatile organ, capable of performing both 
exocrine and endocrine functions that contribute to digestion and vascular homeostasis, 
respectively (VanPutte et al., 2010, Pocock et al., 2013) (Table 1.1). In the context of 
circulatory maintenance, the liver is involved in the synthesis of plasma proteins, detoxification 
of portal blood, the degradation of expired red cells, and the production of bile to aid lipid 
digestion. Finally, the liver is also a storage site for vitamins (in HSCs), and glycogen (in 
hepatocytes) that is broken down into glucose and released during the post-absorptive state.  
 
 
 
Table 1.1. Primary functions of the liver. 
Function Cells involved Examples 
Digestion 
 Nutrient storage 
 Nutrient conversion 
 Fat digestion 
 
 
Excretion 
 Waste clearance 
 Detoxification 
 
Synthesis 
 Blood proteins 
 Hormones 
 
Hepatocyte, HSC 
Hepatocyte 
Hepatocyte, 
cholangiocyte 
 
 
Hepatocyte, KC 
Hepatocyte 
 
 
Hepatocyte 
Hepatocyte, KC 
 
Glycogen, fats, vitamins, trace metals 
Gluconeogenesis, phospholipid synthesis 
Produce bile to emulsify fat droplets 
 
 
 
Excess cholesterol, bilirubin via bile 
Ammonia converted to urea 
 
 
Albumin, globulin, fibrinogen 
IGF1, angiotensinogen, thrombopoietin, 
hepcidin 
 
HSC, hepatic stellate cell; KC, Kupffer cell; IGF1, insulin-like growth factor 1. 
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Given the aforementioned repertoire of functions, diseases of the liver will often have 
downstream consequences that affect a variety of organ systems, resulting in a decline in 
general health (Armstrong et al., 2014). As such, there is an urgent push for effective diagnostic 
tools and therapeutic interventions that limit functional decline of the liver. While successful 
treatments are becoming available for endemic diseases such as viral hepatitis (World Health 
Organization, 2017), recent decades have seen a shift in the primary aetiology to a lifestyle-
related disorder: fatty liver disease. While part of this burden is attributed to alcoholism, the 
rise in prevalence can be best explained by an emerging obesity pandemic, especially 
characteristic of Western countries. Obesity is known to cause a myriad of visceral pathologies, 
collectively identified by the term “metabolic syndrome” (detailed in section 1.2), whereas 
non-alcoholic fatty liver disease is the hepatic manifestation of this syndrome. When compared 
to normal liver function, a fatty liver is characterised by the aberrant regulation of glucose and 
fatty acid metabolism (reviewed in (Petersen et al., 2017)). This is further elaborated in section 
1.2.   
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1.2.  Non-alcoholic Fatty Liver Disease 
 
Non-alcoholic fatty liver disease (NAFLD) is defined by lipid accumulation in at least 5% of 
hepatocytes, determined by histology, in the absence of secondary causes (European 
Association for the Study of the Liver (EASL) et al., 2016, Chalasani et al., 2018). In contrast 
to a similar pathology that develops from chronic alcoholism, NAFLD is instead linked to 
excessive caloric intake and is often recognised as a complication of metabolic disorders such 
as obesity and type 2 diabetes. It is unsurprising then, that the increased prevalence of obesity 
(BMI ≥30kg/m2) in recent decades has seen a parallel increase in NAFLD cases (Loomba and 
Sanyal, 2013); it is estimated that around 25% of individuals are affected globally (Younossi 
et al., 2016), with obese populations being at a greater risk (LaBrecque et al., 2014), where 
NAFLD is almost ubiquitous. In Australia, NAFLD is the leading cause of liver disease by a 
significant margin, and is second only to hepatitis C in terms of mortality, surpassing primary 
liver cancer (Deloitte Access Economics, 2013). It is also the fourth-highest indication for liver 
transplantation (Howell et al., 2016), compared to second-highest in the USA (Cholankeril et 
al., 2017). Therefore, there is an urgency to understand and manage the progression of this 
disease in order to stall both its morbidity and mortality. 
 
However, given the significant prevalence of NAFLD and inherent limitations of current 
diagnostic tools (covered further in section 1.2.2), general screening for the disease is often 
impractical and not advised. With reference to the Wilson and Jungner screening criteria 
adopted by the World Health Organization (Andermann et al., 2008), it is difficult to justify 
the screening for NAFLD in the wider population for a number of reasons, not least due to the 
expense of “case-finding” since there is no reliable, non-invasive test to predict the disease 
severity (Chalasani et al., 2018). However, leading hepatology bodies such as the European 
Association for the Study of the Liver (EASL) and the American Association for the Study of 
Liver Diseases (AASLD) – as well as the World Gastroenterology Organisation – have 
proposed guidelines that recommend the screening of individuals that carry known risk factors 
or comorbidities, including insulin resistance, features of the metabolic syndrome (MetS; 
Figure 1.2A), or an unexpected elevation of the liver enzyme alanine transaminase (ALT) 
(European Association for the Study of the Liver (EASL) et al., 2016, Chalasani et al., 2018, 
LaBrecque et al., 2014).  
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1.2.1.  Pathogenesis of NAFLD 
 
Non-alcoholic fatty liver disease encompasses a spectrum of disorders ranging from simple 
steatosis (or NAFL) in its early development, to the more severe non-alcoholic steatohepatitis 
(NASH). The mechanisms involved in the progression from NAFL to NASH are not well 
understood, however certain anthropometric and clinical parameters have been implicated  
(LaBrecque et al., 2014) (Figure 1.2A). Whereas NAFLD was once dismissed as a benign 
accumulation of hepatic fat, its extrahepatic effects are becoming increasingly recognised 
(Armstrong et al., 2014), such as peripheral insulin resistance and a predisposition to cardiac 
disease, the leading cause of death in NAFLD patients (Ekstedt et al., 2006). Without due 
intervention, NAFLD will further develop into the pro-inflammatory phenotype of NASH, 
which predisposes to more sinister outcomes such as liver cirrhosis (LaBrecque et al., 2014). 
(Note that cases of cryptogenic cirrhosis are often attributed to NASH, as both are determined 
through exclusion criteria.) This “inflammation driving fibrosis” paradigm is one that is 
common among liver diseases, although the mechanisms that perpetuate it are unique to each 
aetiology.  
 
1.2.1.1. Histopathological changes 
 
Changes in liver histology provide the most accurate reflection of the severity of NAFLD 
(European Association for the Study of the Liver (EASL) et al., 2016, Chalasani et al., 2018, 
LaBrecque et al., 2014), however classical features may vary between ethnic populations, or 
between species. In humans, macrovesicular lipid storage in hepatocytes is the hallmark feature 
of NAFLD and the only anomaly present in simple steatosis. Not to be confused with 
hepatocellular ballooning, this storage pattern results in the displacement of nuclei by large 
fatty vacuoles in the cytoplasm (Stern and Castera, 2017) (Figure 1.3B). On the other hand, the 
additional presence of ballooning (engorged, clarified cytoplasm) and inflammatory foci are 
distinguishing features of NASH (Lackner, 2011) (Figure 1.3C). These are frequently, but not 
exclusively, complemented with perisinusoidal fibrosis (Chalasani et al., 2018). As NAFLD 
progresses further, collagen deposits begin to infiltrate the pericellular regions and may link 
together, segregating parenchymal “islands” and forming the bridging fibrosis typically seen 
in pre-cirrhotic and cirrhotic livers. It is now understood that this environment is favourable 
for the development of hepatocellular carcinoma (HCC) (Michelotti et al., 2013).  
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Figure 1.2. Natural history of NAFLD. A. Risk factors for progression from simple steatosis 
(NAFL) to steatohepatitis (NASH) (European Association for the Study of the Liver (EASL) 
et al., 2016). Components of the metabolic syndrome are denoted by an asterix. Development 
of NASH usually occurs over decades, with fibrosis severity described according to the Kleiner 
classification system (F0-F4) (Kleiner et al., 2005). Lipodystrophy and genetic polymorphisms, 
most notably at the PNPLA3 locus, are also less frequent modifiers of NAFLD. B. NAFLD 
histology with three independent biopsies representing increasing grades of steatosis: less than 
33% (S1), 34-66% (S2), and greater than 66% (S3) of hepatocytes containing lipid droplets. 
S0 signifies less than 5% steatosis, or absence of NAFLD (not shown). C. NASH phenotype 
with typical characteristics inset. Hepatocyte ballooning and leukocyte infiltrates distinguish 
NASH from NAFL. Panels B and C adapted from elsewhere (Stern and Castera, 2017).  
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1.2.1.2. Metabolic and molecular changes 
 
On a background of obesity, NAFLD occurs as a consequence of increased fatty acid flux as a 
result of adipose tissue expansion and lipolysis (Byrne et al., 2009, Jensen, 2008). When this 
expansion exceeds the capacity of the adipose extracellular matrix to maintain a stable fat 
depot, ectopic fat deposition is seen in the visceral organs. This is promoted by the migration 
of long-chain fatty acids (LCFA) to the liver, for example (Figure 1.3), and together with 
increased dietary monosaccharides such as glucose and fructose, there is an upregulation of de 
novo lipogenesis (Postic and Girard, 2008). Aside from the formation of hepatocellular lipid 
droplets containing triacylglycerol (TAG), free fatty acids and intermediates of the lipogenesis 
pathway – in particular, diacylglycerol (DAG) – are also responsible for hepatic inflammation 
and insulin resistance (Jornayvaz and Shulman, 2012, Boden et al., 2005). Therefore, an 
increase in hepatic inflammatory cytokines (TNF and IL6), chemokines (MCP1) and growth 
factors (TGF) are typical features of NAFLD (Braunersreuther et al., 2012, Boden et al., 
2005). These are complemented with elevated TAG in both the liver, and in the circulation in 
the form of chylomicrons or very-low density lipoproteins (VLDL), whereas leukocyte 
recruitment and hepatocyte injury become evident in NASH. 
 
Some studies have examined the immediacy of NAFLD pathogenesis in rodent models. For 
instance, Turner and colleagues showed that early events such as increased fasting blood 
glucose and body weight gain, evident after 5-6 weeks of high-fat feeding in mice, are preceded 
by acute changes including glucose intolerance, hyperinsulinaemia, and increased fatty acids 
in the liver (Turner et al., 2013). These changes became present by 1 week, and continued to 
increase in the case of plasma insulin and hepatic TAG, whereas hepatic DAG remained stable 
after the initial increase. A similar study in rats confirmed the early onset of hyperinsulinaemia, 
together with increased liver fatty acids and presence of steatosis (Ciapaite et al., 2011). 
Interestingly, both parameters were also affected by aging, suggesting that the progression of 
NAFLD defined by increased liver lipid may also be influenced by (or synergise with) inherent 
biological factors.  
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To complement this paradigm, a study of obese humans provided an argument for accelerated 
epigenetic “aging” of the liver in NAFLD (Horvath et al., 2014). In this cross-sectional 
analysis, a strong correlation was found between BMI and DNA methylation in the liver 
specifically, when compared to other tissues. Furthermore, these epigenetic changes were not 
reversed by acute weight loss, either in the form of exercise or bariatric surgery, which suggests 
that obesity presence may predispose to more permanent complications. 
 
Systemic changes with obesity are also manifest in the circulation, however the contribution 
of NAFLD specifically is not always clear. Correlative studies have shown that some 
biomarkers are elevated and may be useful in aiding diagnosis (see section 1.2.2.2). It is also 
expected that VLDL, formed during lipogenesis and predominantly comprised of TAG, would 
be more abundant in obese NAFLD (Figure 1.3). Studies of the hepatic and plasma lipidome 
have shown that many other lipid species also become dysregulated (Puri et al., 2007, Puri et 
al., 2009), and are comparable between humans and mice (Gorden et al., 2011), although their 
utility as biomarkers haven’t yet been explored. As in most aetiologies of liver disease, 
circulating liver transaminases are elevated (LaBrecque et al., 2014), hinting at possible 
hepatocellular injury. While both alanine (ALT) and aspartate (AST) transaminase are typically 
present in equal proportion (Botros and Sikaris, 2013), NAFLD tends to favour a De Ritis ratio 
(AST:ALT) of less than 1, which is useful in its differentiation from alcoholic fatty liver disease 
that tends to have a ratio >2 (Sorbi et al., 1999, LaBrecque et al., 2014). However, there are 
some conflicting reports on the utility of circulating liver enzymes for the assessment of 
NAFLD, particularly ALT. For instance, one study has shown that levels of this enzyme may 
fluctuate depending on fibrosis severity (Sorbi et al., 1999), whereas levels within the reference 
range are also commonly observed for NAFLD patients, independently of disease spectrum 
(LaBrecque et al., 2014, Mofrad et al., 2003). 
  
 
 
15 
 
 
 
Figure 1.3. Mechanisms of NAFLD development. Both long-chain fatty acids (LCFA) from 
adipose tissue and glycolytic intermediates are involved in hepatic de novo lipogenesis. This 
process results in the production of triacylglycerol (TAG), which is incorporated into either 
lipid droplets within hepatocytes, or into very-low-density lipoproteins (VLDL) that are 
released into the circulation. TAG may be further broken down into its glycerol and fatty acid 
(FA) components within lipid droplets. Diacylglycerol (DAG), an intermediate of lipogenesis, 
is also involved in mediating hepatic insulin resistance and increasing the expression of 
transcription factors that drive inflammation. Schematic developed from (Perry et al., 2014) 
and (Byrne and Targher, 2015). Abbreviations: G3P, glycerol-3-phosphate; GPAT, G3P 
acyltransferase; LPA, lysophosphatidic acid; PA, phosphatidic acid; mTORC2, mammalian 
target of rapamycin complex 2; PKC, protein kinase C ; JNK, c-Jun N-terminal kinase; 
IKK, inhibitor of nuclear factor kappa . 
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1.2.1.3. Effects of aging 
 
Irrespective of NAFLD, gross changes in liver structure are a recognised feature of aging. The 
most defining of these are reduced total volume – which translates to reduced cell mass with 
compensatory cell hypertrophy – and decreased blood flow (Wynne et al., 1989, Wynne and 
James, 1990). In terms of liver function, there is an impaired capacity to synthesise 
macromolecules or to clear toxins, and response to stress is also less robust (Wynne and James, 
1990). Studies using rodent models have further elucidated the molecular changes that 
accompany aging, namely those affecting fatty acid oxidation and oxidative stress (Houtkooper 
et al., 2011), as well as apoptosis pathways (Fontana et al., 2013). These are paralleled by an 
increase in circulating free fatty acids and a decrease in energy expenditure in older animals 
(Houtkooper et al., 2011, Xiong et al., 2014). This environment may contribute to increased 
fatty acid storage in the liver with age. 
 
The intersection between NAFLD and aging has been extensively studied (Bertolotti et al., 
2014, Gan et al., 2011). A key mechanism involved in both phenomena is insulin resistance; 
impaired signalling downstream of the insulin receptor have been linked to insulin resistance 
in the elderly (Fink et al., 1983, Rowe et al., 1983), which subsequently predisposes to the 
development of hepatic steatosis. In fact, older patients frequently present with more severe 
NAFLD and tend to have a worse prognosis than younger sufferers (Frith et al., 2009). This is 
linked to an increase in risk factors associated with aging, such as hypertension, diabetes, and 
obesity (Frith et al., 2009), which promote the development of fibrosis (Kichian et al., 2003). 
A similar trend was also observed in a mouse model of high-fat feeding (Fontana et al., 2013), 
where aged animals had a (paradoxically) heightened immune response, specifically of a pro-
inflammatory nature (M1 macrophage phenotype). Finally, given that estrogen suppressed the 
rate of NAFLD development and is no longer protective following menopause (Gutierrez-
Grobe et al., 2010), it may be inferred that animal studies often favour the use of male subjects 
to avoid this confounding factor. 
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1.2.2.  Diagnosis of NAFLD 
 
Arguably one of the greatest challenges facing hepatologists in recent decades is the accurate 
diagnosis of NAFLD. Without effective screening measures (see section 1.2) and in the absence 
of evidence-based clinical guidelines (LaBrecque et al., 2014), identification of potential cases 
relies on data from population studies, often with disparate findings due to ethnic variation in 
anthropometric measurements (Almeda-Valdes et al., 2016). This may in turn lead to systemic 
under-diagnosis (Alexander et al., 2018). While some indicators are universally accepted (e.g. 
BMI, waist circumference), an accurate diagnosis requires expensive or sophisticated tools that 
are not generally accessible (Stern and Castera, 2017). Furthermore, invasive procedures such 
as tissue biopsy are still considered the gold standard for the staging of disease severity 
(European Association for the Study of the Liver (EASL) et al., 2016), although the precision 
of first-line imaging techniques has improved in recent years (Table 1.2). With non-invasive 
assessment becoming the focus, much effort has been invested in the discovery of biomarkers 
that are both practical and can provide a reliable snapshot of an individual’s NAFLD status. 
 
1.2.2.1.  Liver biopsy 
 
Technical limitations and confounding factors of non-invasive tools for diagnosis have meant 
that direct histological examination is still the preferred option for the assessment of disease 
grade in NAFLD (reviewed in (Nalbantoglu and Brunt, 2014)). For example, the NAFLD 
activity score (NAS) is an algorithm derived from biopsy information, and has been validated 
by the NASH Clinical Research Network (Kleiner et al., 2005). NAS classification addresses 
steatosis, hepatocellular ballooning, and lobular inflammation to assign a cumulative score 
depending on the severity of each feature. Not unlike many invasive procedures of a similar 
nature, liver biopsy suffers from a number of safety limitations, most of which can be controlled 
given adequate resources. The most common risks include pain and bleeding at the site of 
biopsy, although these usually resolve within 72 hours, while major complications are rare 
(Filingeri et al., 2015). Discrepancies in sampling and pathological assessment are another 
concern, both of which are recognised technical caveats that may further complicate the 
accurate diagnosis of NAFLD (Ratziu et al., 2005, Vuppalanchi et al., 2009). Nevertheless, 
pending adherence to clinical guidelines that attempt to standardise the diagnostic workflow, 
these issues may be circumvented. 
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1.2.2.2.  Non-invasive techniques 
 
Liver biopsy is not a first-line tool for screening patients at a higher risk of NAFLD and is 
usually reserved for cases where NASH is suspected, due to its invasiveness. For a preliminary 
diagnosis, imaging techniques are most commonly used in a clinical practice setting (Table 
1.2). Ultrasound specifically is the favoured option (LaBrecque et al., 2014, European 
Association for the Study of the Liver (EASL) et al., 2016), as the technology is both accessible 
and simple to operate, although it is less sensitive and more error prone when compared to its 
more expensive counterparts such as magnetic resonance techniques (Reeder et al., 2011).  
 
Since liver imaging is often qualitative, circulating biomarkers are also being used – either in 
isolation, or in combination with preclinical parameters – as surrogate markers of NAFLD to 
complement the diagnosis (Table 1.3). While many complex panels have been established, 
including the popular fatty liver index (FLI), none are universally applied in healthcare. It has 
been proposed that this may be due to the fact that such panels do not provide any additional 
information when compared to existing methods, and that their diagnostic superiority is only 
relative to the standards against which they were validated (Stern and Castera, 2017).  
 
Indeed, the combination of biochemical and/or anthropometric parameters cannot accurately 
quantify steatosis (Fedchuk et al., 2014) or differentiate NAFL from NASH, which reinforces 
the necessity for biopsy (European Association for the Study of the Liver (EASL) et al., 2016). 
Furthermore, both imaging and clinical biomarker alternatives are also susceptible to common 
confounders, such as visceral adiposity (Castera et al., 2010) and aging (McPherson et al., 
2017). Of course, this does not preclude the utility of current and potential biomarkers as 
important mediators of disease, however, their activity in vivo may not be reflective of their 
circulating abundance. For the reasons above, a novel diagnostic candidate is required to 
increase the reliability of NAFLD assessment, ergo this thesis will focus on the potential of 
extracellular vesicles (described in section 1.3) in fulfilment of this role. 
 Table 1.2. Imaging techniques used for NAFLD diagnosis. 
Test Advantages Limitations AUROC* Population, n References 
Controlled attenuation 
parameter (CAP) 
 Simple 
 Rapid 
 Accessible 
 Operator-dependent 
 Cut-offs vary 
 FibroScan ™ required 
0.67-0.97 
0.75-0.97 
0.82-0.94 
0.88-0.92 
0.91-0.95 
79 
161 
65 
152 
115 
(Chan et al., 2017) 
(Chan et al., 2014) 
(Karlas et al., 2014) 
(Shen et al., 2014) 
(Sasso et al., 2010) 
Computerised tomography 
(CT) 
 Entire liver  Low sensitivity 
 Radiation exposure 
0.65-0.92 
0.99 
161 
154 
(Lee et al., 2010b) 
(Park et al., 2006) 
Magnetic resonance imaging 
(MRI) 
 Sensitive 
 Reproducible 
 Rapid 
 Entire liver 
 Expensive 
 Less accessible 
0.88-0.99 161 (Lee et al., 2010b) 
Proton magnetic resonance 
spectroscopy (1H-MRS) 
 Sensitive 
 Reproducible 
 Entire liver 
 Expensive 
 Less accessible 
 Time consuming 
 Expertise required 
0.85-0.88 
0.85-0.91 
0.95-0.99 
 
65 
161 
77 
(Karlas et al., 2014) 
(Lee et al., 2010b) 
(McPherson et al., 2009) 
   Sensitivity, %   
Ultrasound (US)  Simple 
 Inexpensive 
 Accessible 
 Operator-dependent 
 Low sensitivity 
 Qualitative 
39-49 
55-80 
187 
100 
(Mottin et al., 2004) 
(Ryan et al., 2002) 
 
*AUROC dependent on cut-off values for steatosis grade. Sensitivity ranges determined by steatosis grade or body mass index. Advantages and 
limitations adapted from elsewhere (Stern and Castera, 2017). Abbreviations: AUROC, area under receiver operator curve. 
 Table 1.3. Biomarkers and complex panels used for NAFLD diagnosis. 
Test Parameters AUROC Population, n References 
NAFL (steatosis)     
Cytokeratin 18 (CK18) Single biomarker, circulating 0.77 424 (Cusi et al., 2014) 
Fatty acid binding protein (FABP) Single biomarker, circulating 0.66 220 (Shen et al., 2012a) 
Fibroblast growth factor 21 (FGF21) Single biomarker, circulating 0.84 220 (Shen et al., 2012a) 
Fatty liver index (FLI) BMI, GGT, TAG, WC 0.84 496 (Bedogni et al., 2006) 
Hepatic steatosis index (HSI) AST/ALT, BMI, DM 0.81 10724 (Lee et al., 2010a) 
Lipid accumulation product (LAP) sex, TAG, WC 0.79 588 (Bedogni et al., 2010) 
NAFLD liver fat score AST/ALT, DM, insulin, MetS 0.87 470 (Kotronen et al., 2009) 
SteatoTest ™ A2M, age, ALT, ApoA1, bilirubin, BMI, 
cholesterol, GGT, glucose, HG, sex, 
TAG 
0.79 744 (Poynard et al., 2005) 
NASH     
Index of NASH (ION) ALT, HOMA-IR, TAG 0.77 4458 (Otgonsuren et al., 2014) 
NashTest ™ A2M, age, ALT, AST, ApoA1, BMI, 
bilirubin, cholesterol, GGT, HG, sex, 
TAG 
0.79 257 (Poynard et al., 2006) 
 
A2M, alpha 2 macroglobulin; ALT, alanine transaminase; AST, aspartate transaminase; ApoA1, apolipoprotein A1; AUROC, area under receiver 
operator curve; BMI, body mass index; DM, diabetes mellitus; GGT, gamma glutamyl transferase; HG, haptoglobin; HOMA-IR, homeostatic 
model assessment of insulin resistance; MetS, metabolic syndrome; TAG, triacylglycerol; WC, waist circumference. 
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1.2.3.  Prognosis and monitoring 
 
NAFLD is often classified as a “benign” disease with respect to its evolution (Chalasani et al., 
2018). However, this is largely dependent on its severity; being a spectrum of disorders, the 
prognosis for NAFLD is heterogeneous, where simple steatosis is understood to have a slower 
progression and better outcomes than NASH (Angulo et al., 2015, Singh et al., 2015). On the 
other hand, NAFLD is a frequent subclinical complication of obesity and T2DM that relies on 
incidental diagnosis due to a lack of screening measures (see section 1.2). If detected early, the 
steatosis may be partially alleviated or stalled from progressing by simple changes to lifestyle 
habits, including diet and physical activity (Vilar-Gomez et al., 2015, Zelber-Sagi et al., 2011). 
In fact, such modifications are the preferred prescription in clinical practice (Ratziu et al., 
2012). However, in the event of a NASH diagnosis, pharmacological intervention may be 
necessary; there are several drugs targeting various elements of NAFL to NASH progression, 
although most are still in the clinical trial phase and are administered off-label (reviewed 
elsewhere by (Perazzo and Dufour, 2017)). Since a large meta-analysis of clinical data has 
revealed that NAFLD increases the overall risk of liver-related mortality, as well as the risk of 
developing T2DM and cardiovascular disease (Musso et al., 2011), monitoring of these patients 
is recommended at 2-3 year intervals (European Association for the Study of the Liver (EASL) 
et al., 2016). For NASH and cases at risk of progression, monitoring should take place annually, 
with a follow-up biopsy at 5 years (at the discretion of the physician). A detailed protocol for 
NAFLD monitoring is available in the EASL-EASD-EASO clinical guidelines (European 
Association for the Study of the Liver (EASL) et al., 2016) or in the recent AASLD practice 
guidance report (Chalasani et al., 2018). 
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1.2.4.  Experimental models 
 
The phenotype of NAFLD has been replicated both in vivo and in vitro with varying degrees 
of biological similarity to the human disease (Chavez-Tapia et al., 2011, Machado et al., 2015, 
Teufel et al., 2016). While certain features of hepatocellular injury in human NAFLD may be 
absent in mice, hypertrophy due to microvesicular steatosis seems to be more predominant in 
the latter (Liang et al., 2014). Rodent models that receive liver specific insults are more prone 
to develop NASH, however, they lack the metabolic features that reflect physiological NAFLD 
development and therefore they are usually favoured for studies examining liver disease in 
isolation (Rinella and Green, 2004). The following sections describe some common 
experimental models of NAFLD, and also outline some genetic and lifestyle interventions that 
have been used to stall or reverse the disease. 
 
1.2.4.1.  Nutritional models 
 
High-fat diet (HFD) is perhaps the most relevant model with respect to the typical aetiology of 
NAFLD, since obesity, insulin resistance, and other features of the metabolic syndrome are 
present. Most HFD formulations contain between 30-80% energy (calories) derived from lipid, 
particularly saturated fats (Hariri and Thibault, 2010). Another key player in obesogenic diets 
is fructose, which has been shown in rodent models to accelerate NAFLD progression to 
NASH: a fructose-enriched HFD promotes oxidative stress, as well as increasing leukocyte 
infiltration and fibrogenesis when compared to HFD alone (Kohli et al., 2010). 
 
Some non-obesogenic diets are also capable of producing steatosis, in the absence of both 
adiposity and insulin resistance. For example, an atherogenic (high-cholesterol) diet has been 
shown to result in hepatomegaly with increased hepatic gene expression of molecules involved 
in fatty acid synthesis and oxidative stress (Matsuzawa et al., 2007). Also commonly used in 
NASH studies, the methionine and choline deficient diet (MCD) is known to disrupt VLDL 
secretion and mitochondrial  oxidation, while closely mimicking the histopathology of human 
NASH but without the metabolic profile (Machado et al., 2015, Rinella and Green, 2004). Due 
to their liver specificity, elevated serum ALT is observed in both diets, while the typical 
changes in serum insulin and triglyceride levels seen with obesogenic diets is absent. See Table 
1.4 for a summary of outcomes from nutritional models. 
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1.2.4.2.  Genetic models 
 
There are several transgenic rodent strains used as preclinical models of NAFLD (reviewed in 
(Jacobs et al., 2016)) (Table 1.4). Here, we focus on models that reflect physiological NAFLD 
progression. Common examples include the leptin mutant (ob/ob) or leptin receptor mutant 
(db/db) mouse, where disruption to the signalling pathway of the leptin hormone causes an 
impaired satiety response and consequent overeating, resulting in obesity and other features of 
the metabolic syndrome (Trak-Smayra et al., 2011). Spontaneous mutation in the leptin 
receptor has also been reported in Zucker rats (Phillips et al., 1996), where the autosomal 
recessive trait (fa/fa) results in “inherited obesity” that is metabolically akin to the ob/ob and 
db/db phenotypes, whereas early-onset insulin resistance has also been documented in this 
model (Durham and Truett, 2006). Finally, the dysfunction of neuronal cilia through an Alms1 
gene mutation (foz/foz) has also been associated with hyperphagia (Heydet et al., 2013), 
although the exact mechanisms are unclear. Of interest, the severity of NAFLD in foz/foz mice 
is strain-dependent; while the mutation results in comparable obesity, C57Bl/6 animals are 
more susceptible to the metabolic and pathological outcomes than their BALB/c counterparts 
(Farrell et al., 2014). 
 
 
 
Table 1.4. Summary of common nutritional and genetic models of NAFLD. 
Model IR Obese Steatosis NASH Fibrosis 
Nutritional 
 High-fat diet (HFD) 
 High-fat with fructose 
 Atherogenic (high cholesterol) # 
 Methionine-choline deficient # 
 
Genetic 
 ob/ob (leptin-/-) 
 db/db, fa/fa (leptin receptor-/-) 
 foz/foz (Alms1 mutation) 
 
yes 
yes 
- 
yes 
 
 
yes 
yes 
yes 
 
yes 
yes 
- 
- 
 
 
yes 
yes 
yes 
 
yes 
yes 
yes 
yes 
 
 
yes 
yes 
yes 
 
yes 
yes 
yes 
yes 
 
 
- 
- 
yes 
 
yes 
yes 
yes 
yes 
 
 
- * 
- 
yes 
 
*This model is resistant to hepatic fibrosis. # Outcomes may differ for rats. Abbreviations: IR, 
insulin resistance. Adapted from (Jacobs et al., 2016) and (Kucera and Cervinkova, 2014). 
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1.2.4.3.  Intervention strategies 
 
The most common interventions for treating NAFLD are non-pharmacological, involving 
either physical activity or a calorie-restricted diet. In animal models, the effect of exercise on 
steatosis has been extensively documented, typically reporting a decrease in insulin resistance, 
hepatic lipogenesis, and inflammation with frequent treadmill running (Alex et al., 2015, Cho 
et al., 2014, Kawanishi et al., 2012). Furthermore, when comparing moderate intensity aerobic 
exercise to high-intensity interval training, the latter seemed to provide a greater protection 
against NAFLD pathogenesis, which was linked to increased FFA oxidation and suppression 
of hypoadiponectinemia (Cho et al., 2015). For information regarding clinical studies using 
exercise intervention on patients with NAFLD, please refer to Chapter 5.1. 
 
Another approach is to interrupt the molecular pathways that mediate NASH, using genetic 
ablation of cytokines and their receptors in rodent models (reviewed in (Braunersreuther et al., 
2012) and (Tilg and Moschen, 2008)). One example is the global gene deletion of TNF, a 
cytokine released by stressed parenchymal cells that is known to play a role in insulin resistance 
by suppressing IRS1 downstream of the insulin receptor (Feinstein et al., 1993, Hotamisligil et 
al., 1994). However, inconsistent findings are testament to the fact that slight differences in 
experimental design will often produce heterogeneous results. These thoughts are developed 
further in Chapter 5.4 – along with details about the biological role of TNF signalling in 
adipogenesis – where outcomes of our genetic manipulation study are explored in context. 
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1.3.  Extracellular Vesicles 
 
Extracellular vesicles (EVs) are submicron, membrane-bound structures released from cells 
during activation, physiological stress, or apoptosis. They are present in all biological fluids 
including blood, urine, bile, semen, milk, amnion, and cerebrospinal fluid and are derived from 
either local or distant tissues, as well as commensal organisms or pathogens (Yanez-Mo et al., 
2015). The rationale for EV-mediated signalling is thought to be increased stability (Kalra et 
al., 2013, Yanez-Mo et al., 2015); that is, to preserve the integrity of bioactive molecules in a 
medium where they would otherwise be degraded by soluble enzymes (Valadi et al., 2007). To 
this end, endogenous EVs increase the efficiency of intercellular communication for their 
cargo, while artificially manipulated or exogenous EVs have been utilised for efficient drug 
delivery (Kooijmans et al., 2012). 
 
1.3.1.  Extracellular vesicle subtypes 
 
Three main subtypes of extracellular vesicles have been classified in animals, and differ in their 
biogenesis. The largest in terms of size are apoptotic bodies (ABs), which have similar 
dimensions to platelets and are often excluded during size-based isolation techniques (Witwer 
et al., 2013). Strictly speaking, ABs aren’t released from cells but rather occur as a product of 
organelle compartmentalisation during cell apoptosis (Akers et al., 2013). For this reason, they 
tend to be neglected from most EV-based studies. Other EV subtypes are described below and 
summarised in Figure 1.4. 
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Figure 1.4. Extracellular vesicle subtypes. Cells respond to a variety of stimuli that cause 
inflammation and metabolic stress, which result in their impaired functioning or apoptosis. 
This mechanism drives the release of EVs, which signal to paracrine or distal effectors the 
condition of the cell microenvironment. Effector cells may, in turn, respond by selectively 
imparting regulatory molecules – small nucleic acids (mRNA and miRNA; blue), lipids, and 
proteins (purple) – contained within EVs, that are taken up by the recipient cell. The EV 
subclasses are identified by membrane markers that denote the site of their biogenesis. 
Exosomes typically express tetraspanins (endosomal membrane protein; green), while micro-
vesicles are understood to contain phosphatidylserine (PS). These lipoproteins are normally 
oriented towards the cytosol to maintain the cell membrane asymmetry, but during conditions 
that stimulate EV release, the molecules become everted. The stimuli and inhibitors of EV 
release described in this figure are in reference to hepatocytes in the context of NAFLD. 
Abbreviations: ESCRT, endosomal sorting complexes required for transport; MVB, multi-
vesicular body; PS, phosphatidylserine. Image retrieved from a publication by the author and 
colleagues (Ban et al., 2016). 
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1.3.1.1. Microvesicles 
 
Microvesicles (MVs) are the larger of the secreted vesicle subtypes (up to 1m), released from 
the cell membrane in a budding fashion (Hugel et al., 2005) (Figure 1.5). MVs are subsequently 
taken up by recipient cells by endocytosis (Costa Verdera et al., 2017). Prior to budding, the 
orientation of membrane phosphatidylserine changes (Hugel et al., 2005); under basal 
conditions, this phospholipid is largely facing the cytosol (asymmetrical) whereas upon cell 
stress, it is everted toward the intercellular space. This change is often associated with apoptosis 
signalling, however in the context of EVs, phosphatidylserine is also a recognised marker of 
MVs. Since the mammalian protein Annexin A5 binds to phosphatidylserine with high affinity 
(Rand et al., 2012), this protein is often used for MV targeting in place of antibodies for 
immunoaffinity assays, such as flow cytometry. 
 
1.3.1.2. Exosomes 
 
Finally, the smallest EV subtype and arguably the most popular for mechanistic studies is the 
exosome. Often referred to as nanovesicles and measuring under 100nm, these EVs are released 
by exocytosis from a subset of late endosomes called multivesicular bodies (MVBs) (Simons 
and Raposo, 2009). Exosomes are formed within MVBs from the endosomal membrane, a 
process involving the endosomal sorting complexes required for transport (ESCRT). These 
cytosolic proteins are responsible for MVB biogenesis and the packaging of molecules destined 
for endo-lysosomal destruction, or release through exosomes (Hessvik and Llorente, 2018). 
Given their origin, recognised markers of exosomes include endosomal proteins such as 
tetraspanins (most commonly, CD9 and CD63) as well as accessory proteins of the ESCRT 
pathway (Alix and TSG101). Exosomes and microvesicles are often difficult to distinguish due 
to their phenotypic overlap (van der Pol et al., 2012, Yanez-Mo et al., 2015). For instance, size-
based comparisons may be erroneous given that smaller MVs are similar in dimension to the 
upper limit of exosomes. Furthermore, while the expression of membrane proteins is 
technically unique to each subtype – reflecting their compartment of origin, respectively – there 
may be considerable overlap in their cytosolic cargo. For this reason, standard techniques for 
EV isolation and characterisation remain a contested subject among researchers (Gould and 
Raposo, 2013), which is discussed in more detail in section 1.3.5. 
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Figure 1.5. Mechanism of microvesicle release. The shedding of vesicles is under the control 
of a series of membrane protein pumps with antagonistic roles. The stability of resting cells is 
determined by flippase activity, which maintains the internalisation of phosphatidylserine (PS). 
During cell stress, a rise in cytosolic Ca2+ activates floppase (PS specific) and scramblase (non-
specific), which together are responsible for “bidirectional redistribution” of phospholipids. 
Further to this, calcium-dependent remodelling of cytoskeletal proteins will ultimately result 
in membrane instability and subsequent MV release. Where necrosis results in the loss of pan-
membrane integrity, MV shedding may occur in the absence of regulation by membrane 
proteins. Image and text modified from elsewhere (Hugel et al., 2005). 
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1.3.2.  Extracellular vesicles in liver disease 
 
Almost all cell types ubiquitously release extracellular vesicles. In normal physiology, most 
circulating EVs are derived from platelets and endothelial cells, and have been shown to be 
important in common haemostatic events such as coagulation (Lynch and Ludlam, 2007). 
While vesicles of the same origin have been implicated in disease complications of a pro-
coagulative nature (Ogasawara et al., 2005, Stravitz et al., 2013), there is still a paucity of 
knowledge regarding the dynamics of EV secretion by different cell types and in particular 
how the secreted EVs interact to advance the pathogenesis of a given disease.  
 
Controlled in vitro experiments have provided the most direct lines of evidence for EV 
regulation, including how the stimulus for release may affect their phenotype (Bernimoulin et 
al., 2009). There is a wealth of research using liver injury models to explore EV-mediated 
fibrosis (Charrier et al., 2014, Chen et al., 2014, Kornek et al., 2011), transcriptomic signalling 
(Fonsato et al., 2012, Kogure et al., 2011, Kogure et al., 2013, Momen-Heravi et al., 2015, 
Takahashi et al., 2014), and targeted immunotherapy (Lv et al., 2012, Xiao et al., 2013, Zhang 
et al., 2014) in artificial cell culture systems. However, in vivo studies present an added degree 
of complexity due to the difficulty of identifying liver specific EVs within the circulating pool. 
For this reason, most studies have opted to focus on circulating vesicle characterisation and 
their temporal changes in relation to liver disease development (Brodsky et al., 2008, Freeman 
et al., 2014, Li et al., 2015, Sugimachi et al., 2015, Sun et al., 2013, Wang et al., 2014), while 
others have pointed to roles in extrahepatic cancer metastasis to the liver (Costa-Silva et al., 
2015, Eldh et al., 2014, Wang et al., 2015), although direct functional relationships have yet to 
be explored.  
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Some groups have approached the study of EVs from a more organ-targeted perspective, 
assessing their role as paracrine mediators. Most of these studies evaluate the effect of EVs in 
fibrogenesis, for example, the shuttling of pro-fibrogenic connective tissue growth factor 
(CTGF) between hepatic stellate cells on the one hand (Charrier et al., 2014), or the CTGF 
inhibiting miRNA-214 between stellate cells and hepatocytes or adjacent stellate cells on the 
other hand (Chen et al., 2014). Immune-mediated modulation has also been suggested; one 
study had demonstrated a role for T cell-derived EVs in the induction of stellate cell fibrolytic 
activity, as defined by an increase in the gene expression of MMPs (Kornek et al., 2011). The 
findings concluded that this response from the stellate cells was likely mediated by the 
homodimeric interaction of CD147 at the EV-cell interface. A pro-inflammatory glycoprotein, 
CD147 had previously been implicated in liver disease pathogenesis by our group (Calabro et 
al., 2014, Lee et al., 2016) as well as having a well documented role in tumour metastasis, 
which more recently had been attributed to EV-mediated translocation (Millimaggi et al., 2007, 
Sidhu et al., 2004, Zhang et al., 2013).  
 
Secreted vesicles have also been linked to paracrine signalling in the tumour micro-
environment, whereby miRNAs shuttled from hepatoma cells were able to modulate protein 
expression in adjacent hepatocytes and to increase their proliferative potential (Kogure et al., 
2011, Kogure et al., 2013). Silencing of these miRNAs, in turn, had abrogated the pro-
tumorigenic effects, while another study had suggested a role for liver stem cell-derived EVs 
in miRNA-mediated tumour suppression (Fonsato et al., 2012). 
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1.3.3.  Extracellular vesicles in NAFLD 
 
Liver research involving EVs as disease mediators faces a number of inherent challenges. The 
most important of these is finding a link between the circulating EV populations and a specific 
contribution from the liver. From a biomarker perspective, it could be argued that a quantitative 
or phenotypic change in circulating EVs with disease may validate their diagnostic utility, 
especially if these changes are intensified with NAFLD progression. Unfortunately, given the 
complex biological determinants of EV secretion, rather than a linear relationship we are more 
likely to see dynamic responses from different tissues during the course of pathogenesis. For a 
start, NAFLD is not an isolated condition and, generally speaking, occurs as a complication of 
other metabolic disorders where global insulin resistance is also present. Therefore, multiple 
tissues may be affected by the resulting oxidative stress and fatty acid flux, which in turn 
promotes the activation of immune cells and their migration to these sites. Consequently, the 
extrahepatic release of EVs may in fact mask the pathogenesis of NAFLD. For this reason, and 
the lack of a specifically hepatic molecular marker, ideal studies should examine the circulating 
EVs against their liver-derived counterparts, where possible. 
 
1.3.3.1. Rodent studies 
 
The fact that such issues remain to be addressed can be explained by the relative infancy of this 
field of research. To date, there are fewer than a dozen studies to have documented a role for 
EV signalling in a model of NAFLD, the earliest reported as late as 2009 in mice (Deng et al., 
2009a). To better define a role for EVs in the development of hepatic steatosis, researchers 
have sought to replicate the clinical observations in rodent models of NAFLD, simulated by 
administering a choline-deficient diet (CDD) or HFD ad libitum for several weeks, the latter 
of which more accurately reflects the development of human metabolic syndrome. It should 
also be noted, that while CDD animals have comparable liver triglycerides to HFD animals, 
and a much more rapid progression to hepatic fibrosis, other typical changes such as increased 
body weight and fat depots, insulin resistance, and elevated fasting glucose and fatty acids are 
not observed (Raubenheimer et al., 2006). In saying that, contrary to what would be expected, 
EV studies in rodent models of NAFLD showed similar trends for both diets. 
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In the original study, Deng and colleagues described a phenomenon in their chronic HFD model 
whereby circulating EVs that were adoptively transferred to healthy animals were engulfed by 
myeloid cells that subsequently accumulated in the liver (Deng et al., 2009a). This phenotype 
was not observed when EVs were transferred from animals on a normal chow diet, which may 
suggest a selective, EV-driven mechanism for hepatic inflammation as a concomitant to 
steatosis. While these findings are yet to be reproduced, other groups have instead begun to 
more comprehensively examine the profile of circulating EVs to better understand their 
temporal regulation, contents, and possible intervention strategies. Indeed, it was shown that 
vesicles tend to increase on a background of NAFLD, and do so in a time-dependent manner, 
according to data obtained from flow cytometry experiments (Ajamieh et al., 2015, Povero et 
al., 2014, Povero et al., 2013).  
 
To evaluate how the liver contributes to this population, EVs were assessed for their expression 
of miRNA-122, a molecule that is enriched in mammalian livers and is shown to be involved 
in early NAFLD progression (Lagos-Quintana et al., 2002, Barad et al., 2004, Yamada et al., 
2015). Consistent with previous findings, rodent studies confirmed an increase in circulating 
EV-associated miRNA-122 accompanied by a decrease in the liver expression of this molecule 
(Csak et al., 2015, Povero et al., 2014, Povero et al., 2013). Furthermore, one study 
demonstrated that when miRNA-122 was trafficked in EVs, it was not associated with its 
protein binding partner AGO2, a phenomenon that is otherwise typically observed in non-
disease conditions (Povero et al., 2014). While other miRNAs and proteins were not correlated 
against disease severity, Povero and colleagues had employed mass spectrometry to identify 
an EV-specific proteome in NAFLD that was distinct from healthy controls (Povero et al., 
2014). These findings complement a previous study done by the group, in which they confirm 
a role for EV-bound Vanin-1 in hepatocyte vesicle uptake by an endothelial cell line, with 
subsequent angiogenic behaviour that is only observed when EVs are derived from hepatocytes 
subjected to lipotoxic stress (Povero et al., 2013). 
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Taken together, these studies establish a solid foundation for understanding the role of EVs in 
NAFLD, however, some notable limitations exist. Firstly, changes in EV phenotype were not 
correlated against histological severity of liver disease, which would otherwise give some 
insight into their prognostic value. Furthermore, perhaps an emphasis on distinguishing 
NAFLD from other underlying liver pathologies would give EVs a stronger diagnostic utility, 
as had been addressed in clinical studies. A summary of the findings are given in Figure 1.6. 
 
 
 
 
Figure 1.6. Extracellular vesicle roles in NAFLD. EVs are involved in intercellular 
communication within the liver tissue, as well as other tissues involved in mediating NAFLD 
pathogenesis, such as adipose and circulating (later resident) leukocytes. Collectively, these 
EVs are involved in a dynamic response that may exacerbate tissue injury, as well as promoting 
repair and matrix remodelling. Abbreviations: CTGF, connective tissue growth factor; HSC, 
hepatic stellate cell; MMP, matrix metalloproteinase. Image retrieved from (Ban et al., 2016). 
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1.3.3.2. Human studies 
 
The pioneering study to involve human subjects was published three years later by Kornek and 
colleagues, who for the first time had suggested a correlation between the circulating 
abundance of leukocyte-derived EVs and disease severity, as determined by liver transaminase 
levels, biopsy grade, and NAFLD activity score (Kornek et al., 2012). These findings still 
provide the most compelling evidence in clinical samples for the prognostic value of EVs in 
NASH development, and have been extensively cited. The authors have additionally noted a 
distinction between the circulating NAFLD EV profile and that seen in hepatitis C patients. 
This is further supported by another study where transcriptomic analysis revealed that serum 
exosome-derived miRNAs are capable of differentiating multiple aetiologies of liver disease, 
as well as disease from normal liver controls (Murakami et al., 2012). Similar to the first study, 
it was shown that the expression levels of some miRNAs were regulated either positively or 
negatively with histological features of disease, such as inflammation and fibrosis. However, 
these results were limited to the cohort with chronic hepatitis and no such data was available 
for NAFLD progression to NASH. 
 
More recent studies have described the modulation of hepatocyte and stellate cell activity by 
EVs isolated from visceral (peritoneal) adipose tissue. While the subjects did not necessarily 
present with NAFLD, the ex vivo experimental designs instead aimed to establish a role for 
EVs in potentially mediating this disease. As such, Kranendonk and colleagues showed that 
adipocyte EVs from non-obese patients were capable of interfering with insulin signalling and 
gluconeogenesis when directly exposed to a hepatocyte cell line (Kranendonk et al., 2014a). 
Furthermore, the concentration of EVs correlated positively with expression of liver 
transaminases, which supports the evidence for their role in hepatocyte dysfunction. In another 
study, albeit on a smaller scale, adipose tissue isolated from obese patients released EVs in 
culture that subsequently altered the gene expression of a matrix metalloprotease inhibitor, 
TIMP-1, in both hepatocytes and hepatic stellate cells (Koeck et al., 2014). Collectively, these 
findings suggest a novel mechanism of NAFLD pathogenesis by EVs through adipocyte-
mediated hepatic cell stress and tissue remodelling. A summary of findings from both human 
and rodent studies is given in Table 1.5. 
 
 
Table 1.5. Important findings for extracellular vesicles in the context of NAFLD. 
Key study findings Model Injury EV source Methods References 
Increased circulating total EVs Rodent HFD, CDD plasma FC (Ajamieh et al., 2015) 
(Povero et al., 2013) 
(Povero et al., 2014) 
Increased circulating liver-derived EVs 
(marker: miR-122) 
Rodent HFD, CDD plasma, serum RT-qPCR (Csak et al., 2015) 
(Povero et al., 2013) 
(Povero et al., 2014) 
EVs correlate with NAFLD severity Human NASH plasma FC (Kornek et al., 2012) 
EVs distinguish NAFLD from other  
liver diseases 
Human NASH plasma, serum FC, microarray (Kornek et al., 2012) 
(Murakami et al., 2012) 
Changes in circulating EV contents Rodent CDD plasma LCMS, WB (Povero et al., 2013) 
(Povero et al., 2014) 
Changes in circulating EV interactions 
with cells 
Rodent HFD plasma FC (Deng et al., 2009a) 
 
CDD, choline deficient diet; EV, extracellular vesicle; FC, flow cytometry; HFD, high-fat diet; LCMS, liquid chromatography with mass 
spectrometry; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; RT-qPCR, real-time quantitative polymerase chain 
reaction; WB, western blot.  
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1.3.4.  Translational utility 
 
With the urgency to develop a non-invasive biomarker for the diagnosis and staging of 
NAFLD, research into the biology of extracellular vesicles has provided an opportunity to 
explore a novel mechanism of disease pathogenesis that can also be harnessed as a clinical tool. 
However, there is still a long way to go before EV-related assays will have translational utility. 
Besides the obvious question of disease and tissue specificity, current techniques used in the 
isolation and characterisation of EVs remain laborious, and suffer from a lack of 
standardisation as well as high variability (detailed further in section 1.3.5). It will undoubtedly 
take a few years before the processing of EVs from blood and other bodily fluids as liquid 
biopsies becomes economically viable, reproducible and validated. Until then we are unlikely 
to see their use in routine clinical practice. 
 
The concept of analysing EVs in the context of NAFLD is still very much a small niche in the 
literature. One reason could be the limitations mentioned above, or a focus on more accessible 
biochemistries such as liver transaminases and soluble miRNA-122. But then why look at 
circulating EVs? Perhaps the answer lies in their active role in disease; they may not only 
confirm the presence of NAFLD, but also give an insight into which tissues are interacting and 
how this is driving pathogenesis. It has been shown that adipose tissue EVs taken from obese 
individuals are capable of signalling to hepatic cells to remodel their extracellular milieu, while 
these cells in turn may communicate via EVs with the sinusoid to promote angiogenesis (Koeck 
et al., 2014, Povero et al., 2013). Circulating vesicles have also been implicated in the innate 
immune response that accompanies steatosis, pointing to a role in the progression from early 
NAFLD to NASH (Deng et al., 2009a, Kornek et al., 2012). From a physiological perspective, 
it makes sense to encapsulate certain molecules that are otherwise prone to enzymatic 
degradation, especially in a complex or unpredictable disease environment. However, if 
preservation of these molecules within EVs leads to a heightened stimulation of inflammatory 
cells, as previously suggested, this mechanism may in turn be responsible for the exacerbation 
of tissue injury. 
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1.3.4.1. EVs in NAFLD treatment 
 
The multifaceted nature of EVs suggests that these structures may have potential value beyond 
their use as circulating biomarkers in NAFLD. For instance, cancer studies have explored the 
transfer of oncogenes and an oncogenic phenotype through EV uptake in cell culture models 
(Bergsmedh et al., 2001, Redzic et al., 2013, He et al., 2015), which may provide a target for 
therapeutic intervention. Indeed, it was shown that incubating hepatoma cells with various anti-
cancer drugs promoted the secretion of immunogenic EVs that were capable of enhancing 
natural killer (NK) cell responses (Lv et al., 2012, Xiao et al., 2013). Conversely, exposing 
macrophages to such drugs may induce the release of EV-derived miRNAs, which suppress 
cancer growth by epigenetic regulation (Zhang et al., 2014). This concept has been extended 
to NAFLD models, where it was found that administering cholesterol-lowering drugs to high-
fat fed rodents can attenuate the release of EVs, however the exact implication of this was not 
discussed, except for a potential reduction in liver cell death (Ajamieh et al., 2015, Baron et 
al., 2011).  
 
Another approach is to use the vesicles themselves as a mode or target of therapy, not simply 
a marker of injury. This idea has been investigated since the late 1980s, whereby synthetic 
vesicles were used as a vehicle for drug delivery in both in vitro and in vivo models of liver 
injury (Farazuddin et al., 2014, Laakso et al., 1988). It is also possible that in the future, 
endogenous EVs may be harvested for similar purposes, providing an efficient technique for 
tissue-specific delivery of molecules. The advantage of this autologous transfer system is that 
the vesicles are less likely to be rejected by the patient, however still sufficiently immunogenic 
to elicit a response (Deng et al., 2009a). 
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1.3.5.  EV analysis 
 
Independently of the EV isolation process, there are a number of considerations with regard to 
sample handling that may affect both the quality and the yield of EVs. For instance, blood 
samples are particularly sensitive to the presence and activity of platelets. Serum tends to 
harbour more EVs than plasma, which are produced during clot formation ex vivo following 
blood collection. Therefore, the use of anticoagulants is recommended for EV based studies, 
however attention must be given to the type of anticoagulant if downstream mechanisms are to 
be considered (for example, the use of chelators such as EDTA are incompatible with the study 
of metalloproteases in EV samples). Heparin is typically discouraged as it interferes with EV 
activity and also acts as a competitive inhibitor during PCR. Finally, diurnal variation and 
fasting status have also been shown to confound EV analyses, which further emphasises the 
importance of consistency in sample collection and handling. 
 
Due to the complexity of EV samples, a number of different isolation methods have been 
developed to accommodate sample type as well as effect on downstream measurements. The 
most frequently cited are described in Table 1.6. For most EV researchers, ultracentrifugation 
following differential spins to eliminate debris seems to be the mainstay, as sample yield is 
maintained and no additional contaminants are introduced. However, this method also suffers 
from potential contamination by lipoproteins and protein aggregates when compared to some 
of its more stringent counterparts, and is often referred to as a “crude” sample. For practical 
purposes and also considering utility for downstream applications, the studies in this thesis 
have used an amended ultracentrifugation protocol (see section 2.4.1. for details). 
 
There is no single predominating technique for the characterisation of EVs (Table 1.6), with 
researchers often using multiple complementary analyses to establish the presence of EV 
subtypes or to enumerate the total population per sample. Traditionally, flow cytometry was 
used to confirm both outcomes, however given the limitations of conventional cytometers for 
EV analysis, a combination of western blot and an optical technique (single particle tracking 
or electron microscopy) may be more robust.  
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Table 1.6. Popular methods of EV sample processing. 
Method Freq, % Features 
Isolation:   
Ultracentrifugation 81 Spin 100,000 – 120,000ൈg after depletion of 
larger fragments (10,000 – 20,000ൈg) 
Density gradient 
centrifugation 
20 Spin through density gradient to separate EVs 
(1.1 – 1.2 g/mL) from contaminants, usually 
overnight 
Filtration 18 Pass through membrane with specific pore 
size, larger fragments trapped on filter 
Size-exclusion 
chromatography 
15 Pass through resin column based on hydro-
dynamic radius, eluted by decreasing size 
Precipitation 14 Polymer-based EV agglutination, usually with 
polyethylene glycol (PEG) 
Immunoaffinity capture 9 Antibody-coated magnetic beads specific to 
EV surface markers 
Characterisation:   
Western blot 74 Protein analysis of typical EV markers 
Single particle tracking 
 NTA 
 TRPS 
 DLS 
72 Optical methods for intact sample 
enumeration, particle sizing, and assessment 
of particle polydispersity 
Electron microscopy 60 Visualisation of EV ultrastructure 
Flow cytometry 
 Direct 
 Immunoaffinity 
41 Protein analysis of EV surface markers with 
quantitation based on particle or bead count 
(cf. protein concentration) 
Protein assay 35 Total or specific protein concentrations 
Atomic force microscopy 9 Cantilever probe scans sample surface to 
determine ultrastructure (nanometre scale)  
 
Popularity (frequency %) determined by a survey of the ISEV community (n=196) reported in 
J Extracell Vesicles (2016) (Gardiner et al., 2016). Additional information sourced from 
(Witwer et al., 2013) and (Taylor and Shah, 2015). Abbreviations: NTA, nanoparticle tracking 
analysis; TRPS, tuneable resistive pulse sensing; DLS, dynamic light scattering. 
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1.4.  Study Aims 
 
The work presented in this thesis aims to evaluate the links between NAFLD pathogenesis and 
the patterns in extracellular vesicle secretion. The studies have been designed to not only 
address some caveats in the literature – for instance, the lack of tissue-derived EV samples used 
in analyses – but also to further understand the role that EVs play in NAFLD development in 
vivo, and ultimately whether they are a useful predictor of disease severity. 
 
1.4.1.  Changing EV profile with NAFLD progression 
 
The aim of Chapter 3 is to optimise some conventional techniques used in EV isolation from 
plasma and conditioned media, and to examine the characteristics of these EVs in the context 
of our study design. The chapter will introduce the high-fat feeding rodent model of NAFLD, 
focussing on the two extremes of the disease spectrum: simple steatosis and NASH. These 
groups will be distinguished by duration of diet, without intervention to accelerate or impede 
NAFLD development. Chapter 4 aims to expand on the previous chapter, with the addition of 
intermediate timepoints to monitor longitudinal changes in the EV profile with NAFLD 
progression. This study will more comprehensively analyse the liver phenotype and pre-clinical 
parameters, and characterise in detail the proteome of liver-derived EVs. 
 
Hypothesis 1: Vesicles isolated from plasma and liver-conditioned media by differential 
centrifugation are expected to express markers that are specific to EV subtypes, and have a size 
range that is typically reported for EVs (50nm to 1m).  
 
Hypothesis 2: An obesogenic high-fat diet (HFD) will induce NAFLD, while its chronic 
consumption will promote development to NASH. Changes in the liver will be reflected in the 
EV abundance and phenotype: it is expected that circulating and liver EV numbers will increase 
with NAFLD and be further elevated by NASH, while the EV proteome will reflect the 
microenvironment of the parent tissue. 
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1.4.2.  Effect of NAFLD intervention on EV profile 
 
Two intervention modalities will be introduced in Chapter 5. In the genetic manipulation arm, 
global deletion of TNF expression will be used to examine how disrupting a key inflammatory 
pathway that also affects insulin resistance may change the NAFLD phenotype and hence the 
corresponding EV profile. For the second aim, exercise interventions in the form of endurance 
or high-intensity training will evaluate not only the optimal program for NAFLD regression, 
but also whether such a treatment will normalise the EV patterns to that of healthy controls. 
All intervention studies will be completed using mouse models, in line with previous chapters. 
 
Hypothesis 3: Animals lacking TNF expression will have increased insulin sensitivity. 
Therefore, the rate of NAFLD development is expected to be reduced and consequently, EV 
abundance may be decreased. 
 
Hypothesis 4: Animals that consume HFD but undergo exercise training will have improved 
metabolic parameters and reduced NAFLD burden. Since exercise also liberates EVs, the 
change in abundance cannot be predicted, however the molecular cargo in EVs of exercised 
animals is expected to promote NAFLD regression. 
  
1.4.3.  Functional studies on the effects of NAFLD-derived EVs 
 
Finally, the effect of EV-cell interactions will be highlighted in Chapter 6. Vesicles obtained 
from either plasma or liver tissue from the aforementioned studies will be co-cultured with a 
mouse hepatocyte cell line in an aim to determine the specific hepato-modulatory effect of 
EVs. Whether the dietary background influences EV uptake will also be explored, as well as 
changes in cellular gene expression after incubation with various EV populations. 
 
Hypothesis 5: Circulating or liver-derived EV populations will be taken up by recipient cells 
and impart molecular signals that either mediate NAFLD progression (EVs from HFD mice, 
especially those with NASH) or are hepatoprotective (EVs from exercised mice). 
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Materials & Methods 
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2.1.  Materials 
 
Table 2.1. Reagents used in this study. 
 
Reagent Manufacturer or supplier 
Animal models:  
AIN-76 mineral mix MP Biomedicals, Santa Ana, CA, USA 
AIN-76 vitamin mix MP Biomedicals, Santa Ana, CA, USA 
bovine serum albumin Sigma-Aldrich, St. Louis, MO, USA 
canola oil Coles Supermarkets, Melbourne, VIC, Australia 
cholesterol Sigma-Aldrich, St. Louis, MO, USA 
choline bitartrate Sigma-Aldrich, St. Louis, MO, USA 
DMEM, high glucose Sigma-Aldrich, St. Louis, MO, USA 
formaldehyde Sigma-Aldrich, St. Louis, MO, USA 
gelatine (McKenzie’s) Coles Supermarkets, Melbourne, VIC, Australia 
insulin (human, Actrapid) Novo Nordisk, Bagværd, Denmark 
lactic acid casein Rogers & Co. Foods, Hampton, VIC, Australia 
lard (Yorkfoods) Coles Supermarkets, Melbourne, VIC, Australia 
methionine Sigma-Aldrich, St. Louis, MO, USA 
oat bran  Coles Supermarkets, Melbourne, VIC, Australia 
starch, from rice MP Biomedicals, Santa Ana, CA, USA 
sucrose Sigma-Aldrich, St. Louis, MO, USA 
 
Plasma biochemistry: 
 
glycerol standard solution Sigma-Aldrich, St. Louis, MO, USA 
rat/mouse insulin ELISA kit Merck, Darmstadt, Germany 
serum triglyceride determination kit Sigma-Aldrich, St. Louis, MO, USA 
 
EV isolation (western blot): 
 
Clarity™ ECL Western Blotting Substrate Bio-Rad Laboratories, Hercules, CA, USA 
DC™ Protein Assay kit Bio-Rad Laboratories, Hercules, CA, USA 
glacial acetic acid Thermo Fisher Scientific, Waltham, MA, USA 
glycerol Thermo Fisher Scientific, Waltham, MA, USA 
goat anti-rabbit IgG Sigma-Aldrich, St. Louis, MO, USA 
Mini-PROTEAN® TGX™ Precast Gels Bio-Rad Laboratories, Hercules, CA, USA 
Ponceau S powder Sigma-Aldrich, St. Louis, MO, USA 
Precision Plus Protein™ Dual Color Standards Bio-Rad Laboratories, Hercules, CA, USA 
rabbit anti-mouse CD63 Sigma-Aldrich, St. Louis, MO, USA 
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skim milk powder Coles Supermarkets, Melbourne, VIC, Australia 
sodium chloride Sigma-Aldrich, St. Louis, MO, USA 
sodium deoxycholate Sigma-Aldrich, St. Louis, MO, USA 
sodium dodecyl sulphate Sigma-Aldrich, St. Louis, MO, USA 
Trans-Blot® Turbo™ Mini Nitrocellulose Bio-Rad Laboratories, Hercules, CA, USA 
Tris-HCl Sigma-Aldrich, St. Louis, MO, USA 
Triton X-100 Sigma-Aldrich, St. Louis, MO, USA 
Tween 20 Sigma-Aldrich, St. Louis, MO, USA 
UltraPure™ Tris base Invitrogen, Carlsbad, CA, USA 
  
EV isolation (flow cytometry):  
AbC™ Antibody Compensation Bead Kit Thermo Fisher Scientific, Waltham, MA, USA 
APC conjugation kit Abcam, Cambridge, UK 
APC-annexin V BioLegend, San Diego, CA, USA 
APC-CD105 antibody Miltenyi Biotec, Bergisch Gladbach, Germany 
APC-CD41 antibody Miltenyi Biotec, Bergisch Gladbach, Germany 
ASGR1/ASGPR1 antibody R&D Systems, Minneapolis, MN, USA 
calcein AM fluorescent dye Biotium, Fremont, CA, USA 
PE-CD63 antibody BioLegend, San Diego, CA, USA 
PerCP/Cy5.5-CD45 antibody BD Biosciences, San Jose, CA, USA 
 
Liver lipid content: 
 
chloroform Thermo Fisher Scientific, Waltham, MA, USA 
ethanol Sigma-Aldrich, St. Louis, MO, USA 
isopropanol Sigma-Aldrich, St. Louis, MO, USA 
methanol Thermo Fisher Scientific, Waltham, MA, USA 
Oil Red O BDH Laboratory Supplies, Poole, UK 
saline, irrigation 0.9% Baxter International, Deerfield, IL, USA 
TAG reagent Roche Diagnostics, Basel, Switzerland 
 
Liver gene expression: 
 
First Strand cDNA synthesis kit Invitrogen, Carlsbad, CA, USA 
glycogen (from mussel) Sigma-Aldrich, St. Louis, MO, USA 
primers, SYBR format Sigma-Aldrich, St. Louis, MO, USA 
SensiMix SYBR Hi-ROX Bioline Reagents, London, UK 
SuperScript III reverse transcriptase Invitrogen, Carlsbad, CA, USA 
TRI Reagent Sigma-Aldrich, St. Louis, MO, USA 
trimethylene bromochloride Sigma-Aldrich, St. Louis, MO, USA 
 
 
 
 
 
46 
Cell culture: 
CFSE Cell Division Tracker kit BioLegend, San Diego, CA, USA 
foetal bovine serum AusGeneX, Molendinar, QLD, Australia 
Gibco™ DMEM:F12 media Thermo Fisher Scientific, Waltham, MA, USA 
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2.2.  Animal Models 
 
All animals used in this study were housed in pathogen-free conditions on site, at the animal 
facilities of Royal Prince Alfred Hospital (RPAH), Centenary Institute, or Charles Perkins 
Centre (CPC), Sydney, Australia. Experimental protocols were approved by the Animal Ethics 
Committees of Sydney South West Area Health Services and/or the University of Sydney, 
Australia (RPAH Protocol No. 2011/004D and 2015/024; CI Protocol No. 2015/005; CPC 
Protocol No. 2015/816). Male C57Bl/6 mice were purchased at age 5 weeks from the Animal 
Resources Centre (ARC), Perth, Australia. Studies commenced promptly after a one week 
acclimation period, or 5 week period for the exercise intervention study.  
 
Genetically modified strains on a C57Bl/6 background were bred on site at the Centenary 
Institute animal facility by Miss Christine Yee. A global deletion model for tumour necrosis 
factor (TNF-/-) (Korner et al., 1997) was used to investigate the effect of perturbing an 
inflammation and insulin resistance pathway in the development of obesity-associated 
NAFLD. Controls for TNF-/- animals were age-matched, C57Bl/6 wild-type mice purchased 
from ARC. Both groups received dietary intervention only, for 12 weeks.  
 
2.2.1.  Dietary Model of NAFLD 
 
A modified high-fat diet (HFD) was used for these studies as it is reflective of clinical NAFLD 
development associated with obesity and metabolic syndrome (Ito et al., 2007, Lo et al., 2011). 
The HFD, containing approx. 45% calories from fat and 0.5% cholesterol (non-atherogenic), 
was prepared in-house and adapted from protocol D12451 provided by Research Diets (New 
Brunswick, NJ). See Table 2.2 for a complete list of ingredients and their caloric contribution. 
For all studies, HFD groups were compared against a control group (matched for age, sex and 
strain) receiving standard laboratory chow (maximum 12% calories from fat). Given the slow 
development of NAFLD as compared to other liver diseases, or alternatively, the longer time 
needed to advance to an inflammatory stage (NASH), an extended time course of up to 52 
weeks of HFD was used for some experiments. The details of the time course studies are 
outlined in Figure 2.1 and again in the relevant chapters. 
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Table 2.2. Modified high-fat diet recipe with added cholesterol. 
 
Ingredient Weight  
(g) 
Cholesterol  
(g) 
Calories  
(kCal) 
Calories  
(%) 
sucrose 224  896 Carbohydrate 
(32.6) starch (from rice) 215  860 
casein 261  1044 Protein 
(20.4) vitamin mix 15  60 
mineral mix 51    
bran 57    
gelatine 23    
methionine 3.4    
choline bitartrate 4.6    
vegetable oil 32  284 Fats/esters 
(47.0) lard (from pork) 250 0.2 2250 
cholesterol 6.0 6.0   
TOTAL 1142 6.2   
 
Final concentration of cholesterol per batch is 0.54% w/w. Total weight excludes sweetened 
condensed milk (approx. 1 Tbsp) added as flavouring, therefore its caloric value is disregarded. 
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A Chapter 3: pilot study 
 
 
 
B Chapter 4: progression study 
 
 
 
C Chapter 5.2: genetic manipulation study 
 
 
 
Figure 2.1. Time course and animal numbers for NAFLD models. For all studies, mice were 
fed either a high-fat diet (HFD) or standard laboratory chow for a specified period. These 
periods are represented by arrows, drawn to scale, containing the sample size for both 
treatments at each timepoint. In Chapter 5, the time course was a single duration: 12 weeks for 
the genetic manipulation study, 20 weeks for the exercise intervention study (the latter detailed 
in Figure 2.2). 
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2.2.2.  Exercise Intervention 
 
To counteract the impact of obesity development using a clinically relevant model without drug 
intervention, two isocaloric exercise regimens were administered and compared to an untrained 
condition (Figure 2.2). After an initial 9 weeks of dietary intervention (as above), mice were 
acclimatised to a level treadmill over 1 week (6 m/min for 10 min) prior to completing a test 
for maximal running capacity (MRC). For the test, animals were exercised to exhaustion, where 
the average MRC was determined for each dietary cohort (chow: 27 m/min, HFD: 21 m/min). 
For the following 10 weeks, mice were trained three times per week on alternating days while 
maintaining their original diet. Each session lasted a total of 40 min with varying degrees of 
aerobic intensity: animals from each diet group were randomly assigned to either an endurance 
training (END) regimen where they were subjected to a constant 70% MRC, or high-intensity 
interval training (HIIT) with alternating 85-90% and 50% MRC in 5 min cycles. Untrained 
groups for each diet acted as controls and were not subjected to further exercise. For ethical 
reasons, animals that failed to perform the MRC test were withdrawn from the study.  
 
The animals described here were part of another study investigating the impact of exercise 
intervention on muscle function. The exercise protocols for this study were developed and 
performed by Sergio Martinez-Huenchullan. Blood and liver samples from these animals were 
obtained by the author of this thesis and were processed for isolation of EVs and analysis of 
NAFLD according to the methods described herein. Results of the liver changes have 
contributed to the publication.  
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A Chapter 5.3: exercise intervention study 
 
 
 
B Exercise intensity during training session 
 
 
Figure 2.2. Exercise intervention study design. (A) Time course for the study, including a diet 
duration of 20 weeks with the exercise program (END, endurance training; HIIT, high-intensity 
interval training) commencing at the halfway point, after 10 weeks. Animals were maintained 
on the same diet for the duration of the study. Discrepancies in sample size from week 10 to 
20 are due to animals being withdrawn from the study if they failed to complete the maximal 
running capacity (MRC) test. (B) Graphical representation of exercise intensity for END and 
HIIT groups during the training sessions. Percentage MRC is relative to the average MRC 
determined for each dietary group (chow: 27 m/min, HFD: 21 m/min). NB: The study design 
represented here was developed by Sergio Martinez-Huenchullan. 
  
 ( 
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2.2.3.  Insulin tolerance test (ITT) 
 
To monitor the effect of HFD on whole-body insulin sensitivity, all animals in the progression 
study (Chapter 4) and exercise intervention study (Chapter 5.3; see below for further details) 
were subjected to an insulin tolerance test in the penultimate week of the respective study. Mice 
were fasted minimum 4 hours prior to an intraperitoneal injection of human insulin (Actrapid, 
Novo Nordisk, Bagværd, Denmark) at a dose of 0.65IU/kg. Blood glucose levels were 
monitored at baseline, then at 5, 15, 30, 60 and 90 min post-injection by collecting blood from 
the tail vein using a blood glucose monitoring system (FreeStyle Lite, Abbott Diabetes Care, 
Alameda, CA). Hypoglycaemic animals were rescued with a 100L intra-peritoneal injection 
of 50% w/v glucose. Insulin sensitivity represented by blood glucose excursion was calculated 
as area under the curve (AUC), and excluded rescued animals (maximum n=2). 
 
2.2.4.  Tissue collection 
 
All animals were weighed at the beginning of the experiment and weekly until termination, 
where they were anaesthetized by inhaled isoflurane prior to exsanguination by cardiac 
puncture. Blood was collected into blood tubes containing 3.2% w/v sodium citrate (Greiner 
Bio-One, Kremsmünster, Austria), which typically recovered approximately 0.5mL plasma 
volume following a 3000ൈg spin for 15 min. Livers were excised and weighed, then portions 
of tissue were either i) snap-frozen in liquid nitrogen and stored at -80oC until further use, ii) 
fixed in 10% neutral buffered formalin for 24 hr and then 70% ethanol prior to paraffin 
embedding, or iii) sections from the right lobe were isolated into phosphate buffered saline 
(PBS) for study of liver-derived EVs. For experiments pertaining to the latter, the right lobe 
(chow: 453±131mg, HFD: 726±225mg in progression study) was diced into approx. 10-20mm3 
segments and immersed in 1.5mL filtered Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 0.1% bovine serum albumin (BSA), as exemplified in Figure 2.3. Diced 
livers were incubated overnight at 37oC in 5% CO2 before collection of conditioned medium 
for isolation of EVs. Liver slices were weighed for normalisation of EV numbers. (Note that 
incubating whole-tissue for EV collection has been performed previously on adipose tissue 
(Koeck et al., 2014, Kranendonk et al., 2014b) but not liver, whereas the validity of incubating 
liver tissue slices has been reviewed (Li et al., 2010)). 
 
 
 
53 
 
A 
 
 
B Extracellular vesicle isolation 
 
 
 
Figure 2.3. Tissue culture of liver slices and EV isolation. (A) Representative liver slices from 
animals fed standard chow (top row) or high-fat diet (bottom row) immersed in DMEM media 
prior to overnight incubation. (B) Conditioned media was collected for extracellular vesicle 
(EV) isolation by a series of differential centrifugation steps (see section 2.4.1). 
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2.3.  Plasma Biochemistry 
 
Whole blood collected at termination was centrifuged at 800ൈg for 15 min to obtain the plasma 
fraction, which was used for biochemical analysis and EV isolation (see section 2.4). Plasma 
insulin was measured with an enzyme-linked immunosorbent assay (ELISA) kit (Merck, 
Darmstadt, Germany) while total triglycerides were quantified using an enzymatic assay 
(Sigma-Aldrich, St. Louis, MO), both according to manufacturers’ instructions. To obtain the 
standard liver function test (LFT) panel, samples were submitted to the Chemical Pathology 
Laboratory of the NSW Health Pathology Facility at Royal Prince Alfred Hospital for 
processing using a Roche Cobas IT-3000 auto-analyser. 
 
2.3.1.  Circulating insulin 
 
All reagents necessary to perform the ELISA were provided in the kit (see Table 2.1) and 
prepared following the manufacturer instructions. Rat insulin standards were used to generate 
a dilution curve (0-10ng/mL), and were compared against two quality controls (QC). The assay 
was sandwich format; 10L of either standard, QC or plasma sample (diluted 2-fold) was added 
to the insulin antibody-coated well, followed by 80L detection antibody (biotinylated anti-
insulin). After 2 hr incubation, unbound substances were washed off and bound antibody was 
conjugated with an enzyme (horseradish peroxidase) for a further 30 min. Assays were washed 
again, before addition of substrate (3,3’,5,5’-tetramethylbenzidine), which reacted rapidly with 
immobilised antibody-enzyme conjugates. Finally, the reaction was stopped by acidification 
and absorbance of the coloured product was determined spectrophotometrically at wavelength 
450nm, corrected to 590nm. The dilution curve was then used to determine the QC and sample 
insulin concentrations. 
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2.3.2.  Circulating triglycerides 
 
Components of the working solution (free glycerol and triglyceride reagents) were provided in 
the kit (see Table 2.1), while the 2.5mg/mL glycerol standard solution was purchased 
separately (Sigma-Aldrich, St. Louis, MO). The assay was performed following the protocol 
for determination of total triglycerides (B1) supplied by the manufacturer, with modification. 
Briefly, free glycerol reagent and triglyceride reagent were combined in a 4:1 ratio to prepare 
the working solution, then incubated with blank (water), glycerol standard, or neat plasma 
samples using a 1:100 dilution. For instance, 2.5L sample was diluted in 250L working 
solution in a 96-well plate format. Following a 15 min incubation at room temperature, during 
which time triglycerides were enzymatically converted to a quinoneimine dye (triolein), the 
absorbance of coloured product was determined at wavelength 540nm. Total triglyceride 
concentration was then calculated using the formula given below, where TAG represents 
triglycerides and ABS is absorbance. 
 
 
TAG  =  [standard]  * 
ABSsample – ABSblank 
ABSstandard – ABSblank 
 
 
2.3.3.  Liver function tests 
 
Reports for LFT panels were generated for standard clinical biomarkers using assays validated 
for human samples. The plasma biomarkers included bilirubin, albumin, protein, gamma-
glutamyl transferase (GGT), alkaline phosphatase (ALP), alanine transaminase (ALT) and 
aspartate transaminase (AST). However, our study focused on the latter two parameters as these 
are the predominantly assessed markers of hepatocellular injury in the clinic, and were most 
affected by our dietary intervention. 
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2.4.  Extracellular Vesicle Isolation 
 
There is no consensus in the literature regarding the isolation of extracellular vesicles, and 
oftentimes the technique depends on the downstream application. A lack of standard protocols 
for the isolation and characterisation of EVs is a caveat that is recognised by the EV research 
community, with guidelines published by the International Society of Extracellular Vesicles 
(Witwer et al., 2013) which have aimed to address this problem. The original and most 
frequently cited technique is still differential centrifugation (see Chapter 1 section 1.3.5). Here, 
the EV fraction is retrieved by a final ultracentrigation step of 100,000 – 200,000ൈg and may 
be further purified by centrifugation through a density gradient, such as with sucrose. This 
study used a basic protocol of “crude” EV isolation modified from a previously described 
protocol (Thery et al., 2006). 
 
2.4.1.  Differential centrifugation 
 
EVs were collected as described earlier (see section 2.2.4). Conditioned media from tissue-
derived vesicles were first cleared of larger cell debris with a 10 min spin at 2,000ൈg. The 
supernatants from these spins, as well as the plasma samples (recovered as per section 2.2.4), 
were then centrifuged at 4oC for 30 min at 10,000ൈg to clear platelets and apoptotic bodies. 
Finally, supernatants were transferred to a hard-walled polypropylene microfuge tube 
(Beckman Coulter, Brea, CA) and EVs were pelleted by ultracentrifugation at 4oC for 1 hr at 
100,000ൈg before resuspending in equal volume filtered PBS (50L for plasma, 100L for 
conditioned media). To maintain stability of their ultrastructure and cargo, EVs were stored at 
-80oC either after the final spin (pilot study) or after the 10,000ൈg spin. For the latter, samples 
were thawed, followed by ultracentrifugation and same-day characterisation. 
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2.4.2.  Transmission electron microscopy 
 
To confirm the presence of EVs, and to determine whether their ultrastructure is changed with 
diet, transmission electron microscopy (TEM) was performed on EV suspensions. Briefly, 
samples were diluted 10-fold and 20L drops were placed on 400-mesh formvar-coated copper 
grids (ProSciTech, Kirwan, QLD, Australia). After drying overnight at room temperature, 
adhered samples were stained with a 2% w/v uranyl acetate solution for 2 min then dabbed dry 
from the edges, before visualising on a JEOL 1400 TEM instrument at the Sydney Microscopy 
and Microanalysis facility, Australian Centre for Microscopy and Microanalysis, University of 
Sydney. Setup and visualisation were performed according to the instrument operation manual, 
with power set to 120kV. Sample magnifications are given with images in the Results section 
(see Chapter 3). 
 
2.4.3.  Validation by western blot 
 
To confirm that samples were enriched with EVs and void of other contaminants, plasma and 
liver-derived EVs were compared against their corresponding liver lysate for positive staining 
of the exosomal marker CD63. Representative samples were diluted in RIPA solubilisation 
buffer (modified from Bio-Rad Buffer Formulations, bulletin 6199; with 10% glycerol) before 
protein quantification using the DC™ Protein Assay kit (Bio-Rad Laboratories, Hercules, CA) 
following the manufacturer instructions. Equal concentration protein (40g) was diluted in 4X 
loading buffer prepared in-house, and loaded into a precast polyacrylamide gel (4-15% Mini-
PROTEAN® TGX™ Precast Protein Gels; Bio-Rad Laboratories) with a molecular weight 
ladder (Precision Plus Protein™ Dual Color Standards; Bio-Rad Laboratories) and run at 120V 
until adequate separation. Protein was transferred at 25V for 7 min to a membrane (Trans-
Blot® Turbo™ Mini Nitrocellulose; Bio-Rad Laboratories) before staining with Ponceau S 
solution (0.5% w/v in 5% glacial acetic acid) to determine transfer efficiency. Given the lack 
of a universal loading control between EVs and tissue lysates, total protein staining with 
Ponceau S was instead used for normalisation. 
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Following SDS-PAGE and sample transfer, the membrane was blocked in 5% w/v skim milk 
power dissolved in TBST buffer (Tris-buffered saline with 0.5% v/v Tween-20) for 1 hr, then 
washed 3 times for 10 min each in TBST buffer. Primary antibody (rabbit anti-mouse CD63; 
Sigma-Aldrich, St. Louis, MO) was diluted 1:500 in TBST with 0.5% w/v skim milk powder 
and incubated with the membrane overnight at 4oC. After washing as above, the membrane 
was incubated with secondary antibody (goat anti-rabbit IgG, peroxidase conjugated; Sigma-
Aldrich) for 2 hr. Following a final wash, the membrane was immersed in chemiluminescent 
substrate (Clarity™ ECL Western Blotting Substrate; Bio-Rad Laboratories) to resolve bands 
on a ChemiDoc™ Imaging System with ImageLab™ software (Bio-Rad Laboratories) for 
sample analysis. The CD63 protein band was expected to resolve at 26kDa (native) or 40-
60kDa (glycosylated). BSA alone was used as a negative control. 
 
2.4.4.  Nanoparticle tracking analysis 
 
Routine enumeration and size distribution of EVs was measured using a NanoSight™ LM10 
instrument (Malvern Panalytical, Malvern, UK) with Nanoparticle Tracking Analysis (NTA) 
software version 2.4 provided by the Molecular Biology Facility of Bosch Institute, University 
of Sydney. The technology utilises the Brownian motion of particles in solution to determine 
size, and thus allows concentrations with respect to size to be calculated by the software. Since 
the machine uses a laser to illuminate particles, all experiments were recorded in the dark. 
Samples in PBS were further diluted to reach an optimal recording concentration of 50-100 
particles per frame, as recommended by the manufacturer. The use of inconsistent dilutions 
was validated by performing dilution curves with either polystyrene beads of known diameter, 
or with EV samples (see Chapter 3). Optimal resolution of particles was achieved by adjusting 
the camera level to 13 during recording (most optimal shutter speed and gain), while a detection 
threshold of 5 was determined to be most sensitive for particle enumeration. 
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2.4.5.  Characterisation by flow cytometry  
 
To examine the utility of flow cytometry for the characterisation of EVs isolated in our study, 
samples were stained with typical markers for cell origin (Ban et al., 2016) and analysed by 
standard cytometry with modified staining protocols.  
 
Using bead-based sample precipitation modified from (Thery et al., 2006) and (Inglis et al., 
2015), polystyrene beads (AbC™ Total Antibody Compensation Bead Kit, Thermo Fisher 
Scientific, Waltham, MA) were used to adsorb 10L EVs overnight at 4oC, prior to blocking 
with 5% w/v BSA or 100mM glycine (1 hr on shaker) and staining with a single antibody of 
interest, together with calcein AM dye (Biotium, Fremont, CA), for 30 min with shaking. Finally, 
stained bead-EV samples were collected by centrifugation at 250ൈg for 5 min. In a parallel 
experiment, individual EVs (no beads) were diluted 1:10 and blocked as above, then stained 
overnight at 4oC before precipitation with polyethylene glycol (final concentration 10% v/v) 
for 2 hr on ice. Precipitated stained EVs were then collected by centrifugation at 3,000ൈg for 
10 min (Weng et al., 2016). Both methods allowed for the removal of residual antibody that 
may contribute to background fluorescent signals. Finally, samples were resuspended in 200L 
PBS before reading on a Guava® easyCyte flow cytometer with Guavasoft InCyte software 
(Merck, Darmstadt, Germany) at the Bosch Institute, University of Sydney. 
 
Antibodies used in this study were diluted as per Table 2.3 in filtered PBS with 0.5% w/v BSA 
prior to staining. They were specific for either platelets (CD41), endothelial cells (CD105), 
leukocytes (CD45), or hepatocytes (ASGPR1). The latter antibody was conjugated in-house 
using an APC conjugation kit (Abcam, Cambridge, UK). To discern the EV subtypes, reagents 
specific to microvesicles (annexin A5) or exosomes (anti-CD63 antibody) were co-incubated 
per sample. Compensation was performed using EVs stained with a single antibody or dye 
(individual method), or beads adhered to a single antibody as per the manufacturer instructions 
(bead-based method). For troubleshooting and gating strategies, see Chapter 3. 
 
 Table 2.3. Anti-mouse antibodies used for EV characterisation by flow cytometry. 
 
Target Antibody clone Conjugate Source Dilution: 
bead method 
Dilution: 
individual method 
PS annexin A5* APC BioLegend - 1:5,000 
CD63 NVG-2 PE BioLegend - 1:5,000 
CD41 MWReg30 APC Miltenyi Biotec 1:10 1:5,000 
CD105 MJ7/18 APC Miltenyi Biotec 1:10 1:5,000 
CD45 30-F11 PerCP/Cy5.5 BD Biosciences 1:50 1:5,000 
ASGPR1 polyclonal APC R&D Systems 1:50 1:5,000 
 
*Not antibody format. Abbreviations: APC, allophycocyanin; ASGPR1, asialoglycoprotein receptor 1; PE, phycoerythrin; PerCP, peridinin 
chlorophyll; PS, phosphatidylserine. 
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2.4.6.  Characterisation by mass spectrometry 
 
Liver-derived EVs from 10 and 50 weeks of either diet (n=3 per group) were used for the study. 
Samples were chosen at random from the progression study (Chapter 4). Conditioned media 
(0.5mL) was ultracentrifuged as previously described, and the frozen EV pellet was submitted 
to the Sydney Mass Spectrometry facility in the Charles Perkins Centre, University of Sydney 
for 1D liquid chromatography-mass spectrometry. The following work-flow was performed by 
Angela Connolly, prior to data acquisition on a Q Exactive™ Plus mass spectrometer (Thermo 
Fisher Scientific, Waltham, MA). 
 
EV pellets were thawed and resuspended in a 6M urea/2M thiourea solution before sonicating 
for 1 min, followed by centrifugation for 5 min at 16,000ൈg. The supernatant (100L) was 
collected for clean-up in a chloroform-methanol (4:1) solution at a final concentration of 80% 
v/v before further centrifugation for 5 min at 9,000ൈg. The sample was washed in methanol, 
spun as before, and the pellet was air-dried. The final protein sample was again resuspended in 
6M urea/2M thiourea solution, sonicated, and quantified using a Qubit fluorometer (Invitrogen, 
Carlsbad, CA). Total protein concentrations for EV samples were in the range of 15-62g, with 
an average of 31g. For protein digestion, samples were reduced in DTT (30 min), alkylated 
in iodoacetamide (30 min) and quenched in DTT, then diluted 10-fold in 100mM HEPES buffer 
before incubating in trypsin (1:50) overnight at 30oC. Prior to spectrometry, samples were 
diluted in trifluoroacetic acid (1% v/v) and spun for 5 min at 6,000ൈg, before hydrophilic-
lipophilic balanced clean-up. Finally, the resulting sample was eluted in a 50% v/v acetonitrile/ 
0.1% v/v trifluoroacetic acid solution, dried, and resuspended to 1g/3L protein. 
 
Following mass spectrometry, the output data was analysed by the author with the assistance 
of Dr Ben Crossett from the Sydney Mass Spectrometry facility. Data was first retrieved from 
the MASCOT® server (Matrix Science, London, UK) then analysed using Scaffold 4 software 
(Proteome Software, Portland, OR). Statistical differences between treatment groups were 
determined by Fisher’s Exact Test. Protein terms in UniProt format were imported into the 
online gene ontology software DAVID Bioinformatics (Huang da et al., 2009) and hierarchical 
clustering of enriched pathways was performed using the online matrix visualisation tool 
Morpheus (https://software.broadinstitute.org/morpheus/).  
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2.5.  Liver Lipid Content 
 
2.5.1.  Intrahepatic lipid staining 
 
Intrahepatic neutral lipids (fatty acid glycerols) were visualised using a semi-quantitative in 
vitro staining method with Oil Red O (ORO), modified from Lillie and Ashburn (Lillie and 
Ashburn, 1943). A 3mg/mL stock solution of ORO in isopropanol was prepared in advance. 
Prior to the experiment, an ORO working solution (3:2 in dH2O) was prepared and passed 
through a 0.1m syringe filter. Homogenised livers (20-100mg) were incubated in 500L 
working solution for 1 hr in darkness, then pelleted by centrifugation at 3000rpm for 10 min. 
Samples were washed in 60% v/v isopropanol, then resuspended in 1mL of 100% v/v 
isopropanol for 1 hr in darkness, to allow lipid-bound ORO to elute back into solution. Finally, 
samples were again pelleted at 5000rpm for 5 min, then 50L supernatant was collected for 
spectrophotometric reading of absorbance at 490nm. Concentrations were determined against 
a 5-fold serial dilution standard curve of ORO stock solution. 
 
2.5.2.  Intrahepatic triglyceride extraction 
 
Tissue triglycerides were quantified using a chloroform-methanol extraction method. Briefly, 
homogenised livers (5-20mg) were vortexed in 2mL chloroform-methanol solution (2:1 v/v) 
before a minimum 2 hr incubation on a rocker. A further 2mL of saline (0.9% w/v solution) 
was then added to samples, followed again by vortexing. To allow phase separation, samples 
were centrifuged at 1580ൈg for 3 min after which 100L infranatant was collected into a glass 
tube. (NB: Air was released from the pipette tip after submerging into infranatant to avoid 
contamination from the supernatant.) The infranatant containing triglycerides was concentrated 
with a nitrogen evaporator for approx. 30 min, or until the sample was dried. Triglyceride 
samples were dissolved in 100L ethanol, where 10L was resuspended in 300L TAG 
reagent (Roche Diagnostics, Basel, Switzerland) and incubated for 15 min before taking 
absorbance readings at 492nm. Sample concentrations were determined against a 2-fold 
dilution standard curve using glycerol standard solution (Sigma-Aldrich, St. Louis, MO) as in 
section 2.3.2. The standards were prepared as per Table 2.4 below. 
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Table 2.4. Standard curve preparation for liver triglyceride extraction. 
 
TAG 
concentration 
(mg/mL) 
Glycerol 
standard 
(L) 
dH2O 
 
(L) 
Serial dilution, 
from previous 
(L) 
Final volume in 
TAG reagent 
(L) 
5.00 20   20 
2.50 10   10 
1.25 15 15  10 
0.62  15 15 10 
0.31  15 15 10 
0.00  10  10 
 
Abbreviations: TAG, triacylglycerol (aka triglyceride). 
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2.6.  Liver Gene Expression 
 
To validate the NAFLD profile, changes in mRNA expression of inflammation and tissue 
remodelling associated molecules were assessed in mouse liver, and in hepatocyte cell lines 
stimulated with EVs from the mouse models. 
 
2.6.1.  RNA extraction 
 
All extraction reagents were acquired from Sigma-Aldrich, St. Louis, MO. Samples were 
homogenised and immersed in 0.5mL TRI Reagent with 0.1mL trimethylene bromochloride, 
vortexed, and allowed to separate into phases for 5-10 min. They were then centrifuged at 
14,000ൈg for 15 min at 4oC, and the aqueous supernatant was collected into equal volume 
(approx. 0.2mL) isopropanol before overnight precipitation at -30oC. Samples were again 
centrifuged under the same conditions, then the RNA pellets were washed twice with cold 70% 
w/v ethanol at 14,000rpm for 10 min at 4oC. Finally, after clearing the ethanol and air-drying 
to avoid contamination, pellets were resuspended in 50L nuclease-free water and assessed for 
yield and purity using a NanoDrop spectrophotometer. Acceptable quality was deemed to be 
>100ng/L RNA with both A260:280 and A260:230 ratios in the range 1.8-2.2. 
 
2.6.2.  RNA integrity 
 
RNA integrity was determined using an Agilent Bioanalyzer which uses a capillary gel 
electrophoresis format for resolving RNA degradation and gDNA contamination. Briefly, 
randomly selected samples were loaded onto a RNA 6000 Nano Chip and handled as per the 
manufacturer’s protocol. After running the chip, the RNA integrity number (RIN) was used to 
validate the extraction quality. Values above 7.0 are considered acceptable for whole liver 
tissue, which was consistently achieved in our samples. For more information about RNA 
integrity, including absorbance ratios from NanoDrop, please see Figure A9 in the appendix. 
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2.6.3.  Reverse transcription 
 
RNA samples were diluted to 100ng/L, of which 10L (1g) was used as synthesis template 
per 20L assay. Oligo-dT, random hexamers, and water were first added to the RNA template 
and placed in a PCR thermocycler for 10 min at 70oC to allow denaturation. Once the 
temperature lowered to 4oC, samples were retrieved and supplemented with deoxy-nucleoside 
triphosphates (dNTPs), dithiothreitol (DTT), reverse transcriptase, and commercial assay 
buffer. Samples were then returned to the machine to complete the annealing (25oC for 10 min) 
and extension steps (42oC for 60 min followed by 70oC for 15 min) of reverse transcription. 
Once cDNA was synthesised, the temperature returned to 4oC until the run was terminated. 
Final concentration for all assay reagents is given in Table 2.5. All reagents used for reverse 
transcription were purchased from Invitrogen, Carlsbad, CA. 
 
2.6.4.  Real-time quantitative PCR 
 
Following reverse transcription, cDNA samples were diluted 5-fold in nuclease free water, of 
which 5L (1L equivalent) was used per 15L assay. The remaining volume consisted of 
sense and anti-sense primers, water, and a commercial master mix (SensiMix SYBR Hi-ROX; 
Bioline Reagents, London, UK), as detailed in Table 2.5. Samples were then amplified on a 
Qiagen Roto-Gene™ real-time PCR machine under standard conditions for 40 cycles, 
including a final melt step to assess primer specificity. Run data was collected on the Roto-
Gene™ 6000 software (version 1.7) available from Corbett Research. Dilution curves were 
generated for each primer set (sequences given in Table 2.6) and used to determine mRNA 
expression for each sample, corrected to an endogenous reference gene (Table 2.6) and control 
group using the delta-delta method. Please see appendix for more details about the reference 
gene consistency during the RT-qPCR studies in Chapter 3 through 6. Where genes of interest 
were compared across multiple runs within an experiment, samples were also corrected to an 
internal control sample.  
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Table 2.5. Working concentrations for PCR reagents. 
 
Reagent Stock 
concentration 
Volume (L) Final 
concentration 
Reverse transcription:    
   Oligo(dT)12-18 0.5g/L 0.5 250ng 
   Random hexamers 2M 0.5 50nM 
   dH2O  1.5  
   5X First Strand buffer 5X 4.0 1X 
   DTT 100mM 2.0 10mM 
   dNTPs 10mM 1.0 0.5mM 
   SuperScript III * 
 
200U/L 0.5 100U 
Real-time qPCR:    
   primer (sense) 10M 0.5 333nM 
   primer (anti-sense) 10M 0.5 333nM 
   SensiMix SYBR Hi-ROX 2X 7.5 1X 
   dH2O  1.5  
 
*SuperScript III used as reverse transcriptase enzyme for cDNA synthesis. Abbreviations: 
DTT, dithiothreitol; dNTPs, deoxy-nucleoside triphosphate cocktail including adenosine 
(dATP), guanosine (dGTP), cytidine (dCTP) and thymidine (dTTP) nucleosides. 
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Table 2.6. SYBR primer sequences used in this study. 
 
Marker Forward (sense) sequence Reverse (anti-sense) sequence 
Inflammation:   
   F4/80 CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 
   MCP1 AGCCAACTCTCACTGAAGCC GCGTTAACTGCATCTGGCTG 
   TNF alpha GTCCCCAAAGGGATGAGAAGT TGAGTGTGAGGGTCTGGG 
ECM remodelling:  
   alpha SMA AGAGCAAGAGAGGGATCCTGA GTCGTCCCAGTTGGTGATGAT 
   collagen I CCCTCGACTCCTACATCTTCTGA GATGACGTGCAATGCAATGAA 
   collagen IV AGCGAGATGTTCAAGAAG TGGACAGTGAGGTACACA 
   CTGF GCATCTCCACCCGAGTTA TTGACAGGCTTGGCGATT 
   MMP9 GCCGACTTTTGTGGTCTTCC AGCGGTACAAGTATGCCTCTG 
   TGF beta TGACGTCACTGGAGTTGTAC GGTTCATGTCATGGATGGTG 
   TIMP1 CACAAGTCCCAGAACCGC GGATTCCGTGGCAGGC 
Lipid metabolism:  
   FABP1 AAGTCAAGGCAGTCGTCAAGCT TGAGTTCAGTCACGGACTTTATGC 
   glucokinase AGGAGGCCAGTGTAAAGATGT CTCCCAGGTCTAAGGAGAGAAA 
   perilipin 2 CTTGTGTCCTCCGCTTATGTC GCAGAGGTCACGGTCTTCAC 
   PPAR alpha CATGTGAAGGCTGTAAGGGCTT TCTTGCAGCTCCGATCACACT 
   PPAR gamma CTGCTCAAGTATGGTGTCCATGA TGAGATGAGGACTCCATCTTTATTCA 
   SREBP-1c TGGATTGCACATTTGAAGACATG TGTCTCACCCCCAGCATAGG 
Endogenous reference:  
   18S GCAATTATTCCCCATGAACG GGCCTCACTAAACCATCCAA 
   36B4 GGCCCTGCACTCTCGCTTT TGCCAGGACGCGCTTGT 
 
All sequences are given 5’-3’ and are specific for Mus musculus cDNA. Abbreviations: MCP1, 
monocyte chemotactic protein 1; TNF alpha, tumour necrosis factor alpha; ECM, extracellular 
matrix; alpha SMA, alpha smooth muscle actin; CTGF, connective tissue growth factor; 
MMP9, matrix metalloproteinase 9; TGF beta, transforming growth factor beta; TIMP1, tissue 
inhibitor of metalloproteases 1; FABP1, fatty acid binding protein 1 (liver type); PPAR, 
peroxisome proliferator-activated receptor; SREBP-1c, sterol regulatory element-binding 
protein 1c. 
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2.6.5.  cDNA array analysis 
 
cDNA was prepared as per section 2.6.3 with a starting RNA concentration of 100ng/L. All 
reagents and instruments described in this section were purchased from Thermo Fisher 
Scientific, Waltham, MA. The Accufill™ and QuantStudio™ 12K Flex real-time PCR systems 
were supplied by the Molecular Biology Facility of the Bosch Institute, University of Sydney. 
Immediately prior to array analysis, samples were prepared as follows: in a 384-well plate, 
cDNA was diluted in equal volume OpenArray™ PCR master mix up to 6L and centrifuged 
at 1000-1500rpm for 1 min with the plate covered. The OpenArray™ chip was equilibrated at 
room temperature for 10-15 min, then placed in the Accufill™ machine with the plate of 
samples and a box of Accufill™ tips. The machine was operated according to standard 
protocols. Upon completion of sample loading, the chip was removed and prepared for analysis 
using the QuantStudio™ system. 
 
Briefly, the top two of three layers of tape were removed from the chip before sealing with the 
lid. Using the provided syringe with immersion fluid, the cap was removed and replaced with 
a tip, and any bubbles were evacuated. The immersion fluid was slowly injected through the 
opening at one end of the chip until completely filled, then the opening was sealed using a 
screw plug. Finally, the assembled chip was placed under a compressor for 20 sec to ensure the 
lid was tightly adhered, then stored in the dark before analysis. 
 
Before initiating the QuantStudio™ program, a USB containing a chip-specific .tsp file was 
inserted into the machine (the file was obtained from https://www.thermofisher.com/au/en/ 
home/products-and-services/product-types/download-openarray-tpf-and-spf-plate-files.html). 
After launching, the chip identification number was entered into the program and the .tsp file 
opened, before being prompted to insert the chip into the machine. The analysis was finally 
configured by following instructions within the program to confirm and run the chip. Once the 
run was completed, data was obtained from and processed using the same program. 
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Table 2.7. Taqman primers used on custom designed OpenArray™ panel. 
 
Target Format Reference Format 
alpha SMA Mm00725412_s1 36B4 Mm00725448_s1 
basigin Mm01144228_g1 aldolase B Mm00523293_m1 
collagen I Mm00801666_g1 HPRT Mm01545399_m1 
collagen IV Mm01210125_m1 ubiquitin C Mm02525934_g1 
CTGF Mm01192932_g1   
CXCL10 Mm00445235_m1   
HGF Mm01135193_m1   
IFN gamma Mm01168134_m1   
IL2 Mm00434256_m1   
IL10 Mm00439614_m1   
MCP1 Mm00441242_m1   
MMP2 Mm00439498_m1   
MMP3 Mm00440295_m1   
MMP9 Mm00442991_m1   
MMP10 Mm01168399_m1   
MMP13 Mm00439491_m1   
MMP14 Mm00485054_m1   
PDGF-B Mm00440677_m1   
TGF beta Mm01178820_m1   
TIMP1 Mm00441818_m1   
TIMP2 Mm00441825_m1   
TNF alpha Mm00443258_m1   
VEGF-A Mm01281449_m1   
VEGF receptor 2 Mm01222421_m1   
 
Abbreviations: alpha SMA, alpha smooth muscle actin; CTGF, connective tissue growth 
factor; CXCL10, chemokine CXC motif ligand 10; HGF, hepatocyte growth factor; IFN 
gamma, interferon gamma; IL, interleukin; MCP1, monocyte chemotactic protein 1; MMP, 
matrix metalloprotease; PDGF-B, platelet-derived growth factor subunit B; TGF beta, 
transforming growth factor beta; TIMP, tissue inhibitor of metalloprotease; TNF alpha, tumour 
necrosis factor alpha; VEGF-A, vascular endothelial growth factor A.   
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2.7.  Liver Histology 
 
Embedding of formalin-fixed liver samples was performed with assistance from Sanaz Maleki 
and Rosie Cheong-Soos at the Histopathology Laboratory, Charles Perkins Centre, University 
of Sydney. Embedded samples were cut into 5m sections. To remove the paraffin wax from 
sections, slides were placed in a 60oC oven for 30 min then passed through two changes of 
xylene for 10 min each. Sections were then rehydrated through two changes of 100% and 95% 
w/v ethanol, then 70% w/v ethanol followed by running water, each for 2 min duration. 
Dewaxed sections were stained as described below. Sections were imaged using an Olympus 
BX53 microscope with cellSens microimaging software (Olympus, Tokyo, Japan). 
 
2.7.1.  Haematoxylin and eosin staining 
 
Haematoxylin and eosin (H&E) staining was used to visualise general morphology, whereby 
nuclei appear blue and cytoplasmic structures are stained pink with acidic eosin. Nuclei were 
first stained with Harris’ haematoxylin for 2 min, then differentiated in acid alcohol (1% HCl 
in 70% ethanol) for 10 sec, and blued in Scott’s bluing solution for 20 sec. After each step, 
sections were washed in running water until excess staining was cleared. Sections were then 
dehydrated through the graded ethanol washes in reverse order, with two 40 sec changes of 
eosin counterstaining after the 70% ethanol wash. Excess ethanol was removed from slides by 
placing in the 60oC oven for 15 min and then in histolene for at least 5 min, before mounting 
with dibutylphthalate xylene (DPX). See Figure 2.4 for an example H&E stain. 
 
 
 
Figure 2.4. Haematoxylin and eosin staining of normal mouse liver (100ൈ magnification). 
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2.7.2.  Picro-Sirius red staining 
 
Picro-Sirius red (PSR) staining of connective tissue was used to assess the severity of fibrosis 
in NASH models. When visualising stained sections, collagen fibres appeared red (Sirius red) 
while cellular structures had yellow hues (picric acid). Deparaffinised and rehydrated liver 
sections were stained with haematoxylin for 10 min. After washing excess stain in water, 
samples were incubated in PSR solution (0.1% w/v Sirius red F3B in aqueous picric acid) for 
1 hr, then drained on filter paper, submerged in acidified water (0.1% HCl) for 3 slow dips, 
drained again then washed in 100% ethanol. (NB: Any items containing residual PSR stain 
were washed thoroughly, as dried picric acid is highly volatile and flammable.) Finally, 
removal of excess ethanol and mounting were performed as in 2.7.1. See Figure 2.5 for an 
example of PSR staining in normal and fibrotic livers. 
 
 
    
Figure 2.5. Picro-Sirius red staining of normal mouse liver (left) and liver with NASH fibrosis 
(100ൈ magnification). 
 
 
For a complete set of the histological images that contributed to the studies in this thesis, please 
refer to Figures A1 to A8 in the appendix. 
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2.8.  Cell Culture 
 
For studies investigating the mechanism of EV action (Chapter 6), EV samples obtained from 
mouse liver or plasma were co-cultured with the Mus musculus hepatocyte cell line AML12, 
kindly donated by Dr Andrew Hoy from the Lipid Metabolism Laboratory at the Charles 
Perkins Centre. The cell line has an adherent epithelial phenotype and is non-tumorigenic. Cells 
were maintained at 37oC with 5% CO2 in DMEM: F12 medium, supplemented with 10% foetal 
bovine serum (FBS) and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin). These 
studies were performed over cell passage numbers 38-40. 
 
2.8.1.  EV uptake by hepatocytes 
 
To investigate the uptake of EVs by AML12 cells using fluorescent tracking, the EVs were 
labelled with 5M carboxyfluorescein succinimidyl ester (CFSE; BioLegend, San Diego, CA) in 
PBS supplemented with 0.5% BSA, for 30 min at 37oC. The reaction was quenched with 10-
fold volume of serum-enriched medium before incubating with cells at 60-80% confluence. 
EV uptake was then monitored at 24 and 48 hours. At the conclusion of each timepoint, media 
was aspirated and cells were washed in PBS to remove peripheral EVs. To quantify uptake by 
flow cytometry, cells were detached into 500uL PBS with a pipette tip then aspirated into a 
1.5mL tube. EV uptake was assessed using the Guava® easyCyte flow cytometer to determine 
the proportion of CFSE-positive cells (Ex 488, Em 525/30).  
 
2.8.2.  Hepatocyte phenotype 
 
The impact on AML12 hepatocyte phenotype after EV uptake was assessed by real-time PCR 
as follows. Briefly, cells were incubated with EVs (1,000/sample) in a 12-well plate for 24 hr 
after which time media was removed, cells were washed with PBS, then covered in 400L TRI 
Reagent (Sigma-Aldrich, St. Louis, MO) before storing at -80oC overnight to aid freeze-thaw 
mediated cell lysis. Cell samples were then scraped to resuspend in the TRI Reagent, aspirated 
from the wells, and processed according to section 2.6. To aid nucleic acid precipitation, 
glycogen (from mussel; Sigma-Aldrich, St. Louis, MO) was added at 1L per sample during 
the isopropanol overnight precipitation step. 
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2.9.  Statistical Analysis 
 
Results are expressed as mean ± standard deviation (SD) for animal characterisation and mean 
± standard error of the mean (SEM) for liver and EV characterisation, unless otherwise stated. 
Where applicable, outliers were removed using the ROUT method, with false discovery rate 
set to 5.0% (Q=5.0). Values were log10-transformed if failing the Shapiro-Wilk normality test. 
Data with two related independent variables were analysed using two-way ANOVA, corrected 
for multiple comparisons using Bonferroni’s post-hoc test (for 2 pairs), Tukey’s test (for >2 
pairs), or Dunnet’s test (comparing multiple groups to a control group). When using two-way 
ANOVA preceding the multiple comparisons, overall effects of a given variable are stated in 
terms of “source of variation” as a percentage of total variation within the analysed data. Data 
with a single variable or two unrelated independent variables were analysed using a Student’s 
t test for isolated pairs, or one-way ANOVA when comparing to a control group. Statistical 
significance was accepted at p<0.05. Linear correlations were analysed using Spearman 
nonparametric analysis to obtain a correlation coefficient (r value) with significance (p value). 
All analyses were performed using GraphPad Prism version 7 (GraphPad Software, San Diego, 
CA). 
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Chapter 3. 
Technique optimisation and application 
in a pilot study of extracellular vesicles 
in NAFLD progression 
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3.1.  Introduction 
 
The study of extracellular vesicles (EVs) in the context of animal models of NAFLD are to our 
knowledge lacking. To date, most studies have examined in vitro models using fatty acid 
stimulation of hepatic cells, or simple rodent models which distinguish the normal and steatotic 
phenotypes (Ban et al., 2016). While both models contribute knowledge, their caveats are 
typically arising from the “missing link” to human disease progression: is the stimulus 
physiologically relevant, or the time course representative of NAFLD development from 
simple steatosis to advanced NASH? The popular choline-deficient diets, for example, 
artificially accelerate the development to NASH without the corresponding metabolic 
disturbances (Machado et al., 2015), whereas in vitro studies provide information regarding 
single cell types with no information about the microenvironment.  
 
Another approach is the use of flow cytometric techniques with “positive controls” (such as 
Annexin A5) to analyse larger vesicles that are theoretically at the threshold of detection for 
most flow cytometric equipment (Arraud et al., 2015, Kornek et al., 2012). However, despite 
this limitation, flow cytometry will likely remain the mainstay for EV characterisation until a 
robust, standardised alternative is developed. Researchers have also started to use other 
technologies such as nanoparticle tracking analysis (NTA), laser diffraction, and tuneable 
resistive pulse sensing (TRPS) for EV enumeration (Gardiner et al., 2016). In other studies 
designed to assess molecular targets, or determine the tissue of origin, antibody labelling is 
often performed in addition to staining with generic cytosolic or membrane (lipophilic) dyes to 
resolve intact EVs (Pospichalova et al., 2015). In this Chapter, we labelled EVs with calcein 
AM dye which reacts with cytosolic esterases, then co-incubated with fluorophore-conjugated 
antibodies against markers of cell of origin (e.g. to platelets, endothelial cells or leukocytes). 
This was used in an attempt to determine absolute population counts, while bead-adsorbed 
samples were used to determine relative changes between treatment groups. These tissue of 
origin studies were complemented with qualitative techniques for EV characterisation, such as 
western blot to examine EV biomarker enrichment within our samples, and electron 
microscopy to visualise the sample itself.  
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Following technique optimisation, particularly for the enumeration of EVs, the Chapter 
continued with a proof of concept study in mice fed a high fat diet for up to 52 weeks to validate 
our approach. The aim of the current work was to model the physiological progression of 
NAFLD in a high-fat fed mouse model for a relatively short time course (12 weeks) as well as 
a long duration of continuous feeding (52 weeks). These two different durations of feeding are 
characterised in the liver by simple lipid accumulation (Lo et al., 2011, Machado et al., 2015) 
and the latter by the NASH phenotype of inflammation and fibrosis (Fontana et al., 2013, Ito 
et al., 2007), which reflects the progression of NAFLD across the human lifespan (Frith et al., 
2009). For a comparison of mouse age with the human equivalent, refer to Figure 3.1 below. 
In this study, the chronological and diet related change in the physical and metabolic phenotype 
of the animals were compared with plasma EV abundance. The impact of these variables on 
liver-derived EVs was also considered; to the best of our knowledge, this is a sample that has 
not yet been explored in any NAFLD study.  
 
 
 
 
 
Figure 3.1. Mouse and human age equivalents. Animals were 6 weeks old (human adolescent) 
at the commencement of the study. The diet duration of 12 and 52 weeks corresponded to final 
mouse ages of 18 weeks (human mature adult) and 58 weeks (human middle age), respectively. 
This in turn relates to the typical progression period from NAFL to NASH seen in humans. 
Figure values were adapted from The Jackson Laboratory website (Hagan, 2017). 
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3.2.  Technique Optimisation 
 
Due to the variety of techniques available for EV isolation, purification and characterisation, 
as well as the diversity of sample type studied, a consistent standard protocol was developed 
for the sample analyses described in this work. The simple isolation procedure described in 
section 2.4.1 was employed without further purification. This procedure yielded small EVs 
without significant lipoprotein contamination, as shown by transmission electron microscopy 
(TEM). Optimal conditions for EV enumeration and phenotyping of origin were established 
using the NanoSight™ system (see section 2.4.4) and the Guava™ easyCyte flow cytometer 
(section 2.4.5), respectively. These conditions were then applied to plasma and liver-derived 
EVs obtained from mice fed either a normal laboratory chow diet or a HFD as mentioned above 
and further described in section 3.3. 
 
3.2.1.  Sample purity and ultrastructure 
 
Electron microscopy was performed to confirm that the isolation and purification technique 
resulted in presence of EVs in the samples obtained by the method described in section 2.4.1. 
Shown in Figure 3.2A, the predominant structures in plasma isolates were vesicles that were 
uniformly round and electron dense, with the characteristic bilayer membrane also visible 
(Figure 3.2A, inset). These structures were also seen in isolates of conditioned media from an 
untreated hepatocyte cell line (Figure 3.2B). At this scale, it was also possible to determine the 
EV diameter; most structures tended to be under 200nm (typical of exosomes or small 
microvesicles), which was further confirmed by enumeration of size using NanoSight™ (see 
section 3.2.2). Further evidence that these structures can be called EVs was shown by western 
blot analysis, whereby the exosome marker CD63 was enriched in the ultracentrifuged pellet, 
compared to pre-ultracentrifugation and whole tissue lysate fractions (Figure 3.3). Together 
these observations suggest that the isolation technique enabled purification of vesicles that 
were predominantly EVs. Furthermore, these structures were shown to take up dyes that are 
subsequently catalysed by cytosolic esterase to produce a fluorescent signal (see section 3.2.3). 
This data further confirmed that the isolated structures were not protein contaminants, or 
lipoproteins with no esterase activity.  
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Figure 3.2. Electron micrograph of extracellular vesicles. A. Sample is of plasma origin from 
animals on a standard chow diet. Inset: Arrows highlight vesicle membrane. B. Sample from 
HepG2 cell line conditioned media. Arrows indicate EVs. Splintered halos around vesicles (*) 
indicate aggregation of uranyl acetate counterstain on EVs, due to insufficient washing. 
Magnifications are 50,000ൈ and scale bars represent 0.2m. 
  
* 
* 
* 
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Figure 3.3. Confirmation of extracellular vesicle presence by western blot. A. Total protein 
staining by Ponceau S for plasma and liver-conditioned media, either prior to ultra-
centrifugation (pre), or the EV pellet (EV) and supernatant (SN) following ultracentrifugation. 
Whole liver lysate and cell lysate of AML12 hepatocytes were used as a positive control. All 
samples except cell lysate were obtained from the same animal on a standard chow diet. B. 
Staining of CD63 exosomal/late endosomal marker in our samples. The native protein 
(expected 26kDa) was not present, while a small glycoform (approx. 40kDa) was enriched in 
plasma EV samples relative to whole plasma or liver and cell lysates. A larger glycoform or 
complex (approx. 70kDa) had the opposite expression pattern, while CD63 was absent from 
liver-conditioned media altogether. A pre-stained molecular weight (MW) ladder was used as 
a reference. 
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3.2.2.  Extracellular vesicle enumeration by NanoSight™ 
 
Prior to study sample analysis, the sensitivity of the NanoSight™ was calibrated using the 
polystyrene beads supplied by the manufacturer (Malvern Panalytical, Malvern, UK). To 
perform this, the three sizes of spherical beads (100, 200 and 400nm) were added in equal 
concentration (one drop) to the same diluent used for sample analysis (PBS) and were then 
enumerated by the Nanoparticle Tracking Analysis (NTA) software. Three parameters were 
assessed for optimisation: the dilution of beads (sample based), the duration of recording 
(instrument based), and the particle detection threshold (software based). With the exception 
of the dilution curve, the graphs in figure 3.4 display sample concentration as a function of the 
particle diameter. Each graph relates dilution and recording time, while different detection 
thresholds were assessed independently. All measurements of EV samples were recorded in 
duplicate for each condition and no statistical analyses were performed. 
 
For smaller beads, neither dilution (1000 to 5000-fold) nor recording duration (60 versus 90 
sec) affected the analysis, that is, the relative number of particles recovered (Figure 3.4A-B). 
However, sensitivity decreased with increasing particle size, and with a higher concentration 
of beads. Reducing the detection threshold – or the visual acuity of image processing – did not 
have an appreciable effect for beads (Figure 3.4B). This and the lack of large peaks at particle 
sizes of 200 and 400nm suggests that the software was most sensitive to the motion of particles 
around 100nm, which is ideal for the analysis of EVs isolated by the technique used in the work 
described in this thesis (see Figure 3.2 for reference).  
 
When analysing the more heterogenous plasma EV samples, peaks had a higher standard 
deviation and were skewed to the right, with most particles smaller than 200nm (Figure 3.4C-
D). The effect of the detection threshold was more relevant for polydispersed samples such as 
the EVs analysed in this work. A threshold of 5 was found to be optimally sensitive, with more 
particles being detected than at the default threshold of 10 for dilutions up to 100-fold (Figure 
3.4E), while more background noise was excluded when compared to lower thresholds. On the 
other hand, higher dilutions were more affected by recording duration, whereby 90 seconds 
gave the most consistent readings.  
 
  
 
82 
Liver-derived EVs were also assessed in a similar manner for comparison. These vesicles were 
slightly larger than plasma EVs, especially at the higher concentrations (Figure 3.4F). Low 
concentrations of EVs (less than 10 ൈ 106 particles/mL) in both plasma and liver-derived 
samples showed greater polydispersity, which may imply that the software is less sensitive to 
polydispersity in more concentrated samples due to the particle swarming effect. Following the 
aforementioned calibrations, the optimal settings for NanoSight™ enumeration of EVs was 
standardised across experiments. These can be viewed in Table 3.1. 
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Figure 3.4. Optimisation of extracellular vesicle enumeration. The technique was calibrated 
using polystyrene beads with the software detection threshold set to default 10 (A) or optimal 
5 (B). Similar plots for plasma EV samples across three dilutions (C-D) with the effect of all 
parameters on total particle concentration (E). Liver-derived EVs are shown for comparison 
(F). Detection threshold (TH) refers to sensitivity, time (60 or 90 sec) refers to recording length 
of particle motion.  
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Table 3.1. Standardisation of NanoSight™ settings. 
 
Calibrated settings  Optimal setting 
Sample parameter: Particle concentration  100 particles/frame * 
Instrument parameter: Recording duration  90 seconds ** 
Software parameter: Detection threshold Level 5 
 
*Manufacturers’ recommendation is 40-100 particles/frame. Samples were diluted to 100 
particles/frame to minimise the swarming effect seen at higher concentrations. Dilution 
depended on sample concentration and was corrected for during data analysis. **Some studies 
used 60 sec recordings, however, recording duration was consistent across samples within each 
study. All sample recordings were performed in at least duplicate to minimise technical error. 
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3.2.3.  EV characterisation by flow cytometry 
 
Following the gold standard for characterising the composition of intact EVs, we employed a 
conventional cytometric technique using an instrument that was optimised for the detection of 
subthreshold particles (0.2m compared to 0.4-0.5m for traditional cytometers). Despite the 
biophysical limitations of exosome assessment by this method (Thery et al., 2006, Witwer et 
al., 2013), we attempted to optimise a protocol for the staining of EVs coupled to latex beads 
versus individual EVs to determine the cell origin of plasma and liver-derived samples using a 
designated cytometer (Guava easyCyte™; Merck, Darmstadt, Germany).  
 
For individual EV characterisation, troubleshooting was performed for a number of parameters 
to compensate for ultracentrifugal washing, which results in sample loss: titration of antibody, 
incubation time and temperature, blocking sample with BSA, and precipitation of stained 
sample with polyethylene glycol (PEG). Findings for blocked, PEG-precipitated samples 
following overnight incubation at 4oC (see section 2.4.5) are shown in Figure 3.5. Sizing beads 
(1.33m) were used to determine the upper limit for forward and side scatter of individual EVs 
(Figure 3.5A). In most samples analysed, the EVs were near the limit of detection for forward 
scatter, or size (Figure 3.5B), while the diluent (filtered PBS) did not contribute to background 
signal (Figure 3.5C). To determine whether the samples were intact, they were stained with 
calcein AM and again analysed by flow cytometry.  Almost all detected events were positive 
when compared to unstained sample (Figure 3.5D), confirming that the samples were unlikely 
to be contaminating lipoproteins or aggregates that lack esterase activity. Additionally, events 
were almost ubiquitously staining double-positive for discrete populations, which included 
exosome (CD63) and microvesicle (Annexin-bound phosphatidylserine) markers (Figure 
3.5E), or markers of cellular origin for endothelial cells (CD105) and leukocytes (CD45) 
(Figure 3.5F). The precipitation of the sample with PEG prior to analysis did reduce 
background “noise”, but it was difficult to accurately delineate the EV origins as there was an 
unexpected overlap between mutually exclusive markers, which may suggest the presence of 
immune complexes. Using the individual EV staining technique, it was not possible to discern 
these complexes from true single-EV staining, given their proximity to the limit of detection. 
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To circumvent this issue, an alternative approach for the analysis of smaller particles is 
immunoprecipitation (see section 2.4.5). In our study, filter gains were first calibrated with 
beads coated directly in our antibodies of interest (positive controls; red), while BSA- or 
glycine-adsorbed beads were used as a negative control (white). Once again, samples were 
gated on bead size (Figure 3.5G), where adsorbed samples were expected to resolve within this 
gate. However, sample recovery was reduced for EV-adsorbed beads (Figure 3.5H) compared 
to beads alone. Following antibody labelling, we concluded that EV sample readings (blue) 
consistently failed to produce a fluorescence intensity greater than that of the respective 
negative controls (Figure 3.5I-K), and therefore, flow cytometry as a means of EV 
characterisation was not pursued in further studies. 
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A Sizing beads 
 
 
B EV unstained 
 
C Diluent 
 
D EV positive stain 
 
E CD63 + Annexin A5 
 
 
F CD45 + CD105 
 
G Beads only 
 
 
H Beads + EV 
 
 
  
I CD45 
 
J CD105 
 
K CD41 
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Figure 3.5. Optimisation of flow cytometric analysis of extracellular vesicles. Panels A-F show 
readings for individual EV detection: 1.33m sizing beads (A); unstained EV sample in diluent 
(B) and diluent only (C); sample stained with calcein alone to show EV-positive events (D), 
EV double-labelled with PE-anti-CD63 (exosome) and APC-Annexin A5 (microvesicle) to 
demonstrate subtype overlap (E) or PerCP/Cy5.5-anti-CD45 (leukocyte) and APC-anti-CD105 
(endothelium) to demonstrate false population overlap (F). Panels G-K show readings for the 
bead-based detection technique: polystyrene beads alone (G) or with EVs adsorbed onto the 
surface (H); polystyrene beads alone as a negative control (white), with antibody adsorbed as 
a positive control (red), or with EV adsorbed prior to antibody labelling (blue) against CD45 
(I), CD105 (J), or the platelet marker CD41 (K). 
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3.3.  Effect of High-Fat Diet on Extracellular Vesicles 
 
Our group has previously shown that mice fed a high-fat diet (HFD) have an increase in body 
weight by up to 30% with elevated liver triglycerides after 15 weeks (Lo et al., 2011). We 
hypothesise from the literature that HFD can alter circulating EVs, but it is not known whether 
they are altered in association with the development of NAFLD. Therefore, the aim of this 
study was to use the developed methodology to examine the impact of HFD on number and 
type of circulating and liver-derived EVs. Whether these changes occur in association with the 
development of NAFLD was also studied.  
 
3.3.1.  Animal characteristics 
 
As described in section 2.2.1, mice were fed either HFD or standard chow for 12 and 52 weeks. 
After 12 weeks of HFD, animals were significantly heavier (43% increase) with hepatomegaly 
(64% increase) compared to their counterparts receiving the standard chow diet (both p<0.01; 
Table 3.2). This pattern was amplified at 52 weeks (body weight: 2-fold increase, liver weight: 
3-fold increase; both p<0.001). Hyperinsulinaemia associated with HFD-induced obesity was 
also present, however, since this parameter was prone to biological variation, significance was 
only reached at 52 weeks (12 weeks: p=0.072, 52 weeks: p=0.002 versus chow). Elevated liver 
enzymes, a typical hallmark of NASH, only became apparent at 52 weeks in HFD mice (ALT: 
17-fold, AST: 5-fold versus 12 week HFD; both p<0.001), although biological variation was 
high for both enzymes. There were no significant changes in these parameters for animals on 
standard chow diet for 52 weeks, when compared to 12 weeks on the same diet.  
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Table 3.2. Animal characteristics in pilot study.  
  
 Chow HFD 
12 weeks 52 weeks 12 weeks 52 weeks 
Weights:     
  body (g) 29.1±1.82 30.8±1.23 41.5±1.97 * 60.4±1.65 *# 
  liver (g) 1.45±0.15 1.30±0.24 2.38±0.15 * 5.53±0.71 *# 
  liver (% body) 4.97±0.22 4.20±0.62 5.75±0.28 9.15±1.00 *# 
 
Plasma chemistry: 
    
  ALT (U/L) 25.0±9.03 23.4±7.47 38.4±37.6 396±72.1 *# 
  AST (U/L) 55.0±31.4 62.0±18.2 85.0±65.7 333±53.6 *# 
  ALT/AST ratio 0.49±0.09 0.40±0.11 0.57±0.30 1.19±0.10 *# 
  triglycerides (mg/dL) 51.6±14.5 29.7±23.8 43.4±10.5 49.1±9.29 
  insulin (pg/mL) 128±17.5 141±39.7 383±306 877±723 * 
 
Data are mean ± SD for n=6 animals per group, excluding outliers determined by the ROUT 
method (Q=5%). Significantly different from age-matched chow control (*) or 12 weeks of 
respective diet (#) accepted at p<0.05 as determined by 2-way ANOVA with Tukey’s test for 
multiple comparisons. Abbreviations: ALT, alanine transaminase; AST; aspartate 
transaminase. 
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3.3.1.1. Hepatic steatosis 
 
Steatosis was quantified in two ways: one approach used ex vivo staining of neutral lipids in 
whole liver tissue with Oil Red O (ORO), while hepatic TAG was extracted prior to 
colorimetric quantification (detailed in section 2.5). The latter revealed a significant increase 
in TAG content in the HFD groups at both timepoints when compared to age-matched chow 
fed animals (p<0.001), which remained stable across time-points (Figure 3.6A). A trend toward 
increased TAG was observed in the older chow group, however this did not reach significance. 
Like TAG levels, the intrahepatic lipid determined by ORO was increased by HFD at both 
timepoints when compared to chow diet (both p<0.001; Figure 3.6B). Interestingly, an aging 
effect was also noted with significantly increased (p<0.001) neutral lipid in the 52 week chow 
fed group. This finding was supported by the liver histology analyses in section 3.3.2. 
 
 
 
A 
 
B 
  
Figure 3.6. Liver lipid quantitation. A. Triacylglycerol (TAG) extracted from homogenised 
liver. B. Neutral lipids (fatty acid glycerols) were stained with Oil Red O (ORO) in 
homogenised liver prior to elution. Data are mean ± SD given per unit tissue, for n=6 animals 
per group. Significantly different from age-matched chow control (*) or 12 weeks of respective 
diet (#) accepted at p<0.05 as determined by 2-way ANOVA with Tukey’s test for multiple 
comparisons. 
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3.3.2.  NAFLD phenotype 
 
To evaluate the histological severity of NAFLD with short-term and long-term HFD leading to 
obesity, liver sections were assessed for general morphology by H&E staining (section 2.7.1) 
or for collagen accumulation (basement and fibrillar) by PSR staining (section 2.7.2). This was 
further complemented with the evaluation of molecular changes – including inflammation and 
ECM remodelling – by using gene expression as a surrogate marker (section 2.6.4). The 
findings herein aimed to demonstrate the typical features of NAFL development to NASH over 
time with HFD consumption, whereas comprehensive histological and molecular profiling was 
beyond the scope of this study. 
 
3.3.2.1. Liver histology 
 
Histological examination of livers revealed changing patterns of steatosis with progressive 
high-fat feeding, and also with age. When compared with standard diet at 12 weeks (Figure 
3.7A), livers of HFD mice had abundant microvesicular steatosis and some hepatocyte 
ballooning, while sparse macrovesiculation was also evident in adjacent regions (Figure 3.7C). 
In contrast, after HFD consumption for 52 weeks, macrovesicular steatosis dominated and 
much of the liver architecture was lost (Figure 3.7G). In this context, the interspersed tissue 
appears highly nucleated, suggesting the increased presence of infiltrating leukocytes that have 
formed multiple inflammatory foci. Pan-collagen staining also showed evidence of periportal 
and pericellular fibrotic bands (Figure 3.7H). In contrast, mice on a standard diet for 52 weeks 
showed no fibrosis or disrupted architecture (Figure 3.7E-F), although mild steatosis and 
ballooning was present. 
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Figure 3.7. Liver histology. Left panels show general morphology using H&E staining, right 
panels show collagen accumulation (red) by PSR staining for respective samples. Animals on 
12 week standard chow diet have normal liver architecture (A-B) while high-fat fed mice show 
the early presence of NAFLD with steatosis but no major scarring (C-D). At 52 weeks, mild 
steatosis is visible in chow fed mice (E-F) while their obese counterparts have demonstrable 
NASH with increased nuclei dense areas by H&E stain and diffuse, non-bridging fibrosis by 
PSR (G-H). Asterix denotes immune infiltrates. Representative images at 100ൈ magnification 
(scale bar = 100m), inset 200ൈ magnification. 
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3.3.2.2. Liver gene expression 
 
To further validate the phenotype of NAFLD and its progression to NASH, changes in the liver 
transcripts of key inflammatory and ECM remodelling markers were assessed by qPCR (see 
section 2.6 for detailed methods). The mRNA levels of genes associated with inflammation 
(TNF and MCP1) peaked early with HFD (6.7 and 10-fold respectively, both p<0.01), with no 
further increase observed at 52 weeks (Figure 3.8A-B). The expression of the macrophage 
marker (F4/80) tended to increase with 12 weeks of HFD, and reached significance compared 
to age matched control (approx. 4-fold, p<0.001) at 52 weeks (Figure 3.8C). On the contrary, 
the presence of activated hepatic stellate cells (SMA) was not altered by HFD at either time-
point (Figure 3.8D), despite an upregulation of collagen transcripts (collagen I by 8-fold and 
collagen IV by 2.4-fold, both p<0.001) at 52 weeks (Figure 3.8E-F). TGF showed a similar 
pattern in gene expression changes when compared to collagens (Figure 3.8G). Interestingly, 
when examining TIMP1 – a key regulator of ECM turnover – there was a 9-fold increase with 
HFD at 52 weeks (p=0.002 versus chow diet) but no change at 12 weeks (Figure 3.8H). This 
finding was likely due to a 5-fold decrease in TIMP1 expression with aging alone, although the 
difference was not significant (p=0.280 versus 12 weeks) and no such pattern existed between 
the HFD groups at different timepoints. 
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Figure 3.8. Liver gene expression. Graphs represent transcripts of inflammatory genes (A-C) 
and genes involved in ECM remodelling or fibrosis (D-H). Data is expressed as mean ± SEM 
of fold-change from 12 weeks chow diet (control group), for n=6 mice excluding outliers. 
Significant difference from chow (*) or 12 weeks of diet (#) accepted at p<0.05 as determined 
by 2-way ANOVA with Tukey’s test for multiple comparisons. Abbreviations: TNF, tumour 
necrosis factor; MCP1, monocyte chemotactic protein 1; SMA, alpha smooth muscle actin; 
Col, collagen; TGF, transforming growth factor beta; TIMP1, tissue inhibitor of metallo-
proteinase 1. 
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3.3.3.  Extracellular vesicle enumeration 
 
Extracellular vesicles isolated from the ultracentrifuged pellet of plasma and respective liver-
conditioned media samples were enumerated by NanoSight™ using Nanoparticle Tracking 
Analysis (NTA) software, in accordance with the optimised parameters from Table 3.1. The 
isolation process of EVs is detailed in Chapter 2 (see section 2.4.1 and 2.4.4). 
 
3.3.3.1. EV abundance in plasma and liver conditioned media 
 
Enumeration of vesicles showed an increase with HFD in the circulation, consistent with the 
literature, however these changes were not significant (Figure 3.9A). Although biological 
variation was large at 52 weeks, aging showed a more convincing effect for both diets, with 
significantly elevated EV abundance at 52 weeks when compared to 12 weeks (chow: 9-fold, 
HFD: 6-fold; both p<0.001). Interestingly, the opposite pattern was seen in the EVs derived 
from the liver-conditioned media, where abundance was decreased by aging (chow: 7-fold, 
HFD: 26-fold; both p<0.001). As with the plasma studies, the number of EVs isolated from 
liver-conditioned media were unaffected by diet at 12 weeks (Figure 3.9B). In contrast, liver 
EVs showed a diet effect at 52 weeks, with a significant decrease in abundance in the HFD 
group (3-fold, p<0.001). This data was corrected for the weight of cultured liver tissue (0.6-
1.2g). However, when the data was adjusted for total liver weight, these significant changes 
were completely abrogated (data not shown).  
 
In addition to the counting of EVs, the NTA technology also enables an estimate of particle 
size. The overall size distribution of EVs was unaffected by either diet or aging, and did not 
differ markedly between the two sampling sites (Figure 3.9C-D).  Liver-derived EVs tended to 
be slightly larger (100nm on average compared to 80nm for plasma EVs), while the abundance 
of plasma EVs was inversely correlated with liver-derived EV samples (r=-0.881, p<0.001) 
with a small 95% CI (-0.949 to -0.735) using Spearman correlation (Figure 3.9E). 
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Figure 3.9. Extracellular vesicle quantitation. Total particles calculated for plasma (A) and 
liver-derived samples (B), with respective size distribution (C-D), using Nanoparticle Tracking 
Analysis. Plasma and liver-derived EVs correlated negatively (E). Panels A-B show mean ± 
SEM for n=6 animals per group. Significantly different from chow (*) or 12 weeks of diet (#) 
accepted at p<0.05 as determined by 2-way ANOVA with Tukey’s test for multiple 
comparisons. Panel E shows linear regression with 95% confidence interval.  
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3.3.3.2. EV correlations with liver changes 
 
Given the aging-predominant changes in the abundance of EVs, most trends that were observed 
in the plasma biochemistry or other animal characteristics – significant or otherwise – were 
largely influenced by diet and therefore, did not relate directly to either circulating or liver EV 
numbers.  
 
Interestingly, when either EV population was correlated against liver gene expression in the 
format delta-delta Ct (log transformed fold-change), most differences were significant by the 
Spearman test; that is, all markers with the exception of SMA were correlated with EV 
abundance, albeit in different directions: positively for plasma and negatively for liver-derived 
samples, respectively (data not shown). However, 95% CI tended to be quite large: for 
example, correlations ranged from slightly significant (p<0.05) against TIMP1 for both plasma 
(r=0.487, CI 0.091 to 0.750) and liver EVs (r=-0.478, CI -0.744 to -0.079), to highly significant 
(p<0.001) against MCP1, again for both plasma (r=0.819, CI 0.606 to 0.923) and liver EV 
samples (r=-0.829, CI -0.927 to -0.625).  
 
Finally, the most convincing relationships were evident between EV number and hepatic lipid 
load. Although the correlations with TAG (Figure 3.10A-B) were not as strong (plasma EV: 
r=0.485, p=0.016; liver EV: r=-0.567, p=0.004) due to divergent clustering of treatment groups, 
this effect was less prominent for neutral lipid measurement by ORO (Figure 3.10C-D) where 
the correlations were highly significant (p<0.001) for both EV populations (plasma EV: 
r=0.846; liver EV: r=-0.898). As expected, plasma EVs correlated positively while liver-
derived EVs correlated negatively with the respective lipid measurements. These findings 
suggest that circulating (or liver) EV abundance may be a reliable predictor of hepatic lipid 
accumulation and may be a potential biomarker for this parameter. 
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Figure 3.10. Extracellular vesicle correlations with liver lipids. Relationship between liver 
triacylglycerol (TAG) and (A) plasma EVs (r=0.485) or (B) liver-derived EVs (r=-0.567). Oil 
Red O (ORO) staining of neutral lipids – representing hepatic lipid droplets – and correlation 
with (C) plasma EVs (r=0.846) or (D) liver EVs (r=-0.898). Treatment groups include 12 weeks 
chow (black) or high-fat diet (red), and 52 weeks chow (green) or high-fat diet (blue). Linear 
regression with 95% confidence interval as determined by Spearman test. All correlations were 
significant (p<0.05). 
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3.4.  Interpretation 
 
The findings from this Chapter highlight the utility of EV enumeration and physical profiling 
by optical methods (NanoSight™) and reiterate the current limitations of EV characterisation 
by flow cytometry. They then continue to explore the relationship between EVs (from plasma 
or liver) and other clinical or molecular parameters associated with NAFLD development, in a 
pilot study of diet-induced obesity in rodents (summarised in 3.4.2). Briefly, it was shown that 
circulating EVs may predict the extent of hepatic steatosis and possibly indicate the level of 
inflammation in the liver (through gene expression of MCP1, for example). Similar patterns 
were also observed for liver-derived EVs, albeit in the inverse direction. To confirm these 
findings, a larger study with more timepoints was addressed in Chapter 4. 
 
3.4.1.  Technique optimisation and validating EV presence 
 
Using a combination of transmission EM, western blot analysis, and intracellular esterase 
staining for flow cytometry, we initially determined the presence of EVs in ultracentrifuged 
plasma and liver-conditioned media. Structures shown under electron microscopy were 
relatively uniform in size and shape, consistent with exosomes, which was further confirmed 
during EV enumeration by NTA. While the bilayer membranes were visible with increased 
contrast, the electron density was unusual for EVs when compared to images in the literature. 
This could be explained by over-staining with counterstain, however, similar findings were 
also documented by some other groups (Jenjaroenpun et al., 2013, Ko et al., 2015).  
 
Probing for CD63 by western blot analysis confirmed the presence of exosomes, as this late-
endosomal protein was enriched in the plasma EV fractions when compared to whole plasma 
or liver lysates. Interestingly, liver-derived EVs more closely resembled whole liver in their 
protein profile and did not show the CD63 enrichment typical of plasma EVs. Given the 
comparable methods of isolation, it is possible that liver vesicles are instead predominantly 
MV subtype as opposed to exosomes.  
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The uptake of calcein dye by particles examined by flow cytometry further confirmed the 
presence of EVs rather than lipoproteins (which lack esterase activity) or contaminating protein 
aggregates. To aid in the phenotypic analysis of smaller EVs using this technique, adsorption 
of sample to larger beads (around 5m) is required to allow for adequate washing following 
the antibody detection step (Inglis et al., 2015). Polystyrene (i.e. latex) beads are particularly 
useful, due to their high-affinity hydrophobic surface which indiscriminately attracts most 
proteins, such as those on the surface of EVs. The limitation of this technique is that it cannot 
predict the proportion of EVs derived from a given population; that is, readings between 
samples (and treatments) are relative. However, as evidenced in this study, even adsorption 
was insufficient to provide a conclusive answer about EV surface markers, as discrete 
populations (such as unrelated cell type origins) were unable to be delineated. One explanation 
could be the formation of immune complexes, which may be circumvented by blocking the Fc 
portion of staining antibodies or alternatively, using Fab fragments conjugated to fluorophores. 
While there is no direct comparison of this method and the protocols used in our study in the 
literature, future studies expanding on the concepts in this thesis may benefit from trialling 
these techniques during cytometric EV analysis. 
 
While ultracentrifugation without a density gradient is considered to be a “crude” technique 
for EV isolation, we were confident that our samples represented EVs of interest. Given the 
known differences in density between EVs and lipoproteins of the same size (Figure 3.11), 
there is a possibility of co-isolation at higher centrifugal speeds (Sodar et al., 2016, Witwer et 
al., 2013); however, the structures would appear as discrete populations under TEM, albeit 
liposomes in the VLDL-chylomicron range (comparable in size to EVs) are largely absent from 
HepG2 cell conditioned media (Thrift et al., 1986). This implies that the electron dense vesicles 
in our HepG2 preparation are in fact EVs, which in turn substantiates the presence of EVs in 
the plasma sample preparation. Were the cytometric techniques successful, antibody labelling 
of EVs would have provided additional information about their tissue origin. This limitation is 
addressed in Chapter 4, where mass spectrometry analysis of liver EVs provided further insight 
into the content of these vesicles, in both NAFL and NASH, as well as their otherwise healthy 
counterparts. 
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Figure 3.11. Physical characteristics of vesicles. Lipoprotein densities generated from 
(Jairam et al., 2012, Memon and Gilani, 1995), EV densities from (Witwer et al., 2013). 
Orange vertical lines represent boundaries between lipoprotein sizes. Abbreviations: HDL, 
high-density lipoprotein (types 2 and 3); LDL, low-density lipoprotein; VLDL, very low-
density lipoprotein; FFA, free fatty acid (albumin conjugated). 
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3.4.2.  Establishing a NAFLD model for the study of EVs 
 
In the pilot study described, C57Bl/6 mice (n=24) were fed HFD or standard chow for 12 or 
52 weeks to observe NAFL progression to NASH. This model reflects features of NAFLD 
development in humans, as the hepatic phenotype is comparable and systemic metabolic 
disturbances are preserved. Indeed, animals in our study were overweight with enlarged fatty 
livers by 12 weeks of HFD, however, their NAFLD was subclinical as determined by the liver 
function test (circulating ALT and AST). There were some perturbations in plasma insulin, 
although intragroup variability was high and hyperinsulinaemia was not recorded at this 
timepoint. By 52 weeks, the HFD group were morbidly obese and the severity of their NAFLD 
was reflected in their grossly elevated liver enzymes. While the group was hyperinsulinaemic 
on average, again the variability was high, which suggests that plasma insulin is not a reliable 
predictor of NAFLD progression. 
 
Examining the liver phenotype – in terms of histology and lipid content – showed that hepatic 
TAG and neutral lipids (all fatty acid glycerols, including TAG) were elevated in the HFD 
group at either timepoint, whereas aging had a compounding effect on the latter. NAFLD 
progression did not affect TAG content relative to tissue weight, however, differences in lipid 
storage pattern were observed by histology. As expected, mice at 12 weeks had pronounced 
steatosis but lacked other features of NASH, while 52 weeks of HFD produced widespread 
punctate (or macrovesicular) steatosis with immune infiltrates and pericellular fibrosis. These 
findings were reinforced by the gene expression data, which showed elevations in both fibrillar 
(type I) and basement (type IV) collagens, with a corresponding increase in TGF. This growth 
factor plays a known role in tissue fibrosis (Biernacka et al., 2011), and has been shown to 
promote NASH (Yang et al., 2014). Markers of inflammation, on the other hand, were 
increased by 12 weeks and remained stable; this suggests an early response to lipotoxic stress 
by the liver parenchyma. Ergo, the limitations of current technologies to detect these subclinical 
changes warranted the use of EVs as a potential biomarker. 
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Interestingly, in our study, aging had the most profound effect on both circulating and liver-
derived EVs, irrespective of diet. That is, enumeration by NanoSight™ showed that 
progression of NAFLD specifically (or even obesity) may not be detectable by changes in the 
plasma EV number when other biological confounders are involved. This pilot data suggests a 
case for the re-evaluation of guidelines that aim to standardise the diagnostic practices for 
NAFLD; while older age is a known risk factor for progression to NASH, it is seldom 
accounted for when developing reference values, although some groups have argued that it 
should be considered (McPherson et al., 2017). Another interesting observation was the inverse 
trend between plasma and liver EVs, whereby aging caused a decrease in the liver-derived 
population. This was magnified at 52 weeks, such that total EVs were further decreased by 
HFD. Despite the lack of observable changes in EVs at 12 weeks, when all samples were 
correlated against hepatic neutral lipid (ORO staining), there was a significant positive and 
negative trend with plasma and liver origin, respectively. The study data suggests that absolute 
EV numbers may not be a strong predictor for NAFLD presence or progression, however they 
could be used as an indicator for liver lipid accumulation. Whether this is applicable 
longitudinally – that is, throughout the development of NAFLD – is examined in detail in the 
following Chapter. 
 
 
 
   107 
 
Chapter 4. 
Extracellular vesicles in a diet-induced 
rodent model of NAFLD progression 
 
 
 
   108 
Chapter 4. Table of contents 
 
4.1. INTRODUCTION .......................................................................................................... 109 
 
4.2. ANIMAL CHARACTERISTICS ................................................................................... 111 
4.2.1. Insulin and insulin tolerance ............................................................................ 111 
4.2.2. Plasma biochemistry ........................................................................................ 112 
4.2.3. Hepatic steatosis............................................................................................... 114 
 
4.3. NAFLD PHENOTYPE ................................................................................................... 115 
4.3.1. Liver histology ................................................................................................. 115 
4.3.1.1. General morphology ......................................................................... 115 
4.3.1.2. Liver fibrosis ..................................................................................... 115 
4.3.2. Liver gene expression ...................................................................................... 119 
4.3.2.1. Inflammation ..................................................................................... 119 
4.3.2.2. ECM remodelling.............................................................................. 119 
 
4.4. EXTRACELLULAR VESICLE PHENOTYPE............................................................. 123 
4.4.1. EV enumeration ............................................................................................... 123 
4.4.1.1. Patterns in EV abundance ................................................................. 123 
4.4.1.2. EV correlations with other parameters ............................................. 127 
4.4.2. EV protein content ........................................................................................... 129 
4.4.2.1. Preliminary analysis of unique proteins ............................................ 129 
4.4.2.2. Comparison with reference datasets ................................................. 131 
4.4.2.3. Enrichment analysis 1: qualitative approach .................................... 134 
4.4.2.4. Enrichment analysis 2: quantitative approach .................................. 138 
 
4.5. INTERPRETATION....................................................................................................... 141 
4.5.1. Non-linear evolution of NAFLD ..................................................................... 141 
4.5.2. EV abundance reflects TAG levels .................................................................. 142 
4.5.3. Liver EV proteome is heterogeneous ............................................................... 144 
4.5.4. Consolidation ................................................................................................... 146 
 
 
   109 
4.1.  Introduction 
 
As described in Chapter 1, NAFLD is an almost ubiquitous complication of obesity, where a 
proportion of sufferers (up to 30%) will advance to NASH (Chalasani et al., 2018). Whether 
the EV number and profile changes in association with the development of NAFLD is not 
known, as most studies in this context have typically been cross-sectional (Ban et al., 2016). In 
the present study, animals were maintained on an obesogenic HFD or standard chow for up to 
50 weeks, to assess NAFLD progression (see Figure 4.1). The effects of both diet and aging 
were examined to compare the effects of extrinsic and intrinsic changes respectively, as well 
as their intersection (defined as NAFLD progression). 
 
In a similar study design by Ito and colleagues, animals were fed a HFD (60%kcal fat) or 
standard chow for up to 50 weeks, with metabolic parameters and liver phenotype recorded 
(Ito et al., 2007). Significant increases in plasma insulin and cholesterol were observed at the 
earliest timepoint (10 weeks), whereas liver enzymes were unchanged up to 19 weeks. While 
liver TAG was increased at all timepoints, evidence of NASH was not present up to 19 weeks 
and fibrosis was only present by 50 weeks, consistent with our findings in Chapter 3. Our group 
has also described previously in a diabetic mouse model that by 20 weeks of HFD, animals 
show early signs of fibrotic changes as well as an increase in liver macrophages (Lo et al., 
2011). Whether the EV signature of these animals can be used to track pathological changes 
has yet to be explored, although shorter-term studies on mice (Povero et al., 2014) and cross-
sectional studies on humans (Kornek et al., 2012) have shown that the circulating EV 
abundance – either total or specific populations – may indeed be a predictor of NAFLD 
severity. Whereas the former mouse study by Povero and colleagues (2014) utilised mass 
spectrometry to characterise plasma EV content, the present Chapter will analyse the protein 
cargo of liver EVs and how these are changed from 10 to 50 weeks of HFD. 
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While the previous chapter identified trends that could be associated with either diet or aging 
in a small sample cohort, the progression study outlined here will focus on temporal changes 
in the liver and EV populations in a larger group of animals and compare this back to the 
findings in Chapter 3. By following the development of NAFLD over one year, fluctuations in 
EVs coinciding with otherwise subclinical events can be further dissected, while changes in 
the EV cargo may hint at their functional role as intercellular messengers. The latter will then 
be explored through functional studies in Chapter 6. 
 
 
 
 
 
 
Figure 4.1. Time course for NAFLD progression study. Arrows represent diet durations for 
either standard chow (CH) or high-fat (HF) diet. Images show representative mouse livers 
following 10 weeks (A), 20 weeks (B), 30 weeks (C) and 50 weeks (D) of HF diet, the latter 
showing evidence of NASH fibrosis. A liver from CH diet (E) is shown for comparison. Images 
were taken immediately following excision (not perfused) at termination. 
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4.2.  Animal Characteristics 
 
Average body weight was increased by HFD at all timepoints (p<0.001) and continued to rise 
with the duration of feeding (Table 4.1). The same trend was observed for subcutaneous fat 
depots. Epididymal fat seemed to expand to capacity by 10 weeks, increasing by over 9-fold 
relative to the chow diet (p=0.001) and remaining stable in weight across the later timepoints 
(p>0.05 versus 10 weeks HFD), although intragroup variation was substantial. HFD did not 
significantly alter liver weight until 20 weeks (p<0.001), however, there was very little change 
in weight between 20 and 30 weeks of HFD (4% decrease) in contrast to other intervals. Finally, 
tissue weights remained stable over time in groups receiving standard chow diet, while body 
weight increased in a manner consistent with the normal growth of rodents: 22% increase from 
10 to 50 weeks, versus 46% increase within the HFD cohort. 
 
4.2.1.  Insulin and insulin tolerance 
 
In HFD animals, increased blood glucose was seen only after 10 weeks (p<0.001) of the diet, 
whereas there was no statistical significance thereafter (Table 4.1). Interestingly, from 30 
weeks, this value dropped in HFD animals compared to the same diet at 10 weeks (p<0.001). 
These trends, in turn, affected the glucose curve after a single dose of insulin; the area under 
the curve was higher with HFD compared to standard chow diet at all timepoints – implying a 
tendency towards insulin resistance – however, these differences were only significant at 10 
weeks (p=0.011) and 20 weeks (p=0.037) with the gap closing thereafter. Plasma insulin levels 
showed a different profile, more comparable to the findings in Chapter 3. Animals on HFD had 
consistently elevated insulin (p<0.001 at all timepoints), which was significantly increased by 
50 weeks compared to 10 weeks HFD (p=0.012), despite the high intra-group variations (Table 
4.1). By comparison, insulin levels remained low in chow-fed animals and were unaffected by 
aging. 
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4.2.2.  Plasma biochemistry 
 
Plasma TAG levels were also similar to previous results in Chapter 3, where HFD tended to 
decrease TAG (between 33% and 53%), although these did not generally reach statistical 
significance, with the exception of a transient decrease at 20 weeks (p=0.002). Liver disease 
severity was reflected in the plasma transaminase levels (Table 4.1), where both ALT and AST 
were elevated by HFD (p<0.001) from 20 weeks onwards and continued to increase before 
plateauing at 50 weeks. Consequently, the values at these later timepoints were higher than at 
10 weeks (p<0.001), where HFD had comparable values to standard chow (ALT: 40% increase, 
AST: 7.5% decrease; both p>0.05). Furthermore, the ALT/AST ratio was increased around 2-
fold by 20 weeks (p<0.001) and up to 3-fold from 30 weeks onwards (p<0.001) in HFD animals 
compared to their chow counterparts, suggesting a proportionally greater increase of plasma 
ALT (representing liver-specific injury). When compared to 10 weeks of HFD, the ALT/AST 
ratio was 2-fold greater for HFD animals at all other timepoints (each p<0.001). No changes 
were observed with age in animals receiving standard chow. 
 Table 4.1. Animal characteristics for NAFLD progression study. 
 
 Chow HFD 
10 weeks 20 weeks 30 weeks 50 weeks 10 weeks 20 weeks 30 weeks 50 weeks 
Weights (g):         
  body 28.8±1.93 31.7±1.39 33.3±2.12 # 35.1±2.95 # 39.0±3.56 * 48.0±4.31 *# 51.9±4.19 *# 57.3±5.24 *# 
  liver 1.23±0.18 1.51±0.10 1.45±0.15 1.60±0.22 1.83±0.34 3.55±0.99 *# 3.84±0.85 *# 5.07±1.24 *# 
  epididymal fat 0.32±0.08 0.31±0.07 0.56±0.27 0.80±0.43 2.34±0.58 * 1.93±0.28 * 2.08±0.39 * 2.13±0.42 * 
  subcutaneous fat 0.20±0.07 0.25±0.07 0.33±0.09 0.34±0.12 1.06±0.27 * 1.70±0.40 *# 2.28±0.36 *# 2.63±0.35 *# 
 
Plasma chemistry: 
        
  ALT (U/L) 25.0±6.71 33.0±7.10 24.5±4.58 23.5±3.53 35.1±12.4 189±103 *# 230±95.6 *# 254±97.8 *# 
  AST (U/L) 73.6±18.2 65.3±5.50 97.4±48.2 87.2±20.7 68.1±12.5 190±99.4 *# 260±116 *# 278±93.6 *# 
  ALT/AST ratio 0.44±0.14 0.46±0.12 0.27±0.09 0.30±0.08 0.53±0.24 1.00±0.28 *# 0.91±0.3 *# 0.90±0.19 *# 
  TAG (mg/dL) 51.7±18.2 75.6±27.7 67.1±30.3 53.3±32.4 40.7±19.3 44.3±16.9 * 39.6±12.0 22.5±2.18 
  insulin (pg/mL) 212±68.4 159±24.3 170±46.3 217±116 567±255 * 610±228 * 736±460 * 1118±552 *# 
 
Insulin tolerance: 
        
  fasting glucose (mM) 7.22±0.80 8.22±1.26 6.78±1.12 7.73±1.35 9.23±1.61 * 8.15±0.90 7.44±0.94 # 7.28±1.09 # 
  ITT (AUC) 263±34.9 314±97.2 328±38.8 # 314±51.1 344±54.5 * 383±85.1 * 365±45.9 323±51.5 
 
Data are mean ± SD for n=11-12 animals per group, excluding outliers determined by the ROUT method (Q=5%). Significant difference from 
age-matched chow (*) or 10 weeks of HFD (#) accepted at p<0.05 as determined by 2-way ANOVA with Bonferroni’s (diet) or Dunnett’s 
(timepoint) post hoc test for multiple comparisons. Abbreviations: ALT, alanine transaminase; AST; aspartate transaminase; TAG, triacylglycerol; 
AUC, area under the curve in arbitrary units. 
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4.2.3.  Hepatic steatosis 
 
Consistent with the findings in Chapter 3, liver TAG was increased by HFD independently of 
diet duration (p<0.001 all timepoints), with a peak at 20 weeks (p<0.001 versus 10 weeks 
HFD), after which time it tended to decline (Figure 4.2A). At 50 weeks of HFD, the hepatic 
TAG level was significantly decreased relative to 10 weeks on the same diet (p=0.001). Mice 
on standard chow had consistently lower hepatic TAG than their HFD counterparts, which was 
unaffected by aging. In contrast, ORO staining of total neutral lipids – generally found in the 
lipid droplets – tended to decline with aging, independently of diet (Figure 4.2B). This decrease 
became significant after 50 weeks of diet within the chow cohort (p=0.010 versus 10 weeks). 
Irrespective of the variability within HFD groups, lipid content was significantly higher than 
the normal chow fed mice at the same timepoints (p=0.008 at 10 weeks, p<0.001 for longer 
duration), except at 20 weeks where there was no difference (cf. peak in TAG level for same 
group). 
 
 
 
A 
 
B 
 
Figure 4.2. Liver lipid quantification. Liver triacylglycerol (TAG) (A) and total neutral lipids 
(B) per unit tissue mass were both increased with HFD. Data are mean ± SD for n=11-12 
animals per group, excluding outliers determined by the ROUT method (Q=5%). Significant 
difference from chow (*) or 10 weeks of diet (#) accepted at p<0.05 as determined by 2-way 
ANOVA with Bonferroni’s (diet pairs) or Dunnett’s (timepoint) post hoc test for multiple 
comparisons. Abbreviations: HFD, high-fat diet; ORO, Oil Red O.  
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4.3.  NAFLD Phenotype 
 
4.3.1.  Liver histology 
 
4.3.1.1. General morphology 
 
Using standard H&E staining, the characteristic evolution of NAFLD could be observed. At 
10 weeks of HFD, the majority of livers (4/6 samples) had developed microvesicular steatosis 
predominantly in the centrilobular regions (Figure 4.3B). By 20 weeks, macrovesicular 
steatosis had also become present (Figure 4.3D). Animals receiving HFD for 30 weeks had 
ubiquitous steatotic bands; these were generally defined by a microvesicular pattern, with 
macrovesicular steatosis becoming more abundant in the adjacent periportal regions (Figure 
4.3F). Finally, after 50 weeks of high-fat feeding, there was a loss of normal liver architecture 
with a macrovesicular pattern of lipid accumulation throughout (Figure 4.3H). Inflammatory 
foci had also become obvious, and pale nuclear staining in the perisinusoidal region suggested 
the presence of hepatic stellate cells. Interesting to note was the fact that “slow progressors” – 
that is, animals with only sparse or diffuse microvesicular steatosis up to 20 weeks – showed 
greater evidence of leukocyte aggregates throughout the liver sections (Figure 4.3I-J). Livers 
of mice on standard chow appeared normal at all timepoints. 
 
4.3.1.2. Liver fibrosis 
 
To delineate the transition between NAFL and advanced NASH, collagen fibres were stained 
red using PSR. As expected, 10 weeks of HFD was insufficient to progress to NASH, with 
collagen staining limited to the basement membrane around vessels (Figure 4.4A). Quite 
surprisingly, pericellular collagen staining was observed in approximately half of the livers 
from HFD mice by 20 weeks (Figure 4.4B) with a similar proportion at 30 weeks (Figure 4.4C). 
Of interest, the collagen bands seen at 20 weeks were often more pronounced when compared 
to 30 weeks of HFD. By 50 weeks, all livers in high-fat fed animals had diffuse but substantial 
collagen staining (Figure 4.4D), with bridging fibrosis evident in half the samples. No fibrosis 
was present in livers of standard chow animals (data not shown).  
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Figure 4.3. Liver morphology by H&E staining. Left panels (excluding I and J) show livers 
from mice on standard chow diet, and right panels are representative livers from mice fed HFD 
showing NAFLD progression, with a predominantly microvesicular to macrovesicular 
transition over time. Animals with delayed steatosis development (slow progressors, SP) at 10 
weeks (I) and 20 weeks (J) HFD have more leukocyte aggregates, denoted by (*) on each. 
Representative images at 100ൈ magnification (scale bar = 100m), inset 200ൈ magnification. 
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Figure 4.4. Liver fibrosis staining by Picro-Sirius red (PSR). No collagen accumulation is seen 
after 10 weeks of HFD (A), with pericellular collagen staining becoming evident from 20 
weeks (B). No increase in staining from 20 to 30 weeks (C), with abundant PSR-positive 
staining at 50 weeks (D) showing evidence of bridging fibrosis. Representative images with 
PSR staining at 100ൈ magnification (scale bar = 100m), inset 200ൈ magnification. 
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4.3.2.  Liver gene expression 
 
4.3.2.1. Inflammation 
 
In accordance with the classical model of liver disease progression, inflammatory changes are 
expected to precede and drive fibrogenesis, as observed in Chapter 3. In the current study, gene 
expression of TNF was significantly higher in HFD animals at all timepoints (minimum 3-fold, 
p=0.002) and did not fluctuate from the initial increase seen after 10 weeks (Figure 4.5A). Gene 
expression of molecules involved in monocyte recruitment (MCP1; Figure 4.5B) and 
macrophage presence (F4/80; Figure 4.5C) only became substantially elevated in HFD mice at 
20 weeks (MCP1: 9-fold, p<0.001; F4/80: 3-fold, p=0.006), reaching a peak at 30 weeks before 
declining towards (or surpassing) the baseline by 50 weeks (MCP1: p>0.05, F4/80: p=0.001 
versus 10 weeks HFD). No notable changes were observed in the chow-fed animals at any of 
the studied timepoints, which was also true for ECM remodelling markers. 
 
4.3.2.2. ECM remodelling 
 
The transcriptomic response to fibrogenesis was much more dynamic. The gene expression of 
-SMA, a surrogate marker of stellate cell activity, did not deviate more than 2-fold from the 
baseline across HFD groups, and tended to decline with age irrespective of diet (Figure 4.5D). 
However, a statistically significant elevation at 20 weeks (p=0.013 versus 10 weeks) also 
coincided with a peak in the expression of collagen I (p<0.001; Figure 4.5E), possibly linking 
stellate cell activity with the production of fibrillar collagen. The mRNA expression pattern of 
collagen I – with another sharp increase at 50 weeks (p=0.013) – also seemed to correlate with 
the increased collagen staining seen by liver histology (refer to Figure 4.4). In contrast, while 
collagen IV became initially elevated at 20 weeks in HFD (p<0.001 versus chow), its gene 
expression plateaued after this time (Figure 4.5F). Irrespective of these varied trends, 
transcription levels for both collagens were significantly higher with HFD compared to chow 
from 20 weeks onwards (collagen I: >6-fold, collagen IV: >2-fold; both p<0.05). Other 
regulators of collagen turnover, TGF (Figure 4.5G) and TIMP1 (Figure 4.5H), were both 
increased up to 30 weeks in HFD mice (p<0.01 versus 10 weeks), before stabilising (TIMP1) 
or returning to baseline (TGF; p>0.05 versus 10 weeks HFD) at 50 weeks. 
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Figure 4.5. Changes in liver gene expression with NAFLD progression. Graphs represent 
transcripts of pro-inflammatory genes (A-C) and genes involved in ECM remodelling or 
fibrosis (D-H) for chow (black) and HFD (blue) animals, calculated as fold-change versus the 
control (10 week chow). Data are mean ± SEM for n=10-12 animals per group, excluding 
outliers determined by the ROUT method (Q=5%). Significant difference from chow (*) or 10 
week HFD (#) accepted at p<0.05 as determined by 2-way ANOVA with Bonferroni’s test (diet 
pairs) or Dunnett’s test (timepoint) for multiple comparisons. Abbreviations: TNF, tumour 
necrosis factor; MCP1, monocyte chemotactic protein 1; SMA, alpha smooth muscle actin; 
Col, collagen; TGF, transforming growth factor beta; TIMP1, tissue inhibitor of 
metalloproteinase 1. 
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With the exception of TGF, the mRNA expression of ECM remodelling genes seemed to 
reflect the findings in Chapter 3. Consistent with this, HFD at 10 weeks did not significantly 
increase any gene of interest above the level of the chow diet. This was not the case for collagen 
IV when using one-sample t testing for HFD fold-change with respect to the corresponding 
age-matched chow group (Figure 4.6). 
 
 
 
A 
 
B 
 
Figure 4.6. Age-adjusted changes in liver gene expression for HFD groups. Data are fold-
change from the chow group at the corresponding timepoint, represented as mean ± SEM for 
n=10-12 animals, excluding outliers. Significant difference from chow (*) accepted at p<0.05 
as determined by a one-sample t test against a hypothetical value of 1 (correcting for the 
respective chow group as the baseline). Changes are relative to timepoint, thus statistical 
differences across timepoints cannot be inferred. Abbreviations: see Figure 4.4. 
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4.4.  Extracellular Vesicle Phenotype 
 
Having established the physical profile of obese animals and the molecular changes in their 
liver at varying stages of NAFLD progression, we next sought to determine whether the EV 
abundance in the plasma or derived from the liver may reflect these subclinical changes and 
hence indicate the severity of disease. To further elaborate on the potential role of liver EVs in 
paracrine signalling, we assessed their protein cargo for changes between simple steatosis and 
NASH, which may be indicative of the phenotype they impart to recipient cells. 
 
4.4.1.  EV enumeration 
 
Interestingly, trends in the total EV number – from both plasma and liver – differed markedly 
from the findings in Chapter 3. (This may be explained by an adjustment in the protocol, 
whereby in the present Chapter, samples were stored frozen prior to the ultracentrifugation 
step, which was performed after thawing and immediately prior to analysis. EVs in Chapter 3 
were stored following ultracentrifugation and thawed prior to analysis.)  
 
4.4.1.1. Patterns in EV abundance 
 
Consistent with our previous findings, the size distribution of both plasma and liver-derived 
EVs showed a lognormal trend (Figure 4.7A). Plasma EVs again had a smaller diameter on 
average when compared to the liver vesicles (83nm versus 106nm, respectively), while the 
variation or standard error across time (10 weeks versus 50 weeks) and between diets was 
small, which implies that EVs within a sampling population are likely to be biophysically 
similar. In terms of sample abundance, plasma EVs from HFD mice were consistently – 
although not significantly – lower than those from their chow counterparts (Figure 4.7B). The 
exception was at 20 weeks, where a peak in the HFD EVs marginally surpassed the chow 
values, before normalising for the remaining timepoints. This peak was also significantly 
elevated (p<0.001) compared to the 10 weeks HFD group. Values for the chow groups, on the 
other hand, remained consistent over time.  
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Unlike the trends observed in Chapter 3, liver-derived EVs in the longitudinal study failed to 
show the same decline with aging or diet. In fact, the abundance increased with time across the 
HFD groups, whereby the values at 50 weeks were significantly higher (p=0.002) than those at 
10 weeks (Figure 4.7C). A similar pattern was also seen for the chow groups, with the exception 
of a sharp elevation at 10 weeks. There were otherwise no differences reported between the 
two diets. When the EV numbers were adjusted for whole liver weight, on the other hand, the 
HFD groups became elevated (though not significantly) over their chow counterparts at 20 and 
30 weeks of diet (Figure 4.7D). Consequently, the EV trend across time in the HFD cohort was 
more linear – both 30 and 50 week groups were significantly greater than 10 weeks (p=0.038 
and p<0.001, respectively) – although the discrepancy between the two diets at 10 weeks was 
still evident.  
 
Among the HFD cohort, there was a statistically significant inverse correlation between plasma 
and liver EVs (r=-0.382, p=0.012), however the 95% CI was high (Figure 4.7E). In an attempt 
to compare the findings of the present study to Chapter 3 (Figure 3.9E), the two EV populations 
were also correlated for the 10 and 50 weeks timepoints for both diets (Figure 4.7F). However, 
this data failed to show any relationships (r=0.088, p=0.577), although this cannot be attributed 
to treatment clustering as intragroup variability was high. 
 
 
 
  
 
 
   125 
 
A  B  
 
C  D  
 
E  F  
 
  
 
 
   126 
Figure 4.7. Plasma and liver EV enumeration and correlations. EV size distributions (A) for 
plasma EVs (peak at 83nm) or liver EVs (peak at 106nm) were similarly lognormal and 
monophasic. Abundance per diameter is normalised and shows mean ± SEM for both curves; 
data for each curve includes EV samples from HFD and standard chow at the 10 and 50 week 
timepoints (n=47). Total plasma EVs (B), liver-derived EVs not adjusted (C) and adjusted (D) 
for total liver weight. Data are mean ± SEM for n=11-12 animals per group, excluding outliers. 
Significant difference from chow (*) or 10 weeks of HFD (#) accepted at p<0.05 as determined 
by 2-way ANOVA with Bonferroni’s test (diet pairs) or Dunnett’s test (timepoint) for multiple 
comparisons. Correlation of the two EV populations (plasma versus liver) showed a significant 
inverse trend (r=-0.382, p=0.012) by the Spearman test when HFD samples from all timepoints 
(n=46) were considered (E). There was no significant trend (r=0.088, p=0.577) when both diets 
from the extreme timepoints (n=47) were considered (F). 
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4.4.1.2. EV correlations with other parameters 
 
When the EVs from HFD animals were correlated against physical and metabolic parameters, 
the strong relationship to hepatic lipids observed in Chapter 3 was no longer present (Table 
4.2). However, other trends became apparent for plasma and liver EVs, respectively. In terms 
of the former, there was a significant positive correlation with plasma TAG (Figure 4.8A; 
values in Table 4.2). Irrespective of a coincident trend with -SMA gene expression, this 
correlation did not reach significance (r=0.262, p=0.098). In the context of liver EVs, there was 
a significant negative correlation when compared against liver TAG (Figure 4.8B; values in 
Table 4.2). There was also a weaker yet significant decline when compared to fasting glucose 
levels, and a positive correlation with plasma AST, body weight, and subcutaneous fat weight 
(Table 4.2), although the latter often suffers from sampling bias.  
 
 
 
A B 
  
Figure 4.8. Extracellular vesicle correlations with TAG. Linear regression shows a positive 
correlation (r=0.548, p<0.001) between plasma EVs and circulating TAG (A) and an inverse 
correlation (r=-0.658, p<0.001) between liver-derived EVs and liver TAG (B). Data represent 
HFD groups (10-50 weeks, w) taken collectively with n=46 per correlation, with significant 
correlations determined by the Spearman test. Abbreviations: TAG, triacylglycerol. 
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Table 4.2. Extracellular vesicle correlations with physical and metabolic parameters. 
 
Parameter Plasma EVs Liver EVs 
r value p value r value p value 
Physical parameters:     
   Body weight (g) -0.096 0.526 0.339 0.028 
   Fat, epididymal (g) -0.172 0.254 0.016 0.919 
   Fat, subcutaneous (g) -0.142 0.346 0.501 0.001 
   Liver weight (g) -0.005 0.972 0.270 0.083 
   Liver TAG (/mg tissue) 0.263 0.078 -0.658 0.000 
   Liver neutral lipids (/mg tissue) -0.088 0.565 -0.199 0.212 
 
Metabolic parameters: 
    
   ALT (U/L) -0.002 0.990 0.246 0.121 
   AST (U/L) -0.084 0.585 0.383 0.013 
   Plasma TAG (mg/dL) 0.548 0.000 -0.274 0.079 
   Plasma insulin (pg/mL) -0.077 0.609 -0.264 0.092 
   Fasting glucose (mM) 0.166 0.277 -0.432 0.005 
   Insulin tolerance, AUC 0.195 0.199 -0.158 0.324 
 
Data represent HFD groups (10-50 weeks) with n=46 per correlation, excluding previously 
determined outliers. Columns show Spearman regression (r value) with significance (p value), 
where significant correlations (p<0.05) are in bold. Both liver TAG and neutral lipids are 
represented as mg/mL/mg liver tissue. Abbreviations: TAG, triacylglycerol; ALT, alanine 
transaminase; AST, aspartate transaminase; AUC, area under the curve in arbitrary units.  
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4.4.2.  EV protein content 
 
To characterise the protein cargo of liver-derived EVs, ultracentrifuged pellets were submitted 
to the Sydney Mass Spectrometry facility, University of Sydney for 1D liquid chromatography 
mass spectrometry (LCMS). Three samples each across four groups were considered (10-week 
HFD and chow, 50-week HFD and chow; total n=12) to highlight differences between early 
steatosis and NASH, as well as changes with aging. The proteomes were first imported and 
analysed for intergroup differences using Scaffold 4 software, while lists of interest in UniProt 
format were entered into an online gene ontology server for functional analysis. 
 
4.4.2.1. Preliminary analysis of unique proteins 
 
When considering all proteins that were present in liver-derived EVs across treatment groups, 
an overwhelming majority were shared between groups upon comparison. For instance, only 
3.8% of proteins on average were uniquely expressed in any given group (intragroup range 1.1-
8.5%) with higher values reported in the younger animals (Figure 4.9A). In this dataset, 744 of 
the total 4,592 proteins (16.2%) were common to all samples. These shared proteins were 
subsequently compared against reference datasets of mouse proteins known to be expressed in 
EVs (see section 4.4.2.2).  
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Figure 4.9. Proteomic analysis of liver-derived extracellular vesicles. Absolute count of total 
proteins within treatment groups (n=3 each), retrieved from Scaffold 4 software, where overlap 
shows proteins common to two or more groups. The number of uniquely expressed proteins 
were: 122/1432 in 10 weeks chow and 10/918 in 50 weeks chow, with 27 proteins overlapping 
between these groups; 32/1331 in 10 weeks HFD and 11/991 in 50 weeks HFD, with 9 proteins 
overlapping. EV proteins that were shared amongst all treatments constituted the largest group, 
with 744 proteins. Values within the Venn diagram were derived from UniProt_ID lists entered 
into the online server InteractiVenn (Heberle et al., 2015). Numbers in brackets represent total 
proteins per group. 
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4.4.2.2. Comparison with reference datasets 
 
The proteome of Mus musculus is well documented and can be accessed from various online 
gene ontology servers, like QuickGo (Binns et al., 2009). Most proteins can be attributed to a 
particular gene ontology identifier, including extracellular vesicles (GO:1903561), which is 
itself a parent term and also an element of multiple hierarchies (Figure 4.10A). The 
predominant daughter term is “extracellular exosome” (GO:0070062), which makes up some 
91% of the 143 recognised EV proteins in this database, including CD63. (Note that the sample 
sources that define this reference set are not explicitly reported.) To determine whether our 
liver-derived EV samples overlap with this set, or alternatively, whether they provide unique 
contributions to EV proteins, the 744 shared proteins (Figure 4.9) were compared against the 
reference set (Figure 4.10B). Interestingly, a vast majority of shared EV proteins were unique 
to our study and excluded the typical exosomal markers. (This was consistent with our western 
blot findings in Chapter 3 (Figure 3.3) where the exosomal marker CD63 was more typical of 
plasma EVs and absent in liver EVs). Proteins of interest included FGGY (carbohydrate 
kinase), FABPL (liver-type fatty acid binding protein), and PLIN2 (perilipin 2), all of which 
are involved in hepatic lipid metabolism and were therefore examined further in Chapter 6.  
 
A more comprehensive database of EV-associated proteins (as well as RNA subtypes and 
lipids) can be found on servers dedicated to EV research, including Exocarta (Keerthikumar et 
al., 2016) and Vesiclepedia (Kalra et al., 2012). These reference datasets provide a pooled 
sample size of 1012 proteins (26 studies) and 4845 proteins (77 studies) from Mus musculus 
tissues, respectively (correct as of August 2018). However, despite their majority concordance 
(89.7% from Exocarta represented in Vesiclepedia), only 196 of 744 shared proteins from our 
sample data (26.3%) were recognised in one or both reference datasets (Figure 4.10C and Table 
A1 in Appendix). In fact, there was no concordance between our samples and the Exocarta set, 
so only Vesiclepedia was used for further comparisons (see Appendix). To this end, 548 
proteins identified in our liver EVs were unique to this study (Figure 4.10C and Table A2). 
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Figure 4.10. Comparison of liver EV proteome with Mus musculus reference datasets. (A) 
Family tree of gene ontology (GO) terms related to extracellular vesicles (image retrieved from 
QuickGo (Binns et al., 2009)). Hierarchy of least specific (top) to most specific terms (bottom 
row); arrows show relationship where more specific terms feed into the more general terms, as 
defined by the legend on the right. (B) A comparison of reference proteins from QuickGo with 
the 744 shared liver EV proteins in our study. (C) These shared proteins were compared against 
a pool of EV proteins from the Exocarta (Keerthikumar et al., 2016) and Vesiclepedia (Kalra 
et al., 2012) large study databases. Values within the Venn diagram were derived from 
UniProt_ID lists entered into the online server InteractiVenn (Heberle et al., 2015). Numbers 
in brackets represent total proteins per group. 
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4.4.2.3. Enrichment analysis 1: qualitative approach 
 
To perform enrichment analysis, our study dataset was compared against the total recognised 
Mus musculus proteome as a reference for fold-enrichment of molecular pathways. Briefly, 
protein symbols were imported into the online gene ontology software DAVID Bioinformatics 
(Huang da et al., 2009) whereupon enriched molecular pathways – that is, KEGG pathways 
(Kyoto Encyclopedia of Genes and Genomes) – were retrieved. Enrichment values were 
obtained for unique proteins that were shared amongst all EVs (n=744), using total proteins per 
treatment group, as per Figure 4.9A. For the comparison of treatment groups, we employed 
hierarchical clustering of enriched pathways using the online matrix visualisation tool 
Morpheus (https://software.broadinstitute.org/morpheus). Pathways for unrelated diseases of 
either a communicable or non-communicable nature were excluded. 
 
When applying the KEGG analysis to the shared EV proteins in our study, 52 pathways were 
reflected in our data after filtering unrelated associations as per above (Figure 4.11). Of these, 
16 (30.8%) were involved in protein metabolism – the largest combined representation – while 
at least 7 (13.5%) were known to be associated with NAFLD pathogenesis. These latter 
pathways included proteins involved in the synthesis (n=8), elongation (n=6) and metabolism 
(n=13) of FFAs, as well as their degradation (n=19) and beta oxidation by PPAR signalling 
(n=15) and peroxisomal activity (n=28). The glycolysis/gluconeogenesis pathway involved in 
energy homeostasis was also highly represented (n=28), and subsequently enriched by over 6-
fold (p<0.001) when compared to the reference proteome. This was unsurprising given that the 
liver is the primary site of this biochemical process.  
 
The enrichment of seemingly antagonistic pathways can be explained by the variations between 
treatment groups. Indeed, when the four treatments were compared for enriched pathways, the 
relative changes between groups were not consistent across many biologically related pathways 
(Figure 4.12). Trends between samples within treatment groups were not consistent either; in 
fact, hierarchical clustering showed that similarities in the sample proteomes were often 
independent of the treatment. Consequently, the fold-change between any two treatment groups 
(on average) was less than 2-fold and therefore unlikely to have large biological significance. 
Whether this is also reflected in functional studies will be investigated further in Chapter 6. 
 
 
   135 
 
 
Figure 4.11. Enriched KEGG pathways for shared liver EVs. Data shows enriched pathways 
within shared unique proteins (n=744) relative to Mus musculus proteomic expression. 
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Figure 4.12. Enriched KEGG pathways across liver EV samples. Unique proteins per sample 
were entered into the DAVID gene ontology software (Huang da et al., 2009) to identify 
enriched pathways. The output data was consolidated for the n=12 samples and pruned to 
exclude pathways where more than three values were not reported. Finally, the dataset was 
entered into the Morpheus online tool (https://software.broadinstitute.org/morpheus) for 
hierarchical clustering of pathways, arranged by Euclidean distance and expressed as fold-
enrichment (range 1 to 10-fold) in a heatmap format.  
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4.4.2.4. Enrichment analysis 2: quantitative approach 
 
A limitation of the LCMS methodology used in this study is that output from the sample data 
is theoretically qualitative; that is, absolute changes in protein abundance are less reliable and 
ought to be expressed as relative changes. Using Scaffold 4 software for paired analyses with 
Fisher’s Exact Test (FET), proteins that were significantly different between treatment groups 
were recorded and subsequently entered into the DAVID gene ontology software (Huang da et 
al., 2009) to identify enriched pathways. Our study focused on three treatment comparisons: 
the effect of diet (10 weeks chow versus 10 week HFD), the effect of aging (10 weeks versus 
50 weeks chow), and changes with NAFL progression to NASH (10 weeks versus 50 weeks 
HFD). The findings for these comparisons are presented in Figure 4.13. 
 
For proteins that were significantly increased in their expression in NASH, enriched pathways 
included those associated with lipid metabolism as well as glycolysis and gluconeogenesis 
(Figure 4.13A). Interestingly, both fatty acid elongation and degradation featured in the 25 
most enriched pathways, which highlights the pleiotropic role of many proteins. As expected, 
just under one third of the pathways involved protein synthesis and metabolism, consistent with 
previous data examining the general proteome across all liver EV samples (Figure 4.11). This 
trend was also reflected in the effect of diet analysis (Figure 4.13B), whereas lipid metabolism 
was similarly overrepresented. As a comparison, the fold-enrichment of pathways involved in 
protein metabolism tended to be greater in the NAFLD progression analysis (Figure 4.13A), 
while those related to lipid metabolism were similar between the two analyses. One notable 
difference in the effect of diet analysis was the presence of a fatty acid biosynthetic pathway 
(Figure 4.13B). Finally, when the effect of aging alone was considered (that is, proteins that 
were significantly increased in 50 weeks versus 10 weeks chow), a majority of the most 
enriched pathways were dedicated to protein synthesis and metabolism (Figure 4.13C), while 
lipid metabolism was no longer present. Examples of pathways that were enriched across all 
three analyses (excluding specific amino acid related) included glyoxylate and dicarboxylate 
metabolism (6-fold to 23-fold) and the pentose phosphate pathway (8-fold to 14-fold), both of 
which are anabolic.  
 
 
 
 
A NAFLD progression B Diet alone 
 
  
C Age alone 
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Figure 4.13. Enriched KEGG pathways for significantly elevated proteins in liver EVs. (A) 
Top 25 most enriched pathways for proteins that were elevated in NAFLD progression, that is, 
EVs from 50 weeks versus 10 weeks of HFD. (B) Top 15 pathways for proteins that were 
elevated in 10 weeks HFD versus chow diet, and (C) elevated in 50 weeks chow diet versus 10 
weeks chow. Statistically elevated proteins were determined by Fisher’s Exact Test (FET). 
Data shows enriched pathways relative to Mus musculus proteomic expression. Amino acid 
abbreviations: Ala, alanine; Asp, aspartate; Glu, glutamate; Gly, glycine; Ser, serine; Thr, 
threonine; Val, valine; Leu, leucine; Ile, isoleucine; Cys, cysteine; Met, methionine. 
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4.5.  Interpretation 
 
The findings from this Chapter highlight the general metabolic and physical profile of animals 
with HFD-induced NAFLD, including the progression from simple steatosis in the liver at 10 
weeks to NASH at 50 weeks. Intermittent timepoints demonstrate the temporal milestones in 
the development of NAFLD and emphasise the fact that disease progression does not tend to 
be linear. In this study, fibrotic changes were completely absent in the earliest stage (10 weeks 
of HFD) whereas collagen staining on histology and gene expression of related markers were 
increased by 20 weeks, but plateaued at 30 weeks before accelerating to widespread fibrosis 
after 50 weeks of HFD. These patterns were also reflected in other parameters – including liver 
TAG and EV abundance – which will be detailed further below. 
 
4.5.1.  Non-linear evolution of NAFLD 
 
While the findings from Chapter 3 were effective in comparing the differences between two 
discrete stages on the NAFLD spectrum – that is, simple steatosis and NASH – this study 
provided a more comprehensive “longitudinal” profile of NAFLD development. For rodents 
commencing on a HFD at an early age (6 weeks, equivalent to adolescent humans; see Figure 
3.1), 10 weeks of diet was sufficient to increase body weight and fat mass in both epididymal 
and subcutaneous depots, as well as plasma insulin levels. This is in line with a previous study 
that investigated the onset of metabolic features in high-fat fed mice (Turner et al., 2013). In 
contrast, preclinical blood glucose and insulin tolerance were inconsistent with the classical 
patterns of insulin resistance expected in progressive obesity (see prediabetes phase in (Ramlo-
Halsted and Edelman, 1999)), although the findings in our study were similar to other rodent 
studies modelling HFD-induced obesity (Ito et al., 2007, Turner et al., 2013). In parallel with 
the increase in NAFLD severity by 20 weeks, the circulating liver enzymes ALT and AST were 
increased above the control (age-matched standard chow diet) as well as the baseline (10 weeks 
HFD). In contrast, plasma TAG in the HFD cohort was consistently below the control groups 
– significantly or otherwise – which is supported by other mouse studies (Gao et al., 2010, Kirk 
et al., 1995) and thought to be a product of decreased hepatic VLDL secretion (Gao et al., 
2010), contrary to humans where plasma TAG is increased in obesity concomitant with insulin 
resistance (Adeli et al., 2001, Lewis and Steiner, 1996). 
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In the context of the liver, 10 weeks of HFD was insufficient to significantly increase the organ 
weight above the control chow group, whereas mild steatosis was already present. Intriguingly, 
the 20 week feeding timepoint was a milestone for dramatic changes in NAFLD pathogenesis; 
these were accompanied by an increase in liver enzymes and a spike in hepatic TAG content, 
as well as significant changes in the gene expression of ECM remodelling markers and MCP1, 
a chemokine responsible for leukocyte recruitment to sites of inflammation (Deshmane et al., 
2009). MCP1 is also known to be sensitive to insulin and is thus increased in obesity and T2DM 
(Rull et al., 2010, Sartipy and Loskutoff, 2003). Most striking, however, were the patterns in 
hepatic lipid accumulation and fibrogenesis as determined by liver histology. When observing 
the HFD cohort across all timepoints, both hepatic TAG and total neutral lipids (all fatty acid 
glycerols, typically in lipid droplets) were consistently elevated above the respective chow 
group, with the exception of the 20 week timepoint: here, TAG was significantly increased and 
neutral lipids decreased when compared to 10 weeks of HFD, and consequently there was no 
difference between the two diets for the latter. Furthermore, while the general morphology in 
terms of steatosis did progress typically from microvesicular to a predominantly 
macrovesicular phenotype, diffuse collagen staining was apparent as early as 20 weeks in some 
animals. Although unusual, this phenomenon had been observed previously (Lo et al., 2011). 
Perhaps unexpectedly, there was no increase in collagen staining at 30 weeks, whereas bridging 
fibrosis was ubiquitous by 50 weeks on HFD; these patterns were in turn reflected in the gene 
expression of collagen I. 
 
4.5.2.  EV abundance reflects TAG levels 
 
When compared to the findings in the previous Chapter, there were several dissimilarities in 
both the plasma and liver-derived EV populations in terms of their abundance. This raises the 
question of sample handling and the need to account for logistical issues; for instance, since 
ultracentrifugation is a low-throughput technique, it was not feasible to complete each step of 
the differential centrifugation series prior to storage at -80oC for the samples in the present 
Chapter. Such variations in the workflow may in turn alter the final EV yield (Jeyaram and Jay, 
2017, Yuana et al., 2015), however, there are currently no universally accepted standards for 
the isolation of EVs according to ISEV guidelines (Witwer et al., 2013, Witwer et al., 2017). 
Due to the random effect on EV yield in our findings (see Figure 4.14), it was important to 
maintain consistency in the isolation method across the remaining studies. 
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Figure 4.14. Effect of storage timing on EV abundance. In Chapter 3, the ultracentrifugation 
step was performed before storage at -80oC (pre-store spin), while in Chapter 4 the EVs were 
stored prior to ultracentrifugation (post-store spin) following the 10,000ൈg spin step. Data 
show mean ± SEM for n=6-12 animals per group. 
 
 
 
Despite these variations, there was a statistically significant inverse correlation between plasma 
and liver-derived EVs when only HFD samples were considered, a trend that is consistent with 
the findings in Chapter 3. However, the same outcome was not achieved when matching the 
treatment conditions to the Chapter 3 data. It is worth noting that the discrepancy also coincides 
with a different trend in hepatic lipid accumulation as measured by ORO staining; this suggests 
that the relationship between absolute hepatic lipid (irrespective of diet) and EV number that 
was seen in Chapter 3 may not be representative of the general population. Therefore, the 
remainder of the analyses in this Chapter considered HFD groups only, over all timepoints. 
Interestingly, when EV abundance by NTA was correlated against other physical and metabolic 
parameters, liver-derived EVs were significantly related to more clinical outcomes than plasma 
EVs. Furthermore, the abundance from each sampling site was reflected in the TAG content 
from the respective site: that is, there was a significant positive correlation between plasma EV 
and plasma TAG concentration, whereas there was a negative correlation between liver EV 
and hepatic TAG. These findings were not only intriguing but also novel, given that in vivo 
studies tend to either correlate EV abundance to NASH fibrosis severity (Kornek et al., 2012, 
Povero et al., 2014, Welsh et al., 2018), or measure EVs as an independent parameter that is 
changed in the treatment group (Baron et al., 2011, Kornek et al., 2011, Kakazu et al., 2016).  
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4.5.3.  Liver EV proteome is heterogeneous 
 
Characterisation of our EV samples was performed using a discovery method (spectrometry) 
rather than a targeted approach (flow cytometry) in the first instance. For the purpose of this 
study, the liver-derived EV proteome was examined to complement previous studies in the 
literature that have analysed the plasma EV proteome in the context of NAFLD (Povero et al., 
2014) or the hepatocyte lipidome following palmitate treatment to promote a NAFLD-like 
lipotoxic environment (Kakazu et al., 2016). The latter reported an increase in C16:0 ceramide 
within the EV cargo of lipotoxic hepatocytes, which was subsequently confirmed in vivo by 
sampling plasma EVs from various models of NASH (Kakazu et al., 2016). Of interest, HFD 
is known to enrich hepatic C16:0 ceramide, which in turn promotes insulin resistance and 
blocks fatty acid beta oxidation (reviewed in (Hla and Kolesnick, 2014)). 
 
In our study, we identified 744 proteins that were expressed across all liver EV samples within 
the confines of the experimental parameters; for example, using a protein threshold of 99% and 
a peptide threshold of 95% (accepting a minimum of 2 peptides). In general, very few proteins 
were unique to any given treatment group, with the majority expressed across all treatments. 
When these shared proteins were considered for gene ontology analysis and mapped to KEGG 
pathways, it was shown that liver EV proteins were predominantly involved in protein and lipid 
metabolism, as well as glycolysis and gluconeogenesis. This suggests that EVs likely play an 
important role in hepatocellular homeostasis, and also highlights their paracrine influence on 
the whole lipid life cycle, from synthesis to oxidation and degradation. The catabolic pathway 
of aromatic compounds was also overrepresented, although the exact implication of this is 
unclear given that many biological molecules – including nucleotides, some amino acids, and 
the haeme portion of haemoglobin – have an aromatic structure, which are chemically more 
stable than their non-aromatic counterparts, such as lipids for example. By comparison, an in 
vitro study using primary or immortalised rodent hepatocytes confirmed the enrichment of fatty 
acid metabolic pathways in the exosomal proteome, whereas pathways related to cell cycle and 
protein synthesis were downregulated (Conde-Vancells et al., 2008). This was the first study 
of its kind to comprehensively examine the EV protein cargo of untreated hepatic cells, and 
has been succeeded by many studies that employ a more targeted profiling and functional 
analysis of hepatocyte EVs in culture (discussed in further detail in Chapter 6). 
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When the liver EV samples from the four treatment groups (10 and 50 weeks HFD and chow) 
were independently analysed for enriched pathways and subjected to hierarchical clustering, it 
was found that their proteomes were heterogeneous. That is, with the exception of 50 weeks 
chow, EV samples that clustered together were not necessarily from the same treatment group. 
Therefore, it was difficult to determine by qualitative analysis which biological pathways are 
affected by aging, diet, or a combination of the two. It is worth noting, however, that these 
inconsistencies may be explained by limitations in the methodology: for instance, a batch effect 
can be observed whereby two samples from different treatment groups that were used for 
calibration (10w HFD3 and 50w HFD3) clustered together across the enriched pathways. The 
small sample size (n=3 per group) is another factor that may have impacted the consistency of 
findings, although a previous study with a similar experimental design did not report on such 
issues (Povero et al., 2014). In contrast to the present study, the authors showed that select 
protein groups tended to cluster samples based on their dietary treatment (Povero et al., 2014), 
whereas age was a stronger predictor of proteomic signature in this study. 
 
On the other hand, quantitative analysis of the liver EV proteome between pairs of treatment 
groups showed that significantly elevated proteins could be mapped to biological pathways, 
which in turn could be assessed for enrichment relative to the species proteome. From here, we 
compared the effect of age (elevated in 50 weeks versus 10 weeks chow), HFD (elevated in 10 
weeks HFD versus chow), and NAFLD progression (elevated in 50 weeks versus 10 weeks 
HFD) on the expression of EV proteins. Interestingly, the two pathways that were enriched 
across all analyses (glyoxylate/dicarboxylate metabolism and the pentose phosphate pathway) 
are both anabolic, in contrast to the homeostatic pathways that were shared across all EVs, 
which were primarily catabolic. The glyoxylate cycle has a similar function to the Krebs (TCA) 
cycle and is involved in gluconeogenesis (Kornberg, 2000), while the pentose phosphate shunt 
occurs in parallel to glycolysis and produces NADPH+ which subsequently protects against 
oxidative stress (Stincone et al., 2015, Wood, 1986). These two pathways were also the most 
enriched in NAFLD progression, in complement to the TCA cycle, glycolysis and 
gluconeogenesis, as well as fatty acid metabolism. Collectively, these enriched pathways 
seemed to imply a protective role for liver EVs in NAFLD, whereas in the study by Povero and 
colleagues, proteins involved in cell stress were elevated in plasma EVs from animals with 
diet-induced steatohepatitis (Povero et al., 2014). 
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The biosynthesis and metabolism of various amino acids were also ubiquitously enriched in 
liver EVs that were subjected to extrinsic (HFD) or intrinsic changes (aging), or the interaction 
of both. In fact, these pathways accounted for the majority of the 15 most enriched pathways 
in terms of EV proteins that were elevated in aging. Again, it is difficult to ascertain the exact 
implications of these findings, although they further highlight the important role of (liver) EVs 
in paracrine homeostasis. In the context of aging, the role of circulating EVs in cell senescence 
has been documented previously (Kadota et al., 2018, Robbins, 2017). However, studies 
examining the EV cargo have tended to focus on a targeted approach, such as western blot or 
protein array (Baek et al., 2016, Takasugi et al., 2017). In the latter, sample clustering based 
on protein co-expression resolved that, much like in our findings, neither aging nor the other 
demographic parameters showed proteomic consistency (Baek et al., 2016). Furthermore, none 
of the studies to date have reported on enriched pathways related to amino acid metabolism in 
either circulating or tissue-derived EVs. The effect of HFD, on the other hand, was comparable 
to the NAFLD progression analysis with a few exceptions, namely the enrichment of fatty acid 
biosynthesis and (perhaps in contradiction) the synthesis of bile acid, which acts to emulsify 
dietary lipids.  
 
4.5.4.  Consolidation 
 
The findings in the present Chapter reinforce the effect of both the intrinsic and extrinsic factors 
that contribute to the development of NAFLD. Subclinical changes in the liver are summarised 
and their relationship to the circulating and liver-derived EV profile are highlighted, whereby 
both EV populations are strongly correlated with TAG levels. Further to their potential role as 
biomarkers of hepatic steatosis, liver EVs were characterised in terms of their proteome, where 
it was determined that while intragroup heterogeneity was present, specific biological pathways 
were enriched in the context of HFD or aging, or their combination (NAFLD progression). The 
cell localisation of proteins that were shared across all liver EV samples in our study are 
illustrated in Figure 4.15. To link the characterisation here with a functional analysis, the 
continuation of this study will investigate the changes in hepatocyte gene expression upon 
exposure to plasma and liver-derived EVs obtained from the current study, which will be 
detailed in Chapter 6. 
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Figure 4.15. Cellular localisation of proteins derived from mouse liver EVs. Numbers indicate 
the protein counts (from n=744 unique liver EV proteins) that were attributed to the given sub-
cellular categories, as determined by gene ontology analysis (Huang da et al., 2009). 
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Chapter 5. 
Impact of genetic manipulation and 
lifestyle intervention for NAFLD on 
extracellular vesicles 
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5.1.  Introduction 
 
While the pathogenesis of NAFLD is complex, much is known about the lifestyle factors that 
exacerbate the disease. Consequently, the impact of physical interventions are well documented 
(Hashida et al., 2017, Keating et al., 2012) and manipulation of the cytokines that drive 
inflammatory tissue injury have also been explored (Chen et al., 2016). The study of EVs in 
either context with respect to NAFLD has not been reported, and thus underpins the 
investigations described in this Chapter (see Figure 5.1 for animal models). 
 
Lifestyle changes are a commonly prescribed therapeutic intervention in NAFLD patients, and 
provide a drug-free alternative to improving liver outcomes in the absence of fibrotic NASH. 
Although there is no consensus on an ideal training program (Keating et al., 2012), aerobic 
exercises seem to provide greater health benefits in terms of decreasing hepatic fat (Ismail et 
al., 2012), irrespective of exercise dose or significant weight loss (Johnson et al., 2009, Keating 
et al., 2015). While most studies have explored moderate-intensity endurance training (END), 
a few have reported on high-intensity interval training (HIIT), a program that is delivered in 
bouts of high intensity exercise interspersed with low intensity recovery periods. Improvements 
to NAFLD burden have been documented in both humans (Hallsworth et al., 2015) and rodents 
(Marcinko et al., 2015) undergoing HIIT. However, the differential effect of END and HIIT 
programs in normalising EV profiles towards a healthy liver baseline is not known. 
 
Similarly, the genetic deletion of pro-inflammatory cytokines such as TNF have been shown 
to affect the development of NAFLD (Salles et al., 2012, Uysal et al., 1997). An upstream 
regulator of NFB signalling in inflammation, TNF is also known to intersect with the insulin 
signalling pathway (Feinstein et al., 1993, Hotamisligil et al., 1994). However, there is a 
paucity in knowledge surrounding the interplay of EVs and the genetic manipulation of 
NAFLD models. The studies described in this Chapter will investigate the impact of HFD on 
EV number in TNF-ablated (TNF-/-) mice bred onsite, using a single 12-week timepoint that 
captures the early stages of NAFLD development and has previously been used for metabolic 
studies on TNF-/- animals (Chen et al., 2016, Turner et al., 2013). The study commenced at 
around 8 weeks of age, similar to the models presented in the previous Chapters. 
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A Genetic model 
 
 
 
B Lifestyle model 
 
 
 
 
Figure 5.1. Schematics for the genetic manipulation or exercise intervention in diet-induced 
NAFLD. (A) Genetic model: transgenic animals lacking expression of TNF ligand (TNF-/-) and 
wild-type C57Bl/6 mice matched for age, gender and strain were administered either a standard 
chow (CH) or high-fat diet (HF; 45%kcal fat) for 12 weeks, commencing at 8 weeks of age. 
(B) Lifestyle model: male C57Bl/6 mice were administered either CH or HF diet for 20 weeks, 
commencing at 10 weeks of age. During the second half of dietary intervention, animals were 
randomly allocated to one of two exercise programs: endurance training (END) or high-
intensity interval training (HIIT), with untrained animals in each diet cohort acting as controls 
for dietary effects. For further details on the methodology of exercise programs, see Chapter 2 
(section 2.2.2). 
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5.2.  Genetic Manipulation: TNF-/- 
 
This study sought to examine the effects of TNF gene inactivation on NAFLD development 
and the release of EVs in this context. The TNF-/- mice were generated by the insertion of a 
modified neomycin resistance cassette into an excised region of exon IV, thereby inhibiting the 
production of functional TNF molecules (Korner et al., 1997). No structural abnormalities were 
detected by histology across the multiple organs examined, including the liver (see previous 
reference). Animal breeding and phenotyping was managed on-site in the animal facility of the 
Centenary Institute by Ms Christine Yee. Mice were commenced on the diet  at 8 weeks of age; 
male TNF-/- mice were fed a HFD or standard chow for a further 12 weeks, and results were 
compared with commercially acquired, gender- and age-matched C57Bl/6 wild-type (WT) 
mice as a control. 
 
5.2.1.  Animal characteristics 
 
While the metabolic profile for the TNF-/- and WT animals maintained on a chow diet were 
comparable, the knockout group had a significantly increased average body weight (by 11%), 
with a negligible increase also seen in the liver weight (Table 5.1). Genetic manipulation and 
HFD seemed to have a synergistic effect, with a much worse metabolic profile seen in TNF-/- 
mice. In the absence of TNF, mice on HFD were obese after 12 weeks (50% heavier than WT) 
with grossly enlarged livers, double the weight of WT controls on the same diet. Liver enzymes 
were also significantly elevated in the knockout group, especially circulating ALT which 
experienced a greater than 6-fold change (p=0.046 versus WT). Despite the biological 
variation, hyperinsulinaemia was also present (greater than 4-fold change, p=0.015), while 
plasma TAG was statistically elevated in TNF-/- mice on HFD compared to their chow 
counterparts (p=0.007). 
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Table 5.1. Animal characteristics in TNF-/- genetic study. 
 
 Chow HFD 
Wild-type TNF -/- Wild-type TNF -/- 
Weights:     
  body (g) 29.3±1.65 32.8±1.09 # 32.5±2.34 * 48.8±0.75 *# 
  liver (g) 1.22±0.18 1.39±0.17 1.36±0.09 3.25±0.84 *# 
  liver as % body 4.16±0.64 4.25±0.59 4.21±0.28 6.63±1.66 *# 
 
Plasma chemistry: 
    
  ALT (U/L) 22.2±5.02 30.0±7.17 26.3±4.50 173±125 *# 
  AST (U/L) 50.4±14.4 49.1±12.6 48.8±13.7 124±54.3 *# 
  ALT/AST ratio 0.45±0.06 0.64±0.19 0.61±0.21 1.30±0.44 *# 
  TAG (mg/mL) 0.70±0.03 0.60±0.14 0.66±0.19 0.89±0.22 * 
  insulin (pg/mL) 137±22.2 276±202 347±141 1623±974 *# 
 
Data are mean ± SD for n=5-8 mice per group, excluding outliers determined by the ROUT 
method (Q=5%). Significant difference from chow (*) or wild-type (#) accepted at p<0.05 as 
determined multiple Student’s t test, per diet or genotype pairs, respectively. Abbreviations: 
ALT, alanine transaminase; AST; aspartate transaminase; TAG, triacylglycerol. 
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5.2.1.1. Hepatic steatosis  
 
Unsurprisingly, liver triglycerides and total neutral lipids – both associated with lipid droplets 
– were ubiquitously elevated by HFD in TNF-/- mice (Figure 5.2). Like previous findings in 
this thesis, TAG extraction seemed to more accurately reflect the liver histology (see Figure 
5.3), whereby the transgenic animals had a significantly increased hepatic TAG content when 
compared to their WT counterparts on HFD (Figure 5.2A), with no changes seen between the 
two genotypes in the chow-fed groups. In contrast, these patterns were not observed when 
examining liver neutral lipid content (Figure 5.2B), although this could be explained by the 
high intragroup variations. An additional increase in ORO staining in the TNF-/- group was 
seen for the chow diet, suggesting that the presence of TNF may regulate the storage of fatty 
acids in the liver as lipid droplets. 
 
 
 
A 
 
B 
  
Figure 5.2. Impact of TNF knockout on liver lipid. A. Triacylglycerol (TAG) extracted from 
homogenised liver. B. Neutral lipids (fatty acid glycerols) were stained with Oil Red O (ORO) 
in homogenised liver prior to elution. Data are mean ± SD given per unit tissue for n=5-8 
animals per group, excluding one chow outlier. Significantly different from chow (*) or wild-
type (#) accepted at p<0.05 as determined by multiple Student’s t test, per diet or genotype 
pairs, respectively.   
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5.2.2.  NAFLD phenotype in TNF-/- mice 
 
5.2.2.1. Liver histology  
 
Liver histology showed a unique pattern of early NAFLD development in TNF-/- mice when 
compared to their WT counterparts. Macrovesicular steatosis was observed in the livers of WT 
animals on HFD (Figure 5.3E), with diffuse pericellular collagen deposits evident in some 
samples (Figure 5.3F). This latter phenomenon was unusual considering the short duration of 
the diet, however, it seemed to indicate a possible protective role of TNF deletion against 
fibrosis development (Figure 5.3H); that is, TNF may promote fibrogenic changes. In contrast, 
knockout mice receiving HFD had diffuse macrovesicular steatosis with large distinct islands 
of microvesiculated hepatocytes, often in periportal regions, giving the liver a histologically 
“foamy” appearance (Figure 5.3G). Enlarged pale staining hepatocyte nuclei were evident in 
HFD animals of both genetic backgrounds (Figure 5.3E and G, inset), although these changes 
were more prominent in the WT group, suggesting heightened levels of cell activity (typically 
protein synthesis). Finally, animals receiving a standard chow diet had seemingly normal livers, 
irrespective of genotype, with basal collagen staining in the perivascular connective tissue 
(Figure 5.3A-B and C-D, respectively). 
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Figure 5.3. Impact of TNF knockout on liver histology. Left panels show general morphology 
by H&E staining, right panels show collagen accumulation (red) by PSR staining for respective 
treatment group. Livers of mice fed chow diet appear normal for both wild-type (WT; A-B) 
and TNF-/- background (C-D), whereas high-fat diet (HFD) livers showed different patterns of 
steatosis in WT (E-F) compared to TNF-/- (G-H), with mild fibrosis in some WT livers (F). 
Representative images at 100ൈ magnification (scale bar = 100m), inset 200ൈ. 
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5.2.2.2. Liver gene expression  
 
To confirm the absence of TNF from the genome of knockout mice, we examined the levels of 
transcript in these animals in relation to their wild-type counterparts (Figure 5.4A). As 
expected, TNF was undetectable in TNF-/- animals on either diet, whereas in WT mice on HFD 
there was a trend toward increased TNF expression, although this was not significant 
(p=0.211). For the remaining genes of interest, no difference was observed between HFD and 
chow groups for WT animals. This was also the case for TNF-/- animals, with the exception of 
the macrophage marker F4/80 which was decreased 3-fold by HFD (p=0.011) in the knockout 
group (Figure 5.4C).  
 
Interestingly, other notable trends (significant or otherwise) tended to occur between TNF-/- 
and corresponding WT groups irrespective of diet. Aside from TNF, the cytokine MCP1 was 
also decreased in knockout animals, although the change only reached significance for the 
chow diet (p=0.009; Figure 5.4B). On the other hand, TNF deletion increased the expression 
of F4/80 (Figure 5.4C) as well as ECM remodelling genes (Figure 5.4D-F), although in most 
cases – as in for MCP1 – the difference was only significant between the chow groups (F4/80: 
p=0.015; collagen IV: p=0.008; TIMP1: p=0.033). The exception was collagen I, where the 
elevation failed to reach statistical significance (Figure 5.4D; p<0.10 both diets). These 
discrepancies could be explained by high biological variability within HFD groups, primarily 
for TNF-/- animals. Furthermore, a defined batch effect was also seen in TIMP1 expression 
(Figure 5.4F) for TNF-/- mice on HFD, where staggering the experiment (n=4+4) had resulted 
in disparate fold-change ranges of approximately 1-5 (p=0.04 versus WT) and 40-140 (p=0.01), 
respectively (overall p=0.14). Therefore, it was difficult to interpret the data related to this 
particular finding. 
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Figure 5.4. Liver gene expression for the genetic study. Graphs represent transcripts of pro-
inflammatory genes (A-C) and genes involved in ECM remodelling or fibrosis (D-F). Data is 
expressed as mean ± SEM of fold-change from control (wild-type (WT) mice on chow diet) 
for n=5-8 mice excluding outliers. Significant difference from chow (*) or WT (#) accepted at 
p<0.05 as determined by multiple Student’s t test, per diet or genotype pairs, respectively. 
Abbreviations: TNF, tumour necrosis factor; MCP1, monocyte chemotactic protein 1; Col, 
collagen; TIMP1, tissue inhibitor of metalloproteinase 1. 
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5.2.3. Extracellular vesicle enumeration 
 
Following 12 weeks of HFD, neither diet nor genotype had an effect on EV enumeration. For 
both EV abundance and normalised size distribution, no trends were observed in our data when 
either plasma (Figure 5.5A-B) or liver EVs (Figure 5.5C-D) were considered. This was 
intriguing, given the obvious changes noted previously in metabolic parameters (Table 5.1), as 
well as the liver phenotype in terms of lipid content (Figure 5.2), histology (Figure 5.3), and 
gene expression (Figure 5.4). With a predominantly genotype effect shown in the latter, it was 
expected that this parameter may contribute to potential EV fluctuations. When liver EV 
abundance was adjusted for total liver weight, there was a 9-fold increase in EVs (p=0.009) for 
high-fat fed knockout mice relative to their WT counterparts (Figure 5.5E). Since the 
unadjusted values were similar between these groups (p=0.732 versus ‘per mg tissue’), this 
change can likely be explained by the accelerated steatosis seen in TNF-/- animals on HFD. 
Finally, while the size distributions were unchanged between treatment groups, the trends were 
consistent with previous findings in this thesis whereby the diameter of plasma EVs tended to 
be around 70nm (Figure 5.5B), while liver EVs were slightly larger at 100nm (Figure 5.5D). 
Together, this data suggests that TNF expression does not affect the EV profile in NAFLD, or 
alternatively, only affects the abundance of liver-derived EVs insofar as the estimated total 
vesicles released from the whole liver, which in turn can be attributed to an increase in liver 
size.  
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Figure 5.5. Extracellular vesicle enumeration for the genetic study. Data for total EVs (left 
panes) shows mean ± SEM for n=5-8 mice per group, excluding outliers. Size distribution 
graphs (right panes) show group normalised mean values for EV diameter. Significant 
difference from respective diet (#) accepted at p<0.05 determined by Student’s t test. No change 
was seen between diets for either genotype. 
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5.3.  Lifestyle Intervention: Exercise 
 
In a study designed to explore how different exercise modalities can impact on obesity and its 
complications (including NAFLD), mice receiving HFD or standard chow were randomly 
assigned to one of three groups: endurance training (END), high-intensity interval training 
(HIIT), or untrained. Following 9 weeks of diet without further intervention, animals were 
acclimated to the treadmill for one week, then continued on one of the three programs above 
for a further 10 weeks while maintaining their original diet. Metabolic parameters were 
recorded, and an ITT performed, in the final week before conclusion of the experiment. For the 
purpose of this study, only the plasma and liver were considered, with the aim of identifying 
changes in their respective EV populations in association with liver changes following HFD 
with or without the exercise intervention.  
 
5.3.1.  Animal characteristics 
 
While it was expected that the burden of most physical and metabolic changes that occur with 
high-fat feeding would be reversed by exercise, this was not seen in our study. The increased 
body weight with HFD was unperturbed by either exercise program (Table 5.2), although this 
is consistent with clinical studies in the literature (Johnson et al., 2009, Keating et al., 2015). 
In contrast, increased liver weight in HFD was decreased by both END and HIIT but did not 
normalise to chow-fed levels, while only HIIT affected the weight of adipose depots; these 
were differentially regulated, with a decrease in the subcutaneous fat mass, and conversely, an 
increase in epididymal fat mass.  
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5.3.1.1. Plasma biochemistry  
 
The findings above were supported by the biochemical profile of the exercised HFD groups. 
Circulating liver enzymes were consistently lower in exercised animals compared to their 
untrained counterpart (Table 5.2). Interestingly, END also increased AST levels outside the 
HFD context (p=0.001 versus untrained chow), a trend that was not seen for ALT and was 
therefore unlikely to be related to changes in the liver. Plasma TAG was normalised by END 
in HFD mice (p=0.010 versus untrained) and was indistinct from the chow group undergoing 
END (p=0.992). In contrast, the hyperinsulinaemia in the END-trained HFD group (p=0.001 
versus untrained) points to a synergy of the combined interventions (p=0.004 interaction of 
sources of variation by two-way ANOVA). Finally, exercise had no impact on the ITT, while 
untrained HFD animals had an elevated AUC (p=0.011 versus chow), suggesting decreased 
insulin sensitivity. 
 
5.3.1.2. Hepatic steatosis  
 
When examining changes in the liver lipid, disparate results were observed between the two 
methodologies used for these measurements. The TAG extraction technique, which is more 
sensitive, showed no effect of exercise on TAG levels in livers of animals fed a standard chow 
diet. However, liver TAG was increased across all HFD groups (p<0.001 for all diet pairs) and 
was further elevated by both END and HIIT (Figure 5.6A; both p<0.001 versus untrained 
HFD). In contrast, the diet effect was much weaker for ORO-stained neutral lipids due to 
intragroup variability, whereas no difference was observed between diets in the HIIT program 
(p=0.314; Figure 5.6B). While ORO staining in the HFD livers was only increased relative to 
chow in the untrained (p=0.014) and END (p<0.001) groups, the HIIT program was capable of 
normalising this parameter (p=0.011 versus untrained HFD). 
 
 
 
 
 
 
 Table 5.2. Animal characteristics for the exercise intervention study. 
 
 Chow   HFD   
Untrained Endurance HIIT Untrained Endurance HIIT 
Weights (g):       
  whole body 33.3±2.35 32.2±1.74 32.9±1.19 47.7±2.63 * 47.5±4.14 * 45.4±4.70 * 
  liver 1.52±0.14 1.46±0.15 1.43±0.18 3.69±0.52 * 2.98±0.93 *# 2.61±0.61 *# 
  epididymal fat 0.70±0.22 0.52±0.11 0.54±0.16 1.76±0.32 * 1.96±0.35 * 2.14±0.30 *# 
  subcutaneous fat 0.35±0.09 0.29±0.05 0.29±0.06 1.81±0.27 * 1.70±0.45 * 1.38±0.44 *# 
 
Plasma chemistry: 
      
  ALT (U/L) 19.0±3.46 36.5±19.2 20.5±4.41 208±116 * 91.5±47.5 *# 41.6±24.3 *# 
  AST (U/L) 57.8±12.5 120±59.3 # 67.3±28.3 160±65.3 * 114±41.0 # 76.9±16.7 # 
  ALT/AST ratio 0.31±0.05 0.34±0.12 0.36±0.11 1.10±0.23 * 0.89±0.36 * 0.61±0.31 *# 
  TAG (mg/mL) 1.83±0.61 1.80±0.57 1.33±0.39 # 1.12±0.30 * 1.77±0.71 # 1.14±0.23 
  insulin (pg/mL) 157±80.4 141±50.0 163±78.4 1193±636 * 4284±1882 *# 1737±937 * 
 
Insulin tolerance test: 
      
  fasting glucose (mM) 7.98±1.14 7.47±0.85 8.11±1.61 8.35±1.54 8.37±1.17 * 8.33±1.42 
  area under curve (AU) 275±52.5 333±127 310±60.8 336±53.6 * 336±31.2 311±52.5 
 
Data are mean ± SD for n=10-12 animals per group, excluding outliers determined by the ROUT method (Q=5%). Significantly different from 
chow (*) or untrained animals on the same diet (#), accepted at p<0.05 as determined by Student’s t test (diet pairs), or 2-way ANOVA (training) 
with Dunnett’s test for multiple comparisons. Abbreviations: ALT, alanine transaminase; AST; aspartate transaminase; TAG, triacylglycerol; AU, 
arbitrary units. 
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Figure 5.6. Impact of exercise on liver lipid. A. Triacylglycerol (TAG) extracted from 
homogenised liver. B. Neutral lipids stained with Oil Red O (ORO) in homogenised liver. Data 
are mean ± SD per unit weight of tissue for n=10-12 animals per group, excluding outliers. 
Significant difference from chow (*) or untrained animals on the same diet (#) accepted at 
p<0.05 as determined by Student’s t test (diet pairs), or 2-way ANOVA (training) with 
Dunnett’s test for multiple comparisons.   
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5.3.2.  NAFLD phenotype in exercised mice 
 
Both structurally and on a molecular level, the livers of animals on a standard chow diet were 
invariably normal, irrespective of exercise intervention. For simplicity of interpretation, 
controls in this section will be represented by the untrained chow group. 
  
5.3.2.1. Liver histology  
 
The livers of mice receiving a standard chow diet appeared unremarkable in either general 
structure (Figure 5.7A) or collagen staining by PSR (data not show), irrespective of exercise. 
In contrast, 20 weeks of HFD without exercise intervention resulted in profound architectural 
changes, including both microvesicular and abundant macrovesicular steatosis (Figure 5.7B), 
although fibrotic changes were mild (Figure 5.7C). The progression of NAFLD appeared to be 
impeded by both END (Figure 5.7D-E) and HIIT (Figure 5.7F-G), however, bands of 
microvesicular steatosis were still present. There was a differential impact of the two exercise 
programs in the HFD mice. In END-trained animals, steatosis tended to be periportal (Figure 
5.7D) and fibrosis was absent (Figure 5.7E); conversely, mild peri-cellular collagen staining 
was evident in the livers of mice undergoing HIIT (Figure 5.7G), although not to the same 
extent as seen in the untrained NAFLD livers. Interestingly, whilst HIIT did not seem to afford 
any benefit over END in terms of visible steatosis, there appeared to be a greater impairment 
of the liver architecture in these animals (Figure 5.7F), such that the lobules were less defined. 
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Figure 5.7. Impact of the exercise programs on liver histology. Left panels are representative 
general morphology by H&E staining, right panels show collagen accumulation (red) by PSR 
staining for respective treatment group. Livers of mice fed chow diet appeared normal (A) 
whereas high-fat diet (HFD) livers showed considerable steatotic changes with some loss of 
architecture and mild fibrosis (B-C). Steatosis was milder following END (D-E) and HIIT (F-
G) in HFD groups, with no or limited fibrotic changes with either exercise. Images given at 
100ൈ magnification (scale bar = 100m), inset 200ൈ. 
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5.3.2.2. Liver gene expression  
 
Changes in the liver transcript levels of inflammatory markers, growth factors, and regulators 
of ECM remodelling were determined using a custom-designed OpenArray™ chip for real-
time qPCR. This included 24 genes of interest and 4 reference genes (see Table 2.7). Of the 
reference genes, aldolase B was most consistently amplified and for this reason was used for 
normalisation. A total of 50 samples were assessed (n=6-10 per group), following exclusion of 
reference gene outliers and samples that failed to express any gene. In addition, some genes 
were undetectable in many of the control animals. Consequently, only genes that were 
expressed in at least three control (untrained chow) animals were reported in this work. A 
heatmap of genes in mice reaching these criteria is shown in Figure 5.8. below. A total of 14 
genes were included in the final analysis. Of these, sufficient data was only available for 7 
genes in the HFD+HIIT group. Analysis of the remaining 7 genes focused only on the effects 
of END on HFD.  
 
Compared to the control group, the expression of 8 of 14 genes was increased in untrained 
HFD animals, whereas END reversed this change in all instances (Figure 5.9). This included 
collagen I and IV, as well as ECM regulators (TGF, TIMP2, and basigin) and chemokines 
(MCP1 and CXCL10). For collagen I, this finding was also reflected in the liver protein 
expression (performed by S. Martinez-Huenchullan, unpublished manuscript). Interestingly, 
the response from the HFD+HIIT group was less consistent: decreasing similar to HFD+END 
(MCP1 and TIMP2), or comparable to HFD alone (CXCL10, TGF, and basigin). These 
findings suggest that the END program may exert a broader effect in terms of normalising gene 
expression in HFD animals. In fact, even where changes with HFD were not observed or 
trended towards a decrease (CTGF, VEGF, and -SMA), the expression levels of these genes 
tended to be further decreased by END training.  
 
Unfortunately, due to the high intragroup variability in untrained animals across multiple 
genes, statistical analyses often failed to show a significant change. Furthermore, given the 
inconsistent fluctuations across functionally related genes, it was difficult to identify specific 
outcomes of exercise intervention in the context of HFD, at least in terms of molecular 
regulation in the liver.  
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Figure 5.8. Heatmap of gene array for exercise intervention study. Non-hierarchical display of 
genes of interest (columns) across respective samples (rows) divided into untrained, endurance 
(END) and high-intensity interval training (HIIT) per diet. Legend represents negative delta-
delta cycle threshold, given as log2(fold-change) versus control group (untrained chow). Empty 
squares where no cycle threshold values were recorded. Gene symbol abbreviations: ACTA, 
alpha smooth muscle actin (also SMA); BSG, basigin; COL1A1 and 4A1, collagen I and IV 
subunit A1; CTGF, connective tissue growth factor; CXCL10, C-X-C motif chemokine 10; 
HGF, hepatocyte growth factor; MCP1, monocyte chemotactic protein 1; MMP14, matrix 
metalloprotease  14; PDGFB, platelet-derived growth factor subunit B; TGFB1, transforming 
growth factor beta subunit 1 (also TGF); TIMP2, tissue inhibitor of metalloprotease 2; 
VEGFA and R2, vascular endothelial growth factor subunit A and receptor 2.  
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Figure 5.9. Liver gene expression for exercise intervention study. Genes where END was more 
effective than HIIT at normalising HFD changes (A-C), END and HIIT were equally as 
effective (D-E), END was effective and HIIT was unknown (F-I). Data show mean ± SEM for 
n=3-10 per group excluding outliers. Significant difference from control, untrained chow (*), 
or HFD (#) as determined by Student’s t test, or where HIIT data was available, 2-way ANOVA 
(vs HFD) with Dunnett’s test for multiple comparisons. See Figure 5.8 for gene abbreviations. 
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5.3.3.  Extracellular vesicle enumeration 
 
Consistent with previous findings in this thesis, dietary intervention (up to 20 weeks) failed to 
change the profile of either circulating or liver-derived EVs in mice. While EV abundance has 
been shown to fluctuate over time irrespective of diet (see Figures 3.8 and 4.7), the present data 
offers a snapshot of the effect of 10 weeks of exercise on these parameters.  
 
At termination, there was no difference between untrained HFD and chow group for either 
plasma (p=0.742) or liver-derived (p=0.931) EV abundance, whereas the effects of the two 
training programs could be seen in both EV populations. Plasma EV number was increased by 
around 2-fold by END independently of diet (chow: p=0.003; HFD: p=0.022), while HIIT 
failed to show any changes (Figure 5.10A). In contrast, both programs similarly decreased 
liver-derived EVs (Figure 5.10B), by at least 15-fold in the chow cohort (END: p=0.019; HIIT: 
p=0.015 versus untrained) and at least 11-fold in the HFD cohort (both p=0.011 versus 
untrained HFD).  
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Figure 5.10. EV enumeration for exercise intervention study. Graphs represent plasma (A) and 
liver-derived EVs (B) corrected for volume and incubated tissue weight, respectively. Data are 
mean ± SEM for n=10-12 animals per group, excluding outliers. Significant difference from 
chow (*) or untrained (#) accepted at p<0.05 as determined by Student’s t test (diet pairs), or 
2-way ANOVA (training) with Dunnett’s test for multiple comparisons 
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5.4.  Interpretation 
 
The outcomes of diet-induced obesity and its metabolic complications, including NAFLD, are 
a well recognised concept in modern healthcare systems. Given the plethora of guidelines that 
address NAFLD specifically (European Association for the Study of the Liver et al., 2016, 
Chalasani et al., 2018, LaBrecque et al., 2014) – from its socioeconomic burden to critique of 
screening efforts and importantly, a lack of reliable tools to assess disease progression – it is 
unsurprising that exploratory research to develop novel biomarkers has become so popular (see 
Table 1.3 in Chapter 1). EVs have also been considered as a desirable candidate (Ban et al., 
2016), however, their translational utility is limited by the current technologies used for their 
isolation and characterisation. Furthermore, it can be expected that comorbidities or physical 
interventions may alter the EV profile, which hence can be used for monitoring disease 
progression. This Chapter aimed to dissect the interaction between HFD and a second variable 
in two models: one examining the role of an immune mediator in NAFLD development (TNF) 
through genetic manipulation of its expression (Chapter 5.2), and another comparing the effect 
of different exercise programs as a lifestyle intervention (Chapter 5.3).  
 
5.4.1.  Diet, TNF expression, and their combined effect on EVs 
 
As described previously in Chapter 1, inflammatory molecules such as TNF are central to 
driving the progression of NAFL to NASH (Braunersreuther et al., 2012), which follows the 
paradigm of liver disease evolution from inflammation through fibrosis. Depending on the 
context, TNF will employ different signalling pathways via its receptors (TNFR1 and TNFR2) 
resulting in disparate outcomes for hepatocyte viability (Cosgrove et al., 2008, Xu et al., 1998). 
Previous studies have shown that steatotic hepatocytes stimulated with TNF in vitro are more 
prone to apoptosis (Zhang et al., 2010), which suggests that the TNFR1 pathway is likely to 
predominate. While viability was not investigated in this thesis, two other widely documented 
phenomena may be considered: TNF-mediated regulation of insulin signalling (leading to 
insulin resistance), and control of adipose tissue development and function.  
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It had been demonstrated in adipocytes that enzymes downstream of TNFR are capable of 
intercepting the insulin signalling pathway (Feinstein et al., 1993, Hotamisligil et al., 1994). 
Subsequent studies in obesity have supported this theory, with a majority of rodent high-fat 
feeding models noting that in the absence of TNF ligand or its receptors, animals fail to develop 
insulin resistance and their NAFLD severity is reduced when compared to WT mice on the 
same diet (Salles et al., 2012, Tomita et al., 2006, Uysal et al., 1997). Similar findings were 
also shown in genetic models of obesity (Kakino et al., 2018, Uysal et al., 1998). However, 
others have reported conflicting findings whereby TNF or TNFR deletion resulted in poorer 
insulin sensitivity and increased liver TAG (Chen et al., 2016, Pamir et al., 2009). One study 
also pointed to an increased propensity for weight gain in TNF-/- mice on HFD for 12 weeks 
when compared to WT (Chen et al., 2016), a phenotype that is consistent with the changes 
observed in our study using a comparable model (see Figure 5.11). In fact, even at baseline the 
transgenic cohort of our study was around 20% heavier, despite matching for age and diet. This 
could be explained by the cytokine’s role in the regulation of adipocyte biology (Cawthorn and 
Sethi, 2008, Warne, 2003); that is, in the absence of TNF, both lipolysis and the associated 
suppression of lipogenesis are likely to be impaired. This in turn leads to an increase in the 
lipid storage/retention within adipose depots. 
 
 
 
 
Baseline body weight 
 
 Weight gain over time 
 
 Epididymal (visceral) fat 
 
Figure 5.11. TNF-/- affects adipose tissue mass and weight gain. Body weight at baseline, 
weight gain during the experimental period (area under curve; AUC), and terminal adipose 
mass (epididymal) were all increased in transgenic mice (green) compared to wild-type (black), 
irrespective of diet. Data for n=4-8 animals per group; statistical analysis by Student’s t tests 
(p<0.05 significant). 
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Therefore, we can assume that the accelerated liver steatosis during high-fat feeding relies on 
a mechanism other than FFA influx due to its liberation from adipose tissue. It is possible that 
1) insulin resistance in transgenic mice (evidenced by hyperinsulinaemia) gives rise to excess 
lipid substrates in the liver through gluconeogenesis, or 2) since TNF is known to suppress 
fatty acid transporters (Memon et al., 1999, Memon et al., 1998), perhaps the increased 
expression of these proteins in TNF deficient animals act in synergy with dietary lipids to 
promote the formation of lipid droplets. Indeed, this was confirmed by a 2-fold elevation in 
hepatic TAG compared to WT mice on a HFD. Hepatic ORO staining was elevated in 
transgenic mice on a standard chow diet, suggesting that TNF alone may be involved in the 
regulation of other neutral lipids (including DAG, a precursor in TAG synthesis).  
 
The gene expressions of fibrogenic markers (both fibrillar and network collagens, as well as 
TIMP1) were also substantially elevated in TNF-/- animals independently of diet, which was 
unusual given that TNF has been reported to promote the survival of hepatic stellate cells in 
the liver (Pradere et al., 2013), although findings on stellate cell activation are mixed (Knittel 
et al., 1999, Saile et al., 1999). In contrast to liver lipid, our histological findings showed an 
increase in collagen staining in WT livers after high-fat feeding, but not in the livers of 
transgenic animals. This pattern is more consistent with the aforementioned “inflammation 
driving fibrosis” paradigm, and therefore, it could be that the gene expression profile doesn’t 
necessarily reflect protein expression or activity. However, this data was not investigated in 
our studies. 
 
With respect to EVs, our data shows that TNF expression does not affect the EV profiles per 
se, however the increased liver size in TNF-/- animals may contribute to a higher abundance of 
liver-derived EVs in the circulation (or biliary system or lymphatics). Furthermore, it was 
shown that genotype does not influence the physical characteristics of EVs, at least in terms of 
their diameter, and together with our previous findings it may be assumed that EV biogenesis 
follows a tissue-specific pattern in mice. On the other hand, while it is possible that the EV 
molecular cargo was varied between treatment groups and may affect the hepatocyte 
phenotype, this was not investigated in our work. 
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5.4.2.  Diet, exercise, and their combined effect on EVs 
 
Lifestyle interventions are the current gold standard for the treatment of non-fibrotic NAFLD. 
These are usually delivered as a hypocaloric diet or aerobic training regimen, the latter of which 
is known to alleviate NAFLD burden, even in the absence of body weight changes (Johnson et 
al., 2009). This phenomenon was also reflected in our study, where a stagnation of weight gain 
was apparent only during the first five weeks of training, before eventually compensating for 
the caloric deficit and again matching the untrained group (see Figure 5.12). By termination, 
only HIIT had affected the fat depot weights (although interestingly, it seems that beige-like 
(Zhang et al., 2018) subcutaneous adipose tissue may have potentially been redistributed to the 
epididymal site, given the inverse changes in their weights). 
 
 
 
 
 
Figure 5.12. Weight gain chart for exercise intervention study. Grey band shows acclimation 
period. Data for n=10-12 animals per group; statistical analysis by 2-way ANOVA with 
Dunnett’s test for multiple comparisons (*p<0.05 HFD+HIIT vs HFD). 
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In terms of the liver, both END and HIIT were effective in reducing the tissue weight as well 
as stabilising the HFD-mediated increase in liver enzymes (ALT and AST). On the other hand, 
these changes did not correlate with a quantitative decrease in hepatic lipids; the modest yet 
statistically significant increase in neutral lipids due to HFD (equivalent to lipid droplet 
formation and its precursors) was only reversed by HIIT, whereas the substantial HFD-induced 
increase in TAG was further elevated (around two-fold) by both training programs. This is 
unsurprising, as exercise is a known inducer of lipolysis in adipose tissue, thereby increasing 
the circulating FFA and compounding the effect of HFD.  
 
The elevated hepatic TAG may also result from a combination of increased FFA influx and 
decreased efflux in VLDL lipoproteins, a phenomenon that has previously been reported in 
clinical exercise studies (Shojaee-Moradie et al., 2016, Sullivan et al., 2012) and in rodent 
models (Gorski et al., 1988, Horton et al., 1999). In this work, we showed an effect of both diet 
and exercise on plasma TAG (usually associated with VLDL), where HFD significantly 
decreased TAG in the absence of exercise, as noted in previous studies (Biddinger et al., 2005, 
Guo et al., 2009). END training prevented this change, which may imply that NAFLD-related 
derangements to VLDL secretion were normalised, liberating more TAG into the circulation. 
In contrast, HIIT showed a reduction in TAG with standard diet and an inability to normalise 
the HFD-induced decrease. In comparison to the quantitative changes in liver lipids, 
histological analysis showed a decrease in hepatocellular lipid droplets and fibrotic staining 
with exercise for mice on HFD. This result confirms the hepatoprotective effect of exercise, as 
most END and HIIT samples had only microvesicular steatosis which is evident in the earlier 
stages of NAFLD. 
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Analysis of gene expression was more specific in differentiating the exercise-related benefits 
on the liver. Using a gene array panel with predominantly inflammation and matrix turnover 
markers that are key to liver disease progression, we noted an intriguing pattern in the liver 
gene expressions relative to the control group (untrained standard chow): these tended to occur 
in two distinct profiles, independently of known molecular links, such that 1) where HFD 
increased gene expression, either exercise normalised these changes; or 2) only END training 
was capable of normalising the change with HFD whereas HIIT had no effect (or gene 
expression was undetectable for a majority of samples). Therefore, it appeared that END was 
more protective against the molecular changes associated with NAFLD progression (c.f. 
steatosis quantitation with ORO where HIIT showed greater efficacy). An example was 
collagen I, a fibrillar collagen subtype linked to hepatic fibrogenesis, which was regulated by 
END at both the mRNA (Figure 5.9) and protein level (Martinez-Huenchullan et al., 
unpublished manuscript). 
 
Finally, the differential effects of exercise were once again reflected in the circulating and liver-
derived EV profiles. Consistent with the trends seen throughout this thesis, there was no change 
concomitant with dietary intervention at this timepoint (20 weeks cross-section), for either of 
the studied EV populations. However, there was a substantial decline (over 10-fold) in vesicles 
released from the liver following either exercise program, with no statistical variation between 
END and HIIT within (and even across) respective dietary cohorts. While the mechanism for 
this is not entirely clear, it is interesting that these differences were maintained for the week 
preceding euthanasia when no exercise was performed. From a global perspective on the role 
of EVs in intercellular communication, it may be that incoming signals to the liver are more 
relevant than outgoing ones, a theory that may in fact be supported by a recent seminal study 
on the biodistribution of EVs following acute exercise (Whitham et al., 2018). Using intravital 
imaging of mice injected with fluorescently labelled EVs from exercised or sedentary donors, 
the authors showed that exercised EVs specifically will home to the liver (Whitham et al., 
2018).  
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On the other hand, the abundance of plasma EVs in our study depended on the type of training: 
while EV numbers were doubled by END training, surprisingly, HIIT had no observable effect 
over untrained conditions for the respective diets. This raises two very interesting points. 
Firstly, the increased secretion of EVs into the circulation during moderate intensity exercise 
has been reported previously (Safdar et al., 2016). Characterisation and functional studies of 
these vesicles further show a link to haematological events (Durrer et al., 2015, Sossdorf et al., 
2011, Wahl et al., 2014, Wilhelm et al., 2016), although their molecular cargo is unsurprisingly 
complex, involved in a diverse range of biological processes (Whitham et al., 2018). Secondly, 
the exercise protocol may impact the EV number, with a majority of studies (including all the 
aforementioned) examining the impact of an acute trial; either a single session, typically on a 
cycle ergometer, or multiple sessions across one week. Despite these limitations, there is 
potential for future studies to explore the correlation between EVs in exercise and other 
relevant clinical parameters such as cardiac output or quantitative muscle injury.  
 
5.4.3.  Functional relevance 
 
Since there were no remarkable changes in the EV profile for transgenic animals on either diet 
(Figure 5.5), they were not investigated for their functional effects in this thesis, although the 
characterisation of these EVs and their physiological role would be of interest in future studies. 
On the other hand, EV samples obtained from exercised humans and mice have been shown to 
be involved in intercellular communication (Whitham et al., 2018). In our study, exercise-
related changes in the EV profile suggest that interventions against diet-induced NAFLD (and 
obesity as a whole) may have a more significant impact on EV signalling than the metabolic 
condition itself. This is especially relevant for the END program, however, the trends in either 
EV profile do not tend to reflect the changes observed in other measured parameters; that is, 
they cannot be correlated with markers of NAFLD development unless the chow cohort is 
excluded from consideration. Given that liver-derived EVs for both END and HIIT groups were 
significantly reduced in abundance, it can be inferred that their collective effect in vivo is 
probably also limited. For this reason, only the highly abundant plasma EVs were considered 
for further mechanistic studies in vitro (Chapter 6). 
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6.1.  Introduction 
 
Previous studies in this thesis have explored the patterns of EV release in vivo in a dietary 
model of NAFLD, characterising both the circulating and liver-derived population of vesicles, 
and whether these were affected by lifestyle and genetic interventions. The two populations 
were found to be dissimilar in both their biogenesis (CD63 protein expression; see Figure 3.2) 
and abundance, with changes reported between treatment groups as well as over time and with 
exercise. However, a linear relationship was not observed between the temporal fluctuation of 
EVs and NAFLD severity defined by fibrosis or gene expression of ECM remodelling and 
inflammatory markers. This result would suggest that simply counting the number of EVs is 
not a useful marker of NAFLD progression. They are, however, useful in predicting steatosis 
level.  
 
Another important point to consider is the link between EV abundance and their downstream 
effect on tissues; is abundance the limiting factor, or is the complex molecular cargo of EVs 
responsible for eliciting the changes seen in receptive cells? Such phenotypic changes have not 
yet been explored in the context of NAFLD, beyond controlled in vitro studies using hepatocyte 
models of lipotoxic stress where EVs from conditioned media were shown to affect hepatic 
stellate cell activation (Lee et al., 2017, Povero et al., 2015), macrophage activation (Cannito 
et al., 2017, Hirsova et al., 2016) and chemotaxis (Ibrahim et al., 2016, Kakazu et al., 2016), 
and angiogenic behaviour in endothelial cells (Povero et al., 2013). Similar studies in models 
of obesity have found that adipocyte-derived EVs may activate ECM remodelling in hepatic 
cells (Koeck et al., 2014) and macrophage-induced insulin resistance (Deng et al., 2009b), 
whereas in contrast, EVs from adipocyte stem cells promote the non-classical M2 polarisation 
of macrophages, in turn leading to increased insulin sensitivity (Zhao et al., 2018). 
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To address the “marker versus mediator” paradigm described in the literature, this Chapter 
aimed to combine ex vivo and in vitro systems to assess the mechanism of action of NAFLD-
derived EVs on hepatocytes. These studies used a mouse hepatocyte cell line (AML12) 
stimulated with either liver-derived or plasma vesicles from animals described in the 
longitudinal study (Chapter 4) and the lifestyle intervention study (Chapter 5.3). Outcomes 
included the quantification of EV uptake by flow cytometry and the effect of this uptake on 
hepatocyte gene expression. Aside from co-culture with EVs, the hepatocyte cell line was 
otherwise untreated. 
 
The gene expression studies assessed typical markers of hepatocyte inflammatory stress (TNF), 
growth factors (CTGF, TGF), tissue remodelling (MMP9, TIMP1) and fibrogenesis (collagen 
I), as in previous Chapters. To elaborate on the functional effect of EVs in an obesity context, 
some key players in hepatic lipid metabolism (Kohjima et al., 2007) were also characterised. 
Perilipin 2 (PLIN2) and liver-type fatty acid binding protein (L-FABP or FABP1) are both 
transporter proteins, however, they have different roles in lipid metabolism. While PLIN2 
facilitates the uptake of neutral lipids into lipid droplets (Okumura, 2011), FABP1 is involved 
in the cellular import of long-chain fatty acids and their subsequent delivery to the peroxisome 
for beta oxidation (Atshaves et al., 2010, Binas and Erol, 2007). This catabolism of fatty acids 
is primarily mediated by the transcription factor peroxisome proliferator-activated receptor 
(PPAR) alpha, which is typically relevant during the post-absorptive state (Kersten et al., 1999, 
Leone et al., 1999), however, there is also a compensatory upregulation during NAFLD to 
handle the excess presence of fatty acids (Patsouris et al., 2006, Redonnet et al., 2001). On the 
other hand, sterol regulatory element-binding protein 1c (SREBP-1c) is a master transcriptional 
regulator for key enzymes that mediate de novo lipogenesis (Shimano et al., 1999) and is most 
abundant during the absorptive state, given its sensitivity to insulin (Foretz et al., 1999). While 
excess fatty acids would normally suppress the activity of SREBP-1c (Xu et al., 2001), both 
human and rodent studies have confirmed its elevation in the context of NAFLD (Kohjima et 
al., 2007, Yahagi et al., 2002).  
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Finally, when considering mass spectroscopic data, there was a significant fold-enrichment of 
carbohydrate kinases (also known as hexokinases) in liver EVs derived from HFD animals 
when compared to chow controls (see Chapter 4, section 4.4.2). Therefore, we also assessed 
the hepatocyte gene expression of the most abundant isoform of hexokinase in the liver, known 
as glucokinase (GCK), following EV stimulation. GCK is a low-affinity glucose sensor that 
phosphorylates its substrate to glucose-6-phosphate (Postic et al., 2001), the first step of 
carbohydrate metabolism and an upstream event of lipogenesis. In accordance with this, the 
bioavailability of GCK is regulated by plasma insulin levels via SREBP-1c in the absorptive 
state (Foretz et al., 1999), whereas an increase in the mRNA levels of GCK (Peter et al., 2011) 
and gene polymorphism of its regulator protein (Petit et al., 2016) are both associated with 
NAFLD development.  
 
The anticipated outcome from this ex vivo study was to establish the possible mechanisms by 
which EVs communicate as “intercellular messengers” in vivo. Specifically, by stimulating 
AML12 hepatocytes with complex plasma and liver EV populations derived from our animal 
models – diluted to an equal concentration (as determined by NanoSight™) – we were able to 
resolve whether EVs have a pathogenic or compensatory role in NAFLD development, and 
whether this role is context dependent. The experimental workflow for the studies in this 
Chapter is shown in Figure 6.1 below. 
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Figure 6.1. Experimental workflow for the functional analysis of EVs. For a more detailed 
explanation of the methodology, refer to Chapter 2 (section 2.8). 
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6.2.  Extracellular Vesicle Uptake 
 
Size is an inherent limitation for visually detecting EV uptake into cells. However, staining of 
EVs with fluorescent dye (lipophilic or cytosolic) allows for the co-localisation of vesicles and 
cell membrane or cytoplasm to be visualised, akin to protein immunofluorescence. Previous 
studies have performed this over an arbitrarily defined period (Koeck et al., 2014, Povero et 
al., 2013, Povero et al., 2015), although image resolution has been a persistent issue in the 
absence of confocal or three-dimensional techniques; that is, to accurately assess the cellular 
localisation of EVs (membrane adherence versus internalised). 
 
Here, we used a quantitative approach to estimate EV uptake over a period of 24 hours. Uptake 
into hepatocytes was determined by quantifying CFSE-positive cells following exposure to 
EVs labelled with the fluorescent dye. Cells not exposed to EVs (“unstimulated”) acted as 
controls; the positive control was CFSE-labelled hepatocytes, while negative controls were 
unlabelled. EV uptake into the cell samples was assessed using flow cytometry, whereby 5,000 
events were recorded and the proportion of fluorescent events (versus unstained cells as the 
baseline) were considered positive for EV uptake. The cytometric gating strategy is outlined in 
Figure 6.2 and below. 
 
6.2.1.  Gating strategy for flow cytometry 
 
Cells were first delineated from electrical noise by gating the population most distal from the 
forward scatter (FSC) threshold, on a forward-side scatter axis (FSC-SSC). This population 
typically represented at least 50% of events (Figure 6.2A). When considering CFSE-positive 
events on a forward scatter-green fluorescence axis, events were delineated by exclusion of the 
negative control population (defined in Figure 6.2B), while the positive control acted as a 
reference only (Figure 6.2C). A representative sample gated on cells, as defined in Figure 6.2A, 
shows the typical low-intensity CFSE staining following EV uptake (Figure 6.2D), whereas a 
green fluorescence histogram (Figure 6.3E) overlays the sample population (blue) with the 
negative control given in Figure 6.2B (white) and the positive control from Figure 6.2C (red). 
Gating with quadrants was also analysed, however, this strategy excluded many CFSE-positive 
events due to the obliqueness of the control populations. 
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Figure 6.2. Gating strategy for hepatocellular EV uptake. A representative sample shows the 
cell gate on the forward-side scatter plot as defined by the unstimulated control populations 
(A). The forward scatter-green fluorescence plot was used to display CFSE negative (B) and 
positive (C) events, which included unstimulated unstained and unstimulated CFSE-stained 
hepatocytes, respectively. The same representative sample from panel A was gated on the cell 
gate (included events red, excluded events not visible) and compared against the negative 
control (CFSE-) gate as the baseline to determine the proportion of CFSE-positive cells (D). 
Finally, a histogram representing the sample (blue) with both controls overlayed (negative: 
white, positive: red) is shown to demonstrate the typical sample fluorescence profile (E). 
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6.2.2.  Quantification of EV uptake by hepatocytes 
 
Applying the gating strategies described above, uptake of fluorescently labelled EVs was 
quantified at 24 or 48 hr for samples isolated from animals in the NAFLD progression study 
(Chapter 4) and lifestyle intervention study (Chapter 5.3). Note that hepatocyte fluorescence 
following EV uptake was quite weak, and that uptake was not present in a majority of cells, 
with the sample population often overlapping the negative control (refer to Figure 6.2E).  
 
6.2.2.1. EV uptake for NAFLD progression study 
 
For hepatocytes exposed to plasma-derived EVs for 24 hr, there was no difference in uptake 
between diets up to 30 weeks, however CFSE-positive cells decreased from approx. 30% to 
20% over time (Figure 6.3A). In contrast, a significant increase in the uptake of HFD-derived 
EVs became apparent at 50 weeks (p=0.009), which suggests a heightened responsiveness of 
hepatocytes to EVs from this context. By 48 hr, EV uptake was confined to less than 20% of 
cells and no differences were seen with either diet or treatment duration (data not shown).  
Furthermore, given that samples were matched across incubation time-points, it was possible 
to describe a significant overall decrease in uptake from 24 to 48 hr (p<0.0001; Wilcoxon 
matched-pairs signed rank test). For this reason, 24 hr was chosen as the desired time-point for 
further investigations on changes in hepatocyte phenotype (section 6.3). 
 
Experiments using the same conditions were performed with liver-derived EVs at 24 hr only 
(Figure 6.3B), as widespread cell death was observed after 48 hr. Even at this time-point, under 
25% of cells were CFSE-positive for all treatment groups. There were no differences between 
diets, with the exception of 20 weeks, where a peak in the uptake of EVs from chow fed animals 
coincided with a transient decrease in the HFD group (p=0.020). The decline in absolute EV 
uptake (as a proportion of cells) can be attributed to discrepancies in EV concentrations: EVs 
from liver were incubated at 50/L while those from plasma were incubated at 1,000/L, owing 
to sample availability.  
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Figure 6.3. Quantification of EV uptake during NAFLD progression. CFSE-labelled EVs were 
incubated with a mouse hepatocyte cell line (AML12) to determine EV uptake, defined by 
percentage of CFSE-positive cells. Hepatocytes were exposed to plasma-derived (A) or liver-
derived EVs (B) for 24 hr. Data is mean ± SEM for n=3-6 samples per group, with significant 
difference from chow accepted at p<0.05 (*) by 2-way ANOVA with Bonferroni’s test for 
multiple comparisons. Abbreviations: CFSE, carboxyfluorescein succinimidyl ester. 
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6.2.2.2. EV uptake for lifestyle intervention study 
 
Given the substantial decline in the number of liver-derived EVs following either exercise 
regimen, both independently of diet (see Chapter 5.3), functional analyses were performed only 
on plasma EVs. Henceforth, EV uptake and hepatocyte phenotype data will refer to plasma-
derived EVs for the lifestyle intervention study. Intriguingly, despite a significant increase in 
the abundance of EVs during END training for both HFD and standard chow diet, exposing 
hepatocytes to a uniform number of vesicles (1,000/L as above) did not impact on their 
responsiveness (Figure 6.4). That is, neither diet nor exercise status of the sample source had a 
significant effect on the uptake of plasma EVs into hepatocytes. 
 
 
 
 
Figure 6.4. Quantification of EV uptake during exercise intervention for NAFLD. CFSE-
labelled EVs were incubated with a mouse hepatocyte cell line (AML12) to determine EV 
uptake, defined by percentage of CFSE-positive cells. Hepatocytes were exposed to plasma-
derived EVs for 24 hr. Data is mean ± SEM for n=4 samples per group, with significant 
difference from chow or untrained accepted at p<0.05 by 2-way ANOVA with Bonferroni’s 
test or Dunnett’s test for multiple comparisons, respectively. Abbreviations: CFSE, carboxy-
fluorescein succinimidyl ester. 
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6.3.  Effects on Hepatocyte Phenotype 
 
In line with the data from previous Chapters, we first assessed whether heterologous EV uptake 
would affect the transcription of molecules involved in ECM remodelling and inflammation in 
hepatocytes (Calabro et al., 2014). Drawing on the data obtained from the characterisation of 
liver EVs by mass spectrometry, we then analysed how these EVs can modulate the hepatocyte 
gene expression of molecules associated with lipid metabolism (detailed in section 6.1). 
 
6.3.1.  Effect of donor EVs from a context of NAFLD progression 
 
For this investigation, hepatocytes were stimulated with either plasma-derived EVs from mice 
spanning the entire progression study (10-50 weeks HFD or chow; see Chapter 4) or liver-
derived EVs from either the young (10 weeks) or old (50 weeks) treatment groups. Two 
unstimulated hepatocyte samples acted as controls. Table 6.1 summarises the contribution of 
diet and age of the EV donors as a source of variation in the hepatocyte gene expression.  
 
As a general rule, there was a significant effect of aging on expression of all markers when the 
mouse hepatocytes were exposed to plasma EVs (Table 6.1). Where aging accounted for a 
lower percentage of the total variation (less than 40%), there was an additional significant effect 
of diet on the mRNA trends (TNF: 13.8%, MMP9: 8.54%, others less than 2% and p>0.05). In 
terms of liver-derived EVs, the outcomes were more heterogeneous. Among the inflammation 
and ECM remodelling markers, only TNF expression was significantly affected by donor EV 
diet but not their age. This time, MMP9 was unaffected by the diet of EV donors whereas their 
age was almost exclusively responsible for any changes observed. In contrast, the expression 
of collagen I and TIMP1 were regulated by both factors. Perhaps the most profound finding, 
on the other hand, was that – with the exception of PLIN2 – there was no effect of donor HFD 
(and by extension, their NAFLD status) on the expression of lipid metabolism markers in 
recipient hepatocytes. As before, aging was a significant driver of gene expression changes 
across most samples, whereas interestingly, SREBP-1c was not significantly affected by either 
factor, despite a relatively higher percentage for diet as a source of variation (14.6%, p=0.192). 
 
 Table 6.1. Effect of diet and age of donor EVs on variation in the recipient hepatocyte phenotype. 
 
Gene of interest Plasma EVs Liver EVs 
Diet effect Age effect Diet effect Age effect 
% p value % p value % p value % p value 
Inflammation and ECM:         
   TNF 13.8 0.010 16.3 0.048 33.3 0.035 2.60 0.515 
   Col1 0.02 0.907 42.7 0.000 5.95 0.014 86.3 0.000 
   MMP9 8.54 0.014 26.3 0.001 0.31 0.545 90.3 0.000 
   TIMP1 0.00 0.970 73.8 0.000 21.3 0.040 33.0 0.014 
   CTGF 0.08 0.805 47.4 0.000 - - - - 
   TGF 1.05 0.347 47.7 0.000 - - - - 
 
Lipid metabolism: 
        
   SREBP-1c - - - - 14.6 0.192 0.22 0.867 
   GCK - - - - 0.14 0.709 89.1 0.000 
   PLIN2 - - - - 28.0 0.043 10.3 0.194 
   PPAR - - - - 2.33 0.468 52.1 0.005 
   PPAR - - - - 7.54 0.232 37.1 0.017 
   FABP1 - - - - 0.52 0.378 93.1 0.000 
 
 
 Data analysis for plasma EVs from whole cohort (10-50 weeks; n=43) or liver EVs from young versus old animals (10 and 50 weeks; n=15). Two-
way ANOVA was used to determine the individual effect of either diet or age (of EV source) on the cell expression of each gene, as a percentage 
of the total variation in that gene (%). The associated p values are also shown; a significant contribution to total variation (p<0.05) is highlighted 
in bold. Abbreviations: ECM, extracellular matrix; TNF, tumour necrosis factor; Col1, collagen I; MMP9, matrix metalloproteinase 9; TIMP1, 
tissue inhibitor of metalloproteinase 1; CTGF, connective tissue growth factor; TGF, transforming growth factor beta; SREBP-1c, sterol 
regulatory element-binding protein 1c; GCK, glucokinase; PLIN2, perilipin 2; PPAR or , peroxisome proliferator activated receptor gamma or 
alpha; FABP1, fatty acid binding protein 1. 
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6.3.1.1. Inflammation, ECM and growth factors 
 
To assess the capacity of EVs to stimulate a NAFLD-like inflammatory stress in hepatocytes, 
the gene expression of cellular TNF was quantified. When exposed to plasma-derived EVs 
from a standard chow background, TNF tended to decrease with the 20 and 30 week EVs when 
compared to unstimulated cells (p<0.003; one sample t test), however, there was no statistically 
significant deviation over time (Figure 6.5A). In contrast, hepatocytes were highly responsive 
to EVs from a NASH background (50 weeks HFD), which resulted in a significantly increased 
TNF expression when compared to either 10 weeks HFD (p=0.019) or age-matched chow 
(p=0.004). In contrast , an opposite pattern was seen for markers of ECM remodelling; collagen 
I (Figure 6.5B) was decreased with increasing age for both diets albeit to a greater extent for 
HFD (chow: p=0.045, HFD: p<0.001; 10 versus 50 weeks), whereas TIMP1 (Figure 6.5C) was 
also decreased relative to unstimulated cells (p<0.001 for all groups except 10 week chow). A 
similar pattern was observed for MMP9 expression (Figure 6.5D), although a transient peak 
from exposure to 20 week chow EVs meant that the aging trends for either diet were rendered 
not significant. Both of the studied hepatocyte growth factors – CTGF (Figure 6.5E) and TGF 
(Figure 6.5F) – declined with the donor EV age, however this effect was more prominent for 
chow-derived samples (p<0.001 both markers; 10 versus 50 weeks) than for HFD samples 
(CTGF: p=0.035, TGF: p=0.095). Due to the relatively small impact of EVs from HFD mice, 
growth factors were not studied for liver-derived EV stimulation.  
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Figure 6.5. Gene expression of ECM markers following plasma EV uptake. Data shows mean 
± SEM as fold-change from control (unstimulated hepatocytes) for n=4-6 animals/ group for 
chow (black line) and HFD (blue line). Analyses for HFD groups that were significantly 
different from age-matched chow (*) or 10 week HFD (#) by 2-way ANOVA with Bonferroni’s 
test (diet) or Dunnett’s test (age) for multiple comparisons. Abbreviations: TNF, tumour 
necrosis factor; Col1, collagen I; TIMP1, tissue inhibitor of metalloproteinase 1; MMP9, matrix 
metalloproteinase 9; CTGF, connective tissue growth factor; TGF, transforming growth 
factor beta. 
 
 
 
To observe the changes in hepatocyte phenotype when stimulated with liver-derived EVs, cells 
were exposed to EVs from mice on either diet at 10 or 50 weeks. Interestingly, cellular TNF 
expression (Figure 6.6A) increased by over 5-fold following stimulation with EVs from any 
treatment group, when compared to the unstimulated control. This reached statistical 
significance for all but the 50 week HFD group (p=0.128), whereas neither the age nor diet 
related changes were significant, despite an apparent decrease with HFD at both timepoints. 
Consistent with the findings in Figure 6.5 using plasma-derived EVs, hepatocyte expression of 
ECM markers were more profoundly influenced by the age of the liver EV source rather than 
by its diet. For collagen I (Figure 6.6B) this is highlighted by an increase over time (p<0.001 
both diets) whereas HFD also produced a further increase at 50 weeks (p=0.027 versus age-
matched chow diet). While HFD did not affect the expression of either TIMP1 (Figure 6.6C) 
or MMP9 (Figure 6.6D) at either timepoint, MMP9 levels were significantly elevated by over 
15-fold at 50 weeks, irrespective of diet (both p<0.001). 
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Figure 6.6. Gene expression of inflammation and ECM markers following liver EV uptake. 
Data shows mean ± SEM as fold-change from control (unstimulated hepatocytes) for n=3-5 
animals/group for standard chow (black line) and high-fat diet (blue line). Significantly 
different from age-matched chow (*) or 10 week diet (#) by 2-way ANOVA with Bonferroni’s 
test for multiple comparisons. Abbreviations: TNF, tumour necrosis factor; Col1, collagen I; 
MMP9, matrix metalloproteinase 9; TIMP1, tissue inhibitor of metalloproteinase 1. 
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6.3.1.2. Lipid metabolism 
 
To complement the findings in Chapter 4 (section 4.4.2), which identified some treatment-
enriched and shared EV proteins involved in lipid metabolism, the hepatocyte transcripts of 
markers involved in lipogenesis, lipid droplet formation and beta oxidation were analysed after 
stimulation with liver-derived EVs. There was no change by either diet or age of EV source for 
the master regulator of de novo lipogenesis, SREBP-1c (Figure 6.7A). On the other hand, 
hepatocyte GCK was significantly elevated following exposure to EVs from 50 weeks of either 
diet (p<0.001), however, there was no difference between the diets (Figure 6.7B). The 
development of lipid droplets was assessed by determining the hepatocyte expression of the 
transporter protein PLIN2 as well as the lipogenic regulator PPAR. Interestingly, PPAR 
expression was unaffected by diet, although stimulation with EVs from 50 weeks HFD was 
statistically elevated (p=0.030) when compared to the effect of EVs from livers at 10 weeks 
HFD (Figure 6.7C). Gene expression of PLIN2 was not changed when stimulated with EVs 
from different treatment groups (Figure 6.7D), and the same was observed for PPAR 
expression (Figure 6.7E). Finally, in a manner similar to GCK, the lipid transporter protein 
FABP1 was increased by the age of the EV source (p<0.001 both HFD and chow), 
independently of any dietary changes (Figure 6.7F). 
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Figure 6.7. Gene expression of lipid metabolism markers following liver EV uptake. Data 
shows mean ± SEM as fold-change from control (unstimulated hepatocytes) for n=3-5 
animals/group for standard chow (black line) and high-fat diet (blue line). Significantly 
different from 10 week diet (#) by 2-way ANOVA with Bonferroni’s test for multiple 
comparisons.  Abbreviations: SREBP-1c, sterol regulatory element-binding protein 1c; GCK, 
glucokinase; PPAR or , peroxisome proliferator activated receptor gamma or alpha; PLIN2, 
perilipin 2; FABP1, fatty acid binding protein 1. 
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6.3.2.  Donor EVs from a context of exercise intervention  
 
While it was predicted that EVs from a NAFLD progression context may promote a NAFLD-
like change in hepatocyte gene expression, on the other hand, it was hypothesised that EVs 
from exercised animals would have a protective effect. The overall contribution of each 
independent variable – that is, diet and exercise – to the changes in gene expression imparted 
by EVs is outlined in Table 6.2. For genes of interest that were significantly affected by either 
variable, further statistical analyses were performed to highlight the changes between specific 
treatment groups (see Figure 6.8). With reference to the source of variation, there was a 
significant effect of donor EV diet but not exercise status for TNF and TIMP1 hepatocyte 
expression, whereas the opposite was true for collagen I and MMP9 (Table 6.2). When markers 
of lipid metabolism were considered, only PLIN2 expression was affected by both diet and 
exercise status of EV donors, while PPAR and SREBP-1c were significantly affected by 
exercise only. Although GCK expression was weakly influenced by exercise status, this trend 
was not significant (p=0.094), whereas neither variable affected the expression of PPAR and 
FABP1. Since the latter two genes are involved in beta oxidation, it was assumed that the 
plasma EVs from this study do not regulate this process, and so no further analysis was 
performed for these genes. 
 
  
 
204 
Table 6.2. Effect of diet and exercise status of donor EVs on variation in the recipient 
hepatocyte phenotype. 
 
Gene of interest Plasma EVs 
Diet effect Exercise effect 
% p value % p value 
Inflammation and ECM:     
   TNF 21.4 0.021 11.7 0.204 
   Col1 0.43 0.731 30.2 0.030 
   MMP9 6.98 0.137 35.0 0.010 
   TIMP1 23.3 0.014 16.5 0.099 
 
Lipid metabolism: 
    
   SREBP-1c 0.18 0.812 37.9 0.009 
   GCK 0.06 0.898 20.3 0.094 
   PLIN2 17.5 0.024 27.9 0.021 
   PPAR 8.86 0.103 35.8 0.010 
   PPAR 3.73 0.336 17.9 0.129 
   FABP1 4.60 0.265 1.65 0.791 
 
Data analysis for plasma EVs, excluding outliers (n=4 per treatment group, n=24 total). Two-
way ANOVA was used to determine the individual effect of either diet or exercise status (of 
EV source) on the cell expression of each gene, as a percentage of the total variation in that 
gene (%). The associated p values are also shown; a significant contribution to total variation 
(p<0.05) is highlighted in bold. Abbreviations: ECM, extracellular matrix; TNF, tumour 
necrosis factor; Col1, collagen I; MMP9, matrix metalloproteinase 9; TIMP1, tissue inhibitor 
of metalloproteinase 1; SREBP-1c, sterol regulatory element-binding protein 1c; GCK, 
glucokinase; PLIN2, perilipin 2; PPAR or , peroxisome proliferator activated receptor 
gamma or alpha; FABP1, fatty acid binding protein 1. 
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When analysing the changes between individual groups, no significant trends were observed 
among the standard chow cohort (data not shown), except for a decrease in collagen I 
expression (p=0.034) following exposure to HIIT-derived EVs versus the untrained group. 
There were also no significant changes between the two diets in the absence of exercise, 
therefore, the data presented in Figure 6.8 only shows the effect of EVs from the HFD cohort 
on hepatocyte gene expression. Overall, the fluctuations in gene expression were quite small 
(less than 2-fold). Due to the high intragroup variation within one or more treatment groups, 
no significant differences were recorded for EV-induced hepatocyte expression of TNF (Figure 
6.8A), collagen I (Figure 6.8B) or TIMP1 (Figure 6.3C). In contrast, MMP9 was decreased 
following stimulation with EVs from donors undergoing either of the exercise regimens (END: 
p=0.015, HIIT: p=0.013) compared to untrained HFD (Figure 6.8D). While a similar pattern 
was observed for GCK expression (Figure 6.8E), the changes were not significant (END: 
p=0.114, HIIT: p=0.065). Finally, plasma EVs from the HIIT but not END regimen were able 
to reduce the gene expression of SREBP-1c (Figure 6.8F), PPAR (Figure 6.8G) and PLIN2 
(Figure 6.8H). 
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Figure 6.8. Gene expression following HFD and exercised plasma EV uptake. Data shows 
mean ± SEM as fold-change from control (untrained standard chow diet) for n=4 animals/group 
for HFD cohort only. Significant difference from untrained HFD (*) by 2-way ANOVA with 
Dunnett’s test for multiple comparisons (analysis of chow cohort not shown). Abbreviations: 
TNF, tumour necrosis factor; Col1, collagen I; TIMP1, tissue inhibitor of metalloproteinase 1; 
MMP9, matrix metalloproteinase 9; SREBP-1c, sterol regulatory element-binding protein 1c; 
GCK, glucokinase; PPAR, peroxisome proliferator activated receptor gamma; PLIN2, 
perilipin 2. 
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6.4.  Interpretation 
 
Ultimately, the aim of the investigations in this Chapter were to observe whether EVs from a 
NAFLD context may recapitulate this phenotype by transferring their molecular information 
to a hepatocyte cell line. Cells were exposed to a uniform number of vesicles to control for any 
variations in EV abundance across samples; in this way, any effects of EV stimulation were 
dependent only on the hepatocyte responsiveness to EVs from a given treatment group. While 
exercise status had a negligible effect on plasma EV uptake, in contrast, vesicles from a NASH 
background (50 weeks HFD) were more likely to be endocytosed by hepatocytes (by almost 
two-fold), which corresponded with an increase in the gene expression of TNF. On the other 
hand, uptake of liver-derived EVs tended to be stable over time, with the exception of a 
statistically significant decrease (around 30%) in the uptake of vesicles from the 20 week HFD 
group. However, in order to align with the EV characterisation studies in Chapter 4, only 10 
and 50 week EV samples – representing NAFL and NASH timepoints, respectively – were 
considered for the hepatocyte phenotype study. 
 
While EV uptake in an in vitro NAFLD system has been previously documented, although not 
necessarily quantified (Koeck et al., 2014, Povero et al., 2013, Povero et al., 2015), hepatocyte 
stimulation with heterologous EVs from plasma or liver has not yet been reported. Rather, most 
models that examine EVs in the context of hepatic lipotoxicity are conducted entirely in vitro, 
whereby the vesicles are isolated from the hepatocyte conditioned media following incubation 
with palmitate; the EVs are then used to stimulate other cell lines, such as hepatic stellate cells 
(Lee et al., 2017, Povero et al., 2015), macrophages (Hirsova et al., 2016) or endothelial cells 
(Povero et al., 2013). These studies effectively highlight the paracrine or endocrine influence 
of steatotic hepatocytes via EVs, however, the reverse interactions are seldom explored and 
may provide some useful insight into the pathogenesis of NAFLD.  
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There have been two studies to date that have examined the phenotypic alterations in 
hepatocytes (HepG2 line) following EV exposure, both having sourced the vesicles from 
adipose tissue explants (Koeck et al., 2014, Kranendonk et al., 2014b). Interestingly, adipose 
EVs tended to impair insulin signalling in hepatocytes (Kranendonk et al., 2014b), whereas the 
gene expression of TIMP1 was reportedly elevated by EV stimulation, irrespective of the 
donor’s obesity status (Koeck et al., 2014). While the latter study was arguably of small scale 
(n=5), it did highlight a dose-independent effect of EVs on hepatocyte phenotype, although 
intriguingly, uptake of EVs was significantly more pronounced when sourced from obese 
donors (Koeck et al., 2014). 
 
These findings were in line with our observations following plasma EV treatment of AML12 
hepatocytes, but this pattern was not reflected upon stimulation of the hepatocytes with liver 
EVs. This may suggest an important discrepancy between systemic or endocrine signalling 
from complex tissue sources and paracrine signalling from the liver. In fact, when taken 
collectively, the age of the plasma EV donor was significantly more likely to modulate the gene 
expression of growth factors and markers of ECM turnover than obesity status (Table 6.1). 
This in turn manifested as a gradual decline over time (Figure 6.5), whereas the opposite trend 
– significant or otherwise – was shown for liver EV stimulation of hepatocytes (Figure 6.6). 
Interestingly, a greater dietary influence was also reported for the latter (Table 6.1).  
 
On the other hand, when markers of lipid metabolism were considered (Figure 6.7), the most 
pronounced changes were noted in discordant biological processes; that is, there was a 
significant positive effect of donor age on the expression of GCK (involved in lipogenesis) as 
well as the lipid transporter FABP1 (involved in beta oxidation). While the mechanisms behind 
these changes remain unclear, studies in rats have shown an age-related decline in liver FABP1 
(Singer et al., 1996) and an impaired efficiency of GCK restoration in the absorptive state 
(Adelman and Freeman, 1972), which seems to imply a compensatory role for liver EVs in this 
context. However, it was suggested in the latter study that a decrease in circulating insulin may 
be responsible for the changes in GCK activity (Adelman and Freeman, 1972), whereas this 
finding was not seen in our EV donor cohort. 
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Hepatocytes were also amenable to plasma EVs from exercised donors, although changes in 
gene expression remained within a modest 2-fold range. While this may be explained by the 
low uptake of plasma EVs (approximately 15% cells), there were statistically significant 
changes across treatment groups within the HFD cohort (Figure 6.8). Firstly, there was a 
tendency for “exercise EVs” to decrease the expression of TNF and markers of ECM 
remodelling; however, only MMP9 was significantly affected when compared to EVs from 
untrained HFD, which was independent of the exercise protocol. A similar pattern was noted 
for GCK, although the higher intragroup variation meant the changes did not reach 
significance. Intriguingly, the hepatocyte expression of lipogenic markers were all suppressed 
by plasma EVs from HIIT-exercised HFD animals, but unaffected by END. Unlike the 
compensatory effects of liver EVs from the NAFLD progression study, these findings seemed 
to indicate an endocrine-mediated protective role, since HIIT itself has been shown to regulate 
both SREBP-1c (Kalaki-Jouybari et al., 2018) and PPAR (Motta et al., 2016) in obese rodent 
livers, while PLIN2 depletion impairs hepatic lipid storage (Chang et al., 2006). A schematic 
of our findings for lipid metabolism genes is shown in Figure 6.9. 
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Figure 6.9. Hepatocyte markers of lipid metabolism and effect of EV exposure. (A) Cellular 
context of markers used in our study. Unbroken lines represent consequence (lipid transport or 
outcome of cellular process) and broken lines represent activation. (B) Summary of the markers 
assigned to their cellular process or context of activity. Red up arrows show increased gene 
expression following stimulation with liver EVs (paracrine) from older mice, blue down arrows 
show decreased gene expression when stimulated with plasma EVs (endocrine) from obese 
HIIT-exercised mice. To generalise the EV effect on hepatocyte phenotype, aging tends to 
promote beta oxidation while exercise suppresses lipid droplet formation. Abbreviations: FA, 
fatty acid; LCFA, long-chain fatty acid; TAG, triacylglycerol; ATP, adenosine triphosphate; 
G6P, glucose 6 phosphate; GCK, glucokinase; SREBP-1c, sterol regulatory element-binding 
protein 1c; PPAR or , peroxisome proliferator activated receptor gamma or alpha; PLIN2, 
perilipin 2; FABP1, fatty acid binding protein 1. 
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7.1.  Conclusions 
 
To reflect on the purpose of this thesis, we aimed to investigate the hypotheses (presented in 
detail in Chapter 1) that EVs isolated from an in vivo model of diet-induced NAFLD may be 
reliably enumerated and characterised, such that they would provide a useful biomarker for the 
assessment of NAFLD progression. Expanding on this, we investigated the effects of intrinsic 
and extrinsic factors – age, lifestyle intervention and genetic manipulation – on EV number or 
phenotype, how this correlated with physical and metabolic parameters, and whether the EVs 
communicated with hepatocytes functionally in vitro. 
 
7.1.1.  Major findings 
 
In the context of our studies mentioned above, the technique optimisation phase provided some 
insight into the general characteristics of our isolated vesicles. Firstly, both plasma and liver-
derived EVs were similarly around 100m in diameter, however, they appear to have differed 
in their biogenesis as plasma EVs were enriched in CD63 (suggesting an endosome origin) 
while the EVs from liver explants did not express this marker. Due to their small size, it was 
difficult to evaluate these populations by conventional flow cytometry, and so mass 
spectrometry was used as an alternative for EV characterisation, despite its own limitations 
(see section 7.1.3). During our preliminary investigations in the in vivo NAFLD model, there 
were distinct trends for an age-related increase in plasma EVs and a decrease in liver-derived 
EVs, independently of diet. The two populations were inversely correlated in terms of 
abundance, whereas both were strongly associated with (absolute) hepatic lipid burden. 
However, these trends were not replicated in the larger scale study of NAFLD progression, 
where plasma EVs only increased in abundance following 20 weeks of HFD and otherwise 
remained stable. Conversely, liver EVs increased with age in the absence of a diet related effect, 
although this population was still reflective of hepatic lipid in terms of TAG levels. Since there 
was little correlation with other parameters of disease severity, it was concluded that 
enumeration of EVs in isolation may not be a reliable biomarker for NAFLD progression. On 
the other hand, the plasma EV spike at 20 weeks was an indication of other subclinical events 
in NAFLD development, such as an increase in the gene expression of some fibrogenic markers 
as well as collagen staining on histology. 
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Using genetically modified mice, we modelled the effect of severe acute lipogenesis in the 
absence of the pleiotropic cytokine TNF. Remarkably, despite the predisposition to obesity and 
steatosis in the TNF-ablated animals on a HFD, there were no changes in either plasma or 
(relative) liver EV numbers. This supported the developing sentiment in our previous findings 
that obesity has a less crucial impact on EV secretion when compared to other biological 
factors, such as age. Importantly, however, the relationship between liver lipid and the absolute 
number of liver-derived EVs was maintained; that is, the number of EVs adjusted for liver 
weight (total secreted per liver) was strongly correlated with hepatic TAG.  
 
The next step was to investigate whether a lifestyle intervention would effectively augment this 
response. By comparing two exercise training regimens in their ability to reverse the burden of 
NAFLD, it was not only demonstrated that END and HIIT impart differential benefits on the 
liver, but that they also modulate the plasma and liver EV populations differentially. For s start, 
only END was capable of increasing plasma EV abundance whereas there was no effect of diet 
(as expected). This was reflected in the liver gene expression profile, where END was superior 
to HIIT in terms of normalising some of the pathological changes (for example, an increase in 
collagen I). In contrast, liver EVs were significantly decreased by 10-fold for animals 
undergoing either exercise regimen irrespective of diets. Interestingly, since hepatic TAG was 
increased by HFD for both exercise groups, it was correlated negatively with the number of 
liver-derived EVs, although the same trend was not observed in lean animals. Therefore, it is 
unlikely that EVs could predict absolute liver lipid in this context.  
 
To clarify the potential mechanistic influence of EVs, we first used proteomics to determine 
the molecular cargo of liver-derived vesicles, as a candidate for paracrine signalling. When all 
samples were examined collectively, it was shown (not unexpectedly) that liver-derived EVs 
are primarily involved in hepatocellular homeostasis, including carbohydrate and fatty acid 
metabolism.  However, individual samples did not cluster according to treatment groups when 
their enriched proteins were considered, implying that EV phenotype tends to be susceptible to 
biological variation, even if they are derived from the same tissue and microenvironment. On 
the other hand, both diet and aging showed an upregulation of molecular pathways involved in 
anabolic processes, most of which are understood to play a protective role in liver homeostasis 
or in NAFLD pathogenesis. 
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This was further investigated using in vitro functional studies, whereby hepatocytes were 
exposed to plasma or liver EVs derived from our various mouse models. Indeed, the liver EVs 
from older mice seemed to compensate for some typical features of metabolic decline seen in 
aging, such as the impairment of hepatic beta oxidation. In contrast, plasma EVs were able to 
suppress the gene expression of fibrogenic markers, which also occurred independently of diet, 
whereas NASH-derived vesicles imparted an inflammatory effect by increasing the TNF levels 
in hepatocytes. Finally, when hepatocytes were stimulated with plasma EVs from HIIT-
exercised HFD animals – but not END exercised animals from the same diet group – we found 
a modest but statistically significant decrease (by at least 2 fold) in the markers associated with 
hepatic lipogenesis. This was particularly interesting in that total hepatic lipid (by ORO 
staining) was also substantially decreased in HFD mice undergoing HIIT, but not in their END-
trained counterparts. A summary of the major findings pertaining to the EV profile in animals 
fed a HFD in the presence of absence of exercise is shown in  Figure 7.1 below.  
 
 
 
 
 
Figure 7.1. Summary of findings for EVs in NAFLD. Within boxes: cross (x) represents no 
change in EV number, arrows represent increase or decrease, depending on the study. Asterix 
(*) implies specific exercise: END increased EV number, HIIT affected hepatocyte phenotype. 
Abbreviations: HF, high fat; ECM, extracellular matrix (remodelling). 
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7.1.2.  Clinical significance 
 
While the underlying purpose of the studies in this thesis were to elaborate on the potential of 
utilising EVs as a novel biomarker candidate for NAFLD, other clinical implications were also 
highlighted. Notably, in the context of diet-induced obesity and the progression of NAFLD to 
NASH, it was demonstrated that fibrogenesis is actually a much earlier event than traditionally 
thought; fibrotic changes start becoming apparent by 20 weeks of HFD, as previously observed 
in our laboratory (Lo et al., 2011), whereas NASH fibrosis was ubiquitously evident following 
50 weeks of HFD. Therefore, it can be extrapolated that a chronically poor diet – in the absence 
of further atherogenic stimuli, fructose, or genetic changes – is sufficient to cause irreversible 
liver damage. Furthermore, it was found that aerobic exercise is universally beneficial to treat 
NAFLD, however, that the training modality may differentially affect the liver. For example, 
HIIT was more successful at reducing steatosis burden (excluding TAG), while END tended 
to outperform HIIT on most other parameters. Interestingly, the opposite was true for other 
insulin-sensitive tissues such as adipose and skeletal muscle (Martinez-Huenchullan et al., 
unpublished manuscript). Another clinically relevant outcome was the discrepancy in EV 
abundance between studies, which was influenced by slight variations in the isolation 
methodology. This finding highlights the impact of sample processing and storage, and that 
technique standardisation is vitally important if EVs were to eventually be used as diagnostic 
markers for NAFLD in the clinic (Lener et al., 2015). 
 
In the context of EV enumeration, it was shown that – within the scope of our investigations – 
the easily accessible plasma-derived population may not be a reliable tool for monitoring the 
progression of NAFLD severity overall. Furthermore, liver EVs may not be contributing to the 
circulating EV pool in the presence of liver disease, especially in the case of NAFLD where 
the systemic metabolic disturbances of obesity are likely to be masking the endocrine presence 
of tissue-specific disorders. It was repeatedly demonstrated, nonetheless, that EVs from either 
source were in some way correlated with hepatic lipid. This suggests that steatosis burden may 
be estimated by circulating EV abundance, although whether this option is practical given the 
currently available tools for the assessment of hepatic lipid (Table 1.2 and (Stern and Castera, 
2017)) – not to mention the timeline for developing an efficient isolation procedure for EVs – 
remains to be seen.  
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On a more positive note, the fundamental role for EVs as “intercellular messengers” in NAFLD 
was supported in our findings, as well as previously by others (Cannito et al., 2017, Hirsova et 
al., 2016, Lee et al., 2017, Povero et al., 2013, Povero et al., 2015). Here we showed the effect 
that both plasma and liver-derived EVs had on hepatocyte phenotype, particularly in their 
ability to regulate lipogenesis and fatty acid beta oxidation at the transcriptional level, which 
shows promise for the therapeutic application of EVs in NAFLD (Ban et al., 2016) and in other 
disorders (Lener et al., 2015). 
 
7.1.3.  Limitations 
 
Given the lack of experimental standardisation in the field of EV research, it is often inevitable 
that findings may not be supported in the literature or recapitulate previous research. Even 
within this thesis, some findings across our studies remain inconclusive due to adjustments in 
the methodology. For instance, the timing of EV storage relative to ultracentrifugation was 
significantly impactful on EV enumeration (see Figure 4.14) and was a major confounding 
factor in the interpretation of this finding. While the optimisation of EV isolation has been 
previously discussed (Jeyaram and Jay, 2017, Yuana et al., 2015), there is no single approach 
that is accepted in the ISEV community (Witwer et al., 2013).  
 
To maintain the validity of EV research findings, however, ISEV has developed guidelines for 
the minimal requirements for the definition of EV structure and function (Lotvall et al., 2014, 
Witwer et al., 2017). This includes the ultracentrifugation-based isolation of EVs, used by over 
80% of researchers (Gardiner et al., 2016) and also within this thesis, despite being considered 
as a “crude” sample fraction in the absence of further purification. Whether this is actually the 
case remains to be resolved. Studies that report on EV structure and downstream applications 
show inconsistent findings in terms of the reliability of ultracentrifugation when compared to 
other methods of isolation, including commercially available kits (Helwa et al., 2017, Rekker 
et al., 2014, Yamashita et al., 2016). Importantly, however, further purification steps are 
recommended prior to assessing the EV proteome to avoid any contamination with protein 
aggregates (Abramowicz et al., 2016). This was not performed during our studies, whereas 
TEM and cytometry showed minimal contaminating particles in our EV samples. 
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Other limitations that were derived from the biophysical properties of EVs were more difficult 
to avoid. The most widely understood example is the use of flow cytometry to characterise the 
EV markers of origin or biogenesis, given that most EV populations are below the size limit of 
detection. While it is possible that some conventional cytometers may be calibrated to resolve 
particles down to <200nm (van der Vlist et al., 2012), this is both laborious and requires a high 
level of technical expertise. Furthermore, this challenge is compounded by the fact that EVs 
have a relatively low, as yet undefined refractive index (Gardiner et al., 2013) that is difficult 
to confirm due to the inherent complexity and heterogeneity of these samples. On the other 
hand, there is an urgency to develop flow cytometry for the continued study of EV phenotype, 
given the low-throughput nature of many of its competitors (Momen-Heravi et al., 2012). 
 
Finally, a more comprehensive elaboration of the study could have yielded more integrative 
results. Changes in hepatic lipid (especially TAG), for instance, may have been better informed 
by physiological data such as caloric intake and cardiac output, and hence related to EV 
abundance, particularly in the exercise intervention study. From the perspective of liver-
derived vesicles, it can be anticipated that the culture of different cell types independently – 
isolated by collagenase digestion of the liver – may have delineated the contribution of the 
different cell populations. In contrast, the intact architecture has the advantage of more 
accurately reflecting the in vivo microenvironment in which liver EVs are secreted, and for the 
incubation period used in this study, it is expected that tissue viability would be largely 
preserved (Li et al., 2010). Since previous studies have dealt with surrogate markers to probe 
for liver-derived EVs in the plasma population (Csak et al., 2015, Povero et al., 2014, Povero 
et al., 2013), it may also be useful to compare this indirect method with the enumeration of 
EVs obtained directly from liver-conditioned media. This would help to determine the utility 
of the traditional approach, since “liver-specific” markers are a misnomer: most of the studied 
markers are enriched in, but not exclusive to, hepatocytes (Ban et al., 2016). 
 
It is worth noting, however, that these logistical caveats arise as a function of practicality: 
although useful, the additional information is beyond the scope of the objectives of this thesis. 
Further integrative approaches to the study of EVs in NAFLD will be discussed in the following 
section, where the contributions of future studies are likely to provide a more holistic picture 
of this system of intercellular communication. 
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7.2.  Future Directions 
 
The study of EVs as biomarkers and mediators of disease is a very much established concept, 
however, its application to metabolic disorders (especially NAFLD) is still an emerging field. 
EV research will continue to face an uphill battle in terms of adequately characterising these 
structures until universal standards for their isolation and phenotyping have been realised. It is 
anticipated that in the future, EVs may be utilised for a variety of diagnostic, prognostic, and 
therapeutic applications (reviewed extensively in (Wauben, 2016)); for example, vaccine trials 
are already underway. 
 
7.2.1.  NAFLD models and translation 
 
There is a wealth of research on obesity and related pathologies that utilise rodent models, both 
dietary and genetic, as described in Chapter 1 (section 1.2.4). While this thesis investigated the 
traditional HFD modified to include a sub-atherogenic level of cholesterol, to reflect a more 
physiological progression of NAFLD, previous studies have used a choline-deficient model to 
isolate and accelerate the liver-specific injury (Povero et al., 2014). It may also be valuable to 
examine EVs in a diabetic context – a phenotype that is known to exacerbate NAFLD (Lo et 
al., 2011) – by adding a streptozotocin insult to the diet-induced metabolic syndrome. Once 
characterised, these EVs would later be useful in distinguishing subsets of patients that may be 
susceptible to obesity-related complications or comorbidities. 
 
However, it is worth considering the fact that obesity as a multisystemic condition would pose 
inherent challenges in terms of using EVs as biomarkers in a “liquid biopsy”. For a start, the 
vesicles that have been mobilised into the circulation are heterogeneous; even under 
homeostatic conditions, the population is a cocktail of signals from multiple organs, many of 
which are simultaneously dysregulated in obesity. Therefore, exploiting EVs to give cues on 
tissue-specific changes will likely be unreliable – as was observed in our studies – especially 
if those specific populations are decreased or perhaps considered to be “rare events”. On the 
other hand, it is possible to use an arbitrary population of EVs as a surrogate marker of changes; 
for example, one clinical study found that vesicles from a particular leukocyte subset were 
strongly associated with the histological severity of NAFLD (Kornek et al., 2012). 
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Nevertheless, until a reliable procedure is validated for the automation of EV detection and 
phenotyping, the translational utility of EVs as a NAFLD biomarker remains dubious. There 
is, however, a strongly recognised potential for a functional (that is, therapeutic) application. 
The “marker versus mediator” paradigm that was introduced in Chapter 1 is now increasingly 
relevant: EVs have an undisputed role in paracrine and endocrine communication in NAFLD, 
as shown in previous studies (Ban et al., 2016) and substantiated in this thesis, as well as other 
diseases ranging from infection to cancer (Wauben, 2016). In contrast, their biomarker utility 
is context (disease) dependent, affected by lifestyle factors and even aging, which dispels the 
idea that plasma EV abundance and disease severity are inextricably linked. 
 
7.2.2.  Experimental considerations 
 
This section will deal with novel or understudied ideas that have the potential to advance our 
knowledge of the functional role of EVs in NAFLD. Some of these concepts have been raised 
previously in the context of homeostatic signalling (Wauben, 2016) and will be expanded upon. 
One such idea is the in vitro modelling of complex biological systems and interactions, using 
either 3D cell culture (organoids), or a transwell apparatus to monitor EV uptake and diffusion 
across a cellular barrier. The latter system would be especially useful to confirm our hypothesis 
in Chapter 3, regarding reduced permeability across liver sinusoidal endothelia as a result of 
age- or diet-induced defenestration (Figure 7.2). It may also be worth examining epithelial 
permeability, beyond the EV uptake capacity of hepatocytes. For instance, since the gut micro-
biome is known to be altered with NAFLD (recently reviewed in (Sharpton et al., 2018)) and 
interacts with the human host via EVs (Shen et al., 2012b), it is possible that enterocytes or 
enteric immunity may be affected (Figure 7.2).  
 
Another often disregarded approach is the examination of the typical EV lifespan, not just their 
functional role. For example, interfering with exosome release by inhibiting the production of 
vesicular ceramide (Kosaka et al., 2010, Trajkovic et al., 2008) may provide a snapshot of the 
cellular phenotype at a static point, and of the longevity of EVs in a given biofluid or medium. 
Blocking EV fusion or endocytosis – both mechanisms of uptake – is another option, although 
these processes are highly versatile (Mulcahy et al., 2014); therefore, interfering with a single 
pathway is likely to be redundant, while blocking multiple pathways may affect viability. 
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Figure 7.2. Future studies of EVs in NAFLD. Blue boxes represent potential scenarios for in 
vitro transwell experiments and how these are linked to the in vivo context (not anatomically 
correct on mouse). Bottom panel: Luminal EVs from the gut microbiome, known as outer 
membrane vesicles (OMVs) from the Gram negative bacteria that are typical of this micro-
environment, may be taken into enterocytes and change epithelial permeability, or diffuse 
across to the leukocytes (representing Peyer’s patches) to modulate their immune activity. In 
the in vivo setting, diffused OMVs – along with the cytokines they have elicited from the 
leukocytes and dietary free fatty acids (FFA) – may enter the portal circulation and establish 
an inflammatory niche in the liver, promoting the development of NAFLD. Top panel: 
Stimulation of (sinusoidal) endothelial cells with FFA to induce defenestration (Cogger et al., 
2016) may change the dynamic of EV uptake into and diffusion across this cell monolayer, 
which in turn affects the availability of circulating EVs to hepatocytes and vice versa. For both 
models, sampling of fluorescently-labelled EVs on either side of the transwell chambers or 
within the cells might give a clue as to the dynamic of EV transport in a particular scenario, 
while molecular profiling of cells and diffused EVs before and after coculture would elucidate 
the functional role of these EVs. 
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Fluorescence microscopy may also be used to determine the uptake of specific EVs. This relies 
on the concept that, for example, fluorescently-labelled hepatocytes or hepatic cells stimulated 
with FFA will secrete fluorescent EVs with an altered cargo. While this type of study is not 
novel, there is potential to expand the design to answer novel questions: for instance, cells that 
have been differentially labelled depending on their treatment will have “colour-coded” EVs, 
hence, the stimulation of recipient cells with a combination of these EV populations can be 
used to monitor the preferential uptake of certain EV phenotypes. Whether cells are more 
receptive to the uptake of lipotoxic EVs derived from FFA-stimulated hepatocytes, versus EVs 
from untreated cells, is not known. However, this concept is supported by our studies in 
Chapter 6 which showed that plasma EVs from obese mice with NASH were more likely to be 
taken up by recipient hepatocytes than EVs from mice with simple steatosis or normal livers.  
 
Differential labelling of EVs in this manner could also be exploited for in vivo tracking studies: 
it is possible that the microenvironment of cells, rather than their tissue origin, determines the 
downstream role of their EVs and therefore, which cells they will interact with. Of course, 
complex systems also pose several limitations, such as the increased potential for vesicle 
degradation and the phenotypic altering of EVs following the capture of soluble molecules that 
are present in the biofluid. This challenges the conventional idea of the “regulated release” of 
EVs and further complicates their characterisation by increasing the heterogeneity of the 
population. Nevertheless, it could be that molecular capture is yet another function of EVs that 
facilitates their role as intercellular messengers; this may in turn be analysed by incubating EVs 
in a complex medium (in vitro) and monitoring their phenotypic changes over time. In theory, 
injecting fluorescent EVs into the mouse circulation would be a more physiological alternative, 
however, difficulties with sample retrieval are an inevitable limitation. 
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7.2.3.  Final remarks 
 
In a recent invited presentation by Marca Wauben (secretary general of ISEV) at the University 
of Sydney, the audience was reminded of the complexities associated with EV research, not 
least of which was the inherent heterogeneity that serves as the greatest pitfall for the utility of 
this ‘holy grail’. The functional redundancy of this method of intercellular communication was 
also discussed, which is important for maintaining and regulating a stable system, in concert 
with other pathways. However, it is interesting to note that, despite the fact that EV secretion 
and signalling is supposedly highly regulated, the diversity in the EV phenotypes and selection 
for uptake may all contribute to the ultimate feedback outcome. 
 
In this thesis, we explored the role of EVs in the context of NAFLD, including their potential 
as circulating biomarkers and their treatment-dependent modulatory effect on hepatocytes. In 
summary, EV release into the circulation or specifically from the liver was regulated by both 
intrinsic and extrinsic factors and, interestingly, this process was least responsive to the HFD. 
However, correlations between EV number and hepatic lipid were evident, while liver-derived 
EVs had a dynamic proteome signature that seemed to be affected by experimental treatment 
as well as biological variation. In this regard, to propose that EVs may be of diagnostic value 
(at least in NAFLD) should be approached with caution. Nevertheless, there was certainly a 
demonstrable effect of EV stimulation on hepatocyte gene expression – be it compensatory or 
protective – which suggests that EVs are indeed a vital aspect of physiological and pathological 
signalling. This is reassuring; our findings show that while disease diagnosis or prognosis may 
not be the key utility of EVs in the context of obesity and its complications, their therapeutic 
potential does deserve further consideration. 
 
  
 
225 
 
References 
 
 
  
 
226 
ABRAMOWICZ, A., WIDLAK, P. & PIETROWSKA, M. 2016. Proteomic analysis of 
exosomal cargo: the challenge of high purity vesicle isolation. Mol Biosyst, 12, 1407-
19. 
ADELI, K., TAGHIBIGLOU, C., VAN IDERSTINE, S. C. & LEWIS, G. F. 2001. 
Mechanisms of hepatic very low-density lipoprotein overproduction in insulin 
resistance. Trends Cardiovasc Med, 11, 170-6. 
ADELMAN, R. C. & FREEMAN, C. 1972. Age-dependent regulation of glucokinase and 
tyrosine aminotransferase activities of rat liver in vivo by adrenal, pancreatic and 
pituitary hormones. Endocrinology, 90, 1551-60. 
AJAMIEH, H., FARRELL, G. C., MCCUSKEY, R. S., YU, J., CHU, E., WONG, H. J., LAM, 
W. & TEOH, N. C. 2015. Acute atorvastatin is hepatoprotective against ischaemia-
reperfusion injury in mice by modulating eNOS and microparticle formation. Liver Int, 
35, 2174-2186. 
AKERS, J. C., GONDA, D., KIM, R., CARTER, B. S. & CHEN, C. C. 2013. Biogenesis of 
extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and 
apoptotic bodies. J Neurooncol, 113, 1-11. 
ALEX, S., BOSS, A., HEERSCHAP, A. & KERSTEN, S. 2015. Exercise training improves 
liver steatosis in mice. Nutr Metab (Lond), 12, 29. 
ALEXANDER, M., LOOMIS, A. K., FAIRBURN-BEECH, J., VAN DER LEI, J., DUARTE-
SALLES, T., PRIETO-ALHAMBRA, D., ANSELL, D., PASQUA, A., LAPI, F., 
RIJNBEEK, P., MOSSEVELD, M., AVILLACH, P., EGGER, P., KENDRICK, S., 
WATERWORTH, D. M., SATTAR, N. & ALAZAWI, W. 2018. Real-world data 
reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med, 16, 130. 
ALMEDA-VALDES, P., AGUILAR-SALINAS, C. A., URIBE, M., CANIZALES-
QUINTEROS, S. & MENDEZ-SANCHEZ, N. 2016. Impact of anthropometric cut-off 
values in determining the prevalence of metabolic alterations. Eur J Clin Invest, 46, 
940-946. 
ANDERMANN, A., BLANCQUAERT, I., BEAUCHAMP, S. & DERY, V. 2008. Revisiting 
Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 
years. Bull World Health Organ, 86, 317-9. 
ANGULO, P., KLEINER, D. E., DAM-LARSEN, S., ADAMS, L. A., BJORNSSON, E. S., 
CHARATCHAROENWITTHAYA, P., MILLS, P. R., KEACH, J. C., LAFFERTY, H. 
D., STAHLER, A., HAFLIDADOTTIR, S. & BENDTSEN, F. 2015. Liver Fibrosis, 
but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients 
With Nonalcoholic Fatty Liver Disease. Gastroenterology, 149, 389-97 e10. 
ARMSTRONG, M. J., ADAMS, L. A., CANBAY, A. & SYN, W. K. 2014. Extrahepatic 
complications of nonalcoholic fatty liver disease. Hepatology, 59, 1174-97. 
ARRAUD, N., GOUNOU, C., LINARES, R. & BRISSON, A. R. 2015. A simple flow 
cytometry method improves the detection of phosphatidylserine-exposing extracellular 
vesicles. J Thromb Haemost, 13, 237-47. 
ATSHAVES, B. P., MARTIN, G. G., HOSTETLER, H. A., MCINTOSH, A. L., KIER, A. B. 
& SCHROEDER, F. 2010. Liver fatty acid-binding protein and obesity. J Nutr 
Biochem, 21, 1015-32. 
BAEK, R., VARMING, K. & JORGENSEN, M. M. 2016. Does smoking, age or gender affect 
the protein phenotype of extracellular vesicles in plasma? Transfus Apher Sci, 55, 44-
52. 
BAN, L. A., SHACKEL, N. A. & MCLENNAN, S. V. 2016. Extracellular Vesicles: A New 
Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease. Int J Mol Sci, 
17, 376. 
 
227 
BARAD, O., MEIRI, E., AVNIEL, A., AHARONOV, R., BARZILAI, A., BENTWICH, I., 
EINAV, U., GILAD, S., HURBAN, P., KAROV, Y., LOBENHOFER, E. K., 
SHARON, E., SHIBOLETH, Y. M., SHTUTMAN, M., BENTWICH, Z. & EINAT, P. 
2004. MicroRNA expression detected by oligonucleotide microarrays: system 
establishment and expression profiling in human tissues. Genome Res, 14, 2486-94. 
BARON, M., LEROYER, A. S., MAJD, Z., LALLOYER, F., VALLEZ, E., BANTUBUNGI, 
K., CHINETTI-GBAGUIDI, G., DELERIVE, P., BOULANGER, C. M., STAELS, B. 
& TAILLEUX, A. 2011. PPARalpha activation differently affects microparticle 
content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and 
NASH. Atherosclerosis, 218, 69-76. 
BATALLER, R. & BRENNER, D. A. 2005. Liver fibrosis. J Clin Invest, 115, 209-18. 
BEDOGNI, G., BELLENTANI, S., MIGLIOLI, L., MASUTTI, F., PASSALACQUA, M., 
CASTIGLIONE, A. & TIRIBELLI, C. 2006. The Fatty Liver Index: a simple and 
accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol, 
6, 33. 
BEDOGNI, G., KAHN, H. S., BELLENTANI, S. & TIRIBELLI, C. 2010. A simple index of 
lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol, 10, 98. 
BERGSMEDH, A., SZELES, A., HENRIKSSON, M., BRATT, A., FOLKMAN, M. J., 
SPETZ, A. L. & HOLMGREN, L. 2001. Horizontal transfer of oncogenes by uptake of 
apoptotic bodies. Proc Natl Acad Sci U S A, 98, 6407-11. 
BERNIMOULIN, M., WATERS, E. K., FOY, M., STEELE, B. M., SULLIVAN, M., FALET, 
H., WALSH, M. T., BARTENEVA, N., GENG, J. G., HARTWIG, J. H., MAGUIRE, 
P. B. & WAGNER, D. D. 2009. Differential stimulation of monocytic cells results in 
distinct populations of microparticles. J Thromb Haemost, 7, 1019-28. 
BERTOLOTTI, M., LONARDO, A., MUSSI, C., BALDELLI, E., PELLEGRINI, E., 
BALLESTRI, S., ROMAGNOLI, D. & LORIA, P. 2014. Nonalcoholic fatty liver 
disease and aging: epidemiology to management. World J Gastroenterol, 20, 14185-
204. 
BIDDINGER, S. B., ALMIND, K., MIYAZAKI, M., KOKKOTOU, E., NTAMBI, J. M. & 
KAHN, C. R. 2005. Effects of diet and genetic background on sterol regulatory 
element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the 
metabolic syndrome. Diabetes, 54, 1314-23. 
BIERNACKA, A., DOBACZEWSKI, M. & FRANGOGIANNIS, N. G. 2011. TGF-beta 
signaling in fibrosis. Growth Factors, 29, 196-202. 
BINAS, B. & EROL, E. 2007. FABPs as determinants of myocellular and hepatic fuel 
metabolism. Mol Cell Biochem, 299, 75-84. 
BINNS, D., DIMMER, E., HUNTLEY, R., BARRELL, D., O'DONOVAN, C. & APWEILER, 
R. 2009. QuickGO: a web-based tool for Gene Ontology searching. Bioinformatics, 25, 
3045-6. 
BODEN, G., SHE, P., MOZZOLI, M., CHEUNG, P., GUMIREDDY, K., REDDY, P., 
XIANG, X., LUO, Z. & RUDERMAN, N. 2005. Free fatty acids produce insulin 
resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. 
Diabetes, 54, 3458-65. 
BOTROS, M. & SIKARIS, K. A. 2013. The de ritis ratio: the test of time. Clin Biochem Rev, 
34, 117-30. 
BRAUNERSREUTHER, V., VIVIANI, G. L., MACH, F. & MONTECUCCO, F. 2012. Role 
of cytokines and chemokines in non-alcoholic fatty liver disease. World J 
Gastroenterol, 18, 727-35. 
BRODSKY, S. V., FACCIUTO, M. E., HEYDT, D., CHEN, J., ISLAM, H. K., KAJSTURA, 
M., RAMASWAMY, G. & AGUERO-ROSENFELD, M. 2008. Dynamics of 
 
228 
circulating microparticles in liver transplant patients. J Gastrointestin Liver Dis, 17, 
261-8. 
BYRNE, C. D., OLUFADI, R., BRUCE, K. D., CAGAMPANG, F. R. & AHMED, M. H. 
2009. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond), 116, 
539-64. 
BYRNE, C. D. & TARGHER, G. 2015. NAFLD: a multisystem disease. J Hepatol, 62, S47-
64. 
CALABRO, S. R., MACZUREK, A. E., MORGAN, A. J., TU, T., WEN, V. W., YEE, C., 
MRIDHA, A., LEE, M., D'AVIGDOR, W., LOCARNINI, S. A., MCCAUGHAN, G. 
W., WARNER, F. J., MCLENNAN, S. V. & SHACKEL, N. A. 2014. Hepatocyte 
produced matrix metalloproteinases are regulated by CD147 in liver fibrogenesis. PLoS 
One, 9, e90571. 
CANNITO, S., MORELLO, E., BOCCA, C., FOGLIA, B., BENETTI, E., NOVO, E., 
CHIAZZA, F., ROGAZZO, M., FANTOZZI, R., POVERO, D., SUTTI, S., 
BUGIANESI, E., FELDSTEIN, A. E., ALBANO, E., COLLINO, M. & PAROLA, M. 
2017. Microvesicles released from fat-laden cells promote activation of hepatocellular 
NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-
alcoholic steatohepatitis. PLoS One, 12, e0172575. 
CASTERA, L., FOUCHER, J., BERNARD, P. H., CARVALHO, F., ALLAIX, D., 
MERROUCHE, W., COUZIGOU, P. & DE LEDINGHEN, V. 2010. Pitfalls of liver 
stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology, 
51, 828-35. 
CAWTHORN, W. P. & SETHI, J. K. 2008. TNF-alpha and adipocyte biology. FEBS Lett, 582, 
117-31. 
CHALASANI, N., YOUNOSSI, Z., LAVINE, J. E., CHARLTON, M., CUSI, K., RINELLA, 
M., HARRISON, S. A., BRUNT, E. M. & SANYAL, A. J. 2018. The diagnosis and 
management of nonalcoholic fatty liver disease: Practice guidance from the American 
Association for the Study of Liver Diseases. Hepatology, 67, 328-357. 
CHAN, W. K., NIK MUSTAPHA, N. R. & MAHADEVA, S. 2014. Controlled attenuation 
parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty 
liver disease. J Gastroenterol Hepatol, 29, 1470-6. 
CHAN, W. K., NIK MUSTAPHA, N. R., WONG, G. L., WONG, V. W. & MAHADEVA, S. 
2017. Controlled attenuation parameter using the FibroScan(R) XL probe for 
quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian 
population. United European Gastroenterol J, 5, 76-85. 
CHANG, B. H., LI, L., PAUL, A., TANIGUCHI, S., NANNEGARI, V., HEIRD, W. C. & 
CHAN, L. 2006. Protection against fatty liver but normal adipogenesis in mice lacking 
adipose differentiation-related protein. Mol Cell Biol, 26, 1063-76. 
CHARRIER, A., CHEN, R., CHEN, L., KEMPER, S., HATTORI, T., TAKIGAWA, M. & 
BRIGSTOCK, D. R. 2014. Exosomes mediate intercellular transfer of pro-fibrogenic 
connective tissue growth factor (CCN2) between hepatic stellate cells, the principal 
fibrotic cells in the liver. Surgery, 156, 548-55. 
CHAVEZ-TAPIA, N. C., ROSSO, N. & TIRIBELLI, C. 2011. In vitro models for the study of 
non-alcoholic fatty liver disease. Curr Med Chem, 18, 1079-84. 
CHEN, L., CHARRIER, A., ZHOU, Y., CHEN, R., YU, B., AGARWAL, K., TSUKAMOTO, 
H., LEE, L. J., PAULAITIS, M. E. & BRIGSTOCK, D. R. 2014. Epigenetic regulation 
of connective tissue growth factor by MicroRNA-214 delivery in exosomes from 
mouse or human hepatic stellate cells. Hepatology, 59, 1118-29. 
 
229 
CHEN, X., GONG, Q., WANG, C. Y., ZHANG, K., JI, X., CHEN, Y. X. & YU, X. J. 2016. 
High-Fat Diet Induces Distinct Metabolic Response in Interleukin-6 and Tumor 
Necrosis Factor-alpha Knockout Mice. J Interferon Cytokine Res, 36, 580-588. 
CHO, J., KIM, S., LEE, S. & KANG, H. 2015. Effect of Training Intensity on Nonalcoholic 
Fatty Liver Disease. Med Sci Sports Exerc, 47, 1624-34. 
CHO, J., LEE, I., KIM, D., KOH, Y., KONG, J., LEE, S. & KANG, H. 2014. Effect of aerobic 
exercise training on non-alcoholic fatty liver disease induced by a high fat diet in 
C57BL/6 mice. J Exerc Nutrition Biochem, 18, 339-46. 
CHOLANKERIL, G., WONG, R. J., HU, M., PERUMPAIL, R. B., YOO, E. R., PURI, P., 
YOUNOSSI, Z. M., HARRISON, S. A. & AHMED, A. 2017. Liver Transplantation 
for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. Dig Dis 
Sci, 62, 2915-2922. 
CIAPAITE, J., VAN DEN BROEK, N. M., TE BRINKE, H., NICOLAY, K., JENESON, J. 
A., HOUTEN, S. M. & PROMPERS, J. J. 2011. Differential effects of short- and long-
term high-fat diet feeding on hepatic fatty acid metabolism in rats. Biochim Biophys 
Acta, 1811, 441-51. 
COGGER, V. C., MOHAMAD, M., SOLON-BIET, S. M., SENIOR, A. M., WARREN, A., 
O'REILLY, J. N., TUNG, B. T., SVISTOUNOV, D., MCMAHON, A. C., FRASER, 
R., RAUBENHEIMER, D., HOLMES, A. J., SIMPSON, S. J. & LE COUTEUR, D. G. 
2016. Dietary macronutrients and the aging liver sinusoidal endothelial cell. Am J 
Physiol Heart Circ Physiol, 310, H1064-70. 
CONDE-VANCELLS, J., RODRIGUEZ-SUAREZ, E., EMBADE, N., GIL, D., 
MATTHIESEN, R., VALLE, M., ELORTZA, F., LU, S. C., MATO, J. M. & 
FALCON-PEREZ, J. M. 2008. Characterization and comprehensive proteome profiling 
of exosomes secreted by hepatocytes. J Proteome Res, 7, 5157-66. 
COSGROVE, B. D., CHENG, C., PRITCHARD, J. R., STOLZ, D. B., LAUFFENBURGER, 
D. A. & GRIFFITH, L. G. 2008. An inducible autocrine cascade regulates rat 
hepatocyte proliferation and apoptosis responses to tumor necrosis factor-alpha. 
Hepatology, 48, 276-88. 
COSTA-SILVA, B., AIELLO, N. M., OCEAN, A. J., SINGH, S., ZHANG, H., THAKUR, B. 
K., BECKER, A., HOSHINO, A., MARK, M. T., MOLINA, H., XIANG, J., ZHANG, 
T., THEILEN, T. M., GARCIA-SANTOS, G., WILLIAMS, C., ARARSO, Y., 
HUANG, Y., RODRIGUES, G., SHEN, T. L., LABORI, K. J., LOTHE, I. M., KURE, 
E. H., HERNANDEZ, J., DOUSSOT, A., EBBESEN, S. H., GRANDGENETT, P. M., 
HOLLINGSWORTH, M. A., JAIN, M., MALLYA, K., BATRA, S. K., JARNAGIN, 
W. R., SCHWARTZ, R. E., MATEI, I., PEINADO, H., STANGER, B. Z., 
BROMBERG, J. & LYDEN, D. 2015. Pancreatic cancer exosomes initiate pre-
metastatic niche formation in the liver. Nat Cell Biol, 17, 816-26. 
COSTA VERDERA, H., GITZ-FRANCOIS, J. J., SCHIFFELERS, R. M. & VADER, P. 2017. 
Cellular uptake of extracellular vesicles is mediated by clathrin-independent 
endocytosis and macropinocytosis. J Control Release, 266, 100-108. 
CSAK, T., BALA, S., LIPPAI, D., SATISHCHANDRAN, A., CATALANO, D., KODYS, K. 
& SZABO, G. 2015. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin 
in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int, 35, 
532-41. 
CUSI, K., CHANG, Z., HARRISON, S., LOMONACO, R., BRIL, F., ORSAK, B., ORTIZ-
LOPEZ, C., HECHT, J., FELDSTEIN, A. E., WEBB, A., LOUDEN, C., GOROS, M. 
& TIO, F. 2014. Limited value of plasma cytokeratin-18 as a biomarker for NASH and 
fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol, 60, 167-74. 
 
230 
DELOITTE ACCESS ECONOMICS. 2013. The economic cost and health burden of liver 
diseases in Australia [Online]. The Gastroenterological Society of Australia. Available: 
http://www.gesa.org.au/resources/economic-cost-and-health-burden-of-liver-disease-
in-australia/ [Accessed May 2017. 
DENG, Z. B., LIU, Y., LIU, C., XIANG, X., WANG, J., CHENG, Z., SHAH, S. V., ZHANG, 
S., ZHANG, L., ZHUANG, X., MICHALEK, S., GRIZZLE, W. E. & ZHANG, H. G. 
2009a. Immature myeloid cells induced by a high-fat diet contribute to liver 
inflammation. Hepatology, 50, 1412-20. 
DENG, Z. B., POLIAKOV, A., HARDY, R. W., CLEMENTS, R., LIU, C., LIU, Y., WANG, 
J., XIANG, X., ZHANG, S., ZHUANG, X., SHAH, S. V., SUN, D., MICHALEK, S., 
GRIZZLE, W. E., GARVEY, T., MOBLEY, J. & ZHANG, H. G. 2009b. Adipose 
tissue exosome-like vesicles mediate activation of macrophage-induced insulin 
resistance. Diabetes, 58, 2498-505. 
DESHMANE, S. L., KREMLEV, S., AMINI, S. & SAWAYA, B. E. 2009. Monocyte 
chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res, 29, 313-
26. 
DOHERTY, D. G. 2016. Immunity, tolerance and autoimmunity in the liver: A comprehensive 
review. J Autoimmun, 66, 60-75. 
DURHAM, H. A. & TRUETT, G. E. 2006. Development of insulin resistance and hyperphagia 
in Zucker fatty rats. Am J Physiol Regul Integr Comp Physiol, 290, R652-8. 
DURRER, C., ROBINSON, E., WAN, Z., MARTINEZ, N., HUMMEL, M. L., JENKINS, N. 
T., KILPATRICK, M. W. & LITTLE, J. P. 2015. Differential impact of acute high-
intensity exercise on circulating endothelial microparticles and insulin resistance 
between overweight/obese males and females. PLoS One, 10, e0115860. 
EKSTEDT, M., FRANZEN, L. E., MATHIESEN, U. L., THORELIUS, L., HOLMQVIST, 
M., BODEMAR, G. & KECHAGIAS, S. 2006. Long-term follow-up of patients with 
NAFLD and elevated liver enzymes. Hepatology, 44, 865-73. 
ELDH, M., OLOFSSON BAGGE, R., LASSER, C., SVANVIK, J., SJOSTRAND, M., 
MATTSSON, J., LINDNER, P., CHOI, D. S., GHO, Y. S. & LOTVALL, J. 2014. 
MicroRNA in exosomes isolated directly from the liver circulation in patients with 
metastatic uveal melanoma. BMC Cancer, 14, 962. 
EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER, EUROPEAN 
ASSOCIATION FOR THE STUDY OF DIABETES & OBESITY, E. A. F. T. S. O. 
2016. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-
alcoholic fatty liver disease. J Hepatol, 64, 1388-402. 
EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (EASL), EUROPEAN 
ASSOCIATION FOR THE STUDY OF DIABETES (EASD) & EUROPEAN 
ASSOCIATION FOR THE STUDY OF OBESITY (EASO) 2016. EASL-EASD-
EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver 
disease. Journal of Hepatology, 64, 1388-1402. 
FARAZUDDIN, M., DUA, B., ZIA, Q., KHAN, A. A., JOSHI, B. & OWAIS, M. 2014. 
Chemotherapeutic potential of curcumin-bearing microcells against hepatocellular 
carcinoma in model animals. Int J Nanomedicine, 9, 1139-52. 
FARRELL, G. C., MRIDHA, A. R., YEH, M. M., ARSOV, T., VAN ROOYEN, D. M., 
BROOLING, J., NGUYEN, T., HEYDET, D., DELGHINGARO-AUGUSTO, V., 
NOLAN, C. J., SHACKEL, N. A., MCLENNAN, S. V., TEOH, N. C. & LARTER, C. 
Z. 2014. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is 
linked to diabetes and inflammatory phenotype. Liver Int, 34, 1084-93. 
 
231 
FEDCHUK, L., NASCIMBENI, F., PAIS, R., CHARLOTTE, F., HOUSSET, C., RATZIU, V. 
& GROUP, L. S. 2014. Performance and limitations of steatosis biomarkers in patients 
with nonalcoholic fatty liver disease. Aliment Pharmacol Ther, 40, 1209-22. 
FEINSTEIN, R., KANETY, H., PAPA, M. Z., LUNENFELD, B. & KARASIK, A. 1993. 
Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of 
insulin receptor and its substrates. J Biol Chem, 268, 26055-8. 
FILINGERI, V., SFORZA, D. & TISONE, G. 2015. Complications and risk factors of a large 
series of percutaneous liver biopsies in patients with liver transplantation or liver 
disease. Eur Rev Med Pharmacol Sci, 19, 1621-9. 
FINK, R. I., KOLTERMAN, O. G., GRIFFIN, J. & OLEFSKY, J. M. 1983. Mechanisms of 
insulin resistance in aging. J Clin Invest, 71, 1523-35. 
FONSATO, V., COLLINO, F., HERRERA, M. B., CAVALLARI, C., DEREGIBUS, M. C., 
CISTERNA, B., BRUNO, S., ROMAGNOLI, R., SALIZZONI, M., TETTA, C. & 
CAMUSSI, G. 2012. Human liver stem cell-derived microvesicles inhibit hepatoma 
growth in SCID mice by delivering antitumor microRNAs. Stem Cells, 30, 1985-98. 
FONTANA, L., ZHAO, E., AMIR, M., DONG, H., TANAKA, K. & CZAJA, M. J. 2013. 
Aging promotes the development of diet-induced murine steatohepatitis but not 
steatosis. Hepatology, 57, 995-1004. 
FORETZ, M., GUICHARD, C., FERRE, P. & FOUFELLE, F. 1999. Sterol regulatory element 
binding protein-1c is a major mediator of insulin action on the hepatic expression of 
glucokinase and lipogenesis-related genes. Proc Natl Acad Sci U S A, 96, 12737-42. 
FREEMAN, C. M., QUILLIN, R. C., 3RD, WILSON, G. C., NOJIMA, H., JOHNSON, B. L., 
3RD, SUTTON, J. M., SCHUSTER, R. M., BLANCHARD, J., EDWARDS, M. J., 
CALDWELL, C. C. & LENTSCH, A. B. 2014. Characterization of microparticles after 
hepatic ischemia-reperfusion injury. PLoS One, 9, e97945. 
FRITH, J., DAY, C. P., HENDERSON, E., BURT, A. D. & NEWTON, J. L. 2009. Non-
alcoholic fatty liver disease in older people. Gerontology, 55, 607-13. 
GAN, L., CHITTURI, S. & FARRELL, G. C. 2011. Mechanisms and implications of age-
related changes in the liver: nonalcoholic Fatty liver disease in the elderly. Curr 
Gerontol Geriatr Res, 2011, 831536. 
GAO, S., HE, L., DING, Y. & LIU, G. 2010. Mechanisms underlying different responses of 
plasma triglyceride to high-fat diets in hamsters and mice: roles of hepatic MTP and 
triglyceride secretion. Biochem Biophys Res Commun, 398, 619-26. 
GARDINER, C., DI VIZIO, D., SAHOO, S., THERY, C., WITWER, K. W., WAUBEN, M. 
& HILL, A. F. 2016. Techniques used for the isolation and characterization of 
extracellular vesicles: results of a worldwide survey. J Extracell Vesicles, 5, 32945. 
GARDINER, C., FERREIRA, Y. J., DRAGOVIC, R. A., REDMAN, C. W. & SARGENT, I. 
L. 2013. Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis. 
J Extracell Vesicles, 2. 
GORDEN, D. L., IVANOVA, P. T., MYERS, D. S., MCINTYRE, J. O., VANSAUN, M. N., 
WRIGHT, J. K., MATRISIAN, L. M. & BROWN, H. A. 2011. Increased 
diacylglycerols characterize hepatic lipid changes in progression of human 
nonalcoholic fatty liver disease; comparison to a murine model. PLoS One, 6, e22775. 
GORSKI, J., NOWACKA, M., NAMIOT, Z. & PUCH, U. 1988. Effect of prolonged exercise 
on the level of triglycerides in the rat liver. Eur J Appl Physiol Occup Physiol, 57, 554-
7. 
GOULD, S. J. & RAPOSO, G. 2013. As we wait: coping with an imperfect nomenclature for 
extracellular vesicles. J Extracell Vesicles, 2. 
GUGLIELMI, A., RUZZENENTE, A., CONCI, S., VALDEGAMBERI, A. & IACONO, C. 
2012. How much remnant is enough in liver resection? Dig Surg, 29, 6-17. 
 
232 
GUO, J., JOU, W., GAVRILOVA, O. & HALL, K. D. 2009. Persistent diet-induced obesity in 
male C57BL/6 mice resulting from temporary obesigenic diets. PLoS One, 4, e5370. 
GUTIERREZ-GROBE, Y., PONCIANO-RODRIGUEZ, G., RAMOS, M. H., URIBE, M. & 
MENDEZ-SANCHEZ, N. 2010. Prevalence of non alcoholic fatty liver disease in 
premenopausal, posmenopausal and polycystic ovary syndrome women. The role of 
estrogens. Ann Hepatol, 9, 402-9. 
HAGAN, C. 2017. When are mice considered old? [Online]. The Jackson Laboratory. 
Available: https://www.jax.org/news-and-insights/jax-blog/2017/november/when-are-
mice-considered-old [Accessed September 2018. 
HALLSWORTH, K., THOMA, C., HOLLINGSWORTH, K. G., CASSIDY, S., ANSTEE, Q. 
M., DAY, C. P. & TRENELL, M. I. 2015. Modified high-intensity interval training 
reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a 
randomized controlled trial. Clin Sci (Lond), 129, 1097-105. 
HARIRI, N. & THIBAULT, L. 2010. High-fat diet-induced obesity in animal models. Nutr 
Res Rev, 23, 270-99. 
HASHIDA, R., KAWAGUCHI, T., BEKKI, M., OMOTO, M., MATSUSE, H., NAGO, T., 
TAKANO, Y., UENO, T., KOGA, H., GEORGE, J., SHIBA, N. & TORIMURA, T. 
2017. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic 
review. J Hepatol, 66, 142-152. 
HE, M., QIN, H., POON, T. C., SZE, S. C., DING, X., CO, N. N., NGAI, S. M., CHAN, T. F. 
& WONG, N. 2015. Hepatocellular carcinoma-derived exosomes promote motility of 
immortalized hepatocyte through transfer of oncogenic proteins and RNAs. 
Carcinogenesis, 36, 1008-1018. 
HEBERLE, H., MEIRELLES, G. V., DA SILVA, F. R., TELLES, G. P. & MINGHIM, R. 
2015. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. 
BMC Bioinformatics, 16, 169. 
HELWA, I., CAI, J., DREWRY, M. D., ZIMMERMAN, A., DINKINS, M. B., KHALED, M. 
L., SEREMWE, M., DISMUKE, W. M., BIEBERICH, E., STAMER, W. D., 
HAMRICK, M. W. & LIU, Y. 2017. A Comparative Study of Serum Exosome Isolation 
Using Differential Ultracentrifugation and Three Commercial Reagents. PLoS One, 12, 
e0170628. 
HERNANDEZ-GEA, V. & FRIEDMAN, S. L. 2011. Pathogenesis of liver fibrosis. Annu Rev 
Pathol, 6, 425-56. 
HESSVIK, N. P. & LLORENTE, A. 2018. Current knowledge on exosome biogenesis and 
release. Cell Mol Life Sci, 75, 193-208. 
HEYDET, D., CHEN, L. X., LARTER, C. Z., INGLIS, C., SILVERMAN, M. A., FARRELL, 
G. C. & LEROUX, M. R. 2013. A truncating mutation of Alms1 reduces the number 
of hypothalamic neuronal cilia in obese mice. Dev Neurobiol, 73, 1-13. 
HIRSOVA, P., IBRAHIM, S. H., KRISHNAN, A., VERMA, V. K., BRONK, S. F., 
WERNEBURG, N. W., CHARLTON, M. R., SHAH, V. H., MALHI, H. & GORES, 
G. J. 2016. Lipid-Induced Signaling Causes Release of Inflammatory Extracellular 
Vesicles From Hepatocytes. Gastroenterology, 150, 956-67. 
HLA, T. & KOLESNICK, R. 2014. C16:0-ceramide signals insulin resistance. Cell Metab, 20, 
703-705. 
HORTON, J. D., SHIMANO, H., HAMILTON, R. L., BROWN, M. S. & GOLDSTEIN, J. L. 
1999. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks 
hyperlipidemia resulting from production of lipid-rich VLDL. J Clin Invest, 103, 1067-
76. 
HORVATH, S., ERHART, W., BROSCH, M., AMMERPOHL, O., VON SCHONFELS, W., 
AHRENS, M., HEITS, N., BELL, J. T., TSAI, P. C., SPECTOR, T. D., DELOUKAS, 
 
233 
P., SIEBERT, R., SIPOS, B., BECKER, T., ROCKEN, C., SCHAFMAYER, C. & 
HAMPE, J. 2014. Obesity accelerates epigenetic aging of human liver. Proc Natl Acad 
Sci U S A, 111, 15538-43. 
HOTAMISLIGIL, G. S., MURRAY, D. L., CHOY, L. N. & SPIEGELMAN, B. M. 1994. 
Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad 
Sci U S A, 91, 4854-8. 
HOUTKOOPER, R. H., ARGMANN, C., HOUTEN, S. M., CANTO, C., JENINGA, E. H., 
ANDREUX, P. A., THOMAS, C., DOENLEN, R., SCHOONJANS, K. & AUWERX, 
J. 2011. The metabolic footprint of aging in mice. Sci Rep, 1, 134. 
HOWELL, J., BALDERSON, G., HELLARD, M., GOW, P., STRASSER, S., STUART, K., 
WIGG, A., JEFFREY, G., GANE, E. & ANGUS, P. W. 2016. The increasing burden 
of potentially preventable liver disease among adult liver transplant recipients: A 
comparative analysis of liver transplant indication by era in Australia and New Zealand. 
J Gastroenterol Hepatol, 31, 434-41. 
HUANG DA, W., SHERMAN, B. T. & LEMPICKI, R. A. 2009. Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 4, 44-
57. 
HUGEL, B., MARTINEZ, M. C., KUNZELMANN, C. & FREYSSINET, J. M. 2005. 
Membrane microparticles: two sides of the coin. Physiology (Bethesda), 20, 22-7. 
IBRAHIM, S. H., HIRSOVA, P., TOMITA, K., BRONK, S. F., WERNEBURG, N. W., 
HARRISON, S. A., GOODFELLOW, V. S., MALHI, H. & GORES, G. J. 2016. Mixed 
lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic 
extracellular vesicles from lipotoxic hepatocytes. Hepatology, 63, 731-44. 
INGLIS, H., NORRIS, P. & DANESH, A. 2015. Techniques for the analysis of extracellular 
vesicles using flow cytometry. J Vis Exp. 
ISMAIL, I., KEATING, S. E., BAKER, M. K. & JOHNSON, N. A. 2012. A systematic review 
and meta-analysis of the effect of aerobic vs. resistance exercise training on visceral 
fat. Obes Rev, 13, 68-91. 
ITO, M., SUZUKI, J., TSUJIOKA, S., SASAKI, M., GOMORI, A., SHIRAKURA, T., 
HIROSE, H., ITO, M., ISHIHARA, A., IWAASA, H. & KANATANI, A. 2007. 
Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to 
high-fat diet. Hepatol Res, 37, 50-7. 
JACOBS, A., WARDA, A. S., VERBEEK, J., CASSIMAN, D. & SPINCEMAILLE, P. 2016. 
An Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present. 
Curr Protoc Mouse Biol, 6, 185-200. 
JAIRAM, V., UCHIDA, K. & NARAYANASWAMI, V. 2012. Pathophysiology of 
Lipoprotein Oxidation. In: FRANK, S. & KOSTNER, G. (eds.) Lipoproteins - Role in 
Health and Diseases. Rijeka: InTech. 
JENJAROENPUN, P., KREMENSKA, Y., NAIR, V. M., KREMENSKOY, M., JOSEPH, B. 
& KUROCHKIN, I. V. 2013. Characterization of RNA in exosomes secreted by human 
breast cancer cell lines using next-generation sequencing. PeerJ, 1, e201. 
JENSEN, M. D. 2008. Role of body fat distribution and the metabolic complications of obesity. 
J Clin Endocrinol Metab, 93, S57-63. 
JEYARAM, A. & JAY, S. M. 2017. Preservation and Storage Stability of Extracellular 
Vesicles for Therapeutic Applications. AAPS J, 20, 1. 
JOHNSON, N. A., SACHINWALLA, T., WALTON, D. W., SMITH, K., ARMSTRONG, A., 
THOMPSON, M. W. & GEORGE, J. 2009. Aerobic exercise training reduces hepatic 
and visceral lipids in obese individuals without weight loss. Hepatology, 50, 1105-12. 
JORNAYVAZ, F. R. & SHULMAN, G. I. 2012. Diacylglycerol activation of protein kinase 
Cepsilon and hepatic insulin resistance. Cell Metab, 15, 574-84. 
 
234 
KADOTA, T., FUJITA, Y., YOSHIOKA, Y., ARAYA, J., KUWANO, K. & OCHIYA, T. 
2018. Emerging role of extracellular vesicles as a senescence-associated secretory 
phenotype: Insights into the pathophysiology of lung diseases. Mol Aspects Med, 60, 
92-103. 
KAKAZU, E., MAUER, A. S., YIN, M. & MALHI, H. 2016. Hepatocytes release ceramide-
enriched pro-inflammatory extracellular vesicles in an IRE1alpha-dependent manner. J 
Lipid Res, 57, 233-45. 
KAKINO, S., OHKI, T., NAKAYAMA, H., YUAN, X., OTABE, S., HASHINAGA, T., 
WADA, N., KURITA, Y., TANAKA, K., HARA, K., SOEJIMA, E., TAJIRI, Y. & 
YAMADA, K. 2018. Pivotal Role of TNF-alpha in the Development and Progression 
of Nonalcoholic Fatty Liver Disease in a Murine Model. Horm Metab Res, 50, 80-87. 
KALAKI-JOUYBARI, F., SHANAKI, M., DELFAN, M., GORGANI-FIROUZJAE, S. & 
KHAKDAN, S. 2018. High-intensity interval training (HIIT) alleviated NAFLD 
feature via miR-122 induction in liver of high-fat high-fructose diet induced diabetic 
rats. Arch Physiol Biochem, 1-8. 
KALRA, H., ADDA, C. G., LIEM, M., ANG, C. S., MECHLER, A., SIMPSON, R. J., 
HULETT, M. D. & MATHIVANAN, S. 2013. Comparative proteomics evaluation of 
plasma exosome isolation techniques and assessment of the stability of exosomes in 
normal human blood plasma. Proteomics, 13, 3354-64. 
KALRA, H., SIMPSON, R. J., JI, H., AIKAWA, E., ALTEVOGT, P., ASKENASE, P., 
BOND, V. C., BORRAS, F. E., BREAKEFIELD, X., BUDNIK, V., BUZAS, E., 
CAMUSSI, G., CLAYTON, A., COCUCCI, E., FALCON-PEREZ, J. M., 
GABRIELSSON, S., GHO, Y. S., GUPTA, D., HARSHA, H. C., HENDRIX, A., 
HILL, A. F., INAL, J. M., JENSTER, G., KRAMER-ALBERS, E. M., LIM, S. K., 
LLORENTE, A., LOTVALL, J., MARCILLA, A., MINCHEVA-NILSSON, L., 
NAZARENKO, I., NIEUWLAND, R., NOLTE-'T HOEN, E. N., PANDEY, A., 
PATEL, T., PIPER, M. G., PLUCHINO, S., PRASAD, T. S., RAJENDRAN, L., 
RAPOSO, G., RECORD, M., REID, G. E., SANCHEZ-MADRID, F., SCHIFFELERS, 
R. M., SILJANDER, P., STENSBALLE, A., STOORVOGEL, W., TAYLOR, D., 
THERY, C., VALADI, H., VAN BALKOM, B. W., VAZQUEZ, J., VIDAL, M., 
WAUBEN, M. H., YANEZ-MO, M., ZOELLER, M. & MATHIVANAN, S. 2012. 
Vesiclepedia: a compendium for extracellular vesicles with continuous community 
annotation. PLoS Biol, 10, e1001450. 
KARLAS, T., PETROFF, D., GARNOV, N., BOHM, S., TENCKHOFF, H., WITTEKIND, 
C., WIESE, M., SCHIEFKE, I., LINDER, N., SCHAUDINN, A., BUSSE, H., KAHN, 
T., MOSSNER, J., BERG, T., TROLTZSCH, M., KEIM, V. & WIEGAND, J. 2014. 
Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled 
attenuation parameter and 1H-MR spectroscopy. PLoS One, 9, e91987. 
KAWANISHI, N., YANO, H., MIZOKAMI, T., TAKAHASHI, M., OYANAGI, E. & 
SUZUKI, K. 2012. Exercise training attenuates hepatic inflammation, fibrosis and 
macrophage infiltration during diet induced-obesity in mice. Brain Behav Immun, 26, 
931-41. 
KEATING, S. E., HACKETT, D. A., GEORGE, J. & JOHNSON, N. A. 2012. Exercise and 
non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol, 57, 
157-66. 
KEATING, S. E., HACKETT, D. A., PARKER, H. M., O'CONNOR, H. T., GEROFI, J. A., 
SAINSBURY, A., BAKER, M. K., CHUTER, V. H., CATERSON, I. D., GEORGE, J. 
& JOHNSON, N. A. 2015. Effect of aerobic exercise training dose on liver fat and 
visceral adiposity. J Hepatol, 63, 174-82. 
 
235 
KEERTHIKUMAR, S., CHISANGA, D., ARIYARATNE, D., AL SAFFAR, H., ANAND, S., 
ZHAO, K., SAMUEL, M., PATHAN, M., JOIS, M., CHILAMKURTI, N., 
GANGODA, L. & MATHIVANAN, S. 2016. ExoCarta: A Web-Based Compendium 
of Exosomal Cargo. J Mol Biol, 428, 688-692. 
KERSTEN, S., SEYDOUX, J., PETERS, J. M., GONZALEZ, F. J., DESVERGNE, B. & 
WAHLI, W. 1999. Peroxisome proliferator-activated receptor alpha mediates the 
adaptive response to fasting. J Clin Invest, 103, 1489-98. 
KICHIAN, K., MCLEAN, R., GRAMLICH, L. M., BAILEY, R. J. & BAIN, V. G. 2003. 
Nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes. Can 
J Gastroenterol, 17, 38-42. 
KIRK, E. A., MOE, G. L., CALDWELL, M. T., LERNMARK, J. A., WILSON, D. L. & 
LEBOEUF, R. C. 1995. Hyper- and hypo-responsiveness to dietary fat and cholesterol 
among inbred mice: searching for level and variability genes. J Lipid Res, 36, 1522-32. 
KLEINER, D. E., BRUNT, E. M., VAN NATTA, M., BEHLING, C., CONTOS, M. J., 
CUMMINGS, O. W., FERRELL, L. D., LIU, Y. C., TORBENSON, M. S., UNALP-
ARIDA, A., YEH, M., MCCULLOUGH, A. J., SANYAL, A. J. & NONALCOHOLIC 
STEATOHEPATITIS CLINICAL RESEARCH, N. 2005. Design and validation of a 
histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41, 1313-
21. 
KMIEĆ, Z. 2001. Cooperation of liver cells in health and disease, Berlin ; New York, Springer. 
KNITTEL, T., MEHDE, M., KOBOLD, D., SAILE, B., DINTER, C. & RAMADORI, G. 
1999. Expression patterns of matrix metalloproteinases and their inhibitors in 
parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-
beta1. J Hepatol, 30, 48-60. 
KO, S. F., YIP, H. K., ZHEN, Y. Y., LEE, C. C., LEE, C. C., HUANG, C. C., NG, S. H. & 
LIN, J. W. 2015. Adipose-Derived Mesenchymal Stem Cell Exosomes Suppress 
Hepatocellular Carcinoma Growth in a Rat Model: Apparent Diffusion Coefficient, 
Natural Killer T-Cell Responses, and Histopathological Features. Stem Cells Int, 2015, 
853506. 
KOECK, E. S., IORDANSKAIA, T., SEVILLA, S., FERRANTE, S. C., HUBAL, M. J., 
FREISHTAT, R. J. & NADLER, E. P. 2014. Adipocyte exosomes induce transforming 
growth factor beta pathway dysregulation in hepatocytes: a novel paradigm for obesity-
related liver disease. J Surg Res, 192, 268-75. 
KOGURE, T., LIN, W. L., YAN, I. K., BRACONI, C. & PATEL, T. 2011. Intercellular 
nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation 
of hepatocellular cancer cell growth. Hepatology, 54, 1237-48. 
KOGURE, T., YAN, I. K., LIN, W. L. & PATEL, T. 2013. Extracellular Vesicle-Mediated 
Transfer of a Novel Long Noncoding RNA TUC339: A Mechanism of Intercellular 
Signaling in Human Hepatocellular Cancer. Genes Cancer, 4, 261-72. 
KOHJIMA, M., ENJOJI, M., HIGUCHI, N., KATO, M., KOTOH, K., YOSHIMOTO, T., 
FUJINO, T., YADA, M., YADA, R., HARADA, N., TAKAYANAGI, R. & 
NAKAMUTA, M. 2007. Re-evaluation of fatty acid metabolism-related gene 
expression in nonalcoholic fatty liver disease. Int J Mol Med, 20, 351-8. 
KOHLI, R., KIRBY, M., XANTHAKOS, S. A., SOFTIC, S., FELDSTEIN, A. E., SAXENA, 
V., TANG, P. H., MILES, L., MILES, M. V., BALISTRERI, W. F., WOODS, S. C. & 
SEELEY, R. J. 2010. High-fructose, medium chain trans fat diet induces liver fibrosis 
and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic 
steatohepatitis. Hepatology, 52, 934-44. 
 
236 
KOOIJMANS, S. A., VADER, P., VAN DOMMELEN, S. M., VAN SOLINGE, W. W. & 
SCHIFFELERS, R. M. 2012. Exosome mimetics: a novel class of drug delivery 
systems. Int J Nanomedicine, 7, 1525-41. 
KORNBERG, H. 2000. Krebs and his trinity of cycles. Nat Rev Mol Cell Biol, 1, 225-8. 
KORNEK, M., LYNCH, M., MEHTA, S. H., LAI, M., EXLEY, M., AFDHAL, N. H. & 
SCHUPPAN, D. 2012. Circulating microparticles as disease-specific biomarkers of 
severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. 
Gastroenterology, 143, 448-58. 
KORNEK, M., POPOV, Y., LIBERMANN, T. A., AFDHAL, N. H. & SCHUPPAN, D. 2011. 
Human T cell microparticles circulate in blood of hepatitis patients and induce 
fibrolytic activation of hepatic stellate cells. Hepatology, 53, 230-42. 
KORNER, H., COOK, M., RIMINTON, D. S., LEMCKERT, F. A., HOEK, R. M., 
LEDERMANN, B., KONTGEN, F., FAZEKAS DE ST GROTH, B. & SEDGWICK, 
J. D. 1997. Distinct roles for lymphotoxin-alpha and tumor necrosis factor in 
organogenesis and spatial organization of lymphoid tissue. Eur J Immunol, 27, 2600-9. 
KOSAKA, N., IGUCHI, H., YOSHIOKA, Y., TAKESHITA, F., MATSUKI, Y. & OCHIYA, 
T. 2010. Secretory mechanisms and intercellular transfer of microRNAs in living cells. 
J Biol Chem, 285, 17442-52. 
KOTRONEN, A., PELTONEN, M., HAKKARAINEN, A., SEVASTIANOVA, K., 
BERGHOLM, R., JOHANSSON, L. M., LUNDBOM, N., RISSANEN, A., 
RIDDERSTRALE, M., GROOP, L., ORHO-MELANDER, M. & YKI-JARVINEN, H. 
2009. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and 
genetic factors. Gastroenterology, 137, 865-72. 
KRANENDONK, M. E., DE KLEIJN, D. P., KALKHOVEN, E., KANHAI, D. A., 
UITERWAAL, C. S., VAN DER GRAAF, Y., PASTERKAMP, G., VISSEREN, F. L. 
& GROUP, S. S. 2014a. Extracellular vesicle markers in relation to obesity and 
metabolic complications in patients with manifest cardiovascular disease. Cardiovasc 
Diabetol, 13, 37. 
KRANENDONK, M. E., VISSEREN, F. L., VAN HERWAARDEN, J. A., NOLTE-'T HOEN, 
E. N., DE JAGER, W., WAUBEN, M. H. & KALKHOVEN, E. 2014b. Effect of 
extracellular vesicles of human adipose tissue on insulin signaling in liver and muscle 
cells. Obesity (Silver Spring), 22, 2216-23. 
KUCERA, O. & CERVINKOVA, Z. 2014. Experimental models of non-alcoholic fatty liver 
disease in rats. World J Gastroenterol, 20, 8364-76. 
LAAKSO, T., EDMAN, P. & BRUNK, U. 1988. Biodegradable microspheres. VII: Alterations 
in mouse liver morphology after intravenous administration of polyacryl starch 
microparticles with different biodegradability. J Pharm Sci, 77, 138-44. 
LABRECQUE, D. R., ABBAS, Z., ANANIA, F., FERENCI, P., KHAN, A. G., GOH, K. L., 
HAMID, S. S., ISAKOV, V., LIZARZABAL, M., PENARANDA, M. M., RAMOS, J. 
F., SARIN, S., STIMAC, D., THOMSON, A. B., UMAR, M., KRABSHUIS, J., 
LEMAIR, A. & WORLD GASTROENTEROLOGY, O. 2014. World 
Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and 
nonalcoholic steatohepatitis. J Clin Gastroenterol, 48, 467-73. 
LACKNER, C. 2011. Hepatocellular ballooning in nonalcoholic steatohepatitis: the 
pathologist's perspective. Expert Rev Gastroenterol Hepatol, 5, 223-31. 
LAGOS-QUINTANA, M., RAUHUT, R., YALCIN, A., MEYER, J., LENDECKEL, W. & 
TUSCHL, T. 2002. Identification of tissue-specific microRNAs from mouse. Curr Biol, 
12, 735-9. 
LEE, A., RODE, A., NICOLL, A., MACZUREK, A. E., LIM, L., LIM, S., ANGUS, P., 
KRONBORG, I., ARACHCHI, N., GORELIK, A., LIEW, D., WARNER, F. J., 
 
237 
MCCAUGHAN, G. W., MCLENNAN, S. V. & SHACKEL, N. A. 2016. Circulating 
CD147 predicts mortality in advanced hepatocellular carcinoma. J Gastroenterol 
Hepatol, 31, 459-66. 
LEE, J. H., KIM, D., KIM, H. J., LEE, C. H., YANG, J. I., KIM, W., KIM, Y. J., YOON, J. 
H., CHO, S. H., SUNG, M. W. & LEE, H. S. 2010a. Hepatic steatosis index: a simple 
screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis, 42, 503-8. 
LEE, S. S., PARK, S. H., KIM, H. J., KIM, S. Y., KIM, M. Y., KIM, D. Y., SUH, D. J., KIM, 
K. M., BAE, M. H., LEE, J. Y., LEE, S. G. & YU, E. S. 2010b. Non-invasive 
assessment of hepatic steatosis: prospective comparison of the accuracy of imaging 
examinations. J Hepatol, 52, 579-85. 
LEE, Y. S., KIM, S. Y., KO, E., LEE, J. H., YI, H. S., YOO, Y. J., JE, J., SUH, S. J., JUNG, 
Y. K., KIM, J. H., SEO, Y. S., YIM, H. J., JEONG, W. I., YEON, J. E., UM, S. H. & 
BYUN, K. S. 2017. Exosomes derived from palmitic acid-treated hepatocytes induce 
fibrotic activation of hepatic stellate cells. Sci Rep, 7, 3710. 
LENER, T., GIMONA, M., AIGNER, L., BORGER, V., BUZAS, E., CAMUSSI, G., 
CHAPUT, N., CHATTERJEE, D., COURT, F. A., DEL PORTILLO, H. A., 
O'DRISCOLL, L., FAIS, S., FALCON-PEREZ, J. M., FELDERHOFF-MUESER, U., 
FRAILE, L., GHO, Y. S., GORGENS, A., GUPTA, R. C., HENDRIX, A., 
HERMANN, D. M., HILL, A. F., HOCHBERG, F., HORN, P. A., DE KLEIJN, D., 
KORDELAS, L., KRAMER, B. W., KRAMER-ALBERS, E. M., LANER-
PLAMBERGER, S., LAITINEN, S., LEONARDI, T., LORENOWICZ, M. J., LIM, S. 
K., LOTVALL, J., MAGUIRE, C. A., MARCILLA, A., NAZARENKO, I., OCHIYA, 
T., PATEL, T., PEDERSEN, S., POCSFALVI, G., PLUCHINO, S., QUESENBERRY, 
P., REISCHL, I. G., RIVERA, F. J., SANZENBACHER, R., SCHALLMOSER, K., 
SLAPER-CORTENBACH, I., STRUNK, D., TONN, T., VADER, P., VAN 
BALKOM, B. W., WAUBEN, M., ANDALOUSSI, S. E., THERY, C., ROHDE, E. & 
GIEBEL, B. 2015. Applying extracellular vesicles based therapeutics in clinical trials 
- an ISEV position paper. J Extracell Vesicles, 4, 30087. 
LEONE, T. C., WEINHEIMER, C. J. & KELLY, D. P. 1999. A critical role for the peroxisome 
proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the 
PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad 
Sci U S A, 96, 7473-8. 
LEWIS, G. F. & STEINER, G. 1996. Acute effects of insulin in the control of VLDL 
production in humans. Implications for the insulin-resistant state. Diabetes Care, 19, 
390-3. 
LI, W. C., RALPHS, K. L. & TOSH, D. 2010. Isolation and culture of adult mouse hepatocytes. 
Methods Mol Biol, 633, 185-96. 
LI, Y., ZHANG, L., LIU, F., XIANG, G., JIANG, D. & PU, X. 2015. Identification of 
endogenous controls for analyzing serum exosomal miRNA in patients with hepatitis 
B or hepatocellular carcinoma. Dis Markers, 2015, 893594. 
LIANG, W., MENKE, A. L., DRIESSEN, A., KOEK, G. H., LINDEMAN, J. H., STOOP, R., 
HAVEKES, L. M., KLEEMANN, R. & VAN DEN HOEK, A. M. 2014. Establishment 
of a general NAFLD scoring system for rodent models and comparison to human liver 
pathology. PLoS One, 9, e115922. 
LILLIE, R. D. & ASHBURN, L. L. 1943. Supersaturated solutions of fat stains in dilute 
isopropanol for demonstration of acute fatty degeneration not shown by Herxheimer’s 
technique. Archives of Pathology, 36, 432-440. 
LO, L., MCLENNAN, S. V., WILLIAMS, P. F., BONNER, J., CHOWDHURY, S., 
MCCAUGHAN, G. W., GORRELL, M. D., YUE, D. K. & TWIGG, S. M. 2011. 
 
238 
Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity 
model of non-alcoholic steatohepatitis. J Hepatol, 55, 435-44. 
LOOMBA, R. & SANYAL, A. J. 2013. The global NAFLD epidemic. Nat Rev Gastroenterol 
Hepatol, 10, 686-90. 
LOTVALL, J., HILL, A. F., HOCHBERG, F., BUZAS, E. I., DI VIZIO, D., GARDINER, C., 
GHO, Y. S., KUROCHKIN, I. V., MATHIVANAN, S., QUESENBERRY, P., 
SAHOO, S., TAHARA, H., WAUBEN, M. H., WITWER, K. W. & THERY, C. 2014. 
Minimal experimental requirements for definition of extracellular vesicles and their 
functions: a position statement from the International Society for Extracellular 
Vesicles. J Extracell Vesicles, 3, 26913. 
LV, L. H., WAN, Y. L., LIN, Y., ZHANG, W., YANG, M., LI, G. L., LIN, H. M., SHANG, 
C. Z., CHEN, Y. J. & MIN, J. 2012. Anticancer drugs cause release of exosomes with 
heat shock proteins from human hepatocellular carcinoma cells that elicit effective 
natural killer cell antitumor responses in vitro. J Biol Chem, 287, 15874-85. 
LYNCH, S. F. & LUDLAM, C. A. 2007. Plasma microparticles and vascular disorders. Br J 
Haematol, 137, 36-48. 
MACHADO, M. V., MICHELOTTI, G. A., XIE, G., ALMEIDA PEREIRA, T., BOURSIER, 
J., BOHNIC, B., GUY, C. D. & DIEHL, A. M. 2015. Mouse models of diet-induced 
nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS 
One, 10, e0127991. 
MARCINKO, K., SIKKEMA, S. R., SAMAAN, M. C., KEMP, B. E., FULLERTON, M. D. 
& STEINBERG, G. R. 2015. High intensity interval training improves liver and adipose 
tissue insulin sensitivity. Mol Metab, 4, 903-15. 
MATSUZAWA, N., TAKAMURA, T., KURITA, S., MISU, H., OTA, T., ANDO, H., 
YOKOYAMA, M., HONDA, M., ZEN, Y., NAKANUMA, Y., MIYAMOTO, K. & 
KANEKO, S. 2007. Lipid-induced oxidative stress causes steatohepatitis in mice fed 
an atherogenic diet. Hepatology, 46, 1392-403. 
MCPHERSON, S., HARDY, T., DUFOUR, J. F., PETTA, S., ROMERO-GOMEZ, M., 
ALLISON, M., OLIVEIRA, C. P., FRANCQUE, S., VAN GAAL, L., 
SCHATTENBERG, J. M., TINIAKOS, D., BURT, A., BUGIANESI, E., RATZIU, V., 
DAY, C. P. & ANSTEE, Q. M. 2017. Age as a Confounding Factor for the Accurate 
Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. Am J Gastroenterol, 112, 740-
751. 
MCPHERSON, S., JONSSON, J. R., COWIN, G. J., O'ROURKE, P., CLOUSTON, A. D., 
VOLP, A., HORSFALL, L., JOTHIMANI, D., FAWCETT, J., GALLOWAY, G. J., 
BENSON, M. & POWELL, E. E. 2009. Magnetic resonance imaging and spectroscopy 
accurately estimate the severity of steatosis provided the stage of fibrosis is considered. 
J Hepatol, 51, 389-97. 
MEMON, R. A., BASS, N. M., MOSER, A. H., FULLER, J., APPEL, R., GRUNFELD, C. & 
FEINGOLD, K. R. 1999. Down-regulation of liver and heart specific fatty acid binding 
proteins by endotoxin and cytokines in vivo. Biochim Biophys Acta, 1440, 118-26. 
MEMON, R. A., FEINGOLD, K. R., MOSER, A. H., FULLER, J. & GRUNFELD, C. 1998. 
Regulation of fatty acid transport protein and fatty acid translocase mRNA levels by 
endotoxin and cytokines. Am J Physiol, 274, E210-7. 
MEMON, R. A. & GILANI, A. H. 1995. An update on hyperlipidemia and its management. J 
Pak Med Assoc, 45, 275-82. 
MICHELOTTI, G. A., MACHADO, M. V. & DIEHL, A. M. 2013. NAFLD, NASH and liver 
cancer. Nat Rev Gastroenterol Hepatol, 10, 656-65. 
 
239 
MILLIMAGGI, D., MARI, M., D'ASCENZO, S., CAROSA, E., JANNINI, E. A., ZUCKER, 
S., CARTA, G., PAVAN, A. & DOLO, V. 2007. Tumor vesicle-associated CD147 
modulates the angiogenic capability of endothelial cells. Neoplasia, 9, 349-57. 
MOFRAD, P., CONTOS, M. J., HAQUE, M., SARGEANT, C., FISHER, R. A., LUKETIC, 
V. A., STERLING, R. K., SHIFFMAN, M. L., STRAVITZ, R. T. & SANYAL, A. J. 
2003. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated 
with normal ALT values. Hepatology, 37, 1286-92. 
MOMEN-HERAVI, F., BALA, S., KODYS, K. & SZABO, G. 2015. Exosomes derived from 
alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and 
sensitize monocytes to LPS. Sci Rep, 5, 9991. 
MOMEN-HERAVI, F., BALAJ, L., ALIAN, S., TIGGES, J., TOXAVIDIS, V., ERICSSON, 
M., DISTEL, R. J., IVANOV, A. R., SKOG, J. & KUO, W. P. 2012. Alternative 
methods for characterization of extracellular vesicles. Front Physiol, 3, 354. 
MOTTA, V. F., AGUILA, M. B. & MANDARIM, D. E. L. C. A. 2016. High-intensity interval 
training (swimming) significantly improves the adverse metabolism and comorbidities 
in diet-induced obese mice. J Sports Med Phys Fitness, 56, 655-63. 
MOTTIN, C. C., MORETTO, M., PADOIN, A. V., SWAROWSKY, A. M., TONETO, M. G., 
GLOCK, L. & REPETTO, G. 2004. The role of ultrasound in the diagnosis of hepatic 
steatosis in morbidly obese patients. Obes Surg, 14, 635-7. 
MULCAHY, L. A., PINK, R. C. & CARTER, D. R. 2014. Routes and mechanisms of 
extracellular vesicle uptake. J Extracell Vesicles, 3. 
MURAKAMI, Y., TOYODA, H., TANAHASHI, T., TANAKA, J., KUMADA, T., 
YOSHIOKA, Y., KOSAKA, N., OCHIYA, T. & TAGUCHI, Y. H. 2012. 
Comprehensive miRNA expression analysis in peripheral blood can diagnose liver 
disease. PLoS One, 7, e48366. 
MUSSO, G., GAMBINO, R., CASSADER, M. & PAGANO, G. 2011. Meta-analysis: natural 
history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-
invasive tests for liver disease severity. Ann Med, 43, 617-49. 
NALBANTOGLU, I. L. & BRUNT, E. M. 2014. Role of liver biopsy in nonalcoholic fatty 
liver disease. World J Gastroenterol, 20, 9026-37. 
O'REILLY, J. N., COGGER, V. C. & LE COUTEUR, D. G. 2010. Old age is associated with 
ultrastructural changes in isolated rat liver sinusoidal endothelial cells. J Electron 
Microsc (Tokyo), 59, 65-9. 
OGASAWARA, F., FUSEGAWA, H., HARUKI, Y., SHIRAISHI, K., WATANABE, N. & 
MATSUZAKI, S. 2005. Platelet activation in patients with alcoholic liver disease. 
Tokai J Exp Clin Med, 30, 41-8. 
OKUMURA, T. 2011. Role of lipid droplet proteins in liver steatosis. J Physiol Biochem, 67, 
629-36. 
OTGONSUREN, M., ESTEP, M. J., HOSSAIN, N., YOUNOSSI, E., FROST, S., HENRY, L., 
HUNT, S., FANG, Y., GOODMAN, Z. & YOUNOSSI, Z. M. 2014. Single non-
invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-
alcoholic steatohepatitis (NASH). J Gastroenterol Hepatol, 29, 2006-13. 
PAMIR, N., MCMILLEN, T. S., KAIYALA, K. J., SCHWARTZ, M. W. & LEBOEUF, R. C. 
2009. Receptors for tumor necrosis factor-alpha play a protective role against obesity 
and alter adipose tissue macrophage status. Endocrinology, 150, 4124-34. 
PARK, S. H., KIM, P. N., KIM, K. W., LEE, S. W., YOON, S. E., PARK, S. W., HA, H. K., 
LEE, M. G., HWANG, S., LEE, S. G., YU, E. S. & CHO, E. Y. 2006. Macrovesicular 
hepatic steatosis in living liver donors: use of CT for quantitative and qualitative 
assessment. Radiology, 239, 105-12. 
 
240 
PATSOURIS, D., REDDY, J. K., MULLER, M. & KERSTEN, S. 2006. Peroxisome 
proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic 
gene expression. Endocrinology, 147, 1508-16. 
PERAZZO, H. & DUFOUR, J. F. 2017. The therapeutic landscape of non-alcoholic 
steatohepatitis. Liver Int, 37, 634-647. 
PERRY, R. J., SAMUEL, V. T., PETERSEN, K. F. & SHULMAN, G. I. 2014. The role of 
hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature, 510, 84-91. 
PETER, A., STEFAN, N., CEGAN, A., WALENTA, M., WAGNER, S., KONIGSRAINER, 
A., KONIGSRAINER, I., MACHICAO, F., SCHICK, F., HARING, H. U. & 
SCHLEICHER, E. 2011. Hepatic glucokinase expression is associated with lipogenesis 
and fatty liver in humans. J Clin Endocrinol Metab, 96, E1126-30. 
PETERSEN, M. C., VATNER, D. F. & SHULMAN, G. I. 2017. Regulation of hepatic glucose 
metabolism in health and disease. Nat Rev Endocrinol, 13, 572-587. 
PETIT, J. M., MASSON, D., GUIU, B., ROLLOT, F., DUVILLARD, L., BOUILLET, B., 
BRINDISI, M. C., BUFFIER, P., HILLON, P., CERCUEIL, J. P. & VERGES, B. 2016. 
GCKR polymorphism influences liver fat content in patients with type 2 diabetes. Acta 
Diabetol, 53, 237-42. 
PHILLIPS, M. S., LIU, Q., HAMMOND, H. A., DUGAN, V., HEY, P. J., CASKEY, C. J. & 
HESS, J. F. 1996. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet, 
13, 18-9. 
POCOCK, G., RICHARDS, C. D. & RICHARDS, D. A. 2013. The Gastrointestinal System. 
Human Physiology. 4th ed.: OUP Oxford. 
POSPICHALOVA, V., SVOBODA, J., DAVE, Z., KOTRBOVA, A., KAISER, K., 
KLEMOVA, D., ILKOVICS, L., HAMPL, A., CRHA, I., JANDAKOVA, E., MINAR, 
L., WEINBERGER, V. & BRYJA, V. 2015. Simplified protocol for flow cytometry 
analysis of fluorescently labeled exosomes and microvesicles using dedicated flow 
cytometer. J Extracell Vesicles, 4, 25530. 
POSTIC, C. & GIRARD, J. 2008. Contribution of de novo fatty acid synthesis to hepatic 
steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest, 
118, 829-38. 
POSTIC, C., SHIOTA, M. & MAGNUSON, M. A. 2001. Cell-specific roles of glucokinase in 
glucose homeostasis. Recent Prog Horm Res, 56, 195-217. 
POVERO, D., EGUCHI, A., LI, H., JOHNSON, C. D., PAPOUCHADO, B. G., WREE, A., 
MESSER, K. & FELDSTEIN, A. E. 2014. Circulating extracellular vesicles with 
specific proteome and liver microRNAs are potential biomarkers for liver injury in 
experimental fatty liver disease. PLoS One, 9, e113651. 
POVERO, D., EGUCHI, A., NIESMAN, I. R., ANDRONIKOU, N., DE MOLLERAT DU 
JEU, X., MULYA, A., BERK, M., LAZIC, M., THAPALIYA, S., PAROLA, M., 
PATEL, H. H. & FELDSTEIN, A. E. 2013. Lipid-induced toxicity stimulates 
hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by 
endothelial cells. Sci Signal, 6, ra88. 
POVERO, D., PANERA, N., EGUCHI, A., JOHNSON, C. D., PAPOUCHADO, B. G., DE 
ARAUJO HORCEL, L., PINATEL, E. M., ALISI, A., NOBILI, V. & FELDSTEIN, A. 
E. 2015. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic 
stellate cell via microRNAs targeting PPAR-gamma. Cell Mol Gastroenterol Hepatol, 
1, 646-663 e4. 
POYNARD, T., RATZIU, V., CHARLOTTE, F., MESSOUS, D., MUNTEANU, M., 
IMBERT-BISMUT, F., MASSARD, J., BONYHAY, L., TAHIRI, M., THABUT, D., 
CADRANEL, J. F., LE BAIL, B., DE LEDINGHEN, V., GROUP, L. S. & GROUP, 
C. S. 2006. Diagnostic value of biochemical markers (NashTest) for the prediction of 
 
241 
non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC 
Gastroenterol, 6, 34. 
POYNARD, T., RATZIU, V., NAVEAU, S., THABUT, D., CHARLOTTE, F., MESSOUS, 
D., CAPRON, D., ABELLA, A., MASSARD, J., NGO, Y., MUNTEANU, M., 
MERCADIER, A., MANNS, M. & ALBRECHT, J. 2005. The diagnostic value of 
biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol, 4, 10. 
PRADERE, J. P., KLUWE, J., DE MINICIS, S., JIAO, J. J., GWAK, G. Y., DAPITO, D. H., 
JANG, M. K., GUENTHER, N. D., MEDERACKE, I., FRIEDMAN, R., DRAGOMIR, 
A. C., ALOMAN, C. & SCHWABE, R. F. 2013. Hepatic macrophages but not dendritic 
cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate 
cells in mice. Hepatology, 58, 1461-73. 
PURI, P., BAILLIE, R. A., WIEST, M. M., MIRSHAHI, F., CHOUDHURY, J., CHEUNG, 
O., SARGEANT, C., CONTOS, M. J. & SANYAL, A. J. 2007. A lipidomic analysis 
of nonalcoholic fatty liver disease. Hepatology, 46, 1081-90. 
PURI, P., WIEST, M. M., CHEUNG, O., MIRSHAHI, F., SARGEANT, C., MIN, H. K., 
CONTOS, M. J., STERLING, R. K., FUCHS, M., ZHOU, H., WATKINS, S. M. & 
SANYAL, A. J. 2009. The plasma lipidomic signature of nonalcoholic steatohepatitis. 
Hepatology, 50, 1827-38. 
RAMLO-HALSTED, B. A. & EDELMAN, S. V. 1999. The natural history of type 2 diabetes. 
Implications for clinical practice. Prim Care, 26, 771-89. 
RAND, M. L., WANG, H., PLUTHERO, F. G., STAFFORD, A. R., NI, R., VAEZZADEH, 
N., ALLISON, A. C., KAHR, W. H., WEITZ, J. I. & GROSS, P. L. 2012. Diannexin, 
an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent 
inhibitor of platelet-mediated events during thrombus formation. J Thromb Haemost, 
10, 1109-19. 
RATZIU, V., CADRANEL, J. F., SERFATY, L., DENIS, J., RENOU, C., DELASSALLE, P., 
BERNHARDT, C. & PERLEMUTER, G. 2012. A survey of patterns of practice and 
perception of NAFLD in a large sample of practicing gastroenterologists in France. J 
Hepatol, 57, 376-83. 
RATZIU, V., CHARLOTTE, F., HEURTIER, A., GOMBERT, S., GIRAL, P., BRUCKERT, 
E., GRIMALDI, A., CAPRON, F., POYNARD, T. & GROUP, L. S. 2005. Sampling 
variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology, 128, 
1898-906. 
RAUBENHEIMER, P. J., NYIRENDA, M. J. & WALKER, B. R. 2006. A choline-deficient 
diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in 
mice fed a high-fat diet. Diabetes, 55, 2015-20. 
REDONNET, A., GROUBET, R., NOEL-SUBERVILLE, C., BONILLA, S., MARTINEZ, A. 
& HIGUERET, P. 2001. Exposure to an obesity-inducing diet early affects the pattern 
of expression of peroxisome proliferator, retinoic acid, and triiodothyronine nuclear 
receptors in the rat. Metabolism, 50, 1161-7. 
REDZIC, J. S., KENDRICK, A. A., BAHMED, K., DAHL, K. D., PEARSON, C. G., 
ROBINSON, W. A., ROBINSON, S. E., GRANER, M. W. & EISENMESSER, E. Z. 
2013. Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-
9, IL-6, TGF-beta1 and EMMPRIN. PLoS One, 8, e71225. 
REEDER, S. B., CRUITE, I., HAMILTON, G. & SIRLIN, C. B. 2011. Quantitative assessment 
of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging, 
34, 729-49. 
REKKER, K., SAARE, M., ROOST, A. M., KUBO, A. L., ZAROVNI, N., CHIESI, A., 
SALUMETS, A. & PETERS, M. 2014. Comparison of serum exosome isolation 
methods for microRNA profiling. Clin Biochem, 47, 135-8. 
 
242 
RINELLA, M. E. & GREEN, R. M. 2004. The methionine-choline deficient dietary model of 
steatohepatitis does not exhibit insulin resistance. J Hepatol, 40, 47-51. 
ROBBINS, P. D. 2017. Extracellular vesicles and aging. Stem Cell Investig, 4, 98. 
ROWE, J. W., MINAKER, K. L., PALLOTTA, J. A. & FLIER, J. S. 1983. Characterization 
of the insulin resistance of aging. J Clin Invest, 71, 1581-7. 
RULL, A., CAMPS, J., ALONSO-VILLAVERDE, C. & JOVEN, J. 2010. Insulin resistance, 
inflammation, and obesity: role of monocyte chemoattractant protein-1 (or CCL2) in 
the regulation of metabolism. Mediators Inflamm, 2010, 326580. 
RYAN, C. K., JOHNSON, L. A., GERMIN, B. I. & MARCOS, A. 2002. One hundred 
consecutive hepatic biopsies in the workup of living donors for right lobe liver 
transplantation. Liver Transpl, 8, 1114-22. 
SAFDAR, A., SALEEM, A. & TARNOPOLSKY, M. A. 2016. The potential of endurance 
exercise-derived exosomes to treat metabolic diseases. Nat Rev Endocrinol, 12, 504-
17. 
SAILE, B., MATTHES, N., KNITTEL, T. & RAMADORI, G. 1999. Transforming growth 
factor beta and tumor necrosis factor alpha inhibit both apoptosis and proliferation of 
activated rat hepatic stellate cells. Hepatology, 30, 196-202. 
SALLES, J., TARDIF, N., LANDRIER, J. F., MOTHE-SATNEY, I., GUILLET, C., BOUE-
VAYSSE, C., COMBARET, L., GIRAUDET, C., PATRAC, V., BERTRAND-
MICHEL, J., DENIS, P., CHARDIGNY, J. M., BOIRIE, Y. & WALRAND, S. 2012. 
TNFalpha gene knockout differentially affects lipid deposition in liver and skeletal 
muscle of high-fat-diet mice. J Nutr Biochem, 23, 1685-93. 
SARTIPY, P. & LOSKUTOFF, D. J. 2003. Monocyte chemoattractant protein 1 in obesity and 
insulin resistance. Proc Natl Acad Sci U S A, 100, 7265-70. 
SASSO, M., BEAUGRAND, M., DE LEDINGHEN, V., DOUVIN, C., MARCELLIN, P., 
POUPON, R., SANDRIN, L. & MIETTE, V. 2010. Controlled attenuation parameter 
(CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of 
hepatic steatosis: preliminary study and validation in a cohort of patients with chronic 
liver disease from various causes. Ultrasound Med Biol, 36, 1825-35. 
SHARPTON, S. R., AJMERA, V. & LOOMBA, R. 2018. Emerging Role of the Gut 
Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clin 
Gastroenterol Hepatol, 17, 296-306. 
SHEN, F., ZHENG, R. D., MI, Y. Q., WANG, X. Y., PAN, Q., CHEN, G. Y., CAO, H. X., 
CHEN, M. L., XU, L., CHEN, J. N., CAO, Y., ZHANG, R. N., XU, L. M. & FAN, J. 
G. 2014. Controlled attenuation parameter for non-invasive assessment of hepatic 
steatosis in Chinese patients. World J Gastroenterol, 20, 4702-11. 
SHEN, J., CHAN, H. L., WONG, G. L., CHOI, P. C., CHAN, A. W., CHAN, H. Y., CHIM, 
A. M., YEUNG, D. K., CHAN, F. K., WOO, J., YU, J., CHU, W. C. & WONG, V. W. 
2012a. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum 
biomarkers. J Hepatol, 56, 1363-70. 
SHEN, Y., GIARDINO TORCHIA, M. L., LAWSON, G. W., KARP, C. L., ASHWELL, J. D. 
& MAZMANIAN, S. K. 2012b. Outer membrane vesicles of a human commensal 
mediate immune regulation and disease protection. Cell Host Microbe, 12, 509-20. 
SHIMANO, H., YAHAGI, N., AMEMIYA-KUDO, M., HASTY, A. H., OSUGA, J., 
TAMURA, Y., SHIONOIRI, F., IIZUKA, Y., OHASHI, K., HARADA, K., GOTODA, 
T., ISHIBASHI, S. & YAMADA, N. 1999. Sterol regulatory element-binding protein-
1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J 
Biol Chem, 274, 35832-9. 
SHOJAEE-MORADIE, F., CUTHBERTSON, D. J., BARRETT, M., JACKSON, N. C., 
HERRING, R., THOMAS, E. L., BELL, J., KEMP, G. J., WRIGHT, J. & UMPLEBY, 
 
243 
A. M. 2016. Exercise Training Reduces Liver Fat and Increases Rates of VLDL 
Clearance But Not VLDL Production in NAFLD. J Clin Endocrinol Metab, 101, 4219-
4228. 
SIDHU, S. S., MENGISTAB, A. T., TAUSCHER, A. N., LAVAIL, J. & BASBAUM, C. 2004. 
The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions. Oncogene, 
23, 956-63. 
SIMONS, M. & RAPOSO, G. 2009. Exosomes--vesicular carriers for intercellular 
communication. Curr Opin Cell Biol, 21, 575-81. 
SINGER, S. S., HENKELS, K., DEUCHER, A., BARKER, M., SINGER, J. & TRULZSCH, 
D. V. 1996. Growth hormone and aging change rat liver fatty acid binding protein 
levels. J Am Coll Nutr, 15, 169-74. 
SINGH, S., ALLEN, A. M., WANG, Z., PROKOP, L. J., MURAD, M. H. & LOOMBA, R. 
2015. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a 
systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol 
Hepatol, 13, 643-54 e1-9; quiz e39-40. 
SODAR, B. W., KITTEL, A., PALOCZI, K., VUKMAN, K. V., OSTEIKOETXEA, X., 
SZABO-TAYLOR, K., NEMETH, A., SPERLAGH, B., BARANYAI, T., GIRICZ, Z., 
WIENER, Z., TURIAK, L., DRAHOS, L., PALLINGER, E., VEKEY, K., 
FERDINANDY, P., FALUS, A. & BUZAS, E. I. 2016. Low-density lipoprotein 
mimics blood plasma-derived exosomes and microvesicles during isolation and 
detection. Sci Rep, 6, 24316. 
SORBI, D., BOYNTON, J. & LINDOR, K. D. 1999. The ratio of aspartate aminotransferase 
to alanine aminotransferase: potential value in differentiating nonalcoholic 
steatohepatitis from alcoholic liver disease. Am J Gastroenterol, 94, 1018-22. 
SOSSDORF, M., OTTO, G. P., CLAUS, R. A., GABRIEL, H. H. & LOSCHE, W. 2011. Cell-
derived microparticles promote coagulation after moderate exercise. Med Sci Sports 
Exerc, 43, 1169-76. 
STERN, C. & CASTERA, L. 2017. Non-invasive diagnosis of hepatic steatosis. Hepatol Int, 
11, 70-78. 
STINCONE, A., PRIGIONE, A., CRAMER, T., WAMELINK, M. M., CAMPBELL, K., 
CHEUNG, E., OLIN-SANDOVAL, V., GRUNING, N. M., KRUGER, A., TAUQEER 
ALAM, M., KELLER, M. A., BREITENBACH, M., BRINDLE, K. M., 
RABINOWITZ, J. D. & RALSER, M. 2015. The return of metabolism: biochemistry 
and physiology of the pentose phosphate pathway. Biol Rev Camb Philos Soc, 90, 927-
63. 
STRAVITZ, R. T., BOWLING, R., BRADFORD, R. L., KEY, N. S., GLOVER, S., 
THACKER, L. R. & GABRIEL, D. A. 2013. Role of procoagulant microparticles in 
mediating complications and outcome of acute liver injury/acute liver failure. 
Hepatology, 58, 304-13. 
SUGIMACHI, K., MATSUMURA, T., HIRATA, H., UCHI, R., UEDA, M., UEO, H., 
SHINDEN, Y., IGUCHI, T., EGUCHI, H., SHIRABE, K., OCHIYA, T., MAEHARA, 
Y. & MIMORI, K. 2015. Identification of a bona fide microRNA biomarker in serum 
exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. 
Br J Cancer, 112, 532-8. 
SULLIVAN, S., KIRK, E. P., MITTENDORFER, B., PATTERSON, B. W. & KLEIN, S. 
2012. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid 
kinetics in nonalcoholic fatty liver disease. Hepatology, 55, 1738-45. 
SUN, L., HU, J., XIONG, W., CHEN, X., LI, H. & JIE, S. 2013. MicroRNA expression profiles 
of circulating microvesicles in hepatocellular carcinoma. Acta Gastroenterol Belg, 76, 
386-92. 
 
244 
TAKAHASHI, K., YAN, I. K., KOGURE, T., HAGA, H. & PATEL, T. 2014. Extracellular 
vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity 
in human hepatocellular cancer. FEBS Open Bio, 4, 458-67. 
TAKASUGI, M., OKADA, R., TAKAHASHI, A., VIRYA CHEN, D., WATANABE, S. & 
HARA, E. 2017. Small extracellular vesicles secreted from senescent cells promote 
cancer cell proliferation through EphA2. Nat Commun, 8, 15729. 
TAYLOR, D. D. & SHAH, S. 2015. Methods of isolating extracellular vesicles impact down-
stream analyses of their cargoes. Methods, 87, 3-10. 
TEUFEL, A., ITZEL, T., ERHART, W., BROSCH, M., WANG, X. Y., KIM, Y. O., VON 
SCHONFELS, W., HERRMANN, A., BRUCKNER, S., STICKEL, F., DUFOUR, J. 
F., CHAVAKIS, T., HELLERBRAND, C., SPANG, R., MAASS, T., BECKER, T., 
SCHREIBER, S., SCHAFMAYER, C., SCHUPPAN, D. & HAMPE, J. 2016. 
Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic 
Fatty Liver Disease and Liver Tissues From Patients. Gastroenterology, 151, 513-525 
e0. 
THERY, C., AMIGORENA, S., RAPOSO, G. & CLAYTON, A. 2006. Isolation and 
characterization of exosomes from cell culture supernatants and biological fluids. Curr 
Protoc Cell Biol, Chapter 3, Unit 3 22. 
THRIFT, R. N., FORTE, T. M., CAHOON, B. E. & SHORE, V. G. 1986. Characterization of 
lipoproteins produced by the human liver cell line, Hep G2, under defined conditions. 
J Lipid Res, 27, 236-50. 
TILG, H. & MOSCHEN, A. R. 2008. Insulin resistance, inflammation, and non-alcoholic fatty 
liver disease. Trends Endocrinol Metab, 19, 371-9. 
TOMITA, K., TAMIYA, G., ANDO, S., OHSUMI, K., CHIYO, T., MIZUTANI, A., 
KITAMURA, N., TODA, K., KANEKO, T., HORIE, Y., HAN, J. Y., KATO, S., 
SHIMODA, M., OIKE, Y., TOMIZAWA, M., MAKINO, S., OHKURA, T., SAITO, 
H., KUMAGAI, N., NAGATA, H., ISHII, H. & HIBI, T. 2006. Tumour necrosis factor 
alpha signalling through activation of Kupffer cells plays an essential role in liver 
fibrosis of non-alcoholic steatohepatitis in mice. Gut, 55, 415-24. 
TRAJKOVIC, K., HSU, C., CHIANTIA, S., RAJENDRAN, L., WENZEL, D., WIELAND, 
F., SCHWILLE, P., BRUGGER, B. & SIMONS, M. 2008. Ceramide triggers budding 
of exosome vesicles into multivesicular endosomes. Science, 319, 1244-7. 
TRAK-SMAYRA, V., PARADIS, V., MASSART, J., NASSER, S., JEBARA, V. & 
FROMENTY, B. 2011. Pathology of the liver in obese and diabetic ob/ob and db/db 
mice fed a standard or high-calorie diet. Int J Exp Pathol, 92, 413-21. 
TURNER, N., KOWALSKI, G. M., LESLIE, S. J., RISIS, S., YANG, C., LEE-YOUNG, R. 
S., BABB, J. R., MEIKLE, P. J., LANCASTER, G. I., HENSTRIDGE, D. C., WHITE, 
P. J., KRAEGEN, E. W., MARETTE, A., COONEY, G. J., FEBBRAIO, M. A. & 
BRUCE, C. R. 2013. Distinct patterns of tissue-specific lipid accumulation during the 
induction of insulin resistance in mice by high-fat feeding. Diabetologia, 56, 1638-48. 
UYSAL, K. T., WIESBROCK, S. M. & HOTAMISLIGIL, G. S. 1998. Functional analysis of 
tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in 
genetic obesity. Endocrinology, 139, 4832-8. 
UYSAL, K. T., WIESBROCK, S. M., MARINO, M. W. & HOTAMISLIGIL, G. S. 1997. 
Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. 
Nature, 389, 610-4. 
VALADI, H., EKSTROM, K., BOSSIOS, A., SJOSTRAND, M., LEE, J. J. & LOTVALL, J. 
O. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism 
of genetic exchange between cells. Nat Cell Biol, 9, 654-9. 
 
245 
VAN DER POL, E., BOING, A. N., HARRISON, P., STURK, A. & NIEUWLAND, R. 2012. 
Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol 
Rev, 64, 676-705. 
VAN DER VLIST, E. J., NOLTE-'T HOEN, E. N., STOORVOGEL, W., ARKESTEIJN, G. 
J. & WAUBEN, M. H. 2012. Fluorescent labeling of nano-sized vesicles released by 
cells and subsequent quantitative and qualitative analysis by high-resolution flow 
cytometry. Nat Protoc, 7, 1311-26. 
VANPUTTE, C. L., REGAN, J. L., RUSSO, A. F. & SEELEY, R. R. 2010. Seeley's essentials 
of anatomy and physiology, Dubuque, McGraw-Hill. 
VILAR-GOMEZ, E., MARTINEZ-PEREZ, Y., CALZADILLA-BERTOT, L., TORRES-
GONZALEZ, A., GRA-ORAMAS, B., GONZALEZ-FABIAN, L., FRIEDMAN, S. L., 
DIAGO, M. & ROMERO-GOMEZ, M. 2015. Weight Loss Through Lifestyle 
Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. 
Gastroenterology, 149, 367-78 e5; quiz e14-5. 
VUPPALANCHI, R., UNALP, A., VAN NATTA, M. L., CUMMINGS, O. W., 
SANDRASEGARAN, K. E., HAMEED, T., TONASCIA, J. & CHALASANI, N. 
2009. Effects of liver biopsy sample length and number of readings on sampling 
variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol, 7, 481-6. 
WAHL, P., JANSEN, F., ACHTZEHN, S., SCHMITZ, T., BLOCH, W., MESTER, J. & 
WERNER, N. 2014. Effects of high intensity training and high volume training on 
endothelial microparticles and angiogenic growth factors. PLoS One, 9, e96024. 
WANG, H., HOU, L., LI, A., DUAN, Y., GAO, H. & SONG, X. 2014. Expression of serum 
exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int, 2014, 
864894. 
WANG, X., DING, X., NAN, L., WANG, Y., WANG, J., YAN, Z., ZHANG, W., SUN, J., 
ZHU, W., NI, B., DONG, S. & YU, L. 2015. Investigation of the roles of exosomes in 
colorectal cancer liver metastasis. Oncol Rep, 33, 2445-53. 
WARNE, J. P. 2003. Tumour necrosis factor alpha: a key regulator of adipose tissue mass. J 
Endocrinol, 177, 351-5. 
WAUBEN, M. H. M. 2016. Extracellular Vesicles. In: BRADSHAW, R. A. & STAHL, P. D. 
(eds.) Encyclopedia of Cell Biology. Waltham: Academic Press. 
WELSH, J. A., SCORLETTI, E., CLOUGH, G. F., ENGLYST, N. A. & BYRNE, C. D. 2018. 
Leukocyte extracellular vesicle concentration is inversely associated with liver fibrosis 
severity in NAFLD. J Leukoc Biol, 104, 631-639. 
WENG, Y., SUI, Z., SHAN, Y., HU, Y., CHEN, Y., ZHANG, L. & ZHANG, Y. 2016. 
Effective isolation of exosomes with polyethylene glycol from cell culture supernatant 
for in-depth proteome profiling. Analyst, 141, 4640-6. 
WHITHAM, M., PARKER, B. L., FRIEDRICHSEN, M., HINGST, J. R., HJORTH, M., 
HUGHES, W. E., EGAN, C. L., CRON, L., WATT, K. I., KUCHEL, R. P., 
JAYASOORIAH, N., ESTEVEZ, E., PETZOLD, T., SUTER, C. M., GREGOREVIC, 
P., KIENS, B., RICHTER, E. A., JAMES, D. E., WOJTASZEWSKI, J. F. P. & 
FEBBRAIO, M. A. 2018. Extracellular Vesicles Provide a Means for Tissue Crosstalk 
during Exercise. Cell Metab, 27, 237-251 e4. 
WILHELM, E. N., GONZALEZ-ALONSO, J., PARRIS, C. & RAKOBOWCHUK, M. 2016. 
Exercise intensity modulates the appearance of circulating microvesicles with 
proangiogenic potential upon endothelial cells. Am J Physiol Heart Circ Physiol, 311, 
H1297-H1310. 
WITWER, K. W., BUZAS, E. I., BEMIS, L. T., BORA, A., LASSER, C., LOTVALL, J., 
NOLTE-'T HOEN, E. N., PIPER, M. G., SIVARAMAN, S., SKOG, J., THERY, C., 
 
246 
WAUBEN, M. H. & HOCHBERG, F. 2013. Standardization of sample collection, 
isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles, 2. 
WITWER, K. W., SOEKMADJI, C., HILL, A. F., WAUBEN, M. H., BUZAS, E. I., DI VIZIO, 
D., FALCON-PEREZ, J. M., GARDINER, C., HOCHBERG, F., KUROCHKIN, I. V., 
LOTVALL, J., MATHIVANAN, S., NIEUWLAND, R., SAHOO, S., TAHARA, H., 
TORRECILHAS, A. C., WEAVER, A. M., YIN, H., ZHENG, L., GHO, Y. S., 
QUESENBERRY, P. & THERY, C. 2017. Updating the MISEV minimal requirements 
for extracellular vesicle studies: building bridges to reproducibility. J Extracell 
Vesicles, 6, 1396823. 
WOOD, T. 1986. Physiological functions of the pentose phosphate pathway. Cell Biochem 
Funct, 4, 241-7. 
WORLD HEALTH ORGANIZATION. 2017. Global Hepatitis Report 2017. Available: 
http://www.who.int/iris/handle/10665/255016 [Accessed Jan 2017]. 
WYNNE, H. A., COPE, L. H., MUTCH, E., RAWLINS, M. D., WOODHOUSE, K. W. & 
JAMES, O. F. 1989. The effect of age upon liver volume and apparent liver blood flow 
in healthy man. Hepatology, 9, 297-301. 
WYNNE, H. A. & JAMES, O. F. 1990. The ageing liver. Age Ageing, 19, 1-3. 
XIAO, W., DONG, W., ZHANG, C., SAREN, G., GENG, P., ZHAO, H., LI, Q., ZHU, J., LI, 
G., ZHANG, S. & YE, M. 2013. Effects of the epigenetic drug MS-275 on the release 
and function of exosome-related immune molecules in hepatocellular carcinoma cells. 
Eur J Med Res, 18, 61. 
XIONG, X., WANG, X., LU, Y., WANG, E., ZHANG, Z., YANG, J., ZHANG, H. & LI, X. 
2014. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated 
downregulation of FXR in aging mice. J Hepatol, 60, 847-54. 
XU, J., TERAN-GARCIA, M., PARK, J. H., NAKAMURA, M. T. & CLARKE, S. D. 2001. 
Polyunsaturated fatty acids suppress hepatic sterol regulatory element-binding protein-
1 expression by accelerating transcript decay. J Biol Chem, 276, 9800-7. 
XU, Y., BIALIK, S., JONES, B. E., IIMURO, Y., KITSIS, R. N., SRINIVASAN, A., 
BRENNER, D. A. & CZAJA, M. J. 1998. NF-kappaB inactivation converts a 
hepatocyte cell line TNF-alpha response from proliferation to apoptosis. Am J Physiol, 
275, C1058-66. 
YAHAGI, N., SHIMANO, H., HASTY, A. H., MATSUZAKA, T., IDE, T., YOSHIKAWA, 
T., AMEMIYA-KUDO, M., TOMITA, S., OKAZAKI, H., TAMURA, Y., IIZUKA, 
Y., OHASHI, K., OSUGA, J., HARADA, K., GOTODA, T., NAGAI, R., ISHIBASHI, 
S. & YAMADA, N. 2002. Absence of sterol regulatory element-binding protein-1 
(SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in 
Lep(ob)/Lep(ob) mice. J Biol Chem, 277, 19353-7. 
YAMADA, H., OHASHI, K., SUZUKI, K., MUNETSUNA, E., ANDO, Y., YAMAZAKI, 
M., ISHIKAWA, H., ICHINO, N., TERADAIRA, R. & HASHIMOTO, S. 2015. 
Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver 
disease. Clin Chim Acta, 446, 267-71. 
YAMASHITA, T., TAKAHASHI, Y., NISHIKAWA, M. & TAKAKURA, Y. 2016. Effect of 
exosome isolation methods on physicochemical properties of exosomes and clearance 
of exosomes from the blood circulation. Eur J Pharm Biopharm, 98, 1-8. 
YANEZ-MO, M., SILJANDER, P. R., ANDREU, Z., ZAVEC, A. B., BORRAS, F. E., 
BUZAS, E. I., BUZAS, K., CASAL, E., CAPPELLO, F., CARVALHO, J., COLAS, 
E., CORDEIRO-DA SILVA, A., FAIS, S., FALCON-PEREZ, J. M., GHOBRIAL, I. 
M., GIEBEL, B., GIMONA, M., GRANER, M., GURSEL, I., GURSEL, M., 
HEEGAARD, N. H., HENDRIX, A., KIERULF, P., KOKUBUN, K., KOSANOVIC, 
M., KRALJ-IGLIC, V., KRAMER-ALBERS, E. M., LAITINEN, S., LASSER, C., 
 
247 
LENER, T., LIGETI, E., LINE, A., LIPPS, G., LLORENTE, A., LOTVALL, J., 
MANCEK-KEBER, M., MARCILLA, A., MITTELBRUNN, M., NAZARENKO, I., 
NOLTE-'T HOEN, E. N., NYMAN, T. A., O'DRISCOLL, L., OLIVAN, M., 
OLIVEIRA, C., PALLINGER, E., DEL PORTILLO, H. A., REVENTOS, J., RIGAU, 
M., ROHDE, E., SAMMAR, M., SANCHEZ-MADRID, F., SANTAREM, N., 
SCHALLMOSER, K., OSTENFELD, M. S., STOORVOGEL, W., STUKELJ, R., 
VAN DER GREIN, S. G., VASCONCELOS, M. H., WAUBEN, M. H. & DE WEVER, 
O. 2015. Biological properties of extracellular vesicles and their physiological 
functions. J Extracell Vesicles, 4, 27066. 
YANG, L., ROH, Y. S., SONG, J., ZHANG, B., LIU, C., LOOMBA, R. & SEKI, E. 2014. 
Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis 
through regulation of cell death and lipid metabolism in mice. Hepatology, 59, 483-95. 
YOUNOSSI, Z. M., KOENIG, A. B., ABDELATIF, D., FAZEL, Y., HENRY, L. & WYMER, 
M. 2016. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic 
assessment of prevalence, incidence, and outcomes. Hepatology, 64, 73-84. 
YUANA, Y., BOING, A. N., GROOTEMAAT, A. E., VAN DER POL, E., HAU, C. M., 
CIZMAR, P., BUHR, E., STURK, A. & NIEUWLAND, R. 2015. Handling and storage 
of human body fluids for analysis of extracellular vesicles. J Extracell Vesicles, 4, 
29260. 
ZELBER-SAGI, S., RATZIU, V. & OREN, R. 2011. Nutrition and physical activity in 
NAFLD: an overview of the epidemiological evidence. World J Gastroenterol, 17, 
3377-89. 
ZHANG, F., HAO, G., SHAO, M., NHAM, K., AN, Y., WANG, Q., ZHU, Y., KUSMINSKI, 
C. M., HASSAN, G., GUPTA, R. K., ZHAI, Q., SUN, X., SCHERER, P. E. & OZ, O. 
K. 2018. An Adipose Tissue Atlas: An Image-Guided Identification of Human-like 
BAT and Beige Depots in Rodents. Cell Metab, 27, 252-262 e3. 
ZHANG, J., SHAN, W. F., JIN, T. T., WU, G. Q., XIONG, X. X., JIN, H. Y. & ZHU, S. M. 
2014. Propofol exerts anti-hepatocellular carcinoma by microvesicle-mediated transfer 
of miR-142-3p from macrophage to cancer cells. J Transl Med, 12, 279. 
ZHANG, W., KUDO, H., KAWAI, K., FUJISAKA, S., USUI, I., SUGIYAMA, T., 
TSUKADA, K., CHEN, N. & TAKAHARA, T. 2010. Tumor necrosis factor-alpha 
accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic 
fatty liver disease. Biochem Biophys Res Commun, 391, 1731-6. 
ZHANG, W., ZHAO, P., XU, X. L., CAI, L., SONG, Z. S., CAO, D. Y., TAO, K. S., ZHOU, 
W. P., CHEN, Z. N. & DOU, K. F. 2013. Annexin A2 promotes the migration and 
invasion of human hepatocellular carcinoma cells in vitro by regulating the shedding of 
CD147-harboring microvesicles from tumor cells. PLoS One, 8, e67268. 
ZHAO, H., SHANG, Q., PAN, Z., BAI, Y., LI, Z., ZHANG, H., ZHANG, Q., GUO, C., 
ZHANG, L. & WANG, Q. 2018. Exosomes From Adipose-Derived Stem Cells 
Attenuate Adipose Inflammation and Obesity Through Polarizing M2 Macrophages 
and Beiging in White Adipose Tissue. Diabetes, 67, 235-247. 
 
 
  
 
248 
 
Appendix 
 
  
 
249 
Table A1. Unique proteins from liver EV dataset recognised in other studies*. 
 
Symbol Protein name 
ACADL Long-chain specific acyl-CoA dehydrogenase, mitochondrial  
ACADM Medium-chain specific acyl-CoA dehydrogenase, mitochondrial  
ACLY ATP-citrate synthase  
ACOT1 Acyl-coenzyme A thioesterase 1  
ACOT2 Acyl-coenzyme A thioesterase 2, mitochondrial  
ACOX1 Peroxisomal acyl-coenzyme A oxidase 1  
ACTB Actin, cytoplasmic 1  
ACTN1 Alpha-actinin-1  
ACTN4 Alpha-actinin-4  
ACYP1 Acylphosphatase-1  
ADK Adenosine kinase  
AHSA1 Activator of 90 kDa heat shock protein ATPase homolog 1  
AIFM1 Apoptosis-inducing factor 1, mitochondrial  
ALDH2 Aldehyde dehydrogenase, mitochondrial  
ALDOA Fructose-bisphosphate aldolase A  
ALDOB Fructose-bisphosphate aldolase B  
AMACR Alpha-methylacyl-CoA racemase  
ANXA2 Annexin A2  
ANXA4 Annexin A4  
ANXA5 Annexin A5  
ANXA6 Annexin A6  
APEH Acylamino-acid-releasing enzyme  
APOA1 Apolipoprotein A-I  
APOB Apolipoprotein B-100  
ARPC2 Actin-related protein 2/3 complex subunit 2  
ARPC3 Actin-related protein 2/3 complex subunit 3  
ARPC4 Actin-related protein 2/3 complex subunit 4  
ARPC5 Actin-related protein 2/3 complex subunit 5  
ATOX1 Copper transport protein ATOX1  
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BLMH Bleomycin hydrolase  
BLVRB Flavin reductase (NADPH)  
BPHL Valacyclovir hydrolase  
BPNT1 3'(2'),5'-bisphosphate nucleotidase 1  
BTF3 Transcription factor BTF3  
CALM1 Calmodulin-1  
CAND1 Cullin-associated NEDD8-dissociated protein 1  
CAP1 Adenylyl cyclase-associated protein 1  
CAPZB F-actin-capping protein subunit beta  
CDV3 Protein CDV3  
CISD3 CDGSH iron-sulfur domain-containing protein 3, mitochondrial  
CLYBL Citrate lyase subunit beta-like protein, mitochondrial  
CNDP2 Cytosolic non-specific dipeptidase  
COMT Catechol O-methyltransferase  
COPB2 Coatomer subunit beta'  
COQ9 Ubiquinone biosynthesis protein COQ9, mitochondrial  
COTL1 Coactosin-like protein  
CREG1 Protein CREG1  
CYB5 Cytochrome b5  
DCPS m7GpppX diphosphatase  
DCXR L-xylulose reductase  
DDAH1 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1  
DDB1 DNA damage-binding protein 1  
DNPEP Aspartyl aminopeptidase  
DPP3 Dipeptidyl peptidase 3  
DPP4 Dipeptidyl peptidase 4  
ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial  
ECI1 Enoyl-CoA delta isomerase 1, mitochondrial  
ERH Enhancer of rudimentary homolog  
ETFA Electron transfer flavoprotein subunit alpha, mitochondrial  
ETFB Electron transfer flavoprotein subunit beta  
FABP4 Fatty acid-binding protein, adipocyte  
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FABP5 Fatty acid-binding protein, epidermal  
FAHD1 Acylpyruvase FAHD1, mitochondrial  
FAS Fatty acid synthase  
FIS1 Mitochondrial fission 1 protein  
FKBP3 Peptidyl-prolyl cis-trans isomerase FKBP3  
FLNB Filamin-B  
GALM Aldose 1-epimerase  
GCDH Glutaryl-CoA dehydrogenase, mitochondrial  
GCSH Glycine cleavage system H protein, mitochondrial  
GLOD4 Glyoxalase domain-containing protein 4  
GMPPA Mannose-1-phosphate guanyltransferase alpha  
GMPPB Mannose-1-phosphate guanyltransferase beta  
GPX1 Glutathione peroxidase 1  
GPX3 Glutathione peroxidase 3  
GRHPR Glyoxylate reductase/hydroxypyruvate reductase  
GSTA1 Glutathione S-transferase A1  
GSTA4 Glutathione S-transferase A4  
GSTM1 Glutathione S-transferase Mu 1  
GSTM2 Glutathione S-transferase Mu 2  
GSTM3 Glutathione S-transferase Mu 3  
GSTM6 Glutathione S-transferase Mu 6  
GSTM7 Glutathione S-transferase Mu 7  
GSTO1 Glutathione S-transferase omega-1  
GSTP1 Glutathione S-transferase P 1  
GSTP2 Glutathione S-transferase P 2  
GSTT3 Glutathione S-transferase theta-3  
HACL1 2-hydroxyacyl-CoA lyase 1  
HDHD2 Haloacid dehalogenase-like hydrolase domain-containing protein 2  
HGD Homogentisate 1,2-dioxygenase  
HINT1 Histidine triad nucleotide-binding protein 1  
HMGB1 High mobility group protein B1  
HMGCL Hydroxymethylglutaryl-CoA lyase, mitochondrial  
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HPRT Hypoxanthine-guanine phosphoribosyltransferase  
IAH1 Isoamyl acetate-hydrolyzing esterase 1 homolog  
IDE Insulin-degrading enzyme  
IIGP1 Interferon-inducible GTPase 1  
IMPA1 Inositol monophosphatase 1  
IPO5 Importin-5  
ITIH2 Inter-alpha-trypsin inhibitor heavy chain H2  
ITIH4 Inter alpha-trypsin inhibitor, heavy chain 4  
ITPA Inosine triphosphate pyrophosphatase  
IVD Isovaleryl-CoA dehydrogenase, mitochondrial  
KNG1 Kininogen-1  
LAMP1 Lysosome-associated membrane glycoprotein 1  
LAMP2 Lysosome-associated membrane glycoprotein 2  
LASP1 LIM and SH3 domain protein 1  
LDHA L-lactate dehydrogenase A chain  
LDHB L-lactate dehydrogenase B chain  
LMNA Prelamin-A/C  
LUM Lumican  
LYZ1 Lysozyme C-1  
MCEE Methylmalonyl-CoA epimerase, mitochondrial  
MEMO1 Protein MEMO1  
MIF Macrophage migration inhibitory factor  
MRC1 Macrophage mannose receptor 1  
MTAP S-methyl-5'-thioadenosine phosphorylase  
MUG1 Murinoglobulin-1  
MVP Major vault protein  
NAMPT Nicotinamide phosphoribosyltransferase  
NIT1 Deaminated glutathione amidase  
NIT2 Omega-amidase NIT2  
NPC2 Epididymal secretory protein E1  
NQO2 Ribosyldihydronicotinamide dehydrogenase [quinone]  
NUDC Nuclear migration protein nudC  
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NUDT7 Peroxisomal coenzyme A diphosphatase NUDT7  
OAT Ornithine aminotransferase, mitochondrial  
OLA1 Obg-like ATPase 1  
OPA1 Dynamin-like 120 kDa protein, mitochondrial  
OTUB1 Ubiquitin thioesterase OTUB1  
PAK2 Serine/threonine-protein kinase PAK 2  
PARK7 Protein/nucleic acid deglycase DJ-1  
PCBP1 Poly(rC)-binding protein 1  
PCCA Propionyl-CoA carboxylase alpha chain, mitochondrial  
PCCB Propionyl-CoA carboxylase beta chain, mitochondrial  
PDIA3 Protein disulfide-isomerase A3  
PDIA4 Protein disulfide-isomerase A4  
PDXK Pyridoxal kinase  
PEBP1 Phosphatidylethanolamine-binding protein 1  
PECR Peroxisomal trans-2-enoyl-CoA reductase  
PEPD Xaa-Pro dipeptidase  
PGAM1 Phosphoglycerate mutase 1  
PGK1 Phosphoglycerate kinase 1  
PGM1 Phosphoglucomutase-1  
PGM2 Phosphoglucomutase-2  
PGP Glycerol-3-phosphate phosphatase  
PPIA Peptidyl-prolyl cis-trans isomerase A  
PPIB Peptidyl-prolyl cis-trans isomerase B  
PPIF Peptidyl-prolyl cis-trans isomerase F, mitochondrial  
PRDX1 Peroxiredoxin-1  
PRDX2 Peroxiredoxin-2  
PRDX3 Thioredoxin-dependent peroxide reductase, mitochondrial  
PRDX4 Peroxiredoxin-4  
PRDX5 Peroxiredoxin-5, mitochondrial  
PRDX6 Peroxiredoxin-6  
PREP Presequence protease, mitochondrial  
PRPS1 Ribose-phosphate pyrophosphokinase 1  
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PSMD9 26S proteasome non-ATPase regulatory subunit 9  
PSME1 Proteasome activator complex subunit 1  
PSME2 Proteasome activator complex subunit 2  
PSME3 Proteasome activator complex subunit 3  
PURA Transcriptional activator protein Pur-alpha  
PYGB Glycogen phosphorylase, brain form  
PYGL Glycogen phosphorylase, liver form  
PZP Pregnancy zone protein  
RAB18 Ras-related protein Rab-18  
RBX1 E3 ubiquitin-protein ligase RBX1  
REEP6 Receptor expression-enhancing protein 6  
RGN Regucalcin  
RPE Ribulose-phosphate 3-epimerase  
RRBP1 Ribosome-binding protein 1  
RSU1 Ras suppressor protein 1  
SARDH Sarcosine dehydrogenase, mitochondrial  
SCLY Selenocysteine lyase  
SDHA Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial  
SEC13 Protein SEC13 homolog  
SET Protein SET  
SRSF2 Serine/arginine-rich splicing factor 2  
STIP1 Stress-induced-phosphoprotein 1  
SYK Lysine--tRNA ligase  
TBCA Tubulin-specific chaperone A  
TGM2 Protein-glutamine gamma-glutamyltransferase 2  
THOP1 Thimet oligopeptidase  
TKT Transketolase  
TLN1 Talin-1  
TPM3 Tropomyosin alpha-3 chain  
TPP2 Tripeptidyl-peptidase 2  
TSN Translin  
TSNAX Translin-associated protein X  
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TWF1 Twinfilin-1  
TXNL1 Thioredoxin-like protein 1  
UBA1 Ubiquitin-like modifier-activating enzyme 1  
UFC1 Ubiquitin-fold modifier-conjugating enzyme 1  
UGDH UDP-glucose 6-dehydrogenase  
WDR1 WD repeat-containing protein 1  
XDH Xanthine dehydrogenase/oxidase  
 
*Compared to a large pooled dataset (n=4845 unique proteins) in Vesiclepedia (Kalra et al., 
2012). Screening of Mus musculus proteins was available from 77 individual studies, using a 
range of techniques including mass spectrometry, western blotting, flow cytometry, protein 
assay, immunoelectron microscopy, or a combination of any two. 
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Table A2. Unique proteins from liver EV dataset novel to study*. 
 
Symbol Protein name 
1433B 14-3-3 protein beta/alpha  
1433E 14-3-3 protein epsilon  
1433F 14-3-3 protein eta  
1433G 14-3-3 protein gamma  
1433T 14-3-3 protein theta  
1433Z 14-3-3 protein zeta/delta  
3HAO 3-hydroxyanthranilate 3,4-dioxygenase  
3HIDH 3-hydroxyisobutyrate dehydrogenase, mitochondrial  
6PGD 6-phosphogluconate dehydrogenase, decarboxylating  
6PGL 6-phosphogluconolactonase  
A16A1 Aldehyde dehydrogenase family 16 member A1  
A1AG1 Alpha-1-acid glycoprotein 1  
A1AT2 Alpha-1-antitrypsin 1-2  
A1AT3 Alpha-1-antitrypsin 1-3  
A1AT4 Alpha-1-antitrypsin 1-4  
A1AT5 Alpha-1-antitrypsin 1-5  
AADAT Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial  
AATC Aspartate aminotransferase, cytoplasmic  
AATM Aspartate aminotransferase, mitochondrial  
ABHEB Protein ABHD14B  
ACADV Very long-chain specific acyl-CoA dehydrogenase, mitochondrial  
ACBP Acyl-CoA-binding protein  
ACOC Cytoplasmic aconitate hydratase  
ACON Aconitate hydratase, mitochondrial  
ACOX2 Peroxisomal acyl-coenzyme A oxidase 2  
ACSM1 Acyl-coenzyme A synthetase ACSM1, mitochondrial  
ACTS Actin, alpha skeletal muscle  
ACTY Beta-centractin  
ACTZ Alpha-centractin  
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ACY1 Aminoacylase-1  
ACY3 N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming)  
ADH1 Alcohol dehydrogenase 1  
ADHX Alcohol dehydrogenase class-3  
ADX Adrenodoxin, mitochondrial  
AGM1 Phosphoacetylglucosamine mutase  
AGT2 Alanine--glyoxylate aminotransferase 2, mitochondrial  
AK1A1 Alcohol dehydrogenase [NADP(+)]  
AK1CD Aldo-keto reductase family 1 member C13  
AKC1H Aldo-keto reductase family 1 member C18  
AL1A1 Retinal dehydrogenase 1  
AL1A7 Aldehyde dehydrogenase, cytosolic 1  
AL1B1 Aldehyde dehydrogenase X, mitochondrial  
AL1L1 Cytosolic 10-formyltetrahydrofolate dehydrogenase  
AL7A1 Alpha-aminoadipic semialdehyde dehydrogenase  
AL8A1 Aldehyde dehydrogenase family 8 member A1  
AL9A1 4-trimethylaminobutyraldehyde dehydrogenase  
ALAT1 Alanine aminotransferase 1  
ALAT2 Alanine aminotransferase 2  
ALBU Serum albumin  
ALR FAD-linked sulfhydryl oxidase ALR  
AMPB Aminopeptidase B  
AMPD2 AMP deaminase 2  
AMPL Cytosol aminopeptidase  
AN32A Acidic leucine-rich nuclear phosphoprotein 32 family member A  
ANT3 Antithrombin-III  
AOXA Aldehyde oxidase 1  
AOXC Aldehyde oxidase 3  
AP1B1 AP-1 complex subunit beta-1  
AP1M1 AP-1 complex subunit mu-1  
AP2A1 AP-2 complex subunit alpha-1  
AP2A2 AP-2 complex subunit alpha-2  
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AP2B1 AP-2 complex subunit beta  
AP2M1 AP-2 complex subunit mu  
AP4A Bis(5'-nucleosyl)-tetraphosphatase [asymmetrical]  
APOH Beta-2-glycoprotein 1  
ARC1A Actin-related protein 2/3 complex subunit 1A  
ARC1B Actin-related protein 2/3 complex subunit 1B  
ARGI1 Arginase-1  
ARK72 Aflatoxin B1 aldehyde reductase member 2  
ARLY Argininosuccinate lyase  
ARP2 Actin-related protein 2  
ARP3 Actin-related protein 3  
ARP5L Actin-related protein 2/3 complex subunit 5-like protein  
AS3MT Arsenite methyltransferase  
ASGL1 Isoaspartyl peptidase/L-asparaginase  
ASPD Putative L-aspartate dehydrogenase  
ASSY Argininosuccinate synthase  
ATPA ATP synthase subunit alpha, mitochondrial  
ATPB ATP synthase subunit beta, mitochondrial  
AUHM Methylglutaconyl-CoA hydratase, mitochondrial  
B2L13 Bcl-2-like protein 13  
BAAT Bile acid-CoA:amino acid N-acyltransferase  
BACH Cytosolic acyl coenzyme A thioester hydrolase  
BHMT1 Betaine--homocysteine S-methyltransferase 1  
BHMT2 S-methylmethionine--homocysteine S-methyltransferase BHMT2  
BODG Gamma-butyrobetaine dioxygenase  
BT3L4 Transcription factor BTF3 homolog 4  
BUP1 Beta-ureidopropionase  
CA050 Uncharacterized protein C1orf50 homolog  
CAH1 Carbonic anhydrase 1  
CAH2 Carbonic anhydrase 2  
CAH3 Carbonic anhydrase 3  
CAH5A Carbonic anhydrase 5A, mitochondrial  
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CAN2 Calpain-2 catalytic subunit  
CAPR1 Caprin-1  
CATA Catalase  
CATC Dipeptidyl peptidase 1  
CATD Cathepsin D  
CATH Pro-cathepsin H  
CAZA1 F-actin-capping protein subunit alpha-1  
CAZA2 F-actin-capping protein subunit alpha-2  
CBR4 Carbonyl reductase family member 4  
CBS Cystathionine beta-synthase  
CCS Copper chaperone for superoxide dismutase  
CDD Cytidine deaminase  
CE162 Centrosomal protein of 162 kDa  
CERU Ceruloplasmin  
CES1D Carboxylesterase 1D  
CES1F Carboxylesterase 1F  
CFAH Complement factor H  
CGL Cystathionine gamma-lyase  
CH10 10 kDa heat shock protein, mitochondrial  
CH60 60 kDa heat shock protein, mitochondrial  
CHM2A Charged multivesicular body protein 2a  
CISY Citrate synthase, mitochondrial  
CK054 Ester hydrolase C11orf54 homolog  
CMBL Carboxymethylenebutenolidase homolog  
CO3 Complement C3  
COF1 Cofilin-1  
COF2 Cofilin-2  
COPD Coatomer subunit delta  
COR1C Coronin-1C  
CP2DQ Cytochrome P450 2D26  
CPPED Serine/threonine-protein phosphatase CPPED1  
CPSM Carbamoyl-phosphate synthase [ammonia], mitochondrial  
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CRYL1 Lambda-crystallin homolog  
CRYM Ketimine reductase mu-crystallin  
CSAD Cysteine sulfinic acid decarboxylase  
CSN4 COP9 signalosome complex subunit 4  
CYBP Calcyclin-binding protein  
CYC Cytochrome c, somatic  
CYTB Cystatin-B  
DCA11 DDB1- and CUL4-associated factor 11  
DDC Aromatic-L-amino-acid decarboxylase  
DECR 2,4-dienoyl-CoA reductase, mitochondrial  
DEOC Deoxyribose-phosphate aldolase  
DESP Desmoplakin  
DEST Destrin  
DHB4 Peroxisomal multifunctional enzyme type 2  
DHB5 Estradiol 17 beta-dehydrogenase 5  
DHB8 Estradiol 17-beta-dehydrogenase 8  
DHDH Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase  
DHE3 Glutamate dehydrogenase 1, mitochondrial  
DHPR Dihydropteridine reductase  
DHSO Sorbitol dehydrogenase  
DLDH Dihydrolipoyl dehydrogenase, mitochondrial  
DOPD D-dopachrome decarboxylase  
DPP2 Dipeptidyl peptidase 2  
DPYD Dihydropyrimidine dehydrogenase [NADP(+)]  
DPYL2 Dihydropyrimidinase-related protein 2  
DPYS Dihydropyrimidinase  
DTD2 Putative D-tyrosyl-tRNA(Tyr) deacylase 2  
DX39B Spliceosome RNA helicase Ddx39b  
DYL2 Dynein light chain 2, cytoplasmic  
ECHD1 Ethylmalonyl-CoA decarboxylase  
ECHD3 Enoyl-CoA hydratase domain-containing protein 3, mitochondrial  
ECHM Enoyl-CoA hydratase, mitochondrial  
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EF1A1 Elongation factor 1-alpha 1  
EF1B Elongation factor 1-beta  
EF1D Elongation factor 1-delta  
EF1G Elongation factor 1-gamma  
EF2 Elongation factor 2  
EI3JA Eukaryotic translation initiation factor 3 subunit J-A  
EIF2A Eukaryotic translation initiation factor 2A  
EIF3A Eukaryotic translation initiation factor 3 subunit A  
EIF3H Eukaryotic translation initiation factor 3 subunit H  
EMAL2 Echinoderm microtubule-associated protein-like 2  
ENOA Alpha-enolase  
EST1 Liver carboxylesterase 1  
EST1C Carboxylesterase 1C  
EST2A Pyrethroid hydrolase Ces2a  
EST2C Acylcarnitine hydrolase  
EST2E Pyrethroid hydrolase Ces2e  
EST3A Carboxylesterase 3A  
EST3B Carboxylesterase 3B  
ESTD S-formylglutathione hydrolase  
ETHE1 Persulfide dioxygenase ETHE1, mitochondrial  
F10A1 Hsc70-interacting protein  
F13A Coagulation factor XIII A chain  
F16P1 Fructose-1,6-bisphosphatase 1  
FAAA Fumarylacetoacetase  
FABPI Fatty acid-binding protein, intestinal  
FABPL Fatty acid-binding protein, liver  
FETUA Alpha-2-HS-glycoprotein  
FGGY FGGY carbohydrate kinase domain-containing protein  
FHIT Bis(5'-adenosyl)-triphosphatase  
FIBA Fibrinogen alpha chain  
FIBB Fibrinogen beta chain  
FIBG Fibrinogen gamma chain  
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FINC Fibronectin  
FKB1A Peptidyl-prolyl cis-trans isomerase FKBP1A  
FPPS Farnesyl pyrophosphate synthase  
FRIH Ferritin heavy chain  
FRIL1 Ferritin light chain 1  
FUMH Fumarate hydratase, mitochondrial  
G3P Glyceraldehyde-3-phosphate dehydrogenase  
G3PT Glyceraldehyde-3-phosphate dehydrogenase, testis-specific  
G6PI Glucose-6-phosphate isomerase  
GABT 4-aminobutyrate aminotransferase, mitochondrial  
GALT Galactose-1-phosphate uridylyltransferase  
GAMT Guanidinoacetate N-methyltransferase  
GCAB Ig gamma-2A chain C region secreted form  
GCSP Glycine dehydrogenase (decarboxylating), mitochondrial  
GDIA Rab GDP dissociation inhibitor alpha  
GDIB Rab GDP dissociation inhibitor beta  
GDIR1 Rho GDP-dissociation inhibitor 1  
GDIR2 Rho GDP-dissociation inhibitor 2  
GEPH Gephyrin  
GFRP GTP cyclohydrolase 1 feedback regulatory protein  
GGACT Gamma-glutamylaminecyclotransferase  
GLNA Glutamine synthetase  
GLO2 Hydroxyacylglutathione hydrolase, mitochondrial  
GLPK Glycerol kinase  
GLRX1 Glutaredoxin-1  
GLUCM D-glutamate cyclase, mitochondrial  
GLYAL Glycine N-acyltransferase-like protein  
GLYAT Glycine N-acyltransferase  
GLYC Serine hydroxymethyltransferase, cytosolic  
GNMT Glycine N-methyltransferase  
GNPI1 Glucosamine-6-phosphate isomerase 1  
GPDA Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic  
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GRP75 Stress-70 protein, mitochondrial  
GRP78 78 kDa glucose-regulated protein  
GRPE1 GrpE protein homolog 1, mitochondrial  
GSH0 Glutamate--cysteine ligase regulatory subunit  
GSH1 Glutamate--cysteine ligase catalytic subunit  
GSHB Glutathione synthetase  
GSHR Glutathione reductase, mitochondrial  
GSTA2 Glutathione S-transferase A2  
GSTA3 Glutathione S-transferase A3  
GSTK1 Glutathione S-transferase kappa 1  
GSTT1 Glutathione S-transferase theta-1  
GSTT2 Glutathione S-transferase theta-2  
GUAD Guanine deaminase  
H14 Histone H1.4  
H2A2A Histone H2A type 2-A  
H2A2B Histone H2A type 2-B  
H2AV Histone H2A.V  
H2B1C Histone H2B type 1-C/E/G  
H32 Histone H3.2  
H33 Histone H3.3  
H4 Histone H4  
HA10 H-2 class I histocompatibility antigen, Q10 alpha chain  
HAOX1 Hydroxyacid oxidase 1  
HBA Hemoglobin subunit alpha  
HBB1 Hemoglobin subunit beta-1  
HCD2 3-hydroxyacyl-CoA dehydrogenase type-2  
HCDH Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial  
HDGF Hepatoma-derived growth factor  
HDHD3 Haloacid dehalogenase-like hydrolase domain-containing protein 3  
HEM2 Delta-aminolevulinic acid dehydratase  
HEM3 Porphobilinogen deaminase  
HEM6 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial  
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HEMO Hemopexin  
HIBCH 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial  
HIUH 5-hydroxyisourate hydrolase  
HMCS2 Hydroxymethylglutaryl-CoA synthase, mitochondrial  
HNMT Histamine N-methyltransferase  
HNRPF Heterogeneous nuclear ribonucleoprotein F  
HNRPK Heterogeneous nuclear ribonucleoprotein K  
HNRPQ Heterogeneous nuclear ribonucleoprotein Q  
HOGA1 4-hydroxy-2-oxoglutarate aldolase, mitochondrial  
HOT Hydroxyacid-oxoacid transhydrogenase, mitochondrial  
HPPD 4-hydroxyphenylpyruvate dioxygenase  
HPT Haptoglobin  
HS105 Heat shock protein 105 kDa  
HS71A Heat shock 70 kDa protein 1A  
HS71L Heat shock 70 kDa protein 1-like  
HS90A Heat shock protein HSP 90-alpha  
HS90B Heat shock protein HSP 90-beta  
HSP74 Heat shock 70 kDa protein 4  
HSP7C Heat shock cognate 71 kDa protein  
HUTH Histidine ammonia-lyase  
HUTI Probable imidazolonepropionase  
HUTU Urocanate hydratase  
HUWE1 E3 ubiquitin-protein ligase HUWE1  
HVM51 Ig heavy chain V region AC38 205.12  
HYES Bifunctional epoxide hydrolase 2  
HYKK Hydroxylysine kinase  
IDHC Isocitrate dehydrogenase [NADP] cytoplasmic  
IDHP Isocitrate dehydrogenase [NADP], mitochondrial  
IF2A Eukaryotic translation initiation factor 2 subunit 1  
IF2G Eukaryotic translation initiation factor 2 subunit 3, X-linked  
IF2H Eukaryotic translation initiation factor 2 subunit 3, Y-linked  
IF4A1 Eukaryotic initiation factor 4A-I  
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IF4A2 Eukaryotic initiation factor 4A-II  
IF5A1 Eukaryotic translation initiation factor 5A-1  
IF6 Eukaryotic translation initiation factor 6  
IGG2B Ig gamma-2B chain C region  
IGH1M Ig gamma-1 chain C region, membrane-bound form  
IGHM Ig mu chain C region  
IGKC Ig kappa chain C region  
INMT Indolethylamine N-methyltransferase  
IPYR Inorganic pyrophosphatase  
IPYR2 Inorganic pyrophosphatase 2, mitochondrial  
ISC2A Isochorismatase domain-containing protein 2A  
ISOC1 Isochorismatase domain-containing protein 1  
KAD2 Adenylate kinase 2, mitochondrial  
KAT1 Kynurenine--oxoglutarate transaminase 1  
KAT3 Kynurenine--oxoglutarate transaminase 3  
KBL 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial  
KCY UMP-CMP kinase  
KHK Ketohexokinase  
KPRA Phosphoribosyl pyrophosphate synthase-associated protein 1  
KPYM Pyruvate kinase PKM  
KPYR Pyruvate kinase PKLR  
KV5AB Ig kappa chain V-V region HP R16.7  
KYNU Kynureninase  
LACB2 Endoribonuclease LACTB2  
LDHD Probable D-lactate dehydrogenase, mitochondrial  
LEG1 Galectin-1  
LEG9 Galectin-9  
LGUL Lactoylglutathione lyase  
LHPP Phospholysine phosphohistidine inorganic pyrophosphate phosphatase  
LIS1 Platelet-activating factor acetylhydrolase IB subunit alpha  
LKHA4 Leukotriene A-4 hydrolase  
LPP60 60 kDa lysophospholipase  
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LYPA1 Acyl-protein thioesterase 1  
LYPA2 Acyl-protein thioesterase 2  
M2GD Dimethylglycine dehydrogenase, mitochondrial  
MAAI Maleylacetoacetate isomerase  
MAOX NADP-dependent malic enzyme  
MAP2 Methionine aminopeptidase 2  
MCCB Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial  
MDHC Malate dehydrogenase, cytoplasmic  
MDHM Malate dehydrogenase, mitochondrial  
METK1 S-adenosylmethionine synthase isoform type-1  
MOES Moesin  
MSRA Mitochondrial peptide methionine sulfoxide reductase  
MTL26 Methyltransferase-like 26  
MTNB Methylthioribulose-1-phosphate dehydratase  
MTND 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase  
MTP Microsomal triglyceride transfer protein large subunit  
MUTA Methylmalonyl-CoA mutase, mitochondrial  
MYDGF Myeloid-derived growth factor  
NACAM Nascent polypeptide-associated complex subunit alpha, muscle-specific form  
NADC Nicotinate-nucleotide pyrophosphorylase [carboxylating]  
NAKD2 NAD kinase 2, mitochondrial  
NDK3 Nucleoside diphosphate kinase 3  
NDKA Nucleoside diphosphate kinase A  
NDKB Nucleoside diphosphate kinase B  
NDRG2 Protein NDRG2  
NEUL Neurolysin, mitochondrial  
NHRF1 Na(+)/H(+) exchange regulatory cofactor NHE-RF1  
NHRF3 Na(+)/H(+) exchange regulatory cofactor NHE-RF3  
NIF3L NIF3-like protein 1  
NIPS1 Protein NipSnap homolog 1  
NLTP Non-specific lipid-transfer protein  
NNRD ATP-dependent (S)-NAD(P)H-hydrate dehydratase  
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NNRE NAD(P)H-hydrate epimerase  
NPL N-acetylneuraminate lyase  
NPM Nucleophosmin  
NPS3B Protein NipSnap homolog 3B  
NTF2 Nuclear transport factor 2  
NUCL Nucleolin  
NUD12 Peroxisomal NADH pyrophosphatase NUDT12  
NUDC2 NudC domain-containing protein 2  
OCTC Peroxisomal carnitine O-octanoyltransferase  
ODO1 2-oxoglutarate dehydrogenase, mitochondrial  
ODO2 Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex, mitochondrial  
ODP2 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial  
OPLA 5-oxoprolinase  
ORN Oligoribonuclease, mitochondrial  
OTC Ornithine carbamoyltransferase, mitochondrial  
PABP1 Polyadenylate-binding protein 1  
PAPS2 Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 2  
PBLD1 Phenazine biosynthesis-like domain-containing protein 1  
PBLD2 Phenazine biosynthesis-like domain-containing protein 2  
PCKGC Phosphoenolpyruvate carboxykinase, cytosolic [GTP]  
PCY2 Ethanolamine-phosphate cytidylyltransferase  
PDIA1 Protein disulfide-isomerase  
PDXD1 Pyridoxal-dependent decarboxylase domain-containing protein 1  
PEPL1 Probable aminopeptidase NPEPL1  
PGBM Basement membrane-specific heparan sulfate proteoglycan core protein  
PH4H Phenylalanine-4-hydroxylase  
PHS Pterin-4-alpha-carbinolamine dehydratase  
PHS2 Pterin-4-alpha-carbinolamine dehydratase 2  
PHYD1 Phytanoyl-CoA dioxygenase domain-containing protein 1  
PICAL Phosphatidylinositol-binding clathrin assembly protein  
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PIPNB Phosphatidylinositol transfer protein beta isoform  
PLAK Junction plakoglobin  
PLAP Phospholipase A-2-activating protein  
PLIN2 Perilipin-2  
PLSL Plastin-2  
PLST Plastin-3  
PMGE Bisphosphoglycerate mutase  
PNCB Nicotinate phosphoribosyltransferase  
PNPH Purine nucleoside phosphorylase  
PNPO Pyridoxine-5'-phosphate oxidase  
PP1A Serine/threonine-protein phosphatase PP1-alpha catalytic subunit  
PP1R7 Protein phosphatase 1 regulatory subunit 7  
PP2AA Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform  
PPA6 Lysophosphatidic acid phosphatase type 6  
PPAC Low molecular weight phosphotyrosine protein phosphatase  
PPCS Phosphopantothenate--cysteine ligase  
PPCT Phosphatidylcholine transfer protein  
PPM1A Protein phosphatase 1A  
PPM1B Protein phosphatase 1B  
PPP5 Serine/threonine-protein phosphatase 5  
PROF1 Profilin-1  
PRRC1 Protein PRRC1  
PSA Puromycin-sensitive aminopeptidase  
PSA1 Proteasome subunit alpha type-1  
PSA2 Proteasome subunit alpha type-2  
PSA3 Proteasome subunit alpha type-3  
PSA4 Proteasome subunit alpha type-4  
PSA5 Proteasome subunit alpha type-5  
PSA6 Proteasome subunit alpha type-6  
PSA7 Proteasome subunit alpha type-7  
PSB1 Proteasome subunit beta type-1  
PSB10 Proteasome subunit beta type-10  
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PSB2 Proteasome subunit beta type-2  
PSB3 Proteasome subunit beta type-3  
PSB4 Proteasome subunit beta type-4  
PSB5 Proteasome subunit beta type-5  
PSB6 Proteasome subunit beta type-6  
PSB7 Proteasome subunit beta type-7  
PSB8 Proteasome subunit beta type-8  
PSB9 Proteasome subunit beta type-9  
PSDE 26S proteasome non-ATPase regulatory subunit 14  
PTER Phosphotriesterase-related protein  
PTGR2 Prostaglandin reductase 2  
PTPS 6-pyruvoyl tetrahydrobiopterin synthase  
PUR6 Multifunctional protein ADE2  
PUR8 Adenylosuccinate lyase  
PURA2 Adenylosuccinate synthetase isozyme 2  
PYC Pyruvate carboxylase, mitochondrial  
QOR Quinone oxidoreductase  
RADI Radixin  
RBBP9 Putative hydrolase RBBP9  
RD23B UV excision repair protein RAD23 homolog B  
RET1 Retinol-binding protein 1  
RET4 Retinol-binding protein 4  
RIDA 2-iminobutanoate/2-iminopropanoate deaminase  
RINI Ribonuclease inhibitor  
RL10A 60S ribosomal protein L10a  
RL12 60S ribosomal protein L12  
RL14 60S ribosomal protein L14  
RL8 60S ribosomal protein L8  
RMD1 Regulator of microtubule dynamics protein 1  
RS18 40S ribosomal protein S18  
RS19 40S ribosomal protein S19  
RS20 40S ribosomal protein S20  
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RS27A Ubiquitin-40S ribosomal protein S27a  
RSSA 40S ribosomal protein SA  
S14L2 SEC14-like protein 2  
SAHH Adenosylhomocysteinase  
SAMH1 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1  
SAP Prosaposin  
SAP3 Ganglioside GM2 activator  
SBP1 Selenium-binding protein 1  
SBP2 Selenium-binding protein 2  
SC23A Protein transport protein Sec23A  
SC23B Protein transport protein Sec23B  
SC31A Protein transport protein Sec31A  
SCRN2 Secernin-2  
SCRN3 Secernin-3  
SH3L1 SH3 domain-binding glutamic acid-rich-like protein  
SH3L3 SH3 domain-binding glutamic acid-rich-like protein 3  
SHPK Sedoheptulokinase  
SIAS Sialic acid synthase  
SKP1 S-phase kinase-associated protein 1  
SODC Superoxide dismutase [Cu-Zn]  
SODM Superoxide dismutase [Mn], mitochondrial  
SOX Peroxisomal sarcosine oxidase  
SPA3K Serine protease inhibitor A3K  
SPA3M Serine protease inhibitor A3M  
SPB6 Serpin B6  
SPEB Agmatinase, mitochondrial  
SPEE Spermidine synthase  
SPRE Sepiapterin reductase  
SPS1 Selenide, water dikinase 1  
SPS2 Selenide, water dikinase 2  
SPTB2 Spectrin beta chain, non-erythrocytic 1  
SPTN1 Spectrin alpha chain, non-erythrocytic 1  
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SPYA Serine--pyruvate aminotransferase, mitochondrial  
SSBP Single-stranded DNA-binding protein, mitochondrial  
SSDH Succinate-semialdehyde dehydrogenase, mitochondrial  
STA10 START domain-containing protein 10  
SUOX Sulfite oxidase, mitochondrial  
SYCC Cysteine--tRNA ligase, cytoplasmic  
SYHC Histidine--tRNA ligase, cytoplasmic  
SYIM Isoleucine--tRNA ligase, mitochondrial  
SYTC Threonine--tRNA ligase, cytoplasmic  
SYWC Tryptophan--tRNA ligase, cytoplasmic  
SYYC Tyrosine--tRNA ligase, cytoplasmic  
T23O Tryptophan 2,3-dioxygenase  
T3HPD Trans-L-3-hydroxyproline dehydratase  
TAGL2 Transgelin-2  
TALDO Transaldolase  
TCPG T-complex protein 1 subunit gamma  
TCTP Translationally-controlled tumor protein  
TEBP Prostaglandin E synthase 3  
TERA Transitional endoplasmic reticulum ATPase  
THIC Acetyl-CoA acetyltransferase, cytosolic  
THIKA 3-ketoacyl-CoA thiolase A, peroxisomal  
THIKB 3-ketoacyl-CoA thiolase B, peroxisomal  
THIL Acetyl-CoA acetyltransferase, mitochondrial  
THIM 3-ketoacyl-CoA thiolase, mitochondrial  
THIO Thioredoxin  
THNS2 Threonine synthase-like 2  
THTM 3-mercaptopyruvate sulfurtransferase  
THTR Thiosulfate sulfurtransferase  
TIM13 Mitochondrial import inner membrane translocase subunit Tim13  
TIM8A Mitochondrial import inner membrane translocase subunit Tim8 A  
TKFC Triokinase/FMN cyclase  
TPIS Triosephosphate isomerase  
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TPMT Thiopurine S-methyltransferase  
TRFE Serotransferrin  
TRXR1 Thioredoxin reductase 1, cytoplasmic  
TRXR2 Thioredoxin reductase 2, mitochondrial  
TTC36 Tetratricopeptide repeat protein 36  
TTC38 Tetratricopeptide repeat protein 38  
TTHY Transthyretin  
TTPA Alpha-tocopherol transfer protein  
TXD17 Thioredoxin domain-containing protein 17  
UB2D3 Ubiquitin-conjugating enzyme E2 D3  
UB2L3 Ubiquitin-conjugating enzyme E2 L3  
UB2V2 Ubiquitin-conjugating enzyme E2 variant 2  
UBE2K Ubiquitin-conjugating enzyme E2 K  
UBE2N Ubiquitin-conjugating enzyme E2 N  
UCRI Cytochrome b-c1 complex subunit Rieske, mitochondrial  
UFD1 Ubiquitin recognition factor in ER-associated degradation protein 1  
UGPA UTP--glucose-1-phosphate uridylyltransferase  
URIC Uricase  
USP9X Probable ubiquitin carboxyl-terminal hydrolase FAF-X  
VATA V-type proton ATPase catalytic subunit A  
VATB2 V-type proton ATPase subunit B, brain isoform  
VATE1 V-type proton ATPase subunit E 1  
VIME Vimentin  
VINC Vinculin  
VMA5A von Willebrand factor A domain-containing protein 5A  
VTDB Vitamin D-binding protein  
XYLB Xylulose kinase  
YBOX1 Nuclease-sensitive element-binding protein 1  
 
*Excluding keratin proteins, likely introduced as contamination. 
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12 weeks 52 weeks 
CHOW HFD CHOW HFD 
 
Figure A1. Liver histology for pilot study (Chapter 3). Sections include all samples that were 
processed (n=6/6 per group) and stained using haematoxylin and eosin (H&E). Magnification 
is 100ൈ and scale bars represent 100m. 
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12 weeks 52 weeks 
CHOW HFD CHOW HFD 
 
Figure A2. Liver histology for pilot study (Chapter 3). Sections include all samples that were 
processed (n=6/6 per group) and stained using picro-sirius red (PSR). Magnification is 100ൈ 
and scale bars represent 100m. 
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10 weeks 20 weeks 
CHOW HFD CHOW HFD 
 
Figure A3. Liver histology for progression study (Chapter 4). Sections include all samples that 
were processed (n=6/12 per group) and stained using haematoxylin and eosin (H&E). 
Magnification is 100ൈ and scale bars represent 100m. 
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30 weeks 50 weeks 
CHOW HFD CHOW HFD 
 
Figure A3. (continued) 
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HFD 
10 weeks 20 weeks 30 weeks 50 weeks 
 
Figure A4. Liver histology for HFD animals in progression study (Chapter 4). Sections include 
all samples that were processed (n=6/12 per group) and stained using picro-sirius red (PSR). 
Magnification is 200ൈ and scale bars represent 50m. 
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Wild-type TNF-/- 
CHOW HFD CHOW HFD 
  
 
Figure A5. Liver histology for genetic intervention study (Chapter 5.2). Sections include all 
samples that were processed (n=5/5 for wild-type; n=4/8 for TNF-/-) and stained using 
haematoxylin and eosin (H&E). Magnification is 100ൈ and scale bars represent 100m. 
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Wild-type TNF-/- 
CHOW HFD CHOW HFD 
  
 
Figure A6. Liver histology for genetic intervention study (Chapter 5.2). Sections include all 
samples that were processed (n=5/5 for wild-type; n=4/8 for TNF-/-) and stained using picro-
sirius red (PSR). Magnification is 100ൈ. The author wishes to thank Ms Christine Yee for 
contributing in part to the acquisition of these images. 
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CHOW 
Untrained END HIIT 
 
Figure A7. Liver histology for lifestyle intervention study (Chapter 5.3). Sections include all 
samples that were processed (n=6/10-12 per group) and stained using haematoxylin and eosin. 
Magnification is 100ൈ and scale bars represent 100m. Abbreviations: END, endurance 
training; HIIT, high-intensity interval training. 
 
(continued over page) 
 
281 
 
HFD 
Untrained END HIIT 
 
Figure A7. (continued) 
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HFD 
Untrained END HIIT 
 
Figure A8. Liver histology for HFD animals in lifestyle intervention study (Chapter 5.3). 
Sections include all samples that were processed (n=6/10-12 per group) and stained using 
picro-sirius red. Magnification is 100ൈ and scale bars represent 100m. Abbreviations: END, 
endurance training; HIIT, high-intensity interval training. 
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NanoDrop™ RNA purity Reference Gene Amplification 
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Figure A9. Analysis of sample quality for gene expression studies (starts on previous page). 
Left panels: A NanoDrop™ spectrophotometer was used to determine absorbance ratios as an 
indicator for RNA contamination. Acceptable values (as a rule of thumb) are approximately 
1.8-2.0 for 260:280 and slightly higher, 2.0-2.2 for 260:230. A greater absorbance at 280 nm 
may imply protein or phenol contamination, while phenol also absorbs strongly at 230 nm. 
Each column represents pooled values for all samples within the study. Right panels: Cycle 
threshold for reference genes in respective studies, following cDNA synthesis and 
amplification. Data show all individual samples, excluding outliers determined by the ROUT 
method (Q=5.0%). Significant difference from control group (chow diet of earliest timepoint, 
wild-type or untrained animals) accepted at p<0.05 (*), determined by two-way ANOVA with 
Dunnett’s test for multiple comparisons. Current page: RNA integrity was determined using 
an Agilent Bioanalyzer™ electrophoresis. Samples were taken at random from the progression 
study 10-week cohort (n=12). High values close to 10 for RNA integrity number (RIN) indicate 
less samples degradation, lower values indicate more degradation. RIN values greater than 7 
are generally accepted as sufficient quality for down-stream analysis by RT-qPCR. 
